4-AZAINDOLE COMPOUNDS

Abstract
Disclosed are compounds of Formula (I)
Description
DESCRIPTION

The present invention generally relates to 4-azaindole compounds useful as inhibitors of signaling through Toll-like receptor 7, 8, or 9 (TLR7, TLR8, TLR9) or combinations thereof. Provided herein are 4-azaindole compounds, compositions comprising such compounds, and methods of their use. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention that are useful for the treatment of conditions related to TLR modulation, such as inflammatory and autoimmune diseases, and methods of inhibiting the activity of TLRs in a mammal.


Toll/IL-1 receptor family members are important regulators of inflammation and host resistance. The Toll-like receptor family recognizes molecular patterns derived from infectious organisms including bacteria, fungi, parasites, and viruses (reviewed in Kawai, T. et al., Nature Immunol., 11:373-384 (2010)). Ligand binding to the receptor induces dimerization and recruitment of adaptor molecules to a conserved cytoplasmic motif in the receptor termed the Toll/IL-1 receptor (TIR) domain with the exception of TLR3, all TLRs recruit the adaptor molecule MyD88. The IL-1 receptor family also contains a cytoplasmic TIR motif and recruits MyD88 upon ligand binding (reviewed in Sims, J. E. et al., Nature Rev. Immunol., 10:89-102 (2010)).


Toll-like receptors (TLRs) are a family of evolutionarily conserved, transmembrane innate immune receptors that participate in the first-line defense. As pattern recognition receptors, the TLRs protect against foreign molecules, activated by pathogen associated molecular patterns (PAMPs), or from damaged tissue, activated by danger associated molecular patterns (DAMPs). A total of 13 TLR family members have been identified, 10 in human, that span either the cell surface or the endosomal compartment. TLR7-9 are among the set that are endosomally located and respond to single-stranded RNA (TLR7 and TLR8) or unmethylated single-stranded DNA containing cytosine-phosphate-guanine (CpG) motifs (TLR9).


Activation of TLR7/8/9 can initiate a variety of inflammatory responses (cytokine production, B cell activation and IgG production, Type I interferon response). In the case of autoimmune disorders, the aberrant sustained activation of TLR7/8/9 leads to worsening of disease states. Whereas overexpression of TLR7 in mice has been shown to exacerbate autoimmune disease, knockout of TLR7 in mice was found to be protective against disease in lupus-prone MRL/lpr mice. Dual knockout of TLR7 and 9 showed further enhanced protection.


As numerous conditions may benefit by treatment involving modulation of cytokines, IFN production and B cell activity, it is immediately apparent that new compounds capable of modulating TLR7 and/or TLR8 and/or TLR9 and methods of using these compounds could provide substantial therapeutic benefits to a wide variety of patients.


The present invention relates to a new class of 4-azaindole compounds found to be effective inhibitors of signaling through TLR7/8/9. These compounds are provided to be useful as pharmaceuticals with desirable stability, bioavailability, therapeutic index, and toxicity values that are important to their drugability.


SUMMARY OF THE INVENTION

The present invention provides compounds of Formula (I) that are useful as inhibitors of signaling through Toll-like receptor 7, 8, or 9 and are useful for the treatment of proliferative diseases, allergic diseases, autoimmune diseases and inflammatory diseases, or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof.


The present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.


The present invention also provides a method for inhibition of Toll-like receptor 7, 8, or 9 comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.


The present invention also provides a method for treating proliferative, metabolic, allergic, autoimmune and inflammatory diseases, comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.


The present invention also provides a method of treating a disease or disorder associated with Toll-like receptor 7, 8, or 9 activity, the method comprising administering to a mammal in need thereof, at least one of the compounds of Formula (I) or salts, solvates, and prodrugs thereof.


The present invention also provides processes and intermediates for making the compounds of Formula (I) including salts, solvates, and prodrugs thereof.


The present invention also provides at least one of the compounds of Formula (I) or salts, solvates, and prodrugs thereof, for use in therapy.


The present invention also provides the use of at least one of the compounds of Formula (I) or salts, solvates, and prodrugs thereof, for the manufacture of a medicament for the treatment of prophylaxis of Toll-like receptor 7, 8, or 9 related conditions, such as allergic disease, autoimmune diseases, inflammatory diseases, and proliferative diseases.


The compound of Formula (I) and compositions comprising the compounds of Formula (I) may be used in treating, preventing, or curing various Toll-like receptor 7, 8, or 9 related conditions. Pharmaceutical compositions comprising these compounds are useful for treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as allergic disease, autoimmune diseases, inflammatory diseases, and proliferative diseases.


These and other features of the invention will be set forth in expanded form as the disclosure continues.







DETAILED DESCRIPTION

The first aspect of the present invention provides at least one compound of Formula (I):




embedded image


N-oxide, or a salt thereof, wherein:

  • G is:




embedded image


(iv) a 9-membered heterocyclic ring selected from:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


(v) 10-membered heterocyclic ring selected from:




embedded image


A is:



  • (i) —O-L1-R6;

  • (ii) —NR7R8;

  • (iii) -L2—C(O)NR9R10;

  • (iv) —(CRxRx)1-3R11, C1-3 aminoalkyl, —(CRxRx)1-3NRxC(O)R11, —(CRxRx)1-2NRxC(O)(CH2)1-2(piperidinyl), —(CRxRx)1-2NRxC(O)O(CH2)1-2(piperidinyl), or —(CRxRx)1-2NRxC(O)(CH2)1-2NRxRx;

  • —CRxR12R13,wherein R12 and R13 together with the carbon atom to which they are attached form a cyclic group selected from azabicyclo[4.1.1]octanyl, azepanyl, azetidinyl, C3-7 cycloalkyl, diazepanyl, azaspiro[3.3]heptanyl, diazaspiro[4.5]decanonyl, morpholinyl, octahydrocyclopenta[c]pyrrolyl, piperazinyl, piperidinyl, pyrrolidinyl, and quinuclidinyl, each substituted with zero to 4 R12a;

  • (vi) —CRx═CRx(piperidinyl); or

  • (vii) an aromatic group selected from [1,2,4]triazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, imidazolyl, indazolyl, isoquinolinyl, oxadiazolyl, oxazolyl, phenyl, pyrazinyl, pyrazolo[3,4-b]pyridinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinonyl, quinolinyl, quinoxalinyl, tetrahydro-[1,2,4]triazolo[1,5-a]pyrazinyl, tetrahydroimidazo[1,2-a]pyrazinyl, tetrahydroisoquinolinyl, tetrahydrothiazolo[5,4-c]pyridinyl, tetrahydrothieno[2,3-c]pyridinyl, thiadiazolyl, thiazolyl, thiooxadiazolyl, and triazolyl, each substituted with zero to 2 R14a and zero to 3 R14b;

  • L1 is bond, —(CRxRx)1-2—, —(CRxRx)1-2CRx(OH)—, —(CRxRx)1-2O—, —CRxRxC(O)—, —CRxRxC(O)NRx(CRxRx)0-4—, —CRxRxNRxC(O)(CRxRx)0-4—, or —CRxRxNRxC(O)(CRxRx)0-4—, or

  • L2 is a bond or —(CRxRx)1-3—;

  • R1 is H, Cl, —CN, C1-4 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, C1-3 hydroxy-fluoroalkyl, —CRv═CH2, C3-6 cycloalkyl, —CH2(C3-6 cycloalkyl), —C(O)O(C1-3 alkyl), or tetrahydropyranyl;

  • each R2 is independently halo, —CN, —OH, —NO2, C1-4 alkyl, C1-2 fluoroalkyl, C1-2 cyanoalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, —O(CH2)0-2OH, —(CH2)0-4O(C1-4 alkyl), C1-3 fluoroalkoxy, —(CH2)1-4O(C1-3 alkyl), —O(CH2)1-2OC(O)(C1-3 alkyl), —O(CH2)1-2NRxRx, —C(O)O(C1-3 alkyl), —(CH2)0-2C(O)NRyRy, —C(O)NRx(C1-5 hydroxyalkyl), —C(O)NRx(C2-6 alkoxyalkyl), —C(O)NRx(C3-6 cycloalkyl), —NRyRy, —NRy(C1-3 fluoroalkyl), —NRy(C1-4 hydroxyalkyl), —NRxCH2(phenyl), —NRxS(O)2(C3-6 cycloalkyl), —NRxC(O)(C1-3 alkyl), —NRxCH2(C3-6 cycloalkyl), —(CH2)0-2S(O)2(C1-3 alkyl), —(CH2)0-2(C3-6 cycloalkyl), —(CH2)0-2(phenyl), morpholinyl, dioxothiomorpholinyl, dimethyl pyrazolyl, methylpiperidinyl, methylpiperazinyl, amino-oxadiazolyl, imidazolyl, triazolyl, or —C(O)(thiazolyl); R2a is C1-6 alkyl, C1-3 fluoroalkyl, C1-6 hydroxyalkyl, C1-3 aminoalkyl, —(CH2)0-4O(C1-3 alkyl), C3-6 cycloalkyl, —(CH2)1-3C(O)NRxRx, —CH2(C3-6 cycloalkyl), —CH2(phenyl), tetrahydrofuranyl, tetrahydropyranyl, or phenyl;

  • each R2b is independently H, halo, —CN, —NRxRx, C1-6 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, C1-3 fluoroalkoxy, —(CH2)0-2O(C1-3alkyl), —(CH2)0-3C(O)NRxRx, —(CH2)1-3(C3-6 cycloalkyl), —C(O)O(C1-3 alkyl), —C(O)NRx(C1-3 alkyl), —CRx═CRxRx, or —CRx═CH(C3-6 cycloalkyl);

  • R2c is R2a or R2b;

  • R2d is R2a or R2b; provided that one of R2c and R2d is R2a, and the other of R2c and R2 is R2b;

  • each R5 is independently F, Cl, —CN, C1-3 alkyl, C1-2 fluoroalkyl, or —OCH3; R6 is:
    • (i) C1-3 alkyl, —CRxRxC(O)NRx(CRxRx)1-3OH, —CRxRxC(O)NRx(CRxRx)1-2NRxRx, or —CRxRxC(O)NRx(CRxRx)1-2CHFCRxRxOH; or
    • (ii) azabicyclo[3.2.1]octanyl, azaspiro[5.5]undecanyl, azetidinyl, C3-6 cycloalkyl, diazabicyclo[2.2.1]heptanyl, diazaspiro[3.5]nonanyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, octahydrocyclopenta[c]pyrrolyl, piperazinyl, piperidinyl, pyrrolidinyl, or quinuclidinyl, each substituted with zero to 3 R6a; each R6a is independently F, Cl, —OH, —CN, C1-6 alkyl, C1-4 fluoroalkyl, C1-6 hydroxyalkyl, —(CH2)1-2O(C1-3 alkyl), —NRyRy, —(CH2)1-2NRxRx, —(CRxRx)1-2S(O)2(C1-3 alkyl), —(CRxRx)1-2C(O)NRxRx, —C(O)(CRxRx)1-2NRxRx, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, isobutylpiperidinyl, piperazinyl, or —O(piperidinyl);

  • R7 is:
    • (i) R7a, —CH2R7a, —(CH2)1-3NRyRy, —(CH2)1-3NRxC(O)(CH2)1-2NRyRy, —C(O)R7a, —C(O)CH(NH2)R7a, —C(O)(CH2)1-3NH2, —C(O)CH(NH2)(C1-4 alkyl), —C(O)CH(NH2)(CH2)1-2C(O)OH, —C(O)CH(NH2)(CH2)2-4NH2, or —C(O)CH(NH2)(CH2)1-3C(O)NH2; or
    • (ii) C3-6 cycloalkyl substituted with one substituent selected from —NRx(CH2)2-3NRyRy, —NRx(methylpiperidinyl), —NRx(CH2)2-3(morpholinyl), dimethylamino piperidinyl, and piperazinyl substituted with a substituent selected from C1-4 alkyl, —C(O)CH3, —(CH2)1-2OCH3, —CH2(methylphenyl), —(CH2)2-3(pyrrolidinyl), C3-6 cycloalkyl, pyridinyl, and methylpiperidinyl;

  • R7a is azaspiro[3.5]nonanyl, C3-6 cycloalkyl, diazaspiro[3.5]nonanyl, diazaspiror[5.5]undecanyl, diazepanonyl, diazepanyl, morpholinyl, phenyl, piperazinyl, piperidinyl, pyrrolidinonyl, pyrrolidinyl, or pyrrolyl, each substituted with zero to 1 substituent selected from C1-3 alkyl, —NH2, methylpiperidinyl, methylpyrrolidinyl, —OCH2CH2(pyrrolidinyl), and —OCH2CH2NHCH2CH3; and zero to 4 substituents selected from —CH3;

  • R7b is:
    • (i) —OH, C1-6 alkyl, C1-4 fluoroalkyl, C1-4 hydroxyalkyl, C1-3 aminoalkyl, —(CH2)2-3C═CH, —(CRxRx)1-2O(C1-2 alkyl), —(CH2)1-3S(O)2(C1-2 alkyl), —(CH2)0-3NRxRy, —(CH2)1-2C(O)NRxRx, —NRyRy, —NRx(C1-4 hydroxyalkyl), —NRy(C1-2 cyanoalkyl), —N(C1-2 cyanoalkyl)2, —NRx(C1-2 fluoroalkyl), —NRx(C2-4 hydroxyfluoroalkyl), —(CRxRx)1-2C(O)NRxRx, —NRx(CH2)1-2C(O)NRxRx, —N((CH2)1-2C(O)NRxRx)2, —NRx(CH2)1-2S(O)2(C1-2 alkyl), —NRx(CH2)1-3NRxRx, —NRxCH2CH2NRxRx, —NRxC(O)(CH2)1-2NRxRx, —NRx(CH2CH2S(O)2CH3), —(CH2)1-2NRxC(O)(CH2)1-2NRxRx, —O(CH2)1-3NRxRx, —C(O)(CRxRx)1-2NRyRy, —C(O)(CRxRx)1-2NRy(C1-4 hydroxyalkyl), —C(O)(CRxRx)1-2NRx(CH2CH2OCH3), —S(O)2CH2CH2N(CH3)2, —(CH2)1-2R7d, —NRxR7d, —NRx(CH2)1-2R7d), —NR7dR7d, —N((CH2)1-2R7d)2, —OR7d, —C(O)R7d, —C(O)(CRxRx)1-2R7d, or —C(O)(CRxRx)1-2NRxR7d; or
    • (ii) azepanyl, azetidinyl, C3-6 cycloalkyl, diazepanyl, dioxotetrahydrothiopyranyl, dioxothiomorpholinyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxetanyl, piperazinonyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydropyranyl, or thiadiazolyl, each substituted with zero to 1 R8a and zero to 3 R8b;

  • each R7c is independently F, Cl, —CN, C1-2 alkyl, —CF3, or —CH2CN;

  • R7d is azaspiro[3.5]nonanyl, azetidinyl, bicyclo[1.1.1]pentanyl, C3-6 cycloalkyl, dioxothiaazaspiro[3.3]heptanyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxaazaspiro[4.4]nonyl, oxetanyl, phenyl, piperidinyl, pyrazolyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, thiadiazolyl, or triazolyl, each substituted with zero to 2 substituents independently selected from F, —OH, C1-3 alkyl, C1-2 hydroxyalkyl, C1-2 alkoxy, —NRxRx, —C(O)CH3, —S(O)2CH3, methylpiperidinyl, methylpyrrolidinyl, tetramethylpiperidinyl, —OCH2CH2(pyrrolidinyl), and —OCH2CH2NHCH2CH3; and zero to 4 substituents selected from —CH3;

  • R8 is H or C1-3 alkyl;

  • or R7 and R8 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidinyl, diazabicyclo[2.2.1]heptanyl, diazabicyclo[2.2.2]octanyl, diazabicyclo[3.1.1]heptanyl, diazabicyclo[3.2.1]octanyl, azaspiro[3.3]heptanyl, diazaspiro[2.5]octanyl, diazaspiro[3.3]heptanyl, diazepanonyl, diazepanyl, diazaspiro[3.5]nonanyl, diazaspiro[5.5]undecanyl, imidazolyl, imidazolidinonyl, octahydro-1H-pyrrolo[3,4-b]pyridinyl, oxadiazabicyclo[3.3.1]nonanyl, piperazinyl, piperazinonyl, piperidinyl, pyrrolidinonyl, pyrrolidinyl, and pyrrolyl, wherein said heterocyclic ring is substituted with zero to 1 R7b and zero to 2 R7c;

  • R8a is —OH, C1-6 alkyl, C1-4 fluoroalkyl, C1-4 hydroxyalkyl, —(CH2)1-2O(C1-3 alkyl), C1-2 alkoxy, —C(O)(C1-3 alkyl), —C(O)O(C1-2 alkyl), —(CH2)1-2(C3-6 cycloalkyl), —(CH2)1-3(methyl phenyl), —(CH2)1-3(pyrrolidinyl), —(CH2)1-3(methylpyrazolyl), —(CH2)1-3(thiophenyl), —NRxRx, C3-6 cycloalkyl, methylpiperidinyl, pyridinyl, or pyrimidinyl;

  • each R8b is independently F, Cl, —CN, C1-3 alkyl, or —CF3;

  • R9 is C1-6 alkyl, C1-4 fluoroalkyl, C1-6 hydroxyalkyl, C1-6 hydroxy fluoroalkyl, C1-3 aminoalkyl, —(CH2)1-2O(C1-3 alkyl), —(CH2)1-3NRxRx, —(CH2)1-2C(O)NRxRx, —(CH2)1-3S(O)2OH, —(CRxRx)1-3NRxS(O)2(C1-2 alkyl), or —(CH2)0-3R9a;

  • R9a is C3-7 cycloalkyl, furanyl, phenyl, piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrrolidinyl, quinuclidinyl, thiazolyl, or octahydrocyclopenta[c]pyrrolyl, each substituted with zero to 3 substituents independently selected from F, Cl, —OH, C1-4 alkyl, C1-3 hydroxyalkyl, C1-3 hydroxy fluoroalkyl, C1-3aminoalkyl, —NRyRy, oxetanyl, phenyl, piperazinyl, piperidinyl, and pyrrolidinyl;

  • R10 is H, C1-4 alkyl, —(CH2)1-3O(C1-2 alkyl), or C3-6 cycloalkyl;

  • or R9 and R10together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azabicyclo[3.1.1]heptanyl, azaspiro[5.5]undecanyl, diazabicyclo[2.2.1]heptanyl, diazabicyclo[3.1.1]heptanyl, diazabicyclo[3.2.0]heptanyl, diazaspiro[3.5]nonanyl, diazaspiro[4.4]nonanyl, diazaspiro[4.5]decanyl, diazepanyl, indolinyl, morpholinyl, octahydropyrrolo[3,4-c] pyrrolyl, piperazinonyl, piperazinyl, piperidinyl, and pyrrolidinyl, each substituted with zero to 3 R10a;

  • each R10a is independently C1-4 alkyl, C1-4 hydroxyalkyl, —(CH2)1-3O(C1-3 alkyl), —(CH2)1-3NRxRx, —(CH2)1-2C(O)NRxRx, —(CH2)1-2(methyltriazolyl), —CH2CH2(phenyl), —CH2CH2(morpholinyl), —C(O)(C1-2 alkyl), —C(O)NRyRy, —C(O)CH2NRyRy, —NRyRy, —NHC(O)(C1-3 alkyl), —C(O)(furanyl), —O(piperidinyl), —C(O)CH2(diethylcarbamoylpiperidinyl), methylpiperazinyl, piperidinyl, methylpiperidinyl, diethylcarbamoylpiperidinyl, isopropylpiperidinyl, pyridinyl, trifluoromethylpyridinyl, pyrimidinyl, or dihydrobenzo[d]imidazolonyl;

  • R11 is azetidinyl, azaspiro[3.5]nonanyl, dioxidothiomorpholinyl, hexahydropyrrolo[3,4-c]pyrrolyl, morpholinyl, piperazinyl, piperidinyl, pyridinyl, or pyrrolidinyl, each substituted with zero to 3 substituents independently selected from halo, —CN, C1-4 alkyl, C1-3 aminoalkyl, —(CH2)1-2(methyloxetanyl), —(CH2)1-2 (triazolyl), —(CH2)1-2(phenyl), —C(O)CH2NRxRx, C1-5 hydroxyalkyl, —(CH2)1-2C(O)NRxRx, —(CH2)1-2S(O)2(C1-3 alkyl), —(CH2)1-2S(O)(C1-3 alkyl), oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl;

  • each R12a is independently F, Cl, —OH, C1-6 alkyl, C1-4 fluoroalkyl, C1-4 cyanoalkyl, C1-6 hydroxyalkyl, —(CH2)1-2O(C1-3 alkyl), —(CH2)1-2C(O)NRxRx, —(CH2)1-2S(O)2(C1-2 alkyl), —(CH2)1-2NRxHS(O)2(C1-2 alkyl), —(CH2)1-2NRxRx, C1-3 alkoxy, —NRyRy, —NRx(C1-4 fluoroalkyl), —NRx(C1-2 cyanoalkyl), —NRxCH2NRxRx, —NRx(C1-4 hydroxyalkyl), —NRx(CRxRxCRxRx)O(C1-3 alkyl), —NRx(CH2C(O)NRxRx), —NRx(C1-3 alkoxy), —NRxCH2CH2S(O)2(C1-2 alkyl), —NRxC(O)CH3, —NRxC(O)(C1-2 fluoroalkyl), —NRxC(O)CRxRxNRxRx, —NRxC(O)CH2NRyRy, —NRxC(O)CH2NRx(C1-4 hydroxyalkyl), —NRx(CH2)1-2C(O)NRxRx, —NRxS(O)2(C1-2 alkyl), —C(O)(C1-5 alkyl), —C(O)(CH2)1-3O(C1-2 alkyl), —C(O)(CRxRx)1-2NRyRy, R12b, —CRxRxR12b, —C(O)R12b, —C(O)CRxRxNRxR12b, —C(O)NRxR12b, —NRxC(O)CRxRxR12b, —NRxR12b, —NRxCRxRxR12b, —N(CH2CN)R12b, —NRxC(O)CRxRxNRxR12b, —NRxC(O)CRxRxNRxCH2R12b, —NRxCRxRxC(O)NRxR12b, or —OR12b; or two R12a and the carbon atom to which they are attached form C═O;

  • R12b is azetidinyl, bicyclo[1.1.1]pentanyl, C3-6 cycloalkyl, diazabicyclo[2.2.1]heptanyl, dioxolanyl, dioxothiaazaspiro[3.3]heptanyl, dioxidotetrahydrothiopyranyl, dioxidothiomorpholinyl, imidazolyl, morpholinyl, octahydrocyclopenta[c]pyrrolyl, octahydropyrrolo[3,4-c]pyrrolyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxaazaspiro[4.4]nonanyl, oxetanyl, phenyl, piperazinyl, piperazinonyl, piperidinyl, pyridinyl, pyrrolidinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, or triazolyl, each substituted with zero to 4 substituents independently selected from F, Cl, —OH, C1-4 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, C1-4 alkoxy, —(CH2)1-2O(C1-3 alkyl), —NRxRx, —C(O)NRxRx, and —(CRxRx)0-1S(O)2(C1-3 alkyl);

  • each R14a is independently is:
    • (i) H, halo, —OH, C1-6 alkyl, C1-23 fluoroalkyl, C1-4 hydroxyalkyl, —(CH2)0-2O(C1-3 alkyl), —CRxRxNRyRy, —CRxRxNRx(C1-3 cyanoalkyl), —CRxRxNRx((CH2)1-2O(C1-2 alkyl)), —CRxRxN((CH2)1-2OCH3)2, —CRxRxNRx(CH2C═CRx), —CRxRxNRx(CH2)1-3NRxRx, —(CRxRx)1-3CRxRxNRxRx, —CRx(NH2)(CH2)1-4NRxRx, —CRxRxNRx(CH2)1-2O(C1-3 alkyl), —CRxRxNRx(CH2)1-2O(CH2)1-2OH, —CRxRxNRx(CH2)1-3S(O)2OH, —CRxRxC(O)NRxRx, —NRxRy, —NRx(CH2)1-3NRxRx, NRxC(O)(C1-3 alkyl), —NRxC(O)(C1-3 fluoroalkyl), —NRxC(O)O(C1-3 alkyl), —NRxC(O)(CH2)1-3NRxRx, —NRxCH2C(O)CH2NRxRx, —C(O)(C1-3 alkyl), —C(O)(CRxRx)1-3OH, —C(O)CRxRxNRxRx, —C(O)NRxRx, —C(O)NRx(C1-2 cyanoalkyl), —C(O)NRx(CRxRx)1-3NRxRx, —C(O)N(CH2CH3)(CRxRx)1-3NRxRx, —C(O)NRx(CRxRx)1-2C(O)NRxRx, —C(O)NRx(CRxRx)1-3NRxC(O)(C1-2 alkyl), —O(CRxRx)1-3NRxRx, —S(O)2NRxRx, or —C(O)(CRxRx)1-2S(O)2(C1-2 alkyl);
    • (ii) 8-azabicyclo[3.2.1]octanyl, azaspiro[3.5]nonanyl, azetidinyl, benzo[c][1,2,5]oxadiazolyl, cyclopentyl, cyclohexyl, diazepanyl, morpholinyl, phenyl, piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrrolidinonyl, quinolinyl, quinuclidinyl, tetrahydroisoquinolinyl, tetrahydropyridinyl, or thiazolidinyl, each substituted with zero to 2 substituents independently selected from C1-4 alkyl, C1-2 fluoroalkyl, C1-4 hydroxyalkyl, —NRxRx, —(CH2)1-2NRxRx, —C(O)(C1-2 alkyl), —C(O)CH2NRxRx, —C(O)O(C1-3 alkyl), —CH2C(O)NRxRx, C3-6 cycloalkyl, —CH2(phenyl), —CH2(pyrrolyl), —CH2(morpholinyl), —CH2(methylpiperazinyl), —CH2(thiophenyl), methylpiperidinyl, isobutylpiperidinyl, and pyridinyl; or
    • (iii) -L3-R14c;

  • each R14b is F, Cl, —OH, —H3, or —OCH3;

  • R14c is adamantanyl, azepanyl, azetidinyl, C3-7 cycloalkyl, diazepanyl, imidazolyl, indolyl, morpholinyl, octahydropyrrolo[3,4-c]pyrrolyl, phenyl, piperazinonyl, piperazinyl, piperidinyl, pyridinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolyl, triazolyl, or tetrazolyl, each substituted with zero to 1 substituent selected from F, —OH, C1-4 alkyl, C1-3 hydroxyalkyl, —NRxRy, —NRxC(O)CH3, —C(O)(C1-2 alkyl), —C(O)NRxRx, —C(O)N(CH2CH3)2, —C(O)(tetrahydrofuranyl), —C(O)O(C1-2 alkyl), —CH2C(O)NRxRy, morpholinyl, methylpiperidinyl, pyrazinyl, pyridinyl, and pyrrolidinyl;

  • L3 is —(CRxRx)1-3—, —CH(NH2)—, —CRxRxNRx—, —C(O)—, —C(O)NRx(CH2)0-4—, —NRx—, —NRxC(O)—, —NRxCH2—, —NRxCH2C(O)—, or —O(CH2)0-2—;

  • Rv is H, C1-2 alkyl, or C1-2 fluoroalkyl;

  • each Rx is independently H or —CH3;

  • each Ry is independently H or C1-6 alkyl;

  • n is zero, 1, or 2; and

  • p is zero, 1, 2, 3, or 4.



The second aspect of the present invention provides at least one compound of Formula (I), N-oxide, or a salt thereof, wherein:

  • G is defined in the first aspect;
  • A is:
  • (i) —O-L1-R6;
  • (ii) —NR7R8;
  • (iii) -L2—C(O)NR9R10;
  • (iv) —(CRxRx)1-3R11, C1-3 aminoalkyl, —(CRxRx)1-3NRxC(O)R11, —(CRxRx)1-2NRxC(O)(CH2)1-2(piperidinyl), —(CRxRx)1-2NRxC(O)O(CH2)1-2(piperidinyl), or —(CRxRx)1-2NRxC(O)(CH2)1-2NRxRx;
  • (v) —CRxR12R13, wherein R12 and R13 together with the carbon atom to which they are attached form a cyclic group selected from azabicyclo[4.1.1]octanyl, azepanyl, azetidinyl, C3-7 cycloalkyl, diazepanyl, diazaspiro[4.5]decanonyl, morpholinyl, octahydrocyclopenta[c]pyrrolyl, piperazinyl, piperidinyl, pyrrolidinyl, and quinuclidinyl, each substituted with zero to 4 R12a;
  • (vi) —CRx═CRx(piperidinyl); or
  • (vii) an aromatic group selected from [1,2,4]triazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, imidazolyl, indazolyl, isoquinolinyl, oxadiazolyl, oxazolyl, phenyl, pyrazinyl, pyrazolo[3,4-b]pyridinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinonyl, quinolinyl, quinoxalinyl, tetrahydro[1,2,4]triazolo[1,5-a]pyrazinyl, tetrahydroimidazo[1,2-a]pyrazinyl, tetrahydroisoquinolinyl, tetrahydrothiazolo[5,4-c]pyridinyl, tetrahydrothieno[2,3-c]pyridinyl, thiadiazolyl, thiazolyl, thiooxadiazolyl, and triazolyl, each substituted with zero to 2 R14a and zero to 3 R14b;
  • L1 is bond, —(CRxRx)1-2—, —(CRxRx)1-2CRx(OH)—, —(CRxRx)1-2O—, —CRxRxC(O)—, —CRxRxC(O)NRx(CRxRx)0-4—, —CRxRxNRxC(O)(CRxRx)0-4—, or —CRxRxNRxC(O)(CRxRx)0-4—;
  • L2 is a bond or —(CRxRx)1-3—;
  • R1 is H, Cl, —CN, C1-4 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, C1-3 hydroxy-fluoroalkyl, —CRv═CH2, C3-6 cycloalkyl, —CH2(C3-6 cycloalkyl), —C(O)O(C1-3 alkyl), or tetrahydropyranyl;
  • each R2 is independently halo, —CN, —OH, —NO2, C1-4 alkyl, C1-2 fluoroalkyl, C1-2 cyanoalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, —O(CH2)1-2OH, —(CH2)0-4O(C1-4 alkyl), C1-3 fluoroalkoxy, —(CH2)1-4O(C1-3 alkyl), —O(CH2)1-2OC(O)(C1-3 alkyl), —O(CH2)1-2NRxRx, —C(O)O(C1-3 alkyl), —(CH2)0-2C(O)NRyRy, —C(O)NRx(C1-5 hydroxyalkyl), —C(O)NRx(C2-6 alkoxyalkyl), —C(O)NRx(C3-6 cycloalkyl), NRyRy, —NRy(C1-3 fluoroalkyl), —NRy(C1-4 hydroxyalkyl), —NRxCH2(phenyl), —NRxS(O)2(C3-6 cycloalkyl), —NRxC(O)(C1-3 alkyl), —NRxCH2(C3-6 cycloalkyl), —(CH2)0-2S(O)2(C1-3 alkyl), —(CH2)0-2(C3-6 cycloalkyl), —(CH2)0-2(phenyl), morpholinyl, dioxothiomorpholinyl, dimethyl pyrazolyl, methylpiperidinyl, methylpiperazinyl, amino-oxadiazolyl, imidazolyl, triazolyl, or —C(O)(thiazolyl);
  • R2a is C1-6 alkyl, C1-3 fluoroalkyl, C1-6 hydroxyalkyl, C1-3 aminoalkyl, —(CH2)0-4O(C1-3 alkyl), C3-6 cycloalkyl, —(CH2)1-3C(O)NRxRx, —CH2(C3-6 cycloalkyl), —CH2(phenyl), tetrahydrofuranyl, tetrahydropyranyl, or phenyl;
  • each R2b is independently H, halo, —CN, —NRxRx, C1-6 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, C1-3 fluoroalkoxy, —(CH2)0-2O(C1-3 alkyl), —(CH2)0-3C(O)NRxRx, —(CH2)1-3(C3-6 cycloalkyl), —C(O)O(C1-3 alkyl), —C(O)NRx(C1-3 alkyl), —CRx═CRxRx, or —CRx═CH(C3-6 cycloalkyl);
  • R2c is R2a or R2b;
  • R2d is R2a or R2b; provided that one of R2c and R2d is R2a, and the other of R2c and R2 is R2b;
  • each R5 is independently F, Cl, —CN, C1-3 alkyl, C1-2 fluoroalkyl, or —OCH3; R6 is:
    • (i) —CRxRxC(O)NRx(CRxRx)1-3OH, —CRxRxC(O)NRx(CRxRx)1-2NRxRx, or —CRxRxC(O)NRx(CRxRx)1-2CHFCRxRxOH; or
    • (ii) azabicyclo[3 .2. 1]octanyl, azaspiro[5.5]undecanyl, azetidinyl, C3-6 cycloalkyl, diazabicyclo[2.2.1]heptanyl, diazaspiro[3.5]nonanyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, octahydrocyclopenta[c]pyrrolyl, piperazinyl, piperidinyl, pyrrolidinyl, or quinuclidinyl, each substituted with zero to 3 R6a;
  • each R6a is independently F, Cl, —OH, —CN, C1-6 alkyl, C1-4 fluoroalkyl, C1-6 hydroxyalkyl, —(CH2)1-2O(C1-3 alkyl), —NRxRx,—(CH2)1-2NRxRx, —(CRxRx)1-2S(O)2(C1-3 alkyl), —(CRxRx)1-2C(O)NRxRx, —C(O)(CRxRx)1-2NRxRx, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, isobutylpiperidinyl, piperazinyl, or —O(piperidinyl);
  • R7 is:
    • (i) R7a, —CH2R7a, —C(O)R7a, —C(O)CH(NH2)R7a, —C(O)(CH2)1-3NH2, —C(O)CH(NH2)(C1-4 alkyl), —C(O)CH(NH2)(CH2)1-2C(O)OH, —C(O)CH(NH2)(CH2)2-4NH2, or —C(O)CH(NH2)(CH2)1-3C(O)NH2; or
    • (ii) C3-6 cycloalkyl substituted with one substituent selected from —NRx(CH2)2-3NRyRy, —NRx(methylpiperidinyl), —NRx(CH2)2-3(morpholinyl), dimethylamino piperidinyl, and piperazinyl substituted with a substituent selected from C1-4 alkyl, —C(O)CH3, —(CH2)1-2OCH3, —CH2(methylphenyl), —(CH2)2-3(pyrrolidinyl), C3-6 cycloalkyl, pyridinyl, and methylpiperidinyl;
  • R7a is azaspiro[3.5]nonanyl, C3-6 cycloalkyl, diazaspiro[3.5]nonanyl, diazaspiro[5.5]undecanyl, diazepanonyl, diazepanyl, morpholinyl, phenyl, piperazinyl, piperidinyl, pyrrolidinonyl, pyrrolidinyl, or pyrrolyl, each substituted with zero to 1 substituent selected from C1-3 alkyl, —NH2, methylpiperidinyl, methylpyrrolidinyl, —OCH2CH2(pyrrolidinyl), and —OCH2CH2NHCH2CH3; and zero to 4 substituents selected from —CH3;
  • R7b is:
    • (i) C1-4 alkyl, C1-3 hydroxyalkyl, —(CH2)2-3C═CH, —(CH2)1-2O(C1-2 alkyl), —(CH2)1-2S(O)2(C1-2 alkyl), —(CH2)0-3NRxRy, —CH2C(O)NRxRx, —NRx(C1-4 hydroxyalkyl), —NRy(C1-2 cyanoalkyl), —NRx(C1-2 fluoroalkyl), —NRx(C2-4 hydroxyfluoroalkyl), —NRx(CH2)1-2C(O)NRxRx, —NRx(CH2)1-3NRxRx, —NRxCH2CH2NRxRx, —NRxC(O)(CH2)1-2NRxRx, —O(CH2)1-3NRxRx, —C(O)CH2NRxRx, —(CH2)1-2R7d, —NHR7d, —NH(CH2)1-2R7d, or —OR7d; or
    • (ii) azepanyl, azetidinyl, diazepanyl, dioxothiomorpholinyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxetanyl, piperazinonyl, piperazinyl, piperidinyl, pyridinyl, pyrrolidinonyl, pyrrolidinyl, or tetrahydroisoquinolinyl, each substituted with zero to 1 R8a and zero to 3 R8b;
  • each R7c is independently F, Cl, —CN, C1-2 alkyl, —CF3, or —CH2CN;
  • R7d is azaspiro[3.5]nonanyl, bicyclo[1.1.1]pentanyl, C3-6 cycloalkyl, morpholinyl, oxetanyl, phenyl, piperidinyl, pyrazolyl, pyrrolidinyl, tetrahydrofuranyl, or tetrahydropyranyl, each substituted with zero to 1 substituent selected from C1-3 alkyl, —NRxRx, —C(O)CH3, methylpiperidinyl, methylpyrrolidinyl, tetramethylpiperidinyl, —OCH2CH2(pyrrolidinyl), and —OCH2CH2NHCH2CH3; and zero to 4 substituents selected from —CH3;
  • R8 is H or C1-3 alkyl;
  • or R7 and R8 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidinyl, diazepanonyl, diazepanyl, diazaspiro[3.5]nonanyl, diazaspiro[5.5]undecanyl, imidazolyl, imidazolidinonyl, octahydro-1H-pyrrolo[3,4-b]pyridinyl, piperazinyl, piperidinyl, pyrrolidinonyl, pyrrolidinyl, and pyrrolyl, wherein said heterocyclic ring is substituted with zero to 1 R7b and zero to 2 R7c;
  • R8a is —OH, C1-6 alkyl, C1-4 fluoroalkyl, hydroxyalkyl, —(CH2)1-2O (C1-3 alkyl), —C(O)(C1-3 alkyl), —(CH2)1-2(C3-6 cycloalkyl), —(CH2)1-3(methyl phenyl), —(CH2)1-3(pyrrolidinyl), —(CH2)1-3(methylpyrazolyl), —(CH2)1-3(thiophenyl), —NRxRx, C3-6 cycloalkyl, methylpiperidinyl, pyridinyl, or pyrimidinyl;
  • each R8b is independently F, Cl, —CN, C1-3 alkyl, or —CF3;
  • R9a is C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 hydroxy fluoroalkyl, C1-3 aminoalkyl, —(CH2)1-2O(C1-3 alkyl), —(CH2)1-3NRxRx, —(CH2)1-2C(O)NRxRx, —(CH2)1-3S(O)2OH, —(CRxRx)1-3NRxS(O)2(C1-2 alkyl), or —(CH2)0-3R9a;
  • R9a is C3-7 cycloalkyl, furanyl, phenyl, piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrrolidinyl, quinuclidinyl, thiazolyl, or octahydrocyclopenta[c]pyrrolyl, each substituted with zero to 3 substituents independently selected from F, Cl, —OH, C1-4 alkyl, C1-3 hydroxyalkyl, C1-3 hydroxy fluoroalkyl, aminoalkyl, —NRyRy, oxetanyl, phenyl, piperazinyl, piperidinyl, and pyrrolidinyl;
  • R10 is H, C1-4 alkyl, —(CH2)1-3O(C1-2 alkyl), or C3-6 cycloalkyl;
  • or R9 and R10 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azabicyclo[3.1.1]heptanyl, azaspiro[5.5]undecanyl, diazabicyclo[2.2.1]heptanyl, diazabicyclo[3.1.1]heptanyl, diazabicyclo[3.2.0]heptanyl, diazaspiro[3.5]nonanyl, diazaspiro[4.4]nonanyl, diazaspiro[4.5]decanyl, diazepanyl, indolinyl, morpholinyl, octahydropyrrolo[3,4-c] pyrrolyl, piperazinonyl, piperazinyl, piperidinyl, and pyrrolidinyl, each substituted with zero to 3 R10a;
  • each R10a is independently C1-4 alkyl, C1-4 hydroxyalkyl, —(CH2)1-3O(C1-3 alkyl), —(CH2)1-3NRxRx, —(CH2)1-2C(O)NRxRx, —(CH2)1-2(methyltriazolyl), —CH2CH2(phenyl), —CH2CH2(morpholinyl), —C(O)(C1-2 alkyl), —C(O)NRyRy, —C(O)CH2NRyRy, —NRyRy, —NHC(O)(C1-3 alkyl), —C(O)(furanyl), —O(piperidinyl), —C(O)CH2(diethylcarbamoylpiperidinyl), methylpiperazinyl, piperidinyl, methylpiperidinyl, diethylcarbamoylpiperidinyl, isopropylpiperidinyl, pyridinyl, trifluoromethylpyridinyl, pyrimidinyl, or dihydrobenzo[d]imidazolonyl;
  • R11 is azetidinyl, azaspiro[3.5]nonanyl, dioxidothiomorpholinyl, hexahydropyrrolo[3,4-c]pyrrolyl, morpholinyl, piperazinyl, piperidinyl, pyridinyl, or pyrrolidinyl, each substituted with zero to 3 substituents independently selected from halo, —CN, C1-4 alkyl, C1-3 aminoalkyl, —(CH2)1-2(phenyl), —C(O)CH2NRxRx,C1-5 hydroxyalkyl, —(CH2)1-2C(O)NRxRx, —(CH2)1-2S(O)2(C1-3 alkyl), —(CH2)1-2S(O)(C1-3 alkyl), oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl;
  • each R12a is independently F, Cl, —OH, C1-6 alkyl, C1-4 fluoroalkyl, C1-4 cyanoalkyl, C1-6 hydroxyalkyl, —(CH2)1-2O(C1-3 alkyl), —(CH2)1-2C(O)NRxRx, —(CH2)1-2S(O)2(C1-2 alkyl), —(CH2)1-2NRxHS(O)2(C1-2 alkyl), —(CH2)1-2NRxRx, C1-3 alkoxy, —NRyRy, —NRx(C1-4 fluoroalkyl), —NRx(C1-2 cyanoalkyl), —NRxCH2NRxRx, —NRx(C1-4 hydroxyalkyl), —NRx(CRxRxCRxRx)O(C1-3 alkyl), —NRx(CH2C(O)NRxRx), —NRx(C1-3 alkoxy), —NRxCH2CH2S(O)2(C1-2 alkyl), —NRxC(O)CH3, —NRxC(O)(C1-2 fluoroalkyl), —NRxC(O)CRxRxNRxRx, —NRxC(O)CH2NRyRy, —NRxC(O)CH2NRx(C1-4 hydroxyalkyl), —NRx(CH2)1-2C(O)NRxRx, —NRxS(O)2(C1-2 alkyl), —C(O)(C1-5 alkyl), —C(O)(CH2)1-3O(C1-2 alkyl), —C(O)CRxRxNRyRy, R12b, —CRxRxR12b, —C(O)R12b, —C(O)CRxRxNRxR12b, —C(O)NRxR12b, —NRxC(O)CRxRxR12b, —NRxR12b, —NRxCRxRxR12b, —N(CH2CN)R12b, —NRxC(O)CRxRxNRxR12b, —NRxC(O)CRxRxNRxCH2R12b, —NRxCRxRxC(O)NRxR12b, or —OR12b; or two R12a and the carbon atom to which they are attached form C═O;
  • R12b is azetidinyl, bicyclo[1.1.1]pentanyl, C3-6 cycloalkyl, diazabicyclo[2.2.1]heptanyl, dioxolanyl, dioxidotetrahydrothiopyranyl, dioxidothiomorpholinyl, imidazolyl, morpholinyl, octahydrocyclopenta[c]pyrrolyl, octahydropyrrolo[3,4-c]pyrrolyl, oxaazaspiro[3.3]heptanyl, oxetanyl, phenyl, piperazinyl, piperazinonyl, piperidinyl, pyridinyl, pyrrolidinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, or triazolyl, each substituted with zero to 4 substituents independently selected from F, Cl, —OH, C1-4 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, C1-4 alkoxy, —(CH2)1-2O(C1-3 alkyl), —NRxRx, —C(O)NRxRx, and —(CRxRx)0-1S(O)2(C1-3 alkyl);
  • each R14a is independently is:
    • (i) H, halo, —OH, C1-6 alkyl, C1-23 fluoroalkyl, C1-4 hydroxyalkyl, —(CH2)0-2O(C1-3 alkyl), —CRxRxNRyRy, —CRxRxNRx(C1-3 cyanoalkyl), —CRxRxNRx((CH2)1-2O(C1-2 alkyl)), —CRxRxN((CH2)1-2OCH3)2, —CRxRxNRx(CH2C═CRx), —CRxRxNRx(CH2)1-3NRxRx, —(CRxRx)1-3CRxRxNRxRx, —CRx(NH2)(CH2)1-4NRxRx, —CRxRxNRx(CH2)1-2O(C1-3 alkyl), —CRxRxNRx(CH2)1-2O(CH2)1-2OH, —CRxRxNRx(CH2)1-3S(O)2OH, —CRxRxC(O)NRxRx, —NRxRy, —NRx(CH2)1-3NRxRx, —NRxC(O)(C1-3 alkyl), —NRxC(O)(C1-3 fluoroalkyl), —NRxC(O)O(C1-3 alkyl), —NRxC(O)(CH2)1-3NRxRx, —NRxCH2C(O)CH2NRxRx, —C(O)(C1-3 alkyl), —C(O)(CRxRx)1-3OH, —C(O)CRxRxNRxRx, —C(O)NRxRx, —C(O)NRx(C1-2 cyanoalkyl), —C(O)NRx(CRxRx)1-3NRxRx, —C(O)N(CH2CH3)(CRxRx)1-3NRxRx, —C(O)NRx(CRxRx)1-2C(O)NRxRx, —C(O)NRx(CRxRx)1-3NRxC(O)(C1-2 alkyl), —O(CRxRx)1-3NRxRx, —S(O)2NRxRx, or —C(O)(CRxRx)1-2S(O)2(C1-2 alkyl);
    • (ii) 8-azabicyclo[3.2.1]octanyl, azaspiro[3.5]nonanyl, azetidinyl, benzo[c][1,2,5]oxadiazolyl, cyclopentyl, cyclohexyl, diazepanyl, morpholinyl, phenyl, piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrrolidinonyl, quinolinyl, quinuclidinyl, tetrahydroisoquinolinyl, tetrahydropyridinyl, or thiazolidinyl, each substituted with zero to 2 substituents independently selected from C1-4 alkyl, C1-2 fluoroalkyl, C1-4 hydroxyalkyl, —NRxRx, —(CH2)1-2NRxRx, —C(O)(C1-2-2 alkyl), —C(O)CH2NRxRx, —C(O)O(C1-3 alkyl), —CH2C(O)NRxRx, C3-6 cycloalkyl, —CH2(phenyl), —CH2(pyrrolyl), —CH2(morpholinyl), —CH2(methylpiperazinyl), —CH2(thiophenyl), methylpiperidinyl, isobutylpiperidinyl, and pyridinyl; or
    • (iii) -L3-T14c;
  • each R14b is F, Cl, —OH, —CH3, or —OCH3;
  • R14c is adamantanyl, azepanyl, azetidinyl, C3-7 cycloalkyl, diazepanyl, imidazolyl, indolyl, morpholinyl, octahydropyrrolo[3,4-c]pyrrolyl, phenyl, piperazinonyl, piperazinyl, piperidinyl, pyridinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolyl, triazolyl, or tetrazolyl, each substituted with zero to 1 substituent selected from F, —OH, C1-4 alkyl, C1-3 hydroxyalkyl, —NRxRy, —NRxC(O)CH3, —C(O)(C1-2 alkyl), —C(O)NRxRx, —C(O)N(CH2CH3)2, —C(O)(tetrahydrofuranyl), —C(O)O(C1-2 alkyl), —CH2C(O)NRxRy, morpholinyl, methylpiperidinyl, pyrazinyl, pyridinyl, and pyrrolidinyl;
  • L3 is —(CRxRx)1-3—, —CH(NH2)—, —CRxRxNRx—, —C(O)—, —C(O)NRxCH2)0-4—, —NRx—, —NRxC(O)—, —NRxCH2—, —NRxCH2C(O)—, or —O(CH2)0-2—;
  • Rv is H, C1-2 alkyl, or C1-2 fluoroalkyl;
  • each Rx is independently H or —CH3;
  • each Ry is independently H or C1-6 alkyl;
  • n is zero, 1, or 2; and
  • p is zero, 1, 2, 3, or 4.


The compounds of Formula (I) or salts thereof in which A is —CRxR12R13; and R12 and R13 together with the carbon atom to which they are attached form a cyclic group and the cyclic group has one or more heteroatoms, the cyclic group is bonded to the indole ring by a carbon atom in the cyclic group.


One embodiment provides a compound of Formula (I) or a salt thereof wherein G is:




embedded image


and A, R1, R5, and n are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I) or a salt thereof wherein G is:




embedded image


and A, R1, R2, R5, n, and p are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I) or a salt thereof wherein G is




embedded image


and A, R1, R2a, R2b, R2c, R2d, R5, n, and p are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which R2a is C1-4 alkyl, C1-2 fluoroalkyl, C1-4 hydroxyalkyl, —(CH2)1-3OCH3, C3-6 cycloalkyl, —CH2C(O)NRxRx, —CH2(C3-6 cycloalkyl), —CH2(phenyl), tetrahydrofuranyl, or phenyl; and each R2b is independently H, F, Cl, —CN, —NRxRx, C1-6 alkyl, C1-2 fluoroalkyl, C1-3 hydroxyalkyl, —(CH2)0-2O(C1-2 alkyl), —(CH2)0-2C(O)NRxRx, —(CH2)1-3(cyclopropyl), —C(O)O(C1-2 alkyl), —C(O)NRx(C1-3 alkyl), —CRx═CH2, or —CH═CH(C3-6 cycloalkyl). Also included in this embodiment are compounds in which R2a is —CH3; and each R2b is independently H, Cl, or —CH3.


One embodiment provides a compound of Formula (I) or a salt thereof wherein G is a 9-membered heterocyclic ring selected from:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


and A, R1, R2, R5, n, and p are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I) or a salt thereof wherein G is a 10-membered heterocyclic ring selected from:




embedded image


and A, R1, R2, R5, n, and p are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein

  • A is:
  • (i) —O-L1-R6;
  • (ii) —NR7R8;
  • (iii) -L2—C(O)NR9R10;
  • (iv) —(CRxRx)1-2R11, C1-2 aminoalkyl, —(CRxRx)1-2NRXC(O)R11, —CH2NRxC(O)(CH2)1-2(piperidinyl), —CH2NRx(O)OCH2(piperidinyl), or —CH2NRxC(O)(CH2)1-2NRxRx;
  • (v) —CRxR12R13,wherein R12 and R13 together with the carbon atom to which they are attached form a cyclic group selected from azabicyclo[4.1.1]octanyl, azepanyl, azetidinyl, C3-7 cycloalkyl, diazepanyl, azaspiro[3.3]heptanyl, diazaspiro[4.5]decanonyl, morpholinyl, octahydrocyclopenta[c]pyrrolyl, piperazinyl, piperidinyl, pyrrolidinyl, and quinuclidinyl, each substituted with zero to 3 R12a;
  • (vi) —CRx═CRx(piperidinyl); or
  • (vii) an aromatic group selected from [1,2,4]triazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, imidazolyl, indazolyl, isoquinolinyl, oxadiazolyl, oxazolyl, phenyl, pyrazinyl, pyrazolo[3,4-b]pyridinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinonyl, quinolinyl, quinoxalinyl, tetrahydro[1,2,4]triazolo[1,5-a]pyrazinyl, tetrahydroimidazo[1,2-a]pyrazinyl, tetrahydroisoquinolinyl, tetrahydrothiazolo[5,4-c]pyridinyl, tetrahydrothieno[2,3-c]pyridinyl, thiadiazolyl, thiazolyl, thiooxadiazolyl, and triazolyl, each substituted with zero to 2 R14a and zero to 3 R14b;
  • L1 is bond, —(CRxRx)1-2—, —CH2C(O)—, —CH2C(O)NRx(CRxRx)0-2—, —CH2NRxC(O)—, or —CH2NRxC(O)CH2—;
  • L2 is a bond or —(CRxRx)1-2—;
  • R1 is H, Cl, —CN, C1-4 alkyl, C1-2 fluoroalkyl, C1-2 hydroxyalkyl, or —C(O)O(C1-2 alkyl);
  • each R2 is independently F, Cl, —CN, —OH, C1-3 alkyl, C1-2 fluoroalkyl, C1-2 cyanoalkyl, C1-3 hydroxyalkyl, C1-2 aminoalkyl, —(CH2)0-2O(C1-3 alkyl), C3-6 cycloalkyl, —NRxRx, —(CH2)0-2C(O)NRxRx, —(CH2)0-2S(O)2(C1-3 alkyl), —CH2(C3-6 cycloalkyl), —CH2(phenyl), or phenyl;
  • R2a is C1-4 alkyl, C1-2 fluoroalkyl, C1-4 hydroxyalkyl, —(CH2)1-3OCH3, C3-6 cycloalkyl, —CH2C(O)NRxRx, —CH2(C3-6 cycloalkyl), —CH2(phenyl), tetrahydrofuranyl, or phenyl;
  • each R2b is independently H, F, Cl, —CN, —NRxRx, C1-6 alkyl, C1-2 fluoroalkyl, C1-3 hydroxyalkyl, —(CH2)0-2O(C1-2 alkyl), —(CH2)0-2C(O)NRxRx, —(CH2)1-3(cyclopropyl), —C(O)O(C1-2 alkyl), —C(O)NRx(C1-3 alkyl), —CRx═CH2, or —CH═CH(C3-6 cycloalkyl);
  • each R5 is independently F, Cl, —CN, C1-2 alkyl, or —OCH3;
  • R6 is:
    • (i) C1-2 alkyl, —CH2C(O)NHCH2CRxRxOH, —CH2C(O)NHCH2CH2CRxRxOH, —CH2C(O)NHCH2CH2NRxRx, or —CH2C(O)NHCH2CHFCRxRxOH; or
    • (ii) azabicyclo[3.2.1]octanyl, azaspiro[5.5]undecanyl, azetidinyl, C3-6 cycloalkyl, diazabicyclo[2.2.1]heptanyl, diaz,aspiro[3.5]nonanyl, morpholinyl, tetrahydropyranyl, octahydrocyclopenta[c]pyrrolyl, piperazinyl, piperidinyl, pyrrolidinyl, or quinuclidinyl, each substituted with zero to 3 R6a;
  • each R6a is independently F, —OH, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 hydroxyalkyl, —(CH2)1-2OCH3, —NRxRx, —N(C2-3 alkyl)2, —(CH2)1-2NRxRx, —(CH2)1-2S(O)2(C1-2 alkyl), —(CH2)1-2C(O)NRxRx, —C(O)CH2NRxRx, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, isobutylpiperidinyl, piperazinyl, or —O(piperidinyl);
  • R7 is:
    • (i) R7a, —CH2R7a, —(CH2)1-2NRxRx, —(CH2)1-2NRxC(O)CH2NRxRx, —C(O)R7a, —C(O)CH(NH2)R7a, —C(O)(CH2)1-3NH2, —C(O)CH(NH2)(C1-4 alkyl), —C(O)CH(NH2)(CH2)1-2C(O)OH, —C(O)CH(NH2)(CH2)2-4NH2, or —C(O)CH(NH2)(CH2)1-3C(O)NH2; or
    • (ii) C3-6 cycloalkyl substituted with one substituent selected from —NRx(CH2)2-3NRxRx, —NH(CH2)2-3NHCH3, —NH(methylpiperidinyl), —NH(CH2)2-3(morpholinyl), dimethylamino piperidinyl, and piperazinyl substituted with a substituent selected from C1-4 alkyl, —C(O)CH3, —(CH2)1-2OCH3, —CH2(methylphenyl), —(CH2)2-3(pyrrolidinyl), C3-6 cycloalkyl, pyridinyl, and methylpiperidinyl;
  • R7b is:
    • (i) —OH, C1-6 alkyl, C1-4 fluoroalkyl, C1-4 hydroxyalkyl, C1-2 aminoalkyl, —(CH2)2-3C═CH, —(CRxRx)1-2O(C1-2 alkyl), —(CH2)1-3S(O)2(C1-2 alkyl), —(CH2)0-3NRxRy, —(CH2)1-2C(O)NRxRx, —NRyRy, —NRx(C1-4 hydroxyalkyl), —NRy(C1-2 cyanoalkyl), —N(C1-2 cyanoalkyl)2, —NRx(C1-2 fluoroalkyl), —NRx(C2-4 hydroxyfluoroalkyl), —(CRxRx)1-2C(O)NRxRx, —NRx(CH2)1-2C(O)NRxRx, —N((CH2)1-2C(O)NRxRx)2, —NRx(CH2)1-2S(O)2(C1-2 alkyl), —NRx(CH2)1-3NRxRx, —NRxCH2CH2NRxRx, —NRxC(O)(CH2)1-2NRxRx, —NRx(CH2CH2S(O)2CH3), —(CH2)1-2NRxC(O)(CH2)1-2NRxRx, —O(CH2)1-3NRxRx, —C(O)(CRxRx)1-2NRyRy, —C(O)(CRxRx)1-2NRy(C1-4 hydroxyalkyl), —C(O)(CRxRx)1-2NRx(CH2CH2OCH3), —S(O)2CH2CH2N(CH3)2, —(CH2)1-2R7d, —NRxR7d, —NRx(CH2)1-2R7d), —NR7dR7d, —N((CH2)1-2R7d)2, —OR7d, —C(O)R7d, —C(O)(CRxRx)1-2R7d, or —C(O)(CRxRx)1-2NRxR7d; or
    • (ii) azepanyl, azetidinyl, C3-6 cycloalkyl, diazepanyl, dioxotetrahydrothiopyranyl, dioxothiomorpholinyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxetanyl, piperazinonyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydropyranyl, or thiadiazolyl, each substituted with zero to 1 R8a and zero to 3 R8b;
  • each R7c is independently F, —CH3 or —CH2CN;
  • R7d is azaspiro[3.5]nonanyl, azetidinyl, bicyclo[1.1.1]pentanyl, C3-6 cycloalkyl, dioxothiaazaspiro[3.3]heptanyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxaazaspiro[4.4]nonyl, oxetanyl, phenyl, piperidinyl, pyrazolyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, thiadiazolyl, or triazolyl, each substituted with zero to 2 substituents independently selected from F, —OH, C1-3 alkyl, C1-2 hydroxyalkyl, C1-2 alkoxy, —NRxRx, —C(O)CH3, —S(O)2CH3, methylpiperidinyl, methylpyrrolidinyl, tetramethylpiperidinyl, —OCH2CH2(pyrrolidinyl), and —OCH2CH2NHCH2CH3; and zero to 4 substituents selected from —CH3;
  • R8 is H or C1-2 alkyl;
  • or R7 and R8 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidinyl, diazabicyclo[2.2.1]heptanyl, diazabicyclo[2.2.2]octanyl, diazabicyclo[3.1.1]heptanyl, diazabicyclo[3.2.1]octanyl, azaspiro[3.3]heptanyl, diazaspiro[2.5]octanyl, diazaspiro[3.3]heptanyl, diazepanonyl, diazepanyl, diazaspiro[3.5]nonanyl, diazaspiro[5.5]undecanyl, imidazolyl, imidazolidinonyl, octahydro-1H-pyrrolo[3,4-b]pyridinyl, oxadiazabicyclo[3.3.1]nonanyl, piperazinyl, piperazinonyl, piperidinyl, pyrrolidinonyl, pyrrolidinyl, and pyrrolyl, wherein said heterocyclic ring is substituted with zero to 1 R7b and zero to 2 R7c;
  • R8a is —OH, C1-4 alkyl, C1-3 fluoroalkyl, —(CH2)1-2O(C1-2 alkyl), C1-2 alkoxy, —C(O)(C1-2 alkyl), —C(O)O(C1-2 alkyl), —CH2(C3-6 cycloalkyl), —(CH2)1-2(methyl phenyl), —(CH2)1-3(pyrrolidinyl), —(CH2)1-2(methylpyrazolyl), —(CH2)1-2(thiophenyl), —NRxRx, C3-6 cycloalkyl, methylpiperidinyl, or pyridinyl;
  • each R8b is independently F or —CH3;
  • R9 is C1-3 alkyl, C1-3 fluoroalkyl, C1-5 hydroxyalkyl, C2-5 hydroxy fluoroalkyl, C1-2 aminoalkyl, —(CH2)1-2O(C1-2 alkyl), —(CH2)1-3N(CH3)2, —(CH2)1-2C(O)NH2, —(CH2)1-2S(O)2OH, —(CH2)1-2CRxRxNHS(O)2CH3, or —(CH2)0-3R9a;
  • R9a is C5-7 cycloalkyl, furanyl, phenyl, piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrrolidinyl, quinuclidinyl, thiazolyl, or octahydrocyclopenta[c]pyrrolyl, each substituted with zero to 2 substituents independently selected from —OH, C1-3 alkyl, —NRxRx, oxetanyl, phenyl, piperazinyl, piperidinyl, and pyrrolidinyl;
  • R10 is H, C1-3 alkyl, —(CH2)1-2O(C1-2 alkyl), or C3-6 cycloalkyl;
  • or R9 and R10 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azabicyclo[3.1.1]heptanyl, azaspiro[5.5]undecanyl, diazabicyclo[2.2.1]heptanyl, diazabicyclo[3.1.1]heptanyl, diazabicyclo[3.2.0]heptanyl, diazaspiro[3.5]nonanyl, diazaspiro[4.4]nonanyl, diazaspiro[4.5]decanyl, diazepanyl, indolinyl, morpholinyl, octahydropyrrolo[3,4-c]pyrrolyl, piperazinonyl, piperazinyl, piperidinyl, and pyrrolidinyl, each substituted with zero to 3 R10a;
  • each R10a is independently C1-3 alkyl, C1-3 hydroxyalkyl, —(CH2)1-2O(C1-2 alkyl), —(CH2)1-2NRxRx, —CH2C(O)NRxRx, —CH2(methyltriazolyl), —CH2CH2(phenyl), —CH2CH2(morpholinyl), —C(O)(C1-2 alkyl), —C(O)NH2, —C(O)N(C1-2 alkyl)2, —C(O)CH2NRxRx, —NRxRx, —NHC(O)(C1-2 alkyl), —C(O)(furanyl), —O(piperidinyl), —C(O)CH2(diethylcarbamoylpiperidinyl), methylpiperazinyl, piperidinyl, methylpiperidinyl, diethylcarbamoylpiperidinyl, isopropylpiperidinyl, pyridinyl, trifluoromethylpyridinyl, pyrimidinyl, or dihydrobenzo[d]imidazolonyl;
  • R11 is azetidinyl, azaspiro[3.5]nonanyl, dioxidothiomorpholinyl, hexahydropyrrolo[3,4-c]pyrrolyl, morpholinyl, piperazinyl, piperidinyl, pyridinyl, or pyrrolidinyl, each substituted with zero to 3 substituents independently selected from F, Cl, —CN, C1-3 alkyl, C1-2 aminoalkyl, —CH2(methyloxetanyl), —CH2(triazolyl), —CH2(phenyl), —C(O)CH2NRxRx, —CH2CRxRxOH, —CH2C(O)NRxRx, —CH2CH2S(O)2(C1-3 alkyl), —CH2CH2S(O)(C1-3 alkyl), oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl;
  • each R12a is independently —OH, C1-4 alkyl, C1-3 fluoroalkyl, C1-2 cyanoalkyl, C1-4 hydroxyalkyl, —(CH2)1-2O(C1-2 alkyl), —CH2C(O)NRxRx, —(CH2)1-2S(O)2(C1-2 alkyl), —(CH2)1-2NHS(O)2(C1-2 alkyl), —(CH2)1-2NRxRx, C1-2 alkoxy, —NRyRy, —NRx(C1-3 fluoroalkyl), —NRx(CH2CRxRx)OCH3), —NRx(C1-2 cyanoalkyl), —NRxCH2NRxRx, —NRx(C1-4 hydroxyalkyl), —NRx(CH2C(O)NH2), —NRx(OCH3), —NRxCH2CH2S(O)2(C1-2 alkyl), —NRx(CH2CRxRx)OCH3), —NRxC(O)CH3, —NRxC(O)(C1-4 fluoroalkyl), —NRx(O)CRxRxNRxRx, —NRxC(O)CH2NRyRy, —NRxC(O)CH2NRx(C1-4 hydroxyalkyl), —NRxCH2C(O)NRxRx, —NRxS(O)2CH3, —C(O)(C1-5 alkyl), —C(O)CH2O(C1-2 alkyl), —C(O)CH2CH2O(C1-2 alkyl), —C(O)(CH2)1-2NRxRx, —C(O)CHRxNRyRy, R12b, —CRxRxR12b, —C(O)R12b, —C(O)CH2NRxR12b, —C(O)NRxR12b, —NRxC(O)CRxRxR12b, —NRxR12b, —NRxCRxRxR12b, —N(CH2CN)R12b, —NRxC(O)CH2NRxR12b, —NRxC(O)CH2NRxCH2R12b, —NRxCH2C(O)NRxR12b, or —OR12b; or two R12a and the carbon atom to which they are attached form C═O;
  • R12b is azetidinyl, bicyclo[1.1.1]pentanyl, C3-6 cycloalkyl, diazabicyclo[2.2.1]heptanyl, dioxolanyl, dioxothiaazaspiro[3.3]heptanyl, dioxidotetrahydrothiopyranyl, dioxidothiomorpholinyl, imidazolyl, morpholinyl, octahydrocyclopenta[c]pyrrolyl, octahydropyrrolo[3,4-c]pyrrolyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxaazaspiro[4.4]nonanyl, oxetanyl, phenyl, piperazinyl, piperazinonyl, piperidinyl, pyridinyl, pyrrolidinyl, quinuclidinyl, tetrahydropyranyl, tetrahydropyranyl, or triazolyl, each substituted with zero to 4 substituents independently selected from F, Cl, —OH, C1-3 alkyl, C1-2 hydroxyalkyl, C1-2 alkoxy, —(CH2)1-2O(C1-2 alkyl), —NRxRx, —C(O)NRxRx, —S(O)2(C1-2 alkyl), and —CH2S(O)2(C1-2 alkyl); each R14a is independently:
    • (i) H, F, Cl, —OH, C1-5 alkyl, C1-2 fluoroalkyl, C1-2 hydroxyalkyl, —(CH2)0-2OCH3, —CHRxNRx (C1-5 alkyl), —CHRxNRx(C1-2 cyanoalkyl), —CHRxNRx((CH2)1-5OCH3), —CHRxN((CH2)1-2OCH3)2, —CH2NRx(CH2CCRx), —CH2NRxCH2CH2NRxRx, —(CH2)1-3CRxRxNRxRx, —CH(NH2)(CH2)3-4NRxRx, —CH2NRx(CH2)1-2O(C1-3 alkyl), —CH2NRx(CH2)1-2O(CH2)1-2OH, —CH2NH(CH2)1-2S(O)2OH, —CH2C(O)NRxRx, —NRxRy, —NRx(CH2)2-3NRxRx, —NRxC(O)(C1-2 alkyl), —NRxC(O)(C1-2 fluoroalkyl), —NRxC(O)O(C1-3 alkyl), —NRxC(O)(CH2)1-2NRxRx, —NRxCH2C(O)CH2NRxRx, —C(O)(C1-2 alkyl), —C(O)CH2CRxRxOH, —C(O)CH2NRxRx, —C(O)NRxRx, —C(O)NRx(CH2CN), —C(O)NRx(CRxRx)2-3NRxRx, —C(O)N(CH2CH3)(CRxRx)2-3NRxRx, —C(O)NRxCH2C(O)NRxRx, —C(O)NRxCH2CH2NRxC(O)CH3, —O(CRxRx)2-3NRxRx, —S(O)2NRxRx, or —C(O)CH2S(O)2(C1-2 alkyl);
    • (ii) 8-azabicyclo[3.2.1]octanyl, azaspiro[3.5]nonanyl, azetidinyl, benzo[c][1,2,5]oxadiazolyl, cyclopentyl, cyclohexyl, diazepanyl, morpholinyl, phenyl, piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrrolidinonyl, quinolinyl, quinuclidinyl, tetrahydroisoquinolinyl, tetrahydropyridinyl, or thiazolidinyl, each substituted with zero to 2 substituents independently selected from C1-4 alkyl, C1-2 fluoroalkyl, C1-4 hydroxyalkyl, —NRxRx, —(CH2)1-2NRxRx, —C(O)(C1-2 alkyl), —C(O)CH2NRxRx, —C(O)O(C1-3 alkyl), —CH2C(O)NRxRx, C3-6 cycloalkyl, —CH2(phenyl), —CH2(pyrrolyl), —CH2(morpholinyl), —CH2(methylpiperazinyl), —CH2(thiophenyl), methylpiperidinyl, isobutylpiperidinyl, and pyridinyl; or
    • (iii) -L3-R14c;
  • each R14b is F, —CH3, or —OCH3;
  • L3 is —(CRxRx)1-3—, —CH(NH2)—, —CRxRxNH—, —C(O)—, —C(O)NRx(CH2)0-4—, —NRx—, —NRxC(O)—, —NRxCH2—, —NRxCH2C(O)—, —O—, or —O(CH2)1-2—; and
    • R14c is adamantanyl, azetidinyl, C3-6 cycloalkyl, diazepanyl, imidazolyl, indolyl, morpholinyl, octahydropyrrolo[3,4-c]pyrrolyl, phenyl, piperazinonyl, piperazinyl, piperidinyl, pyridinyl, pyrrolidinonyl, pyrrolidinyl, or tetrazolyl, each substituted with zero to 1 substituent selected from F, —OH, C1-4 alkyl, C1-3 hydroxyalkyl, —NRxRy, —NRxC(O)CH3, —C(O)(C1-2 alkyl), —C(O)NRxRx, —C(O)N(CH2CH3)2, —C(O)(tetrahydrofuranyl), —C(O)O(C1-2 alkyl), —CH2C(O)NRxRy, morpholinyl, methylpiperidinyl, pyrazinyl, pyridinyl, and pyrrolidinyl;
  • and G, n, and p is defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein:

  • A is:
  • (i) —O-L1-R6;
  • (ii) —NR7R8;
  • (iii) -L2—C(O)NR9R10;
  • (iv) —CHRxR11, —CH2CH2R11, —CH2NH2, —CH2NHC(O)R11, —CH2NHC(O)CH2CH2(piperidinyl), —CH2NHC(O)OCH2(piperidinyl), or —CH2NHC(O)CH2CH2N(CH3)2;
  • (v) —CHR12P13, wherein R12 and R13 together with the carbon atom to which they are attached form a cyclic group selected from azabicyclo[4.1.1]octanyl, azepanyl, azetidinyl, C3-6 cycloalkyl, azaspiro[3.3]heptanyl, diazaspiro[4.5]decanonyl; morpholinyl, octahydrocyclopenta[c]pyrrolyl, piperidinyl, pyrrolidinyl, and quinuclidinyl, each substituted with zero to 3 R12a;
  • (vi) —CH═CH(piperidinyl); or
  • (vii) an aromatic group selected from [1,2,4]triazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, imidazolyl, indazolyl, isoquinolinyl, oxadiazolyl, oxazolyl, phenyl, pyrazinyl, pyrazolo[3,4-b]pyridinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinonyl, quinolinyl, quinoxalinyl, tetrahydro[1,2,4]triazolo[1,5-a]pyrazinyl, tetrahydroimidazo[1,2-a]pyrazinyl, tetrahydroisoquinolinyl, tetrahydrothiazolo[5,4-c]pyridinyl, tetrahydrothieno[2,3-c]pyridinyl, thiadiazolyl, thiazolyl, thiooxadiazolyl, and triazolyl, each substituted with zero to 2 R14a and zero to 3 R14b;
  • L1 is bond, —CH2—, —CH2CH2—, —CH2C(O)—, —CH2C(O)NH—, —CH2C(O)N(CH3)—, —CH2C(O)NHCH2—, or —CH2C(O)NHCH2CH2—;
  • L2 is a bond, —CH(CH3)—, —C(CH3)2—, or —CH2CH2—;
  • each R5 is independently F, Cl, —CN, C1-2 alkyl, or —OCH3;
  • R6 is:
    • (i) —CH3, —CH2C(O)NHCH2C(CH3)2OH, —CH2C(O)NHCH2CH2C(CH3)2OH, —CH2C(O)NHCH2CH2NH2, or —CH2C(O)NHCH2CHFC(CH3)2OH; or
    • (ii) azabicyclo[3.2.1]octanyl, azaspiro[5.5]undecanyl, azetidinyl, cyclohexyl, diazabicyclo[2.2.1]heptanyl, diazaspiro[3.5]nonanyl, morpholinyl, octahydrocyclopenta[c]pyrrolyl, piperazinyl, piperidinyl, pyrrolidinyl, or quinuclidinyl, each substituted with zero to 2 R6a;
  • each R6a is independently F, —OH, —CH3, —CH2CH2CH3, —C(CH3)2, —CH2CH(CH3)2, —CH2CH2CH2CF3, —CH2CH2OH, —CH2CH2CH2OH, —CH2CH(CH3)OH, —CH2C(CH3)2OH, —CH2CH2OCH3, —NH2, —N(CH3)2, —N(CH2CH2CH3)2, —CH2NH2, —CH2CH2NH2, —CH2CH2S(O)2CH3, —CH2C(O)N(CH3)2, —C(O)CH2N(CH3)2, oxetanyl, tetrahydropyranyl, piperidinyl, isobutylpiperidinyl, or —O(piperidinyl);
  • R7 is:
    • (i) —CH2CH2NH2, —CH2CH2NHC(O)CH2N(CH3)2, —CH2(isopropyl azaspiro[3.5]nonanyl), —CH2(methylpyrrolidinyl), —C(O)(CH2)1-3NH2, —C(O)CH(NH2)CH2CH2CH3, —C(O)CH(NH2)CH2CH(CH3)2, —C(O)CH(NH2)CH(CH3)CH2CH3, —C(O)CH(NH2)CH2CH2C(O)OH, —C(O)CH(NH2)(CH2)3-4NH2, —C(O)CH(NH2)(CH2)1-2C(O)NH2, —C(O)CH(NH2)(cyclohexyl), —C(O)CH(NH2)(phenyl), —C(O)(aminocyclohexyl), —C(O)(morpholinyl), —C(O)(pyrrolidinyl), pentamethylpiperidinyl, methylpiperidinyl-piperidinyl, methylpyrrolidinyl-pyrrolidinyl, or phenyl substituted with —OCH2CH2(pyrrolidinyl) or —OCH2CH2NHCH2CH3; or
    • (ii) cyclohexyl substituted with —NRx(CH2)2-3N(CH3)2, —NHCH2CH2NHCH3, —NH(methylpiperidinyl), —NH(CH2)2-3(morpholinyl), dimethylamino piperidinyl, or piperazinyl substituted with —CH3, —CH2CH3, —C(CH3)3, —CH2CH(CH3)2, —C(O)CH3, —CH2CH2OCH3, —CH2(methylphenyl), —(CH2)2-3(pyrrolidinyl), cyclopentyl, pyridinyl, or methylpiperidinyl;
  • R7b is:
    • (i) —OH, C1-6 alkyl, C3-4 fluoroalkyl, C3-4 hydroxyalkyl, —CH2CN, —CH2CH2CN, —CH2CH2CH2C═CH, —(CRxRx)1-2OCH3, —(CH2)2-3S(O)2CH3, —(CH2)1-2NRxRx, —(CH2)1-2C(O)NRxRx, —NRyRy, —NRx(C1-4 hydroxyalkyl), —NH(CH2CH2OCH3), —NRy(C1-2 cyanoalkyl), —N(CH2CH2CN)2, —NRx(C1-2 fluoroalkyl), —NRx(C2-4 hydroxyfluoroalkyl), —(CH2)1-2C(O)NRxRx, —NRx(CH2)1-2C(O)NRxRx, —N((CH2)1-2C(O)NRxRx)2, —NRx(CH2)1-2S(O)2(C1-2 alkyl), —NRx(CH2)1-3NRxRx, —NRxCH2CH2N(CH3)2, —NRxC(O)(CH2)1-2NRxRx, —NRx(CH2CH2S(O)2CH3), —OCH2CH2N(CH3)2, —C(O)(CRxRx)1-2NRyRy, —C(O)(CRxRx)1-2NRy(C1-4 hydroxyalkyl), —C(O)(CRxRx)1-2NRx(CH2CH2OCH3), —S(O)2CH2CH2N(CH3)2, —(CH2)1-2R7d, —NRxR7d, —NRx(CH2)1-2R7d), —NR7dR7d, —N((CH2)1-2R7d)2, —OR7d, —C(O)R7d, —C(O)(CRxRx)1-2R7d, or —C(O)(CRxRx)1-2NRxR7d; or
    • (ii) azepanyl, azetidinyl, cyclobutyl, cyclohexyl, diazepanyl, dioxotetrahydrothiopyranyl, dioxothiomorpholinyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxetanyl, piperazinonyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydropyranyl, or thiadiazolyl, each substituted with zero to 1 R8a and zero to 3 R8b;
  • each R7c is independently —CH3 or —CH2CN;
  • R7d is azaspiro[3.5]nonanyl, azetidinyl, bicyclo[1.1.1]pentanyl, C3-6 cycloalkyl, dioxothiaazaspiro[3.3]heptanyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxaazaspiro[4.4]nonyl, oxetanyl, phenyl, piperidinyl, pyrazolyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, thiadiazolyl, or triazolyl, each substituted with zero to 2 substituents selected from F, —OH, C1-3 alkyl, —CH2OH, —OCH3, —NRxRx, —C(O)CH3, —S(O)2CH3, methylpiperidinyl, methylpyrrolidinyl, tetramethylpiperidinyl, —OCH2CH2(pyrrolidinyl), and —OCH2CH2NHCH2CH3; and zero to 4 substituents selected from —CH3;
  • R8 is H, —CH3 or —CH2CH3;
  • or R7 and R8 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidinyl, diazabicyclo[2.2.1]heptanyl, diazabicyclo[2.2.2]octanyl, diazabicyclo[3.1.1]heptanyl, diazabicyclo[3.2.1]octanyl, azaspiro[3.3]heptanyl, diazaspiro[2.5]octanyl, diazaspiro[3.3]heptanyl, diazepanonyl, diazepanyl, diazaspiro[3.5]nonanyl, diazaspiro[5.5]undecanyl, imidazolidinonyl, octahydro-1H-pyrrolo[3,4-b]pyridinyl, oxadiazabicyclo[3.3.1]nonanyl, piperazinyl, piperazinonyl, piperidinyl, pyrrolidinonyl, and pyrrolidinyl, wherein said heterocyclic ring is substituted with zero to 1 R7b and zero to 2 R7c;
  • R8a —OH, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CH2CH(CH3)2, —CH2CH2OCH3, —CH2CH2CF3, —OCH3, —C(O)CH3, —C(O)OCH3, —CH2(cyclopropyl), —CH2(methyl phenyl), —(CH2)2-3(pyrrolidinyl), —CH2(methylpyrazolyl), —CH2(thiophenyl), —NRxRx, cyclopentyl, methylpiperidinyl, or pyridinyl;
  • R8a —OH, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CH2CH(CH3)2, —CH2CH2OCH3, —CH2CH2CF3, —OCH3, —C(O)CH3, —C(O)OCH3, —CH2(cyclopropyl), —CH2(methyl phenyl), —(CH2)2-3(pyrrolidinyl), —CH2(methylpyrazolyl), —CH2(thiophenyl), —NRxRx, cyclopentyl, methylpiperidinyl, or pyridinyl;
  • each R8b is —CH3;
  • R9 is —CH3, —CH2CH2CF3, —CH2CH2OH, —CH2C(CH3)2OH, —CH2C(CH3)2CH2OH, —CH2CHFC(CH3)2OH, —CH2CH2C(CH3)2OH, —CH(CH2OH)2, —CH2CH2OCH3, —CH2CH2NH2, —CH2CH2N(CH3)2, —CH2CH2CH2N(CH3)2, —CH2CH2C(O)NH2, —CH2S(O)2OH, —CH2CH2C(CH3)2NHS(O)2CH3, or —(CH2)0-3R9a;
  • R9a a is cyclohexyl, cycloheptyl, furanyl, phenyl, piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrrolidinyl, quinuclidinyl, thiazolyl, or octahydrocyclopenta[c]pyrrolyl, each substituted with zero to 2 substituents independently selected from —OH, C1-3 alkyl, —NH2, —N(CH3)2, oxetanyl, phenyl, piperazinyl, piperidinyl, and pyrrolidinyl;
  • R10 is H, —CH3, —CH2CH3, —CH2CH2OCH3, or cyclopropyl; or R9 and R10 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azabicyclo[3.1.1]heptanyl, azaspiro[5.5]undecanyl, diazabicyclo[2.2.1]heptanyl, diazabicyclo[3.1.1]heptanyl, diazabicyclo[3.2.0]heptanyl, diazaspiro[3.5]nonanyl, diazaspiro[4.4]nonanyl, diazaspiro[4.5]decanyl, diazepanyl, indolinyl, morpholinyl, octahydropyrrolo[3,4-c]pyrrolyl, piperazinonyl, piperazinyl, piperidinyl, and pyrrolidinyl, each substituted with zero to 2 R10a;
  • each R10a is independently —CH3, —CH2CH3, —CH(CH3)2, —CH2OH, —CH2CH2OH, —CH2OCH3, —CH2CH2OCH3, —CH2NH2, —CH2CH2NH2, —CH2CH2NH(CH3), —CH2C(O)NH(CH3), —CH2C(O)N(CH3)2, —CH2(methyltriazolyl), —CH2CH2(phenyl), —CH2CH2(morpholinyl), —C(O)CH3, —C(O)NH2, —C(O)N(CH2CH3)2, —C(O)CH2NH(CH3), —C(O)CH2N(CH3)2, —NH2, —N(CH3)2, —NHC(O)CH3, —C(O)(furanyl), —O(piperidinyl), —C(O)CH2(diethylcarbamoylpiperidinyl), methylpiperazinyl, piperidinyl, methylpiperidinyl, diethylcarbamoylpiperidinyl, isopropylpiperidinyl, pyridinyl, trifluoromethylpyridinyl, pyrimidinyl, or dihydrobenzo[d] imidazolonyl;
  • R11 is azetidinyl, azaspiro[3.5]nonanyl, dioxidothiomorpholinyl, hexahydropyrrolo[3,4-c]pyrrolyl, morpholinyl, piperazinyl, piperidinyl, or pyrrolidinyl, each substituted with zero to 2 substituents independently selected from F, —CH3, —CH(CH3)2, —CH2CN, —CH2(methyloxetanyl), —CH2(triazolyl), —CH2(phenyl), —C(O)CH2N(CH3)2, —CH2C(CH3)2OH, —CH2C(O)N(CH3)2, —CH2CH2S(O)2CH3, —CH2CH2S(O)CH3, oxetanyl, and tetrahydropyranyl;
  • each R12a is independently —OH, —CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CF3, —CH2CF3, —CH2CH2CH2CF3, —CH2CN, —CH2C(CH3)2OH, —CH2CH2OCH3, —CH2C(O)NH(CH3), —CH2C(O)N(CH3)2, —CH2C(O)NH2, —CH2CH2S(O)2CH3, —CH2CH2NHS(O)2CH3, —CH2NRxRx, —CH2CH2NH(CH3), —OCH3, —NRxRy, —NRx(C2-4 fluoroalkyl), —NRx(CH2CRxRxH2OCH3), —NH(CH2CN), —N(CH3)CH2N(CH3)2, —NH(CH2C(CH3)2OH), —NRx(CH2C(O)NH2), —N(CH3)(OCH3), —NRxCH2CH2S(O)2CH3, —NHC(O)CH3, —NHC(O)CH2CF3, —NHC(O)CHRxNH(CH3), —NRxC(O)CH2N(CH3)2, —NHC(O)CH2N(CH3)(CH2CH3), —NHC(O)CH2N(CH2CH3)2, —NHC(O)CH2NH(CH2C(CH3)2OH), —NHCH2C(O)NRx(CH3), —NHS(O)2CH3, —C(O)C(CH3)3, —C(O)CH(CH2CH3)2, —C(O)CH2OCH3, —C(O)CH2CH2OCH3, —C(O)CH2NH(CH3), —C(O)CH2N(CH3)2, —C(O)CH2CH2N(CH3)2, —C(O)CH(CH3)NH(CH3), —C(O)CH2N(CH3)(CH2CH3), —C(O)CH2N(CH2CH3)2, R12b, —CH2R12b, —C(O)R12b, —C(O)CH2R12b, —C(O)CH2NHR12b, —C(O)NRxR12b, —NRxC(O)CH2R12b, —NRyR12b, —NRxCH2R12b, —N(CH2CN)R12b, —NHC(O)CH2NRxR12b, —NHC(O)CH2NRxCH2R12b, —NHCH2C(O)NHR12b, or —OR12b; or two R12a and the carbon atom to which they are attached form CO═O;
  • R12b is azetidinyl, bicyclo[1.1.1]pentanyl, cyclopropyl, diazabicyclo[2.2.1]heptanyl, dioxolanyl, dioxothiaazaspiro[3.3]heptanyl, dioxidotetrahydrothiopyranyl, dioxidothiomorpholinyl, imidazolyl, morpholinyl, octahydrocyclopenta[c]pyrrolyl, octahydropyrrolo[3,4-c]pyrrolyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxaazaspiro[4.4]nonanyl, oxetanyl, phenyl, piperazinyl, piperazinonyl, piperidinyl, pyridinyl, pyrrolidinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, or triazolyl, each substituted with zero to 4 substituents independently selected from F, —OH, —CH3, —CH(CH3)2, —CH2OH, —OCH3, —CH2CH2OCH3, —NRxRx, —C(O)NH2, —C(O)N(CH3)2, —S(O)2CH3, and —CH2S(O)2CH3;
  • each R14a is independently:
    • (i) H, F, Cl, —OH, —CH3, —CH(CH3)2, —CH(CH3)(CH2CH3), —CH2CH2CH2C(CH3)2, —CF3, —CH2CF3, —CH2OH, —OCH3, —CH2CH2OCH3, —CHRxNRx(CH3), —CH2N(CH3)(CH(CH3)2), —CH2NH(CH2C(CH3)3), —CH2NH(CH2CN), —CH2N(CH3)(CH2CH2OCH3), —CH2N(CH2CH2OCH3)2, —CH2NRx(CH2C═CH), —CH2NHCH2CH2N(CH3)2, —CH2CH2NRx(CH3), —CH2CRx(CH3)NH2, —CH2CH2CH2N(CH3)2, —CH2CH2CH2CH2NH2, —CH(NH2)(CH2)3-41NH2, —CH2NHCH2CH2O(C1-3 alkyl), —CH2NHCH2CH2OCH2CH2OH, —CH2NHCH2CH2S(O)2OH, —CH2C(O)NRx(CH3), —NRxRx, —NH(CH(CH3)2), —NHCH2CH2NH(CH3), —NHCH2CH2CH2N(CH3)2, —NHC(O)CH3, —NHC(O)CF3, —NHC(O)OC(CH3)3, —NHC(O)CH2N(CH3)2, —NHC(O)CH2CH2N(CH3)2, —NHCH2C(O)CH2NH(CH3), —C(O)CH3, —C(O)CH2CH(CH3)OH, —C(O)CH2NRx(CH3), —C(O)NRxRx, —C(O)NH(CH2CN), —C(O)NHCH2CH2CH2NRxRx, —C(O)NHCH2CH(CH3)CH2NH2, —C(O)NHCH2C(O)NH2, —C(O)N(CH3)CH2CH2CH2N(CH3)2, —C(O)N(CH2CH3)CH2CH2N(CH3)2, —OCH2CH2CH2N(CH3)2, —C(O)NHCH2CH2NHC(O)CH3, —S(O)2NH2, or —C(O)CH2S(O)2CH3;
    • (ii) 8-azabicyclo[3.2.1]octanyl, azaspiro[3.5]nonanyl, azetidinyl, benzo[c][1,2,5]oxadiazolyl, cyclopentyl, cyclohexyl, diazepanyl, morpholinyl, phenyl, piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrrolidinonyl, quinolinyl, quinuclidinyl, tetrahydroisoquinolinyl, tetrahydropyridinyl, or thiazolidinyl, each substituted with zero to 2 substituents independently selected from —CH3, —CH(CH3)2, —CH2CH(CH3)2, —CF3, —CH2CH2CF3, —CH2CH2OH, —CH2CH2CH(CH3)OH, —NH2, —CH2N(CH3)2, —CH2CH2NH(CH3), —C(O)CH3, —C(O)CH2NH(CH3), —C(O)CH2N(CH3)2, —C(O)O(C(CH3)3), —CH2C(O)NRx(CH3), cyclobutyl, cyclopentyl, —CH2(phenyl), —CH2(pyrrolyl), —CH2(morpholinyl), —CH2(methylpiperazinyl), —CH2(thiophenyl), methylpiperidinyl, isobutylpiperidinyl, and pyridinyl; or
    • (iii) -L3-R14c;
  • each R14b is —CH3;
  • L3 is —(CH2)1-3—, —CH(CH3)—, —CH(NH2)—, —CH2NH—, —C(O)—, —C(O)NH(CH2)0-4—, —C(O)N(CH3)CH2CH2—, —NH—, —NHC(O)—, —NHCH2—, —NHCH2C(O)—, —O—, or —OCH2CH2—;
  • R14c is adamantanyl, azetidinyl, cyclopropyl, cyclohexyl, diazepanyl, imidazolyl, indolyl, morpholinyl, octahydropyrrolo[3,4-c]pyrrolyl, phenyl, piperazinonyl, piperazinyl, piperidinyl, pyridinyl, pyrrolidinonyl, pyrrolidinyl, or tetrazolyl, each substituted with zero to 1 substituent selected from —OH, —CH3, —CH(CH3)2, —CH2CH(CH3)2, —C(CH3)2OH, —NH2, —N(CH3)2, —NH(C(CH3)2, —NHC(O)CH3, —C(O)CH3, —C(O)NH2, —C(O)N(CH2CH3)2, —C(O)(tetrahydrofuranyl), —C(O)OCH2CH3, —CH2C(O)NH(CH(CH3)2, morpholinyl, methylpiperidinyl, pyrazinyl, pyridinyl, and pyrrolidinyl;
  • n is zero or 1; and
  • p is zero, 1, 2, or 3.


One embodiment provides a compound of Formula (I), or a salt thereof, wherein: G is:




embedded image


A is:



  • (i) —OR6 or —(CRxRx)1-2—R6;

  • (ii) —NR7R8;

  • (iii) —C(O)NR9R10;

  • (vi) —CH2CH2R11;

  • (v) —CHR12R13, wherein R12 and R13 together with the carbon atom to which they are attached form a cyclic group selected from azetidinyl, C3-6 cycloalkyl, morpholinyl, or piperidinyl, each substituted with zero to 3 R12a; or

  • (vi) an aromatic group selected from pyrazolyl substituted with zero to 1 R14a;

  • R1 is —CH3 or —CH(CH3)2;

  • each R2 is independently Cl, —CH3, —CH2CH3, —CH2OH, —CH2CH2OH, —CH2CN, —OCH3, —CH2OCH3, or —CH2CH2S(O)2CH3;

  • R6 is:
    • (a) —CH3; or
    • (b) azctidinyl, cyclohexyl, or piperidinyl, each substituted with zero to 2 R6a;

  • each R6a is independently —CH3, —CH2CH2CH3, —C(CH3)2, —CH2C(CH3)2OH, —N(CH3)2, —N(CH2CH2CH3)2, —CH2CH2S(O)2CH3, —CH2C(O)N(CH3)2, or tetrahydropyranyl;

  • R7 and R8 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidinyl, diazepanyl, diazaspiro[3.5]nonanyl, piperazinonyl, piperazinyl, piperidinyl, and pyrrolidinyl, wherein said heterocyclic ring is substituted with zero to 1 R7b and zero to 2 R7c;

  • R7b is:
    • (a) —NRxRx, C1-6 alkyl, C2-3 fluoroalkyl, C1-4 hydroxyalkyl, C1-2 cyanoalkyl, —CHRxCH2OCH3, —CH2C(O)NRxRx, —CH2CH2C(O)NRxRx, —1(CH2)2-3S(O)2CH3, —CH2CH2NHS(O)2CH3, —NRxRx, —N(CH3)(CH2CH3), —N(CH2CH3)2, —NH(CH2CN), —N(CH2CN)2, —NRxCH2C(O)N(CH3)2, —NRxC(O)CH2N(CH3)2, —NH(CH2CH2S(O)2CH3), —N(CH2C(O)N(CH3)2)2, —S(O)2CH2CH2N(CH3)2, —C(O)CH2CH2N(CH3)2, —C(O)CH2N(CH3)2, —C(O)CH2NH(CH(CH3)2), —C(O)CH2NH(CH2CH2OCH3), —C(O)CH2NH(CH2CH2OH), —CH2(cyclopropyl), —CH2(methyloxetanyl), —CH2(tetrahydrofuranyl), —CH2(methyltriazolyl), —CH2CH2(morpholinyl), —NRx(cyclobutyl), —NRx(oxetanyl), —NRx(pyrimidinyl), —NRx(tetrahydropyranyl), —NHCH2(methylsulfonylcyclopropyl), —NHCH2(methyloxetanyl), —NHCH2(methoxypyrimidinyl), —(O)CH2NH(cyclobutyl), —N(CH2(dimethoxypyrimidinyl))2, —N(CH2(methoxypyrimidinyl))2, —N(CH2(triazolyl))2, —N(CH2(methyltriazolyl))2, —N(CH3)CH2(cyclopropyl), —N(CH3)CH2(methylpyrazolyl), —N(CH3)CH2(pyrimidinyl), —N(CH3)CH2(methylpyrimidinyl), —N(CH3)CH2(dimethoxypyrimidinyl), —N(CH3)CH2(methoxypyrimidinyl), —N(CH3)CH2(thiadiazolyl), —N(CH3)CH2(methyltriazolyl), —NH(CH2(methylpyrimidinyl))2, —NH(CH2(thiadiazolyl), —C(O)CH2(azetidinyl), —C(O)CH2(morpholinyl), —C(O)CH2(hydroxypiperidinyl), —C(O)CH2(pyrrolidinyl), or —C(O)CH2NHCH2(cyclopropyl); or
    • (b) cyclobutyl, cyclohexyl, dioxothiomorpholinyl, oxetanyl, piperazinyl, piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl, each substituted with zero to 1 R8a and zero to 3 R8b;

  • each R7c is independently —CH3 or —CH2CN;

  • R8a is —OH, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CH2CH(CH3)2, —CH2CH2OCH3, —CH2CH2CF3, —C(O)CH3, —C(O)OCH3, —CH2(cyclopropyl), —CH2(methyl phenyl), —(CH2)2-3(pyrrolidinyl), —CH2(methylpyrazolyl), —CH2(thiophenyl), —NRxRx, cyclopentyl, methylpiperidinyl, or pyridinyl;

  • each R8b is —CH3;

  • R9 is —CH2CH2CF3 or —CH2CH2N(CH3)2;

  • R10 is H or C1-2 alkyl;

  • or R9 and R10 together with the nitrogen atom to which they are attached form a heterocyclic ring selected piperidinyl substituted with —C(O)CH3 or —CH(CH3)2;

  • R11 is azetidinyl or piperidinyl, each substituted with zero to 1 substituent selected from —CH2(triazolyl), —CH2(methyloxetanyl), —C(O)CH2N(CH3)2, —CH2C(CH3)2OH, —CH2C(O)N(CH3)2, —CH2CH2S(O)2CH3, and oxetanyl;

  • each R12a is independently —OH, —CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2CN, —CH2C(CH3)2OH, —CH2C(O)NH(CH3), —CH2C(O)N(CH3)2, —CH2C(O)NH2, —C(CH3)2CH2C(O)N(CH3)2, —CH2CH2S(O)2CH3, —NRxRy, —NRx(CH2CHF2), —N(Rx)(CH2CH2CF3), —NRx(CH2CH2OCH3), —NRx(C1-2 cyanoalkyl), —NRx(CH2CH2OH), —N(CH2CH2OH)(CH2C(O)N(CH3)2), —N(CH2CH2OH)(CH2CH2S(O)2CH3), —N(CH2CH2S(O)2CH3)2, —NRx(CH2CH2OCH3), —NRxCH2CRxRxS(O)2CH3, —NRxCH2CH2S(O)2CF3, —NRxCH2CH2S(O)2NH2, —NRxC(O)CH3, —NRxC(O)CH2N(CH3)2, —NRx(CRxRxC(O)NRxRx), —NHCH2C(O)NRx(C(CH3)3), —NRx(CRxRxC(O)CH2NRxRx), —NH(CH2C(O)N(CH3)CH2CH2OCH3), —N(CH2CH3)2, —N(CH2CH3)(CH2C(O)N(CH3)2), —N(CH2CH3)(CH2CH2S(O)2CH3), —N(CH2CN)2, —N(CH2CN)(CH2C(O)N(CH3)2), —N(CH2CN)(CH2CH2S(O)2CH3), —N(CH2C(O)NRxRx)2, —N(CH2(methyloxetanyl))2, —C(O)CH2N(CH3)2, —C(O)CH2CH2N(CH3)2, R12b, —CH2R12b, —NRxR12b, —N(cyclopropyl)R12b, —NRxCHRxR12b, —NHC(O)R12b, —NHCRxRxC(O)R12b, —N(CH2CH3)(CH2R12b), —N(CH2CH2OH)R12b, —N(CH2CH2OH)(CH2R12b), —N(CH2CN)R12b, —N(CH2CN)(CH2R12b), or —N(CH2(methyloxetanyl))2; or two R12a and the carbon atom to which they are attached form C═O;

  • R12b is azaspiro[3.5]nonanyl, azetidinyl, cyclopropyl, cyclopentyl, dioxotetrahydrothiofuranyl, dioxidotetrahydrothiopyranyl, dioxothiaazaspiro[3.3]heptanyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxazolyl, oxetanyl, phenyl, piperazinonyl, piperidinyl, pyrazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl, tetrahydropyranyl, or triazolyl, each substituted with zero to 4 substituents independently selected from F, —CN, —CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2OH, —CH2CH2OH, C1-2 cyanoalkyl, —OCH 3, —CH2C(O)NH(CH3), —C(O)NRxRx, —S(O)2CH3, —S(O)2CH3, and —CH2S(O)2CH3; and

  • R14a is piperidinyl or —CH2CH2(morpholinyl);

  • and R5 and n are defined in the first aspect or the second aspect.



One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein:


G is:



embedded image


A is:



  • (i)—OR6 or —O(CRxRx)1-2—R6;

  • (ii)—NR7R8;

  • (iii)—C(O)NR9R10;

  • (vi)—CH2CH2R11;

  • (v)—CHR12R13, wherein R12 and R13 together with the carbon atom to which they are attached form a cyclic group selected from azetidinyl, C3-6 cycloalkyl, morpholinyl, or piperidinyl, each substituted with zero to 3 R12a; or

  • (vi) an aromatic group selected from pyrazolyl substituted with zero to 1 R14a;

  • R1 is —CH(CH3)2;

  • each R2 is independently Cl, —CH3, —CH2CH3, —CH2OH, —CH2CH2OH, —OCH3, —CH2OCH3, or —CH2CH2S(O)2CH3;

  • R6 is:
    • (a) —CH3; or
    • (b) azetidinyl, cyclohexyl, or piperidinyl, each substituted with zero to 2 R6a;

  • each R6a is independently —CH3, —CH2CH2CH3, —C(CH3)2, —CH2C(CH3)2OH, —N(CH3)2, —N(CH2CHCH)2, —CH2CH2S(O)2CH3, —CH2C(O)N(CH3)2, or tetrahydropyranyl;

  • R7 and R8 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidinyl, diazepanyl, diazaspiro[3.5]nonanyl, piperazinonyl, piperazinyl, piperidinyl, and pyrrolidinyl, wherein said heterocyclic ring is substituted with zero to 1 R7b and zero to 2 R7c;

  • R7b is:
    • (a) —NRxRx, C1-6 alkyl, C2-3 fluoroalkyl, C1-4 hydroxyalkyl, C1-2 cyanoalkyl, —CHRxCH2OCH3, —CH2C(O)NRxRx, —CH2CH2C(O)NRxRx, —(CH2)2-3S(O)2CH3, —CH2CH2NHS(O)2CH3, —NRxRx, —N(CH3)(CH2CH3), —N(CH2CH3)2, —NH(CH2CN), —N(CH2CN)2, —NRxCH2C(O)N(CH3)2, —NRxC(O)CH2N(CH3)2, —NH(CH2CH2S(O)2CH3), —N(CH2C(O)N(CH3)2)2, —S(O)2CH2CH2N(CH3)2, —C(O)CH2CH2N(CH3)2, —C(O)CH2N(CH3)2, —C(O)CH2NH(CH(CH3)2), —C(O)CH2NH(CH2CH2OCH3), —C(O)CH2NH(CH2CH2OH), —CH2(cyclopropyl), —CH2(methyloxetanyl), —CH2(tetrahydrofuranyl), —CH2(methyltriazolyl), —CH2CH2(morpholinyl), —NRx(cyclobutyl), —NRx(oxetanyl), —NRx(pyrimidinyl), —NRx(tetrahydropyranyl), —NHCH2(methylsulfonylcyclopropyl), —NHCH2(methyloxetanyl), —NHCH2(methoxypyrimidinyl), —C(O)CH2NH(cyclobutyl), —N(CH2(dimethoxypyrimidinyI))2, —N(CH2(methoxypyrimidinyl))2, —N(CH2(triazolyl))2, —N(CH2(methyltriazolyl))2, —N(CH3)CH2(cyclopropyl), —N(CH3)CH2(methylpyrazolyl), —N(CH3)CH2(pyrimidinyl), —N(CH3)CH2(methylpyrimidinyl), —N(CH3)CH2(dimethoxypyrimidinyl), —N(CH3)CH2(methoxypyrimidinyl), —N(CH3)CH2(thiadiazolyl), —N(CH3)CH2(methyltriazolyl), —NH(CH2(methylpyrimidinyl))2, —NH(CH2(thiadiazolyl), —C(O)CH2(azetidinyl), —C(O)CH2(morpholinyl), —C(O)CH2(hydroxypiperidinyl), —C(O)CH2(pyrrolidinyl), or —C(O)CH2NHCH2(cyclopropyl); or
    • (b) cyclobutyl, cyclohexyl, dioxothiomorpholinyl, oxetanyl, piperazinyl, piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl, each substituted with zero to 1 R8a and zero to 3 R8b;

  • each R7c is independently —CH3 or —CH2CN;

  • R8a is —OH, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CH2CH(CH3)2, —CH2CH2OCH3, —CH2CH2CF3, —C(O)CH3, —C(O)OCH3, —CH2(cyclopropyl), —CH2(methyl phenyl), —(CH2)2-3(pyrrolidinyl), —CH2(methylpyrazolyl), —CH2(thiophenyl), —NRxRx, cyclopentyl, methylpiperidinyl, or pyridinyl;

  • each R8b is —CH3;

  • R9 is —CH2CH2CF3 or —CH2CH2N(CH3)2;

  • R10 is H or Cl1-2 alkyl;

  • or R9 and R10 together with the nitrogen atom to which they are attached form a heterocyclic ring selected piperidinyl substituted with —C(O)CH3 or —CH(CH3)2;

  • R11 is azetidinyl or piperidinyl, each substituted with zero to 1 substituent selected from —CH2(triazolyl), —CH2(methyloxetanyl), —C(O)CH2N(CH3)2, —CH2C(CH3)2OH, —CH2C(O)N(CH3)2, —CH2CH2S(O)2CH3, and oxetanyl;

  • each R12a is independently —OH, —CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2CN, —CH2C(CH3)2OH, —CH2C(O)NH(CH3), —CH2C(O)N(CH3)2, —CH2C(O)NH2, —C(CH3)2CH2C(O)N(CH3)2, —CH2CH2S(O)2CH3, —NRxRy, —NRx(CH2CHF2), —N(Rx)(CH2CH2CF3), —NRx(CH2CH2OCH3), —NRx(C1-2 cyanoalkyl), —NRx(CH2CH2OH), —N(CH2CH2OH)(CH2C(O)N(CH3)2), —N(CH2CH2OH)(CH2CH2S(O)2CH3), —N(CH2CH2S(O)2CH3)2, —NRx(CH2CH2OCH3), —NRxCH2CRxRxS(O)2CH3, —NRxCH2CH2S(O)2CF3, —NRxCH2CH2S(O)2NH2, —NRxC(O)CH3, —NRxC(O)CH2N(CH3)2, —NRx(CRxRxC(O)NRxRx), NHCH2C(O)NRx(C(CH3)3), —NRx(CRxRxC(O)CH2NRxRx), —NH(CH2C(O)N(CH3)CH2CH2OCH3), —N(CH2CH3)2, —N(CH2CH3)(CH2C(O)N(CH3)2), —N(CH2CH3)(CH2CH2S(O)2CH3), —N(CH2CN)2, —N(CH2CN)(CH2C(O)N(CH3)2), —N(CH2CN)(CH2CH2S(O)2CH3), —N(CH2C(O)NRxRx)2, —N(CH2(methyloxetanyl))2, —C(O)CH2N(CH3)2, —C(O)CH2CH2N(CH3)2, R12b, —CH2R12b, —NRxR12b, —N(cyclopropyl)R12b, —NRxCHRxR12b, —NHC(O)R12b, —NHCRxRxC(O)R12b, —N(CH2CH3)(CH2R12b), —N(CH2CH2OH)R12b, —N(CH2CH2OH)(CH2R12b), —N(CH2CN)R012b, —N(CH2CN)(CH2R12b), or —N(CH2(methyloxetanyl))2; or two R12a and the carbon atom to which they are attached form C═O;

  • R12b is azaspiro[3.5]nonanyl, azetidinyl, cyclopropyl, cyclopentyl, dioxotetrahydrothiofuranyl, dioxidotetrahydrothiopyranyl, dioxothiaazaspiro[3.3]heptanyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxazolyl, oxetanyl, phenyl, piperazinonyl, piperidinyl, pyrazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl, tetrahydropyranyl, or triazolyl, each substituted with zero to 4 substituents independently selected from F, —CN, —CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2OH, —CH2CH2OH, C1-2 cyanoalkyl, —OCH3, —CH2C(O)NH(CH3), —C(O)NRxRx, —S(O)2CH3, and —CH2S(O)2CH3;

  • R14a is piperidinyl or —CH2CH2(morpholinyl);

  • and G, n, R5, and p are defined in the first aspect or the second aspect



One embodiment provides a compound of Formula (I) or a salt thereof wherein G is:




embedded image


A is —NR7R8; and R1, R2, R5, n, and p are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I) or a salt thereof wherein G is:




embedded image


R1 is —CH(CH3)2; A is piperazinyl; and R1, R2, R5, n, and p are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I) or a salt thereof wherein G is




embedded image


A is —CRxR12R13, wherein R12 and R13 together with the carbon atom to which they are attached form a cyclic group selected from azetidinyl, C4-6 cycloalkyl, or piperidinyl, each substituted with zero to 4 R12a; and R1, R2, R2a, R2b, R5, R12a, n, and p are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I) or a salt thereof wherein G is




embedded image


A is —CRxR12R13, wherein R12 and R13 together with the carbon atom to which they are attached form a cyclic group selected from cyclopentyl and cyclohexyl, each substituted with zero to 1 R12a; R1 is —CH(CH3)2; R12a is —NRyRy, —NRx(C1-3 fluoroalkyl), —NRx(CH2CH2O(C1-3 alkyl)), —NRx(C1-2 cyanoalkyl), —NRxCH2NRxRx, —NRx(C1-4 hydroxyalkyl), —NRx(CH2C(O)NRxRx), —CRxRxR12b, —NRxR12b, or —NRxCRxRxR12b; R12b is cyclopropyl, cyclopentyl, dioxotetrahydrothiofuranyl, dioxidotetrahydrothiopyranyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxazolyl, oxetanyl, phenyl, piperidinyl, pyrazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl, tetrahydropyranyl, or triazolyl, each substituted with zero to 4 substituents independently selected from F, —CN, —CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2OH, —CH2CH2OH, C1-2 cyanoalkyl, —OCH3, —CH2C(O)NH(CH3), —C(O)NRxRx, —S(O)2CH3, and —CH2S(O)2CH3; and R2, R5, n, and p are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I) or a salt thereof, wherein R1 is H, Cl, —CN, C1-4 alkyl, C1-2 fluoroalkyl, C1-2 hydroxyalkyl, or —C(O)O(C1-2 alkyl); and G, A, R5, and n are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which R1 is —CH3, —CH2CH3, —CH(CH3)2, —CH2CHF2, or —CH2CF3. Also included in this embodiment are compounds in which R1 is —CH3 or —CH(CH3)2. Additionally, included in this embodiment are compounds in which R1 is —CH(CH3)2.


One embodiment provides a compound of Formula (I) or a salt thereof, wherein each R2 is independently F, Cl, —CN, —OH, C1-3 alkyl, C1-2 fluoroalkyl, C1-2 cyanoalkyl, C1-3 hydroxyalkyl, C1-2 aminoalkyl, —(CH2)0-2O(C1-3 alkyl), C3-6 cycloalkyl, —NRxRx, —(CH2)0-2C(O)NRxRx, —(CH2)0-2S(O)2(C1-3 alkyl), —CH2(C3-6 cycloalkyl), —CH2(phenyl), or phenyl; and G, A, R1, R5, Rx, and n are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which each R2 is independently Cl, —CH3, —CH2CH3, —CH2OH, —CH2CH2OH, —CH2CN, —OCH3, —CH2OCH3, or —CH2CH2S(O)2CH3. Also, included in this embodiment are compounds in which each R2 is independently Cl, —CH3, —CH2CH3, —CH2OH, —CH2CH2OH, —OCH3, —CH2OCH3, or —CH2CH2S(O)2CH3.


One embodiment provides a compound of Formula (I) or a salt thereof wherein A is —O-L1-R6; and G, R1, R5, R6, Rx, L1, and n are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which L1 is bond, —(CRxRx)1-2—, —CH2C(O)—, —CH2C(O)NRx(CRxRx)0-2—, —CH2NRxC(O)—, or —CH2NRxC(O)CH2—; and each R6a is independently F, —OH, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 hydroxyalkyl, —(CH2)1-2OCH3, —NRxRx, —N(C2-3 alkyl)2, —(CH2)1-2NRxRx, —(CH2)1-2S(O)2(C1-2 alkyl), —(CH2)1-2C(O)NRxRx, —C(O)CH2NRxRx, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, isobutylpiperidinyl, piperazinyl, or —O(piperidinyl). Also included in this embodiment are compounds in which each R6a is independently F, —OH, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 hydroxyalkyl, —(CH2)1-2OCH3, —NRxRx, —(CH2)1-2NRxRx, —(CH2)1-2S(O)2(C1-2 alkyl), —(CH2)1-2C(O)NRxRx, —C(O)CH2NRxRx, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, isobutylpiperidinyl, piperazinyl, or —O(piperidinyl).


One embodiment provides a compound of Formula (I) or a salt thereof wherein A is —O-L1-R6; L1 is bond, —(CRxRx)1-2—, —CH2C(O)—, —CH2C(O)NRx(CRxRx)0-2—, —CH2NRxC(O)—, or —CH2NRxC(O)CH2—; R6 is: (i) C1-2 alkyl, —CH2C(O)NHCH2CRxRxOH, —CH2C(O)NHCH2CH2CRxRxOH, —CH2C(O)NHCH2CH2NRxRx, or —CH2C(O)NHCH2CHFCRxRxOH; or (ii) azabicyclo[3.2.1]octanyl, azaspiro[5.5]undecanyl, azetidinyl, C3-6 cycloalkyl, diazabicyclo[2.2.1]heptanyl, diazaspirop[3.5]nonanyl, morpholinyl, tetrahydropyranyl, octahydrocyclopenta[c]pyrrolyl, piperazinyl, piperidinyl, pyrrolidinyl, or quinuclidinyl, each substituted with zero to 3 R6a; and each R6a is independently F, —OH, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 hydroxyalkyl, —(CH2)1-2OCH3, —NRxRx, —N(C2-3 alkyl)2, —(CH2)1-2NRxRx, —(CH2)1-2S(O)2(C1-2 alkyl), —(CH2)1-2C(O)NRxRx, —C(O)CH2NRxRx, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, isobutylpiperidinyl, piperazinyl, or —O(piperidinyl). Also included in this embodiment are compounds in which each R6a is independently F, —OH, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 hydroxyalkyl, —(CH2)1-2OCH3, —NRxRx, —(CH2)1-2NRxRx, —(CH2)1-2S(O)2(C1-2 alkyl), —(CH2)1-2C(O)NRxRx, —C(O)CH2NRxRx, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, isobutylpiperidinyl, piperazinyl, or —O(piperidinyl); and G, R1, R5, Rx, and n are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I) or a salt thereof wherein A is —NR7R8; and G, R1, R5, R7, R8, Rx, Ry, n, and p are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which R7 is: (i) —CH2CH2NH2, —CH2CH2NHC(O)CH2N(CH3)2, —CH2(isopropyl azaspiro[3.5]nonanyl), —CH2(methylpyrrolidinyl), —C(O)(CH2)1-3NH2, —C(O)CH(NH2)CH2CH2CH3, —C(O)CH(NH2)CH2CH(CH3)2, —C(O)CH(NH2)CH(CH3)CH2CH3, —C(O)CH(NH2)CH2CH2C(O)OH, —C(O)CH(NH2)(CH2)3-4NH2, —C(O)CH(NH2)(CH2)1-2C(O)NH2, —C(O)CH(NH2)(cyclohexyl), —C(O)CH(NH2)(phenyl), —C(O)(aminocyclohexyl), —C(O)(morpholinyl), —C(O)(pyrrolidinyl), pentamethylpiperidinyl, methylpiperidinyl-piperidinyl, methylpyrrolidinyl-pyrrolidinyl, or phenyl substituted with —OCH2CH2(pyrrolidinyl) or —OCH2CH2NHCH2CH3; or (ii) cyclohexyl substituted with —NRx(CH2)2-3N(CH3)2, —NHCH2CH2NHCH3, —NH(methylpiperidinyl), —NH(CH2)2-3(morpholinyl), dimethylamino piperidinyl, or piperazinyl substituted with —CH3, —CH2CH3, —C(CH3)3, —CH2CH(CH3)2, —C(O)CH3, —CH2CH2OCH3, —CH2(methylphenyl), —(CH2)2-3(pyrrolidinyl), cyclopentyl, pyridinyl, or methylpiperidinyl; R7b is: (i) —OH, C1-6alkyl, C3-4 fluoroalkyl, C3-4 hydroxyalkyl, —CH2CN, —CH2CH2CN, —CH2CH2CH2C═CH, —(CRxRx)1-2OCH3, —(CH2)2-3S(O)2CH3, —(CH2)1-2NRxRx, —(CH2)1-2C(O)NRxRx, —NRyRy, —NRx(C1-4 hydroxyalkyl), —NH(CH2CH2OCH3), —NRy(C1-2 cyanoalkyl), —N(CH2CH2CN)2, —NRx(C1-2 fluoroalkyl), —NRx(C2-4 hydroxyfluoroalkyl), —(CH2)1-2C(O)NRxRx, —NRx(CH2)1-2C(O)NRxRx, —N((CH2)1-2C(O)NRxRx)2, —NRx(CH2)1-2S(O)2(C1-2 alkyl), —NRx(CH2)1-3NRxRx, —NRxCH2CH2N(CH3)2, —NRx(O)(CH2)1-2NRxRx, —NRx(CH2CH2S(O)2CH3), —OCH2CH2N(CH3)2, —C(O)(CRxRx)1-2NRyRy, —C(O)(CRxR)1-2NRy(C1-4 hydroxyalkyl), —C(O)(CRxRx)1-2NRx(CH2CH2OCH3), —S(O)2CH2CH2N(CH3)2, —(CH2)1-2R7d, —NRxR7d, —NRx(CH2)1-2R7d), —NR7dR7d, —N((CH2)1-2R7d)2, —OR7d, —C(O)R7d, —C(O)(CRxRx)1-2R7d, or —C(O)(CRxRx)1-2NRxR7d; or (ii) azepanyl, azetidinyl, cyclobutyl, cyclohexyl, diazepanyl, dioxotetrahydrothiopyranyl, dioxothiomorpholinyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxetanyl, piperazinonyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydropyranyl, or thiadiazolyl, each substituted with zero to 1 R8a and zero to 3 R8b; R7d is azaspiro[3.5]nonanyl, azetidinyl, bicyclo[1.1.1]pentanyl, C3-6 cycloalkyl, dioxothiaazaspiro[3.3]heptanyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxaazaspiro[4.4]nonyl, oxetanyl, phenyl, piperidinyl, pyrazolyl, pyrrolidinyl, tetrahydropyranyl, tetrahydropyranyl, thiadiazolyl, or triazolyl, each substituted with zero to 2 substituents selected from F, —OH, C1-3 alkyl, —CH2OH, —OCH3, —NRxRx, —C(O)CH3, —S(O)2CH3, methylpiperidinyl, methylpyrrolidinyl, tetramethylpiperidinyl, —OCH2CH2(pyrrolidinyl), and —OCH2CH2NHCH2CH3; and zero to 4 substituents selected from —CH3; R8 is H, —CH3 or —CH2CH3; R8a is —OH, C1-4 alkyl, C1-3 fluoroalkyl, —(CH2)1-2O(C1-2 alkyl), C1-2 alkoxy, —C(O)(C1-2 alkyl), —C(O)O(C1-2 alkyl), —CH2(C3-6 cycloalkyl), —(CH2)1-2(methyl phenyl), —(CH2)1-3(pyrrolidinyl), —(CH2)1-2(methylpyrazolyl), —(CH2)1-2(thiophenyl), —NRxRx, C3-6 cycloalkyl, methylpiperidinyl, or pyridinyl; and each R8b is independently F or —CH3.


One embodiment provides a compound of Formula (I) or a salt thereof wherein A is —NR7R8; and G, R1, R5, R7, R8, Rx, and n are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which R7 is: R7a, —CH2R7a, —C(O)R7a, —C(O)CH(NH2)R7a, —C(O)(CH2)1-3NH2, —C(O)CH(NH2)(C1-4 alkyl), —C(O)CH(NH2)(CH2)1-2C(O)OH, —C(O)CH(NH2)(CH2)2-4NH2, or —C(O)CH(NH2)(CH2)1-3C(O)NH2; or (ii) C3-6 cycloalkyl substituted with one substituent selected from —NRx(CH2)2-3NRxRx, —NH(CH2)2-3NHCH3, —NH(methylpiperidinyl), —NH(CH2)2-3(morpholinyl), dimethylamino piperidinyl, and piperazinyl substituted with a substituent selected from C1-4 alkyl, —C(O)CH3, —(CH2)1-2OCH3, —CH2(methylphenyl), —(CH2)2-3(pyrrolidinyl), C3-6 cycloalkyl, pyridinyl, and methylpiperidinyl; R7b is: (i) C1-4 alkyl, C1-3 hydroxyalkyl, —(CH2)2-3C═CH, —(CH2)0-3NRxRx, —NRx(CH2)1-3NRxRx, —N(CH3)CH2CH2NH2, —O(CH2)1-3NRxRx, —(CH2)1-2R7d, —NH(CH2)1-2R7d, or —OR7d; or (ii) azepanyl, diazepanyl, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrrolidinonyl, pyrrolidinyl, or tetrahydroisoquinolinyl, each substituted with zero to 1 R8a and zero to 3 R8b; R7d is azaspiro[3.5]nonanyl, C3-6 cycloalkyl, morpholinyl, phenyl, piperidinyl, or pyrrolidinyl, each substituted with zero to 1 substituent selected from C1-3 alkyl, —NH2, methylpiperidinyl, methylpyrrolidinyl, —OCH2CH2(pyrrolidinyl), —OCH2CH2NHCH2CH3; and zero to 4 substituents selected from —CH3; and R8 is H or C1-2 alkyl; R8a is —OH, C1-4 alkyl, C1-3 fluoroalkyl, —(CH2)1-2O(C1-2 alkyl), —C(O)(C1-2 alkyl), —CH2(C3-6 cycloalkyl), —(CH2)1-2(methyl phenyl), —(CH2)1-3(pyrrolidinyl), —(CH2)1-2(methylpyrazolyl), —(CH2)1-2(thiophenyl), —NRxRx, C3-6 cycloalkyl, methylpiperidinyl, or pyridinyl; and each R8b is independently F or —CH3.


One embodiment provides a compound of Formula (I) or a salt thereof wherein A is —NR7R8; and G, R1, R5, R7, R8, Rx, Ry, and n are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which R7 and R8 together with the nitrogen atom to which they are attached form a heterocyclic ring selected azetidinyl, diazabicyclo[2.2.1]heptanyl, diazabicyclo[2.2.2]octanyl, diazabicyclo[3.1.1]heptanyl, diazabicyclo[3.2.1]octanyl, azaspiro[3.3]heptanyl, diazaspiro[2.5]octanyl, diazaspiro[3.3]heptanyl, diazepanonyl, diazepanyl, diazaspiro[3.5]nonanyl, diazaspiro[5.5]undecanyl, imidazolyl, imidazolidinonyl, octahydro-1H-pyrrolo[3,4-b]pyridinyl, oxadiazabicyclo[3.3.1]nonanyl, piperazinyl, piperazinonyl, piperidinyl, pyrrolidinonyl, pyrrolidinyl, and pyrrolyl, wherein said heterocyclic ring is substituted with zero to 1 R7b and zero to 2 R7c; R7b is: (i) —OH, C1-6 alkyl, C1-4 fluoroalkyl, C1-4 hydroxyalkyl, C1-2 aminoalkyl, —(CH2)2-3C═CH, —(CRxRx)1-2O (C1-2 alkyl), —(CH2)1-3S(O)2(C1-2 alkyl), —(CH2)0-3NRxRy, —(CH2)1-2C(O)NRxRx, —NRyRy, —NRx(C1-4 hydroxyalkyl), —NRy(C1-2 cyanoalkyl), —N(C1-2 cyanoalkyl)2, —NRx(C1-2 fluoroalkyl), —NRx(C2-4 hydroxyfluoroalyl), —(CRxRx)1-2C(O)NRxRx, —NRx(CH2)1-2C(O)NRxRx, —N((CH2)1-2C(O)NRxRx)2, —NRx(CH2)1-2S(O)2(C1-2 alkyl), —NRx(CH2)1-3NRxRx, —NRxCH2CH2NRxRx, —NRxC(O)(CH2)1-2NRxRx, —NRx(CH2CH2S(O)2CH3), —(CH2)1-2NRxC(O)(CH2)1-2NRxRx, —O(CH2)1-3NRxRx, —C(O)(CRxRx)1-2NRyRy, —C(O)(CRxRx)1-2NRy(C1-4 hydroxyalkyl), —C(O)(CRxRx)1-2NRx(CH2CH2OCH3), —S(O)2CH2CH2N(CH3)2, —(CH2)1-2R7d, —NRxR7d, —NRx(CH2)1-2R7d), —NR7dR7d, —N((CH2)1-2R7d)2, —OR7d, —C(O)R7d, —C(O)(CRxRx)1-2R7d, or —C(O)(CRxRx)1-2NRxR7d; or (ii) azepanyl, azetidinyl, C3-6 cycloalkyl, diazepanyl, dioxotetrahydrothiopyranyl, dioxothiomorpholinyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxetanyl, piperazinonyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydropyranyl, or thiadiazolyl, each substituted with zero to 1 R8a and zero to 3 R8b; each R7c is independently F, —CH3 or —CH2CN; R7d is azaspiro[3.5]nonanyl, azetidinyl, bicyclo[1.1.1]pentanyl, C3-6 cycloalkyl, dioxothiaazaspiro[3.3]heptanyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxaazaspiro[4.4]nonyl, oxetanyl, phenyl, piperidinyl, pyrazolyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, thiadiazolyl, or triazolyl, each substituted with zero to 2 substituents independently selected from F, —OH, C1-3 alkyl, C1-2 hydroxyalkyl, C1-2 alkoxy, —NRxRx, —C(O)CH3, —S(O)2CH3, methylpiperidinyl, methylpyrrolidinyl, tetramethylpiperidinyl, —OCH2CH2(pyrrolidinyl), and —OCH2CH2NHCH2CH3; and zero to 4 substituents selected from —CH3; R8a is —OH, C1-4 alkyl, C1-3 fluoroalkyl, —(CH2)1-2O(C1-2 alkyl), C1-2 alkoxy, —C(O)(C1-2 alkyl), —C(O)O(C1-2 alkyl), —CH2(C3-6 cycloalkyl), —(CH2)1-2(methyl phenyl), —(CH2)1-3(pyrrolidinyl), —(CH2)1-2(methylpyrazolyl), —(CH2)1-2(thiophenyl), —NRxRx, C3-6 cycloalkyl, methylpiperidinyl, or pyridinyl; and each R8b is independently F or —CH3.


One embodiment provides a compound of Formula (I) or a salt thereof wherein A is —NR7R8; and G, R1, R5, R7, R8, and n are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which R7 and R8 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidinyl, diazepanonyl, diazepanyl, diazaspiro[3.5]nonanyl, diazaspiro[5.5]undecanyl, imidazolyl, imidazolidinonyl, octahydro-1H-pyrrolo[3,4-b]pyridinyl, piperazinyl, piperidinyl, pyrrolidinonyl, pyrrolidinyl, and pyrrolyl, wherein said heterocyclic ring is substituted with zero to 1 R7b and zero to 2 R7c; R7b is: (i) C1-4 alkyl, C1-3 hydroxyalkyl, —(CH2)2-3C═CH, —(CH2)0-3NRxRx, —NRx(CH2)1-3NRxRx, —N(CH3)CH2CH2NH2, —O(CH2)1-3NRxRx, —(CH2)1-2R7d, —NHR7d, —NH(CH2)1-2R7d, or —OR7d; or (ii) azepanyl, diazepanyl, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrrolidinonyl, pyrrolidinyl, or tetrahydroisoquinolinyl, each substituted with zero to 1 R8a and zero to 3 R8b; each R7c is independently F, —CH3 or —CH2CN; R8a is —OH, C1-4 alkyl, C1-3 fluoroalkyl, —(CH2)1-2O(C1-2 alkyl), —C(O)(C1-2 alkyl), —CH2(C3-6 cycloalkyl), —(CH2)1-2(methyl phenyl), —(CH2)1-3(pyrrolidinyl), —(CH2)1-2(methylpyrazolyl), —(CH2)1-2(thiophenyl), —NRxRx, C3-6 cycloalkyl, methylpiperidinyl, or pyridinyl; and each R8b is independently F or —CH3.


One embodiment provides a compound of Formula (I) or a salt thereof wherein A is —(CRxRx)1-3R11, —(CRxRx)1-3NRxC(O)R11, or —(CRxRx)1-2NRxC(O)(CH2)1-2NRxRx; and G, R1, R5, R11, Rx, and n are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which R11 is azetidinyl, azaspiro[3.5]nonanyl, dioxidothiomorpholinyl, hexahydropyrrolo[3,4-c]pyrrolyl, morpholinyl, piperazinyl, piperidinyl, pyridinyl, or pyrrolidinyl, each substituted with zero to 3 substituents independently selected from F, Cl, —CN, C1-3 alkyl, C1-2 aminoalkyl, —CH2(methyloxetanyl), —CH2(triazolyl), —CH2(phenyl), —C(O)CH2NRxRx, —CH2CRxRxOH, —CH2C(O)NRxRx, —CH2CH2S(O)2(C1-3 alkyl), —CH2CH2S(O)(C1-3 alkyl), oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl. Also included in this embodiment are compounds in which Rut is azetidinyl, azaspiro[3.5]nonanyl, dioxidothiomorpholinyl, hexahydropyrrolo[3,4-c]pyrrolyl, morpholinyl, piperazinyl, piperidinyl, pyridinyl, or pyrrolidinyl, each substituted with zero to 3 substituents independently selected from F, Cl, —CN, C1-3 alkyl, C1-2 aminoalkyl, —CH2(phenyl), —C(O)CH2NRxRx, —CH2CRxRxOH, —CH2C(O)NRxRx, —CH2CH2S(O)2(C1-3 alkyl), —CH2CH2S(O)(C1-3 alkyl), oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl.


One embodiment provides a compound of Formula (I) or a salt thereof wherein A is —CRxR12R13, wherein R12 and R13 together with the carbon atom to which they are attached form a cyclic group selected from azabicyclo[4.1.1]octanyl, azepanyl, azetidinyl, C3-7 cycloalkyl, diazepanyl, azaspiro[3.3]heptanyl, diazaspiro[4.5]decanonyl, morpholinyl, octahydrocyclopenta[c]pyrrolyl, piperazinyl, piperidinyl, pyrrolidinyl, and quinuclidinyl, each substituted with zero to 4 R12a, and G, R1, R5, R12, R13, Rx, Ry, and n are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which R12 and R13 together with the carbon atom to which they are attached form a cyclic group selected from azabicyclo[4.1.1]octanyl, azepanyl, azetidinyl, C3-7 cycloalkyl, diazepanyl, diazaspiro[4.5]decanonyl, morpholinyl, octahydrocyclopenta[c]pyrrolyl, piperazinyl, piperidinyl, pyrrolidinyl, and quinuclidinyl, each substituted with zero to 4 R12a. Also included in this embodiment are compounds in which each R12a is independently —OH, C1-4 alkyl, C1-3 fluoroalkyl, C1-2 cyanoalkyl, C1-4 hydroxyalkyl, —(CH2)1-2O(C1-2 alkyl), —CH2C(O)NRxRx, —(CH2)1-2S(O)2(C1-2 alkyl), —(CH2)1-2NHS(O)2(C1-2 alkyl), —(CH2)1-2NRxRx, C1-2 alkoxy, —NRyRy, —NRx(C1-3 fluoroalkyl), —NRx(CH2CH2O(C1-2 alkyl)), —NRx(C1-2 cyanoalkyl), —NRxCH2NRxRx, —NRx(C1-4 hydroxyalkyl), —NRx(CH2C(O)NH2), —NRx(OCH3), —NRxCH2CH2S(O)2(C1-2 alkyl), —NRxC(O)CH3, —NRxC(O)(C1-2 fluoroalkyl), —NRxC(O)CRxRxNRxRx, —N RxC(O)CH2NRyRy, —NRxC(O)CH2NRx(C1-4 hydroxyalkyl), —NRxCH2C(O)NRxRx, —NRxS(O)2CH3, —C(O)(C1-5alkyl), —C(O)CH2O(C1-2 alkyl), —C(O)CH2CH2O(C1-2 alkyl), —C(O)(CH2)1-2NRxRx, —C(O)CHRxNRyRy, R12b, —CRxRxR12b, —C(O)R12b, —C(O)CH2NRxR12b, —C(O)NRxR12b, —NRxC(O)CRxRxR12b, —NRxR12b, —NRxCRxRxR12b, —NRxC(O)CH2NRxR12b, —NRxC(O)CH2NRxCH2R12b, —NRxCH2C(O)NRxR12b, or —OR12b; and R12b is azetidinyl, bicyclo[1.1.1]pentanyl, C3-6 cycloalkyl, diazabicyclo[2.2.1]heptanyl, dioxolanyl, dioxothiaazaspiro[3.3]heptanyl, dioxidotetrahydrothiopyranyl, dioxidothiomorpholinyl, imidazolyl, morpholinyl, octahydrocyclopenta[c]pyrrolyl, octahydropyrrolo[3,4-c]pyrrolyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxaazaspiro[4.4]nonanyl, oxetanyl, phenyl, piperazinyl, piperazinonyl, piperidinyl, pyridinyl, pyrrolidinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, or triazolyl, each substituted with zero to 4 substituents independently selected from F, Cl, —OH, C1-3 alkyl, C1-2 hydroxyalkyl, C1-2 alkoxy, —(CH2)1-2O(C1-2 alkyl), —NRxRx, —C(O)NRxRx, and —CH2S(O)2(C1-2 alkyl).


One embodiment provides a compound of Formula (I) or a salt thereof wherein A is an aromatic group selected from [1,2,4]triazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, imidazolyl, indazolyl, isoquinolinyl, oxadiazolyl, oxazolyl, phenyl, pyrazinyl, pyrazolo[3,4-b]pyridinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinonyl, quinolinyl, quinoxalinyl, tetrahydro[1,2,4]triazolo[1,5-a]pyrazinyl, tetrahydroimidazo[1,2-a]pyrazinyl, tetrahydroisoquinolinyl, tetrahydrothiazolo[5,4-c]pyridinyl, tetrahydrothieno[2,3-c]pyridinyl, thiadiazolyl, thiazolyl, thiooxadiazolyl, and triazolyl, each substituted with zero to 2 R14a and zero to 3 R14b; and G, R1, R5, R14a, R14b, Rx, Ry, and n are defined in the first aspect. Included in this embodiment are compounds in which each R14a is independently: (i) H, F, Cl, —OH, C1-5 alkyl, C1-2 fluoroalkyl, C1-2 hydroxyalkyl, —(CH2)0-2OCH3, —CHRxNRx(C1-5 alkyl), —CHRxNRx(C1-2 cyanoalkyl), —CHRxNRx((CH2)1-2OCH3), —CHRxN((CH2)1-2OCH3)2, —CH2NRx(CH2C═CRx), —CH2NRxCH2CH2NRxRx, —(CH2)1-3CRxRxNRxRx, —CH(NH2)(CH2)3-4NRxRx, —CH2NRx(CH2)1-2O(C1-3 alkyl), —CH2NRx(CH2)1-2O(CH2)1-2OH, —CH2NH(CH2)1-2S(O)2OH, —CH2C(O)NRxRx, —NRxRy, —NRx(CH2)2-3NRxRx, —NRxC(O)(C1-2 alkyl), —NRx(O)(C1-2 fluoroalkyl), —NRxC(O)O(C1-3 alkyl), —NRxC(O)(CH2)1-2NRxRx, —NRxCH2C(O)CH2NRxRx, —C(O)(C1-2 alkyl), —C(O)CH2CRxRxOH, —C(O)CH2NRxRx, —C(O)NRxRx, —C(O)NRx(CH2CN), —C(O)NRx(CRxRx)2-3NRxRx, —C(O)N(CH2CH3)(CRxRx)2-3NRxRx, —C(O)NRxCH2C(O)NRxRx, —C(O)NRxCH2CH2NRxC(O)CH3, —O(CRxRx)2-3NRxRx, —S(O)2NRxRx, or —C(O)CH2S(O)2(C1-2 alkyl); (ii) 8-azabicyclo[3.2.1]octanyl, azaspiro[3.5]nonanyl, azetidinyl, benzo[c][1,2,5]oxadiazolyl, cyclopentyl, cyclohexyl, diazepanyl, morpholinyl, phenyl, piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrrolidinonyl, quinolinyl, quinuclidinyl, tetrahydroisoquinolinyl, tetrahydropyridinyl, or thiazolidinyl, each substituted with zero to 2 substituents independently selected from C1-4 alkyl, C1-2 fluoroalkyl, C1-4 hydroxyalkyl, —NRxRx, —(CH2) 1-2NRxRx, —C(O)(C1-2 alkyl), —C(O)CH2NRxRx, —C(O)O(C1-3 alkyl), —CH2C(O)NRxRx, C3-6 cycloalkyl, —CH2(phenyl), —CH2(pyrrolyl), —CH2(morpholinyl), —CH2(methylpiperazinyl), —CH2(thiophenyl), methylpiperidinyl, isobutylpiperidinyl, and pyridinyl; or (iii) -L3-R14c; each R14b is F, —CH3, or —OCH3; and R14c is adamantanyl, azepanyl, azetidinyl, C3-7 cycloalkyl, diazepanyl, imidazolyl, indolyl, morpholinyl, octahydropyrrolo[3,4-c]pyrrolyl, phenyl, piperazinonyl, piperazinyl, piperidinyl, pyridinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolyl, triazolyl, or tetrazolyl, each substituted with zero to 1 substituent selected from F, —OH, C1-4 alkyl, C1-3 hydroxyalkyl, —NRxRy, —NRxC(O)CH3, —C(O)(C1-2 alkyl), —C(O)NRxRx, —C(O)N(CH2CH3)2, —C(O)(tetrahydrofuranyl), —C(O)O(C1-2 alkyl), —CH2C(O)NRxRy, morpholinyl, methylpiperidinyl, pyrazinyl, pyridinyl, and pyrrolidinyl.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein said compound has the structure:




embedded image


wherein G, R1, R2, R5, R7b, R7c, n, and p are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which G is




embedded image


and R1 is —CH(CH3)2. Also included in this embodiment are compounds in which n is zero.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein said compound has the structure:




embedded image


wherein G, R1, R2, R5, R7b, R7c, n, and p are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which G is




embedded image


and R1 is —CH(CH3)2. Also included in this embodiment are compounds in which n is zero.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein said compound has the structure:




embedded image


wherein G, R1, R2, R5, R7b, R7c, n, and p are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which G is




embedded image


and R1 is —CH(CH3)2. Also included in this embodiment are compounds in which n is zero.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein said compound has the structure:




embedded image


wherein R7b is —C(O)(CRxRx)1-2NRyRy, —C(O)(CRxRx)1-2NRy(C1-4 hydroxyalkyl), or —C(O)(CRxRx)1-2NRx(CH2CH2OCH3); and G, R1, R2, R5, Rx, Ry, n, and p are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which G is




embedded image


R1 is —CH(CH3)2; and n is zero. Also included in this embodiment are compounds in which R7b is —C(O)(CRxRx)1-2NRyRy. Additionally, included in this embodiment are compounds in which G is




embedded image


R1 is —CH(CH3)2; R7b is —C(O)CH2N(CH3)2 or —C(O)CH2CH2N(CH3)2 or and n is zero.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein said compound has the structure:




embedded image


wherein G, R1, R2, R5, R7b, n, and p are defined in the first aspect or the second aspect.


Included in this embodiment are compounds in which G is




embedded image


and R1 is —CH(CH3)2. Also included in this embodiment are compounds in which n is zero.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein said compound has the structure:




embedded image


wherein G, R1, R2, R5, R7b, n, and p are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which G is




embedded image


and R1 is —CH(CH3)2. Also included in this embodiment are compounds in which compounds in which G is




embedded image


Additionally, included in this embodiment are compounds in which n is zero.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein said compound has the structure:




embedded image


wherein G, R1, R2, R5, R12a, n, and p are defined in the first aspect or the second aspect.


Included in this embodiment are compounds in which G is




embedded image


and R1 is —CH(CH3)2. Also included in this embodiment are compounds in which n is zero.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein said compound has the structure:




embedded image


wherein G, R1, R2, R5, R12a, n, and p are defined in the first aspect or the second aspect.


Included in this embodiment are compounds in which G is




embedded image


and R1 is —CH(CH3)2. Also included in this embodiment are compounds in which n is zero.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein said compound has the structure:




embedded image


wherein G, R1, R2, R5, R12a, n, and p are defined in the first aspect or the second aspect.


Included in this embodiment are compounds in which G is




embedded image


and R1 is —CH(CH3)2. Also included in this embodiment are compounds in which n is zero.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein said compound has the structure:




embedded image


wherein G, R1, R2, R5, R12a, n, and p are defined in the first aspect or the second aspect.


Included in this embodiment are compounds in which G is




embedded image


and R1 is —CH(CH3)2. Also included in this embodiment are compounds in which compounds in which G is




embedded image


Additionally, included in this embodiment are compounds in which n is zero.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein said compound has the structure:




embedded image


wherein G, R1, R2, R5, R12a, n, and p are defined in the first aspect or the second aspect.


Included in this embodiment are compounds in which G is




embedded image


and R1 is —CH(CH3)2. Also included in this embodiment are compounds in which compounds in which G is




embedded image


Additionally, included in this embodiment are compounds in which n is zero.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein said compound has the structure:




embedded image


wherein R12a is —NRxCRxRxR12b; R12b is C3-6 cycloalkyl, each substituted with —S(O)2(C1-2 alkyl) or —CH2S(O)2(C1-2 alkyl); and G, R1, R2, R5, Rx, n, and p are defined in the first aspect or the second aspect. Included in this embodiment are compounds in which G is




embedded image


and R1 is —CH(CH3)2. Also included in this embodiment are compounds in which compounds in which G is




embedded image


R1 is —CH(CH3)2; R12b is cyclopropyl substituted with —S(O)2(C1-2 alkyl) or —CH2S(O)2(C1-2 alkyl); and n is zero.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof, wherein:


G is




embedded image


R1 is —CH(CH3)2; each R2 is independently Cl, —CH3, —CH2CH3, —CH2OH, —CH2CH2OH, —CH2CN, —OCH3, —CH2OCH3, or —CH2CH2S(O)2CH3; and A is —CRxR12R13, wherein R12 and R13 together with the carbon atom to which they are attached form a cyclic group selected from azaspiro[3.3]heptanyl, C4-6 cycloalkyl,




embedded image


each substituted with zero to 2 R12a; and R2a, R2b, R5, R12a, n, and p are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I) or a salt thereof wherein: G is




embedded image


R1 is —CH(CH3)2; each R2 is independently —CH3 or —OCH3; A is —CH2CH2R11; and R11 is azetidinyl or piperidinyl, each substituted with zero to 2 substituents independently selected from —CH2(methyloxetanyl), —CH2(triazolyl), —C(O)CH2N(CH3)2, —CH2C(CH3)2OH, —CH2C(O)N(CH3)2, —CH2CH2S(O)2CH3, and oxetanyl; and R5, n, and p are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I) or a salt thereof wherein: G is




embedded image


A is —C(O)NR9R10; R1 is —CH(CH3)2; each R2 is —OCH3; R9 is —CH2CH2CF3, —CH2CH2N(CH3)2, or —(CH2)0-3R9a; R9a is piperidinyl substituted with —CH(CH3)2; R10 is H, —CH3, or —CH2CH3; or R9 and R10 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from piperazinyl substituted with —C(O)CH3; and R5, n, and p are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I) or a salt thereof wherein: G is




embedded image


G is A is —NR7R8; R1 is —CH(CH3)2; each R2 is independently —CH3, —CH2OH, or —OCH3; R7 and R8 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidinyl, diazabicyclo[2.2.1]heptanyl, diazabicyclo[2.2.2]octanyl, diazabicyclo[3.1.1]heptanyl, diazabicyclo[3.2.1]octanyl, azaspiro[3.3]heptanyl, diazaspiro[2.5]octanyl, diazaspiro[3.3]heptanyl, diazepanyl, diazaspiro[3.5]nonanyl, oxadiazabicyclo[3.3.1]nonanyl, piperazinyl, piperazinonyl, piperidinyl, and pyrrolidinyl, wherein said heterocyclic ring is substituted with zero to 1 R7b and zero to 2 R7c; R7b is: (i) —OH, C1-6 alkyl, C3-4 fluoroalkyl, C3-4 hydroxyalkyl, —CH2CN, —CH2CH2CN, —(CRxRx)1-2OCH3, —(CH2)2-3S(O)2CH3, —(CH2)2-3NHS(O)2CH3, —(CH2)1-2NRxRx, —(CH2)1-2C(O)NRxRx, —NRyRy, —NRx(C1-4 hydroxyalkyl), —NH(CH2CH2OCH3), —N(CH2CH2CN)2, —(CH2)1-2C(O)NRxRx, —N((CH2)1-2C(O)NRxRx)2, —NRxC(O)(CH2)1-2NRxRx, —NRx(CH2CH2S(O)2CH3), —C(O)(CRxRx)1-2NRyRy, —C(O)(CRxRx)1-2NRx(CH2CH2OCH3), —NRxR7d, —NRx(CH2)1-2R7d), —NR7dR7d, —N((CH2)1-2R7d)2, —C(O)R7d, or —C(O)(CRxRx)1-2R7d; or (ii) azetidinyl, cyclobutyl, cyclohexyl, dioxotetrahydrothiopyranyl, dioxothiomorpholinyl, morpholinyl, oxaazaspiro[4.3]octanyl, oxetanyl, piperazinyl, piperidinyl, pyrimidinyl, tetrahydrofuranyl, tetrahydropyranyl, or thiadiazolyl, each substituted with zero to 1 R8a and zero to 3 R8b; each R7c is independently —CH3 or —CH2CN; each R7d is independently azetidinyl, C3-6 cycloalkyl, dioxothiaazaspiro[3.3]heptanyl, morpholinyl, oxaazaspiro[3.3]heptanyl, oxaazaspiro[4.3]octanyl, oxaazaspiro[4.4]nonyl, oxetanyl, piperidinyl, pyrimidinyl, pyrazolyl, pyrrolidinyl, tetrahydropyranyl, thiadiazolyl, or triazolyl, each substituted with zero to 2 substituents selected from F, —OH, C1-3 alkyl, —CH2OH, —OCH3, —NRxRx, and —S(O)2CH3; R8a is —OH, —CH3, —OCH3, —C(O)CH3, or —C(O)OCH3; each R8b is —CH3; and R2, Rx, RyR5, n, and p are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I) or a salt thereof wherein: G is




embedded image


A is —O-L1-R6; L1 is bond or —CH2—; R1 is —CH(CH3)2; each R2 is independently —CH3 or —OCH3; R6 is: (i) —CH3,; or (ii) azetidinyl, cyclohexyl, or piperidinyl, each substituted with zero to 2 R6a; each R6a is independently —CH3, —CH2CH2CH3, —C(CH3)2, —CH2C(CH3)2OH, —N(CH3)2, —N(CH2CH2CH3)2, —CH2CH2S(O)2CH3, —CH2C(O)N(CH3)2, or tetrahydropyranyl; and R5, n, and p are defined in the first aspect or the second aspect.


One embodiment provides a compound of Formula (I) or a salt thereof wherein: G is




embedded image


R1 is —CH(CH3)2; A is —CHR12R13, wherein R12 and R13 together with the carbon atom to which they are attached form a cyclohexyl group; R1 is —CH(CH3)2; and n is zero.


One embodiment provides a compound of Formula (I) or a salt thereof wherein: G is




embedded image


R1 is —CH(CH3)2; each R2 is independently —CH3 or —OCH3; A is —CHR12R13, wherein R12 and R13 together with the carbon atom to which they are attached form a C4-6 cyclohexyl group substituted with R12a;

  • R12ais:




embedded image


p is 1 or 2; and n is zero or 1. Included in this embodiment are compounds in which R12 and R13 together with the carbon atom to which they are attached form a cyclohexyl group substituted with R12a.


One embodiment provides a compound of Formula (I) or a salt thereof wherein A is:




embedded image


and G, R1, R1, R5, R12a, n, and p are defined in the first aspect. Included in this embodiment are compounds in which G is




embedded image


R1 is —CH(CH3)2; and n is zero. Also included in this embodiment are compounds in which G is




embedded image


R1 is —CH(CH3)2; R12a is:




embedded image


and n is zero.


One embodiment provides a compound of Formula (I) or a salt thereof wherein compound is:




embedded image


One embodiment provides a compound of Formula (I) or a salt thereof wherein compound is:




embedded image


One embodiment provides a compound of Formula (I) or a salt thereof wherein compound is:




embedded image


One embodiment provides a compound of Formula (I) or a salt thereof wherein said compound is:




embedded image


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof wherein said compound is selected from Examples 1 to 1078.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof wherein said compound is selected from Examples 1 to 736.


One embodiment provides a compound of Formula (I), N-oxide, or a salt thereof wherein said compound is selected from Examples 737 to 1078.


The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. The invention encompasses all combinations of the aspects and/or embodiments of the invention noted herein. It is understood that any and all embodiments of the present invention may be taken in conjunction with any other embodiment or embodiments to describe additional embodiments. It is also to be understood that each individual element of the embodiments is meant to be combined with any and all other elements from any embodiment to describe an additional embodiment.


Definitions


The features and advantages of the invention may be more readily understood by those of ordinary skill in the art upon reading the following detailed description. It is to be appreciated that certain features of the invention that are, for clarity reasons, described above and below in the context of separate embodiments, may also be combined to form a single embodiment. Conversely, various features of the invention that are, for brevity reasons, described in the context of a single embodiment, may also be combined so as to form sub-combinations thereof. Embodiments identified herein as exemplary or preferred are intended to be illustrative and not limiting.


Unless specifically stated otherwise herein, references made in the singular may also include the plural. For example, “a” and “an” may refer to either one, or one or more.


As used herein, the phrase “compounds” refers to at least one compound. For example, a compound of Formula (I) includes a compound of Formula (I) and two or more compounds of Formula (I).


Unless otherwise indicated, any heteroatom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences.


The definitions set forth herein take precedence over definitions set forth in any patent, patent application, and/or patent application publication incorporated herein by reference.


Listed below are definitions of various terms used to describe the present invention. These definitions apply to the terms as they are used throughout the specification (unless they are otherwise limited in specific instances) either individually or as part of a larger group.


Throughout the specification, groups and substituents thereof may be chosen by one skilled in the field to provide stable moieties and compounds.


In accordance with a convention used in the art,




embedded image


is used in structural formulas herein to depict the bond that is the point of attachment of the moiety or substituent to the core or backbone structure.


The terms “halo” and “halogen,” as used herein, refer to F, Cl, Br, and I.


The term “cyano” refers to the group —CN.


The term “amino” refers to the group —NH2.


The term “oxo” refers to the group ═O.


The term “alkyl” as used herein, refers to both branched and straight-chain saturated aliphatic hydrocarbon groups containing, for example, from 1 to 12 carbon atoms, from 1 to 6 carbon atoms, and from 1 to 4 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and i-propyl), butyl (e.g., n-butyl, i-butyl, sec-butyl, and t-butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl. When numbers appear in a subscript after the symbol “C”, the subscript defines with more specificity the number of carbon atoms that a particular group may contain. For example, “C1-6 alkyl” denotes straight and branched chain alkyl groups with one to six carbon atoms.


The term “fluoroalkyl” as used herein is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups substituted with one or more fluorine atoms. For example, “C1-4 fluoroalkyl” is intended to include C1, C2, C3, and C4 alkyl groups substituted with one or more fluorine atoms. Representative examples of fluoroalkyl groups include, but are not limited to, —CF3 and —CH2CF3.


The term “cyanoalkyl” includes both branched and straight-chain saturated alkyl groups substituted with one or more cyano groups. For example, “cyanoalkyl” includes —CH2CN, —CH2CH2CN, and C1-4 cyanoalkyl.


The term “aminoalkyl” includes both branched and straight-chain saturated alkyl groups substituted with one or more amine groups. For example, “aminoalkyl” includes —CH2NH2, —CH2CH2NH2, and C1-4 aminoalkyl.


The term “hydroxyalkyl” includes both branched and straight-chain saturated alkyl groups substituted with one or more hydroxyl groups. For example, “hydroxyalkyl” includes —CH2OH, —CH2CH2OH, and C1-4 hydroxyalkyl.


The term “hydroxy-fluoroalkyl” includes both branched and straight-chain saturated alkyl groups substituted with one or more hydroxyl groups and one or more fluorine atoms. For example, “hydroxy-fluoroalkyl” includes —CHFCH2OH, —CH2CHFC(CH3)2OH, and C1-4 hydroxy-fluoroalkyl.


The term “cycloalkyl,” as used herein, refers to a group derived from a non-aromatic monocyclic or polycyclic hydrocarbon molecule by removal of one hydrogen atom from a saturated ring carbon atom. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl. When numbers appear in a subscript after the symbol “C”, the subscript defines with more specificity the number of carbon atoms that a particular cycloalkyl group may contain. For example, “C3-C6 cycloalkyl” denotes cycloalkyl groups with three to six carbon atoms.


The term “alkoxy,” as used herein, refers to an alkyl group attached to the parent molecular moiety through an oxygen atom, for example, methoxy group (—OCH3). For example, “C1-3 alkoxy” denotes alkoxy groups with one to three carbon atoms.


The term “alkoxyalkyl,” as used herein, refers to an alkoxy group attached through its oxygen atom to an alkyl group, which is attached to the parent molecular moiety, for example, methoxymethyl group (—CH2OCH3). For example, “C2-4 alkoxyalkyl” denotes alkoxyalkyl groups with two to four carbon atoms, such as —CH2OCH3, —CH2CH2OCH3, —CH2OCH2CH3, and —CH2CH2OCH2CH3.


The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.


The compounds of Formula (I) can be provided as amorphous solids or crystalline solids. Lyophilization can be employed to provide the compounds of Formula (I) as amorphous solids.


It should further be understood that solvates (e.g., hydrates) of the compounds of Formula (I) are also within the scope of the present invention. The term “solvate” means a physical association of a compound of Formula (I) with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolable solvates. Exemplary solvates include hydrates, ethanolates, methanolates, isopropanolates, acetonitrile solvates, and ethyl acetate solvates. Methods of solvation are known in the art.


Various forms of prodrugs are well known in the art and are described in:


a) The Practice of Medicinal Chemistry, Camille G. Wèrmuth et al., Ch 31, (Academic Press, 1996);


b) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985);


c) A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds. Ch 5, pgs 113-191 (Harwood Academic Publishers, 1991); and


d) Hydrolysis in Drug and Prodrug Metabolism, Bernard Testa and Joachim M. Mayer, (Wiley-VCH, 2003).


In addition, compounds of Formula (I), subsequent to their preparation, can be isolated and purified to obtain a composition containing an amount by weight equal to or greater than 99% of a compound of Formula (I) (“substantially pure”), which is then used or formulated as described herein. Such “substantially pure” compounds of Formula (I) are also contemplated herein as part of the present invention.


“Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. The present invention is intended to embody stable compounds.


“Therapeutically effective amount” is intended to include an amount of a compound of the present invention alone or an amount of the combination of compounds claimed or an amount of a compound of the present invention in combination with other active ingredients effective to act as an inhibitor to TLR7/8/9, or effective to treat or prevent autoimmune and/or inflammatory disease states, such as SLE, IBD, multiple sclerosis (MS), and Sjögren's syndrome, and rheumatoid arthritis.


As used herein, “treating” or “treatment” cover the treatment of a disease-state in a mammal, particularly in a human, and include: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, i.e., arresting its development; and/or (c) relieving the disease-state, i.e., causing regression of the disease state.


The compounds of the present invention are intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium (D) and tritium (T). Isotopes of carbon include 13C and 14C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. For example, methyl (—CH3) also includes deuterated methyl groups such as —CD3.


Utility


The human immune system has evolved to defend the body from micro-organisms, viruses, and parasites that can cause infection, disease or death. Complex regulatory mechanisms ensure that the various cellular components of the immune system target the foreign substances or organisms, while not causing permanent or significant damage to the individual. While the initiating events are not well understood at this time, in autoimmune disease states the immune system directs its inflammatory response to target organs in the afflicted individual. Different autoimmune diseases are typically characterized by the predominate or initial target organ or tissues affected; such as the joint in the case of rheumatoid arthritis, the thyroid gland in the case of Hashimoto's thyroiditis, the central nervous system in the case of multiple sclerosis, the pancreas in the case of type I diabetes, and the bowel in the case of inflammatory bowel disease.


The compounds of the invention inhibit signaling through Toll-like receptor 7, or 8, or 9 (TLR7, TLR8, TLR9) or combinations thereof. Accordingly, compounds of Formula (I) have utility in treating conditions associated with the inhibition of signaling through one or more of TLR7, TLR8, or TLR9. Such conditions include TLR7, TLR8, or TLR9 receptor associated diseases in which cytokine levels are modulated as a consequence of intracellular signaling.


As used herein, the terms “treating” or “treatment” encompass the treatment of a disease state in a mammal, particularly in a human, and include: (a) preventing or delaying the occurrence of the disease state in a mammal, in particular, when such mammal is predisposed to the disease state but has not yet been diagnosed as having it; (b) inhibiting the disease state, i.e., arresting its development; and/or (c) achieving a full or partial reduction of the symptoms or disease state, and/or alleviating, ameliorating, lessening, or curing the disease or disorder and/or its symptoms.


In view of their activity as selective inhibitors of TLR7, TLR8, or TLR9, compounds of Formula (I) are useful in treating TLR7, TLR8, or TLR9 family receptor associated diseases, but not limited to, inflammatory diseases such as Crohn's disease, ulcerative colitis, asthma, graft versus host disease, allograft rejection, chronic obstructive pulmonary disease; autoimmune diseases such as Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, cutaneous lupus, psoriasis; auto-inflammatory diseases including Cryopyrin-Associated Periodic Syndromes (CAPS), TNF Receptor Associated Periodic Syndrome (TRAPS), Familial Mediterranean Fever (FMF), adult onset stills, systemic onset juvenile idiopathic arthritis, gout, gouty arthritis; metabolic diseases including type 2 diabetes, atherosclerosis, myocardial infarction; destructive bone disorders such as bone resorption disease, osteoarthritis, osteoporosis, multiple myeloma-related bone disorder; proliferative disorders such as acute myelogenous leukemia, chronic myelogenous leukemia; angiogenic disorders such as angiogenic disorders including solid tumors, ocular neovascularization, and infantile haemangiomas; infectious diseases such as sepsis, septic shock, and Shigellosis; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury, oncologic and viral diseases such as metastatic melanoma, Kaposi's sarcoma, multiple myeloma, and HIV infection and CMV retinitis, AIDS, respectively.


More particularly, the specific conditions or diseases that may be treated with the inventive compounds include, without limitation, pancreatitis (acute or chronic), asthma, allergies, adult respiratory distress syndrome, chronic obstructive pulmonary disease, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, graft vs. host disease, inflammatory reaction induced by endotoxin, tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, pancreatic β-cell disease; diseases characterized by massive neutrophil infiltration; rheumatoid spondylitis, gouty arthritis and other arthritic conditions, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, allograft rejections, fever and myalgias due to infection, cachexia secondary to infection, keloid formation, scar tissue formation, ulcerative colitis, pyresis, influenza, osteoporosis, osteoarthritis, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, sepsis, septic shock, and Shigellosis; Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury; angiogenic disorders including solid tumors, ocular neovascularization, and infantile haemangiomas; viral diseases including acute hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), HIV infection and CMV retinitis, AIDS, ARC or malignancy, and herpes; stroke, myocardial ischemia, ischemia in stroke heart attacks, organ hypoxia, vascular hyperplasia, cardiac and renal reperfusion injury, thrombosis, cardiac hypertrophy, thrombin-induced platelet aggregation, endotoxemia and/or toxic shock syndrome, conditions associated with prostaglandin endoperoxidase syndase-2, and pemphigus vulgaris. Included in this embodiment are methods of treatment in which the condition is selected from lupus including lupus nephritis and systemic lupus erythematosus (SLE), Crohn's disease, ulcerative colitis, allograft rejection, rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, and pemphigus vulgaris. Also included are methods of treatment in which the condition is selected from ischemia reperfusion injury, including cerebral ischemia reperfusions injury arising from stroke and cardiac ischemia reperfusion injury arising from myocardial infarction. Another method of treatment is one in which the condition is multiple myeloma.


In one embodiment, the compounds of Formula (I) are useful in treating cancer, including Waldenstrom's Macroglobulinemia (WM), diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), cutaneous diffuse large B cell lymphoma, and primary CNS lymphoma.


In addition, the TLR7, TLR8, or TLR9 inhibitors of the present invention inhibit the expression of inducible pro-inflammatory proteins such as prostaglandin endoperoxide synthase-2 (PGHS-2), also referred to as cyclooxygenase-2 (COX-2), IL-1, IL-6, IL-18, chemokines. Accordingly, additional TLR7/8/9 associated conditions include edema, analgesia, fever and pain, such as neuromuscular pain, headache, pain caused by cancer, dental pain and arthritis pain. The inventive compounds also may be used to treat veterinary viral infections, such as lentivirus infections, including, but not limited to equine infectious anemia virus; or retrovirus infections, including feline immunodeficiency virus, bovine immunodeficiency virus, and canine immunodeficiency virus.


The present invention thus provides methods for treating such conditions, comprising administering to a subject in need thereof a therapeutically-effective amount of at least one compound of Formula (I) or a salt thereof. “Therapeutically effective amount” is intended to include an amount of a compound of the present invention that is effective when administered alone or in combination to inhibit autoimmune disease or chronic inflammatory disease.


The methods of treating TLR7, TLR8, or TLR9 associated conditions may comprise administering compounds of Formula (I) alone or in combination with each other and/or other suitable therapeutic agents useful in treating such conditions. Accordingly, “therapeutically effective amount” is also intended to include an amount of the combination of compounds claimed that is effective to inhibit TLR7, TLR8, or TLR9 and/or treat diseases associated with TLR7, TLR8, or TLR9.


Exemplary of such other therapeutic agents include corticosteroids, rolipram, calphostin, cytokine-suppressive anti-inflammatory drugs (CSAIDs), Interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear translocation inhibitors, such as deoxyspergualin (DSG); non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, celecoxib and rofecoxib; steroids such as prednisone or dexamethasone; antiviral agents such as abacavir; antiproliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, PROGRAF®); anti-malarials such as hydroxychloroquine; cytotoxic drugs such as azathiprine and cyclophosphamide; TNF-α inhibitors such as tenidap, anti-TNF antibodies or soluble TNF receptor, and rapamycin (sirolimus or RAPAMUNE®) or derivatives thereof.


The above other therapeutic agents, when employed in combination with the compounds of the present invention, may be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art. In the methods of the present invention, such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the inventive compounds. The present invention also provides pharmaceutical compositions capable of treating TLR7/8/9 receptor-associated conditions, including IL-1 family receptor-mediated diseases as described above.


The inventive compositions may contain other therapeutic agents as described above and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (e.g., excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.


Accordingly, the present invention further includes compositions comprising one or more compounds of Formula (I) and a pharmaceutically acceptable carrier.


A “pharmaceutically acceptable carrier” refers to media generally accepted in the art for the delivery of biologically active agents to animals, in particular, mammals. Pharmaceutically acceptable carriers are formulated according to a number of factors well within the purview of those of ordinary skill in the art. These include without limitation the type and nature of the active agent being formulated; the subject to which the agent-containing composition is to be administered; the intended route of administration of the composition; and, the therapeutic indication being targeted. Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media, as well as a variety of solid and semi-solid dosage forms. Such carriers can include a number of different ingredients and additives in addition to the active agent, such additional ingredients being included in the formulation for a variety of reasons, e.g., stabilization of the active agent, binders, etc., well known to those of ordinary skill in the art. Descriptions of suitable pharmaceutically acceptable carriers, and factors involved in their selection, are found in a variety of readily available sources such as, for example, Remington's Pharmaceutical Sciences, 17th Edition (1985), which is incorporated herein by reference in its entirety.


Compounds in accordance with Formula (I) can be administered by any means suitable for the condition to be treated, which can depend on the need for site-specific treatment or quantity of Formula (I) compound to be delivered.


Also embraced within this invention is a class of pharmaceutical compositions comprising a compound of Formula (I) and one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as “carrier” materials) and, if desired, other active ingredients. The compounds of Formula (I) may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The compounds and compositions of the present invention may, for example, be administered orally, mucosally, or parenterally including intravascularly, intravenously, intraperitoneally, subcutaneously, intramuscularly, and intrasternally in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. For example, the pharmaceutical carrier may contain a mixture of mannitol or lactose and microcrystalline cellulose. The mixture may contain additional components such as a lubricating agent, e.g. magnesium stearate and a disintegrating agent such as crospovidone. The carrier mixture may be filled into a gelatin capsule or compressed as a tablet. The pharmaceutical composition may be administered as an oral dosage form or an infusion, for example.


For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, liquid capsule, suspension, or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. For example, the pharmaceutical composition may be provided as a tablet or capsule comprising an amount of active ingredient in the range of from about 0.1 to 1000 mg, preferably from about 0.25 to 250 mg, and more preferably from about 0.5 to 100 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, can be determined using routine methods.


Any pharmaceutical composition contemplated herein can, for example, be delivered orally via any acceptable and suitable oral preparations. Exemplary oral preparations, include, but are not limited to, for example, tablets, troches, lozenges, aqueous and oily suspensions, dispersible powders or granules, emulsions, hard and soft capsules, liquid capsules, syrups, and elixirs. Pharmaceutical compositions intended for oral administration can be prepared according to any methods known in the art for manufacturing pharmaceutical compositions intended for oral administration. In order to provide pharmaceutically palatable preparations, a pharmaceutical composition in accordance with the invention can contain at least one agent selected from sweetening agents, flavoring agents, coloring agents, demulcents, antioxidants, and preserving agents.


A tablet can, for example, be prepared by admixing at least one compound of Formula (I) with at least one non-toxic pharmaceutically acceptable excipient suitable for the manufacture of tablets. Exemplary excipients include, but are not limited to, for example, inert diluents, such as, for example, calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate; granulating and disintegrating agents, such as, for example, microcrystalline cellulose, sodium crosscarmellose, corn starch, and alginic acid; binding agents, such as, for example, starch, gelatin, polyvinyl-pyrrolidone, and acacia; and lubricating agents, such as, for example, magnesium stearate, stearic acid, and talc. Additionally, a tablet can either be uncoated, or coated by known techniques to either mask the bad taste of an unpleasant tasting drug, or delay disintegration and absorption of the active ingredient in the gastrointestinal tract thereby sustaining the effects of the active ingredient for a longer period. Exemplary water soluble taste masking materials, include, but are not limited to, hydroxypropyl-methylcellulose and hydroxypropyl-cellulose. Exemplary time delay materials, include, but are not limited to, ethyl cellulose and cellulose acetate butyrate.


Hard gelatin capsules can, for example, be prepared by mixing at least one compound of Formula (I) with at least one inert solid diluent, such as, for example, calcium carbonate; calcium phosphate; and kaolin.


Soft gelatin capsules can, for example, be prepared by mixing at least one compound of Formula (I) with at least one water soluble carrier, such as, for example, polyethylene glycol; and at least one oil medium, such as, for example, peanut oil, liquid paraffin, and olive oil.


An aqueous suspension can be prepared, for example, by admixing at least one compound of Formula (I) with at least one excipient suitable for the manufacture of an aqueous suspension. Exemplary excipients suitable for the manufacture of an aqueous suspension, include, but are not limited to, for example, suspending agents, such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, alginic acid, polyvinyl-pyrrolidone, gum tragacanth, and gum acacia; dispersing or wetting agents, such as, for example, a naturally-occurring phosphatide, e.g., lecithin; condensation products of alkylene oxide with fatty acids, such as, for example, polyoxyethylene stearate; condensation products of ethylene oxide with long chain aliphatic alcohols, such as, for example heptadecaethylene-oxycetanol; condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol, such as, for example, polyoxyethylene sorbitol monooleate; and condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, such as, for example, polyethylene sorbitan monooleate. An aqueous suspension can also contain at least one preservative, such as, for example, ethyl and n-propyl p-hydroxybenzoate; at least one coloring agent; at least one flavoring agent; and/or at least one sweetening agent, including but not limited to, for example, sucrose, saccharin, and aspartame.


Oily suspensions can, for example, be prepared by suspending at least one compound of Formula (I) in either a vegetable oil, such as, for example, arachis oil; olive oil; sesame oil; and coconut oil; or in mineral oil, such as, for example, liquid paraffin. An oily suspension can also contain at least one thickening agent, such as, for example, beeswax; hard paraffin; and cetyl alcohol. In order to provide a palatable oily suspension, at least one of the sweetening agents already described hereinabove, and/or at least one flavoring agent can be added to the oily suspension. An oily suspension can further contain at least one preservative, including, but not limited to, for example, an anti-oxidant, such as, for example, butylated hydroxyanisol, and alpha-tocopherol.


Dispersible powders and granules can, for example, be prepared by admixing at least one compound of Formula (I) with at least one dispersing and/or wetting agent; at least one suspending agent; and/or at least one preservative. Suitable dispersing agents, wetting agents, and suspending agents are as already described above. Exemplary preservatives include, but are not limited to, for example, anti-oxidants, e.g., ascorbic acid. In addition, dispersible powders and granules can also contain at least one excipient, including, but not limited to, for example, sweetening agents; flavoring agents; and coloring agents.


An emulsion of at least one compound of Formula (I) thereof can, for example, be prepared as an oil-in-water emulsion. The oily phase of the emulsions comprising compounds of Formula (I) may be constituted from known ingredients in a known manner. The oil phase can be provided by, but is not limited to, for example, a vegetable oil, such as, for example, olive oil and arachis oil; a mineral oil, such as, for example, liquid paraffin; and mixtures thereof. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Suitable emulsifying agents include, but are not limited to, for example, naturally-occurring phosphatides, e.g., soy bean lecithin; esters or partial esters derived from fatty acids and hexitol anhydrides, such as, for example, sorbitan monooleate; and condensation products of partial esters with ethylene oxide, such as, for example, polyoxyethylene sorbitan monooleate. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. An emulsion can also contain a sweetening agent, a flavoring agent, a preservative, and/or an antioxidant. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate alone or with a wax, or other materials well known in the art.


The compounds of Formula (I) can, for example, also be delivered intravenously, subcutaneously, and/or intramuscularly via any pharmaceutically acceptable and suitable injectable form. Exemplary injectable forms include, but are not limited to, for example, sterile aqueous solutions comprising acceptable vehicles and solvents, such as, for example, water, Ringer's solution, and isotonic sodium chloride solution; sterile oil-in-water microemulsions; and aqueous or oleaginous suspensions.


Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules using one or more of the carriers or diluents mentioned for use in the formulations for oral administration or by using other suitable dispersing or wetting agents and suspending agents. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride solution, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art. The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water, or with cyclodextrin (i.e. Captisol), cosolvent solubilization (i.e. propylene glycol) or micellar solubilization (i.e. Tween 80).


The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.


A sterile injectable oil-in-water microemulsion can, for example, be prepared by 1) dissolving at least one compound of Formula (I) in an oily phase, such as, for example, a mixture of soybean oil and lecithin; 2) combining the Formula (I) containing oil phase with a water and glycerol mixture; and 3) processing the combination to form a microemulsion.


A sterile aqueous or oleaginous suspension can be prepared in accordance with methods already known in the art. For example, a sterile aqueous solution or suspension can be prepared with a non-toxic parenterally-acceptable diluent or solvent, such as, for example, 1,3-butane diol; and a sterile oleaginous suspension can be prepared with a sterile non-toxic acceptable solvent or suspending medium, such as, for example, sterile fixed oils, e.g., synthetic mono- or diglycerides; and fatty acids, such as, for example, oleic acid.


Pharmaceutically acceptable carriers, adjuvants, and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-alpha-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, polyethoxylated castor oil such as CREMOPHOR surfactant (BASF), or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as alpha-, beta-, and gamma-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.


The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals. The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc. Tablets and pills can additionally be prepared with enteric coatings. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.


The amounts of compounds that are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex, the medical condition of the subject, the type of disease, the severity of the disease, the route and frequency of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. A daily dose of about 0.001 to 100 mg/kg body weight, preferably between about 0.0025 and about 50 mg/kg body weight and most preferably between about 0.005 to 10 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day. Other dosing schedules include one dose per week and one dose per two day cycle.


For therapeutic purposes, the active compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered orally, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.


Pharmaceutical compositions of this invention comprise at least one compound of Formula (1) and optionally an additional agent selected from any pharmaceutically acceptable carrier, adjuvant, and vehicle. Alternate compositions of this invention comprise a compound of the Formula (I) described herein, or a prodrug thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.


The present invention also encompasses an article of manufacture. As used herein, article of manufacture is intended to include, but not be limited to, kits and packages. The article of manufacture of the present invention, comprises: (a) a first container; (b) a pharmaceutical composition located within the first container, wherein the composition, comprises: a first therapeutic agent, comprising: a compound of the present invention or a pharmaceutically acceptable salt form thereof; and (c) a package insert stating that the pharmaceutical composition can be used for the treatment of an inflammatory disorder and/or an autoimmune disease (as defined previously). In another embodiment, the package insert states that the pharmaceutical composition can be used in combination (as defined previously) with a second therapeutic agent to treat an inflammatory disorder and/or an autoimmune disease. The article of manufacture can further comprise: (d) a second container, wherein components (a) and (b) are located within the second container and component (c) is located within or outside of the second container. Located within the first and second containers means that the respective container holds the item within its boundaries.


The first container is a receptacle used to hold a pharmaceutical composition. This container can be for manufacturing, storing, shipping, and/or individual/bulk selling. First container is intended to cover a bottle, jar, vial, flask, syringe, tube (e.g., for a cream preparation), or any other container used to manufacture, hold, store, or distribute a pharmaceutical product.


The second container is one used to hold the first container and, optionally, the package insert. Examples of the second container include, but are not limited to, boxes (e.g., cardboard or plastic), crates, cartons, bags (e.g., paper or plastic bags), pouches, and sacks. The package insert can be physically attached to the outside of the first container via tape, glue, staple, or another method of attachment, or it can rest inside the second container without any physical means of attachment to the first container. Alternatively, the package insert is located on the outside of the second container. When located on the outside of the second container, it is preferable that the package insert is physically attached via tape, glue, staple, or another method of attachment. Alternatively, it can be adjacent to or touching the outside of the second container without being physically attached.


The package insert is a label, tag, marker, etc. that recites information relating to the pharmaceutical composition located within the first container. The information recited will usually be determined by the regulatory agency governing the area in which the article of manufacture is to be sold (e.g., the United States Food and Drug Administration). In one embodiment, the package insert specifically recites the indications for which the pharmaceutical composition has been approved. The package insert may be made of any material on which a person can read information contained therein or thereon. For example, the package insert is a printable material (e.g., paper, plastic, cardboard, foil, adhesive-backed paper or plastic, etc.) on which the desired information has been formed (e.g., printed or applied).


Methods of Preparation


The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety by reference.


The compounds of this invention may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and work up procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents that are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts (Protective Groups In Organic Synthesis, Third Edition, Wiley and Sons, 1999).


EXAMPLES

Preparation of compounds of Formula (I), and intermediates used in the preparation of compounds of Formula (I), can be prepared using procedures shown in the following Examples and related procedures. The methods and conditions used in these examples, and the actual compounds prepared in these Examples, are not meant to be limiting, but are meant to demonstrate how the compounds of Formula (I) can be prepared. Starting materials and reagents used in these examples, when not prepared by a procedure described herein, are generally either commercially available, or are reported in the chemical literature, or may be prepared by using procedures described in the chemical literature.


Abbreviations

  • Ac acetyl
  • ACN acetonitrile
  • AcOH acetic acid
  • anhyd. anhydrous
  • aq. aqueous
  • Bn benzyl
  • Bu butyl
  • Boc tert-butoxycarbonyl
  • CV Column Volumes
  • DCE dichloroethane
  • DCM dichloromethane
  • DMAP dimethylaminopyridine
  • DMF dimethylformamide
  • DMSO dimethylsulfoxide
  • EtOAc ethyl acetate
  • Et ethyl
  • EtOH ethanol
  • H or H2 hydrogen
  • h, hr or hrs hour(s)
  • hex hexane
  • i iso
  • IPA isopropyl alcohol
  • HCl hydrochloric acid
  • HPLC high pressure liquid chromatography
  • LC liquid chromatography
  • M molar
  • mM millimolar
  • Me methyl
  • MeOH methanol
  • MHz megahertz
  • min. minute(s)
  • mins minute(s)
  • M+1 (M+H)+
  • MS mass spectrometry
  • n or N normal
  • NBS n-bromosuccinimide
  • nm nanometer
  • nM nanomolar
  • NMP N-methylpyrrolidine
  • Pd/C palladium on carbon
  • Ph phenyl
  • PPh3 triphenylphosphine
  • Pr propyl
  • PSI pounds per square inch
  • Ret Time retention time
  • sat. saturated
  • SFC supercritical fluid chromatography
  • TBAF tetrabutylammoniurn fluoride
  • TEA triethylamine
  • TFA trifluoroacetic acid
  • THF tetrahydrofuran
  • T3P 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide
  • 2nd Generation RuPhos Precatalyst: chloro(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)
  • 2nd Generation Xphos precatalyst: chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)


Analytical and Preparative HPLC Conditions;



  • QC-ACN-AA-XB: Column: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.

  • QC-ACN-TFA-XB: Column: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.

  • Method A1: L3 Acquity: Column: (LCMS) UPLC BEH C18, 2.1×50 mm, 1.7 μm particles; Mobile Phase: (A) water; (B) acetonitrile; Buffer: 0.05% TFA; Gradient Range: 2%-98% B (0 to 1 min) 98% B (to 1.5 min) 98%-2% B (to 1.6 min); Gradient Time: 1.6 min; Flow Rate: 0.8 mL/min; Analysis Time: 2.2 min; Detection: Detector 1: UV at 220 nm; Detector 2: MS (ESI+).

  • Method B1: L2 Aquity(4); Column: (LCMS) UPLC BEH C18, 2.1×50 mm, 1.7 μm particles; Mobile Phase: (A) water; (B) acetonitrile; Buffer: 0.05% TFA; Gradient Range: 2%-98% B (0 to 1 min) 98% B (to 1.5 min) 98%-2% B (to 1.5 min); Gradient Time: 1.8 min; Flow Rate: 0.8 mL/min; Analysis Time: 2.2 min; Detection: Detector 1: UV at 220 nm; Detector 2: MS (ESI+).

  • Method D1 SCP: Column: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes, then a 0.75 minute hold at 100% B; Flow: 1.11 mL/min; Detection: UV at 220 nm.

  • Method D2 SCP: Column: XBridge C18, 19×200 mm, 5μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 5 minute hold at 100% B; Flow: 20 mL/min. Detection: UV at 220 nm.

  • Method D3 SCP: Column: XBridge C18, 19×200 mm, 5 μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: 6-46% B over 20 minutes, then a 4 minute hold at 100% B; Flow: 20 mL/min. Detection: UV at 220 nm.

  • Method E1 iPAC: Column: Waters Xbridge C18 4.6×50 mm 5 um particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate. Temperature: 50° C.; Gradient: 0-100% B over 1 minute; Flow: 4 mL/min; Detection: UV at 220 nm.

  • Method F1 iPAC: Column: Waters Acquity BEH C18 2.1×50 mm 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0-100% B over 2.20 minutes; Flow: 0.800 mL/min; Detection: UV at 220 nm.

  • Method G1: Column: Symmetry C8, (250×4.6 mm), 5 μm particles; Mobile Phase A: 1:1 acetonitrile:TFE with 10 mM ammonium acetate; Mobile Phase B: 1:1 acetonitrile: TFE with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0-100% B over 25 minutes, then a 0.75 minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.

  • Method H1 (SFC): Column: Luxcellulose-4 (250×4.6 mm), 5 μm particles; % CO2: 50%, % Cosolvent: 50% of 0.4% isopropyl amine in methanol; Temperature 30° C.; Flow: 120 g/min; Detection: UV at 230 nm.

  • (A): Column-Ascentis Express C18 (50×2.1 mm-2.7 μm) Mphase A: 10 mM NH4COOH in water: ACN (98:02); Mphase B: 10 mM NH4COOH in water: ACN (02:98), Gradient: 0-100% B over 3 minutes, Flow=1 mL/min.

  • (D): Kinetex XB-C18 (75×3 mm) 2.6 micron; Solvent A: 10 mM ammonium formate in water: acetonitrile (98:02); Mobile Phase B: 10 mM ammonium formate in water: acetonitrile (02:98); Temperature: 50° C.; Gradient: 0-100% B over 3 minutes; Flow rate: 1.1 mL/min; Detection: UV at 220 nm.

  • (E): Column: Ascentis Express C18 (50×2.1)mm, 2.7 μm; Mobile Phase A: 5:95 acetonitrile: water with 10 mM NH4OAc; Mobile Phase B: 95:5 acetonitrile: water with 10 mM NH4OAc; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes; Flow: 1.1 mL/min.

  • (F): Column: Ascentis Express C18 (50×2.1)mm, 2.7 μm; Mobile Phase A: 5:95 acetonitrile: water with 0.1% TFA; Mobile Phase B: 95:5 acetonitrile: water with 0.1% TFA; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes; Flow: 1.1 mL/min.

  • (G): Column: Waters Acquity UPLC BEH C18 (2.1×50 mm), 1.7 micron; Solvent A=100% water with 0.05% TFA; Solvent B=100% acetonitrile with 0.05% TFA; gradient=2-98% B over 1 minute, then a 0.5-minute hold at 98% B; Flow rate: 0.8 mL/min; Detection: UV at 220 nm.

  • (H): Column: Acentis Express C18 (50×2.1 mm) 1.7 μm, Acentis C8 NH4COOH 5 min. M, Mobile Phase A: 10 mM ammonium formate: ACN (98:2), Mobile Phase B: 10 mM ammonium formate: ACN (2:98), gradient: 20%-100% B (0-4 min); 100% B (4-4.6 min); Flow: 1 mL/min

  • (I) Column: Sunfire C18 (4.6×150) mm, 3.5 μm; Mobile Phase A: 5:95 acetonitrile: water with 0.05% TFA; Mobile Phase B: 95:5 acetonitrile: water with 0.05% TFA; Temperature: 50° C.; Gradient:10-100% B over 12 minutes; Flow:1 mL/min.

  • (J) Column: Sunfire C18 (4.6×150)mm, 3.5 μm; Mobile Phase A: 5:95 acetonitrile: water with 0.05% TFA; Mobile Phase B: 95:5 acetonitrile: water with 0.05% TFA.

  • (K) Waters Acquity SDS Mobile Phase: A: water B: ACN; 5%-95% B in 1 min; Gradient Range: 50%-98% B (0-0.5 min); 98% B (0.5 min-1 min); 98%-2% B (1-1.1 min); Run time: 1.2 min; Flow Rate: 0.7 mL/min; Analysis Time: 1.7 min; Detection: Detector 1: UV at 220 nm; Detector 2: MS (ES+).

  • (L) Acquity UPLC BEH C18 (3.0×50 mm) 1.7 μm. Buffer: 5 mM ammonium acetate Mobile phase A: Buffer:ACN (95:5); Mobile phase B:Buffer:ACN (5:95) Method: % B: 0 min-20%:1.1 min -90%:1.7 min-90%. Run time: 2.25 min; Flow Rate: 0.7 mL/min; Detection: Detector 1: UV at 220 nm; Detector 2: MS (ES+).

  • (M): Kinetex SBC18 (4.6×50 mm) 5 micron; Solvent A: 10 mM ammonium formate in water: acetonitrile (98:02); Mobile Phase B: 10 mM ammonium formate in water: acetonitrile (02:98); Temperature: 50° C.; Gradient: 30-100% B (0-4 min), 100% B (4-4.6 min), 100-30% B (4.6-4.7 min), 30% B (4.7-5.0 min); Flow rate: 1.5 mL/min; Detection: UV at 220 nm.

  • (N): Column-Ascentis Express C18 (50×2.1 mm 2.7 μm) Mphase A: 10 mM NH4COOH in water: ACN (98:02); Mphase B: 10 mM NH4COOH in water: ACN (02:98), Gradient: 0-100% B (0-1.7 minutes); 100% B (1.7-3.4 minutes). Flow=1 mL/min.

  • (O) Waters Acquity SDS Column BEH C18 (2.1×50 mm) 1.7 μm. Phase A: buffer in water; Mphase B: buffer in ACN, Gradient: 20-98% B (0-1.25 minutes); 98% B (1.25-1.70 minutes); 98%-2% B (1.70-1.75 minutes); Flow=0.8 mL/min.

  • (P): Column: XBridge BEH XP C18 (50×2.1)mm, 2.5 μm; Mobile Phase A: 5:95 acetonitrile: water with 10 mM NH4OAc; Mobile Phase B: 95:5 acetonitrile: water with 10 mM NH4LOAc; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes; Flow: 1.1 mL/min.

  • (Q): Column: XBridge BEH XP C18 (50×2.1)mm, 2.5 μm; Mobile Phase A: 5:95 acetonitrile: water with 0.1% TFA; Mobile Phase B: 95:5 acetonitrile: water with 0.1% TFA; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes; Flow: 1.1 mL/min.

  • (R): Column-ZORBAX SB-C18 (50×4.6mm-5.0 μm) Mphase A: 10 mM NH4COOH in water:ACN(98:02) Mphase B: 10 mM NH4COOH in water:ACN (02:98). Gradient: 0 min-30%, 4.0 min-100%, 4.6 min-100%, 4.7 min-30%. Flow\min. 1.5 mL.

  • (TS): Column: Waters Acquity UPLC BEH C18 (2.1×50 mm), 1.7 micron; Solvent A=100% water with 0.05% TFA; Solvent B =100% acetonitrile with 0.05% TFA; gradient=2-98% B over 1 minute, then a 0.5 minute hold at 98% B; Flow rate: 0.8 mL/min; Detection: UV at 254 nm.

  • (DDS) Aquity: Column: (LCMS) UPLC BEH C18, 3.0×50 mm, 1.7 μm particles; Mobile Phase: (A) 10 mM NH4OAc: acetonitrile (95:5) Phase B) 10 mM NH4OAc: acetonitrile (5:95): Method: % B: 0 min-20:2 min-100:2.3 min-1001.8 min; Flow Rate: 0.7 mL/min; Detection: Detector 1: UV at 220 nm; Detector 2: MS (ESI+).

  • (DDS2) Acquity: Column: (LCMS) UPLC BEH C18, 3.2×50 mm, 1.7 μm particles; Buffer: 10 mM Ammonium Acetate Mobile Phase A:Buffer: ACN (95:5) Mobile Phase B:Buffer:ACN (5:95); Method % B: 0 min-20%:2 min-100%:2.2 min-100%; Flow rate=0.7 mL/min, Detection: Detector 1: UV at 220 nm; Detector 2: MS (ESI+).



Example 1
1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-4-yl)azetidin-3-amine



embedded image


Intermediate 1A: 2-bromo-5-hydrazinylpyridine



embedded image


A solution of 6-bromopyridin-3-amine (10.0 g, 57.8 mmol) in 6 M aqueous HCI (111 mL) was cooled to 0° C. A solution of sodium nitrite (3.99 g, 57.8 mmol) in water (148 mL), precooled to 0° C., was added over 5 min and the reaction mixture was stirred for 45 minutes at 0° C. Tin(II) chloride dihydrate (32.6 g, 144 mmol) was suspended in 6 M aqueous HCl(111 mL), precooled to 0° C., and was added to the reaction mixture over 5 min. The reaction mixture was stirred for 60 min more at 0° C. Upon completion, the reaction was quenched via addition of 40% w/w solution of KOH in water until the solution was basic as judged by pH paper. The mixture was diluted with water and DCM. The organic layer was separated and the aqueous layer was extracted with DCM. The combined organic layers were dried over sodium sulfate, filtered, and concentrated to afford 2-bromo-5-hydrazinylpyridine (8.08 g, 43.0 mmol, 74.3% yield). LCMS retention time 0.41 min [A1]. MS (E+) m/z: 190.1 [(M+2)+H+]. 1H NMR (499 MHz, CHLOROFORM-d) δ7.98 (d, J=3.0 Hz, 1H), 7.28 (app d, J=8.5 Hz, 1H), 7.10 (dd, J=8.7, 3.0 Hz, 1H), 5.25 (br app s, 1H), 3.62 (br app s, 2H).


Intermediate 1B: 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine



embedded image


2-bromo-5-hydrazinylpyridine (8.08 g, 43.0 mmol) was suspended in 5% v/v H2SO4 in water (215 mL) to form a chunky suspension. 3-Methylbutanal (5.19 mL, 47.3 mmol) was added and the suspension was stirred for 20 min at room temperature, then heated with a reflux condenser at 110° C. for 20 hours. Upon completion, the mixture was cooled in an ice bath. The reaction was quenched via the addition of 40% w/w solution of KOH in water until the pH was basic as judged by pH paper. Water and DCM were added until all solids had dissolved. The organic layer was separated and the aqueous layer was extracted twice with DCM. The combined organics were dried over sodium sulfate, filtered, and concentrated to afford a crude orange solid which was purified on silica gel column chromatography (Hex/EtOAc 0-50%) to afford 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b] pyridine (6.19 g, 25.9 mmol, 60% yield). LCMS retention time 0.90 min [A1]. MS (E+) m/z: 239.1 (M+H). 1H NMR (499 MHz, CHLOROFORM-d) δ8.71-8.43 (m, 1H), 7.48 (d, J=8.4 Hz, 1H), 7.22-7.17 (m, 2H), 3.37 (spt, J=6.8 Hz, 1H), 1.35 (d, J=6.8 Hz, 6H).


Intermediate 1C: tert-butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To a solution of 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine (5.0 g, 20.9 mmol) in THF (84 mL) were added Et3N (4.37 mL, 31.4 mmol) and DMAP (0.255 g, 2.09 mmol). The mixture was cooled to 0° C. BOC-anhydride 30% in toluene (16.73 g, 23.0 mmol) was added in a single portion and the reaction mixture was stirred for 1 hour. Another aliquot of BOC-anhydride 30% in toluene (2.0 g, 2.75 mmol) was added and the reaction mixture was stirred for 10 min. Upon completion, the reaction mixture was concentrated and the crude material was purified on silica gel column chromatography (Hex/EtOAc 0-40%) to afford tert-butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (6.98 g, 20.6 mmol, 98% yield). LCMS retention time 1.14 min [TS]. MS (Er+) m/z: 339.1 (M+H).


Intermediate 1D: tert-butyl 5-(3-((tert-butoxycarbonyl)amino)azetidin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


A suspension of tert-butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (1.05 g, 3.10 mmol), tert-butyl azetidin-3-ylcarbamate (0.693 g, 4.02 mmol), RuPhos 2nd Generation precatalyst (0.120 g, 0.155 mmol), and Cs2CO3 (3.03 g, 9.29 mmol) was made in 1,4-dioxane (21 mL). The suspension was degassed with nitrogen for 5 min, sealed, and placed in a heating block at 130° C. for 4 h and 20 min. Upon completion, the reaction mixture was filtered, concentrated and purified using silica gel column chromatography (Hex/EtOAc 0-50%) to afford tert-butyl 5-(3-((tert-butoxycarbonyl)amino)azetidin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (970 mg, 2.253 mmol, 72.8% yield). LCMS retention time 0.86 min [TS]. MS (E+) m/z: 431.2 (M+H). 1H NMR (499 MHz, CHLOROFORM-d) δ8.19-7.98 (m, 1H), 7.45-7.29 (m, 1H), 6.26 (d, J=8.8 Hz, 1H), 5.07-4.88 (m, 1H), 4.68-4.51 (m, 1H), 4.35 (br t, J=7.6 Hz, 2H), 3.78 (dd, J=8.6, 5.4 Hz, 2H), 3.24-3.15 (m, 1H), 1.65 (s, 9H), 1.46 (s, 9H), 1.35 (d, J=7.0 Hz, 6H).


Intermediate 1E: tert-butyl 5-(3-((tert-butoxycarbonypamino)azetidin-1-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


A solution containing tert-butyl 5-(3-((tert-butoxycarbonypamino)azetidin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (802 mg, 1.86 mmol) and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.49 mL, 2.42 mmol) in dry THY (9.3 mL), under a nitrogen atmosphere was cooled to −78° C. and treated with LDA (2M in THF) (2.33 mL, 4.66 mmol). The mixture was warmed to −30° C. over 30 min and stirred at −30° C. for 30 min, then allowed to warm slowly to 0° C. The reaction mixture was treated with saturated aqueous ammonium chloride solution, water, and DCM. The organic layer was dried over sodium sulfate, filtered and concentrated. The crude material was purified on silica gel column chromatography (Hex/EtOAc 0-50%) to afford tert-butyl 5-(3-((tert-butoxycarbonypamino)azetidin-1-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (830 mg, 1.49 mmol, 80% yield). LCMS retention time 1.05 min [TS]. MS (E+) m/z: 557.7 (M+H). 1H NMR (499 MHz, CHLOROFORM-d) δ7.84 (d, J=8.8 Hz, 1H), 6.21 (d, J=8.8 Hz, 1H), 5.05-4.86 (m, 1H), 4.70-4.53 (m, 1H), 4.34 (br t, J=7.5 Hz, 2H), 3.77 (dd, J=8.5, 5.3 Hz, 2H), 3.29-3.14 (m, 1H), 1.64 (s, 9H), 1.46 (s, 9H), 1.44-1.41 (m, 18H).


Intermediate 1F: (1-(3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidin-3-yl)carbamate



embedded image


tert-butyl 5-(3-((tert-butoxycarbonyl)amino)azetidin-1-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (830 mg, 1.49 mmol) was heated neat under nitrogen atmosphere with slow stirring at 165° C. for 100 min. Upon completion, the material was dissolved in DCM and concentrated to obtain tert-butyl(1-(3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidin-3-yl)carbamate as an off-white foam. LCMS retention time 0.92 min [TS]. MS (E+) m/z: 457.7 (M+H). 1H NMR (499 MHz, CHLOROFORM-d) δ8.06 (br s, 1H), 7.42 (d, J=8.8 Hz, 1H), 6.29 (d, J=8.7 Hz, 1H), 5.07-4.85 (m, 1H), 4.66-4.54 (m, 1H), 4.39-4.29 (m, 2H), 3.77 (dd, J=8.7, 5.5 Hz, 2H), 3.68-3.59 (m, 1H), 1.48 (d, J=7.0 Hz, 6H), 1.46 (s, 9H), 1.34 (s, 12H).


Intermediate 1G: tert-butyl (1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidin-3-yl)carbamate



embedded image


To a suspension of tert-butyl (1-(3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidin-3-yl)carbamate (227 mg, 0.497 mmol), 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (124 mg, 0.547 mmol), and 2nd Generation XPhos precatalyst (19.6 mg, 0.025 mmol) in dioxane (3.3 mL) was added 2M aqueous potassium phosphate tribasic (0.75 mL, 1.49 mmol). The biphasic mixture was degassed with nitrogen for 10 min. The vial was sealed and stirred at 70° C. for 2 hours. Upon completion, the reaction mixture was cooled to room temperature and concentrated. The crude material was taken up in DCM and purified by silica gel column chromatography (0-100% Hex/EtOAc) to afford tert-butyl (1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl) azetidin-3-yl)carbamate (170 mg, 0.357 mmol, 72% yield). LCMS retention time 0.77 min [TS]. MS (E+) m/z: 476.6 (M+H).


Example 1

To a suspension of tert-butyl (1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidin-3-yl)carbamate (170 mg, 0.357 mmol) in DCM (14 mL) at room temperature was added TFA (3.6 mL). The reaction mixture was stirred at room temperature for 30 minutes. Upon completion, the reaction mixture was concentrated. The crude material was taken up in DMF (3.6 mL) and Et3N (0.15 mL, 1.07 mmol), tetrahydro-4H-pyran-4-one (71.5 mg, 0.714 mmol), and sodium triacetoxyborohydride (151 mg, 0.714 mmol) were added sequentially. After stirring for 3 hours, additional DMF (3.6 mL) and Et3N (0.15 mL, 1.07 mmol), tetrahydro-4H-pyran-4-one (71.5 mg, 0.714 mmol), and sodium triacetoxyborohydride (151 mg, 0.714 mmol) were added sequentially. After stirring for 2 hours more at room temperature, the reaction was quenched by the addition of water, aqueous K2HPO4 1.5M dibasic solution and DCM. The organic layer was separated, dried over sodium sulfate, concentrated and the crude material was purified by SFC chromatography using the following conditions: CHIRAL IC 25×3.0 cm ID, 5 μm column; 85.0 mL/min flow rate; 60/40 CO2/methanol with 0.1% diethylamine mobile phase; 260 nm detector wavelength to obtain 1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-4-yl)azetidin-3-amine (95 mg, 0.203 mmol, 57% yield). LCMS retention time 0.53 min [TS]. MS (E+) m/z: 460.7 (M+H). 1H NMR (499 MHz, DMSO-d6) δ10.80 (s, 1H), 8.75 (s, 1H), 8.46 (s, 1H), 7.50 (d, J=8.7 Hz, 1H), 6.27 (d, J=8.7 Hz, 1H), 4.11 (t, J=7.3 Hz, 2H), 3.86-3.73 (m, 3H), 3.57 (t, J=6.8 Hz, 2H), 3.32-3.25 (m, 3H), 2.84-2.75 (m, 1H), 2.58 (s, 3H), 2.15 (s, 3H), 1.75-1.66 (m, 2H), 1.36 (br d, J=6.8 Hz, 6H), 1.31-1.21 (m, 2H).


Example 2
6-(3-isopropyl-5-(piperazin-1-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


Intermediate 2A: tert-butyl 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


A suspension of tert-butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (2.0 g, 5.90 mmol), tert-butyl piperazine-1-carboxylate (1.32 g, 7.07 mmol), 2nd generation RuPhos precatalyst (0.114 g, 0.147 mmol), and Cs2CO3 (4.80 g, 14.7 mmol) in 1,4-dioxane (20 mL) in a reaction vial with a pressure-relief septum-lined cap and stir bar was degassed with nitrogen gas for 5 minutes. The reaction vial was sealed and placed in a heating block with stirring at 100° C. for 3 hours. An identical reaction following the same protocol was set up in parallel, and the two reactions were combined for workup and purification. Upon completion, the combined reactions were filtered and concentrated. The crude material was purified by silica gel column chromatography on a Teledyne Isco instrument eluting with Hex/EtOAc 0-60% to give tert-butyl 5-(4-(tert-butoxycarbonyl) piperazin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (4.64 g total) as an off-white foam. LCMS retention time 1.13 [TS]. MS (E+) 445.3 (M+H). 1H NMR (499 MHz, CHLOROFORM-d) δ8.13 (br s, 1H), 7.39 (br s, 1H), 6.65 (br d, J=9.0 Hz, 1H), 3.64-3.57 (m, 4H), 3.57-3.50 (m, 4H), 3.28-3.14 (m, 1H), 1.65 (s, 9H), 1.49 (s, 9H), 1.36 (d, J=6.9 Hz, 6H).


Intermediate 2B: tert-butyl 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


A solution containing tert-butyl 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (4.64 g, 10.4 mmol) and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.19 mL, 15.66 mmol) in dry THF (52 mL), under a nitrogen atmosphere was cooled in a dry ice/acetone bath to −78° C. and treated with LDA (2M in THF, 10.4 mL, 20.8 mmol). The mixture was allowed to warm to 0° C. over the course of 5 hours. Upon completion, the reaction was quenched by the addition of saturated aqueous NH4Cl solution, water, and EtOAc. The organic layer was separated, dried over magnesium sulfate, filtered and concentrated. The crude material was purified by silica gel column chromatography eluting with Hex/EtOAc 0-50% to give tert-butyl 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (5.29 g, 9.27 mmol, 89% yield). LCMS retention time 1.23 [TS]. MS (E+) m/z: 571.2. 1H NMR (499 MHz, CHLOROFORM-d) δ7.86 (d, J=9.1 Hz, 1H), 6.59 (d, J=9.1 Hz, 1H), 3.62-3.55 (m, 4H), 3.55-3.49 (m, 4H), 3.20 (spt, J=7.0 Hz, 1H), 1.64 (s, 9H), 1.49 (s, 9H), 1.44 (d, J=6.9 Hz, 6H), 1.42 (s, 12H).


Intermediate 2C: tert-butyl 4-(3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)piperazine-1-carboxylate



embedded image


tert-Butyl 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (5.29 g, 9.27 mmol) was heated neat at 170° C. under a nitrogen atmosphere with stirring for 6 hours. The reaction mixture was cooled to room temperature and remained at room temperature for 3 days. The reaction mixture was then reheated to 170° C. under a nitrogen atmosphere with stirring for another 4 hours. Upon completion, the material was dissolved in DCM and concentrated to afford tert-butyl 4-(3-isopropyl-2-(4,4,5,5-tetramethy-1-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)piperazine-1-carboxylate (4.02 g, 8.55 mmol, 92% yield) as a light brown foam. The material was carried forward without additional purification. Observed significant conversion to boronic acid on LCMS, although NMR indicated that the product was purely the compound. Boronic acid LCMS retention time 0.74 [TS]. Boronic acid MS (E+) m/z: 389.1 (M+H). Product characterization: LCMS retention time 0.93 [TS]. MS (E+) m/z: 471.2 (M+H). 1H NMR (499 MHz, CHLOROFORM-d) δ8.07 (s, 1H), 7.46 (d, J=8.9 Hz, 1H), 6.69 (d, J=9.1 Hz, 1H), 3.68-3.55 (m, 5H), 3.55-3.47 (m, 4H), 1.51-1.48 (m, 15H), 1.34 (s, 12H).


Intermediate 2D: tert-butyl 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)piperazine-1-carboxylate



embedded image


To a mixture of tert-butyl 4-(3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)piperazine-1-carboxylate (2.5 g, 5.31 mmol), 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (1.44 g, 6.38 mmol), and 2nd generation XPhos precatalyst (0.209 g, 0.266 mmol) in 1,4-dioxane (27 mL) was added aqueous K3PO4 solution (2M, 7.97 mL, 15.9 mmol). The biphasic mixture was degassed with nitrogen gas for 10 min. The reaction vessel was sealed, a line of nitrogen gas was affixed, and the reaction mixture was stirred at 70° C. for 3 hours. Upon completion, the reaction mixture was cooled to room temperature and diluted with EtOAc and water. The layers were separated, and the aqueous layer was extracted with EtOAc. The combined organic layer was dried over MgSO4 and concentrated to afford a crude brown oil. This material was by silica gel column chromatography on a Teledyne Isco instrument eluting with 0-100% Hex/EtOAc to afford tert-butyl 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)piperazine-1-carboxylate (2.31 g, 4.72 mmol, 89% yield). LCMS retention time 0.77 [TS]. MS (E+) m/z: 490.2 (M+H). 1H NMR (499 MHz, DMSO-d6) δ10.89 (s, 1H), 8.77 (s, 1H), 8.47 (s, 1H), 7.56 (d, J=8.9 Hz, 1H), 6.77 (d, J=8.9 Hz, 1H), 3.54-3.40 (m, 8H), 2.79 (spt, J=6.8 Hz, 1H), 2.58 (s, 3H), 2.16 (s, 3H), 1.43 (s, 9H), 1.38 (d, J=6.9 Hz, 6H).


Example 2

To a suspension of tert-butyl 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)piperazine-1-carboxylate (223 mg, 0.455 mmol) in DCM (5 mL) at room temperature was added TFA (1 mL). The reaction mixture was stirred at room temperature for 90 min and then concentrated to afford crude 6-(3-isopropyl-5-(piperazin-1-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine. A portion (10%) of this material was purified using preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5 μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM ammonium acetate; Gradient: a 0-minute hold at 5% B, 5-45% B over 20 minutes, then a 4 minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS and UV signals. Fractions containing the product were combined and dried via centrifugal evaporation to afford 6-(3-isopropyl-5-(piperazin-1-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (15.9 mg, 0.040 mmol). LCMS retention time 0.77 min [QC-ACN-TFA-XB]. MS (E+) m/z: 390.3 (M+H). NMR (500 MHz, DMSO-d6) δ10.70 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.53 (d, J=8.8 Hz, 1H), 6.71 (d, J=8.9 Hz, 1H), 3.46-3.36 (m, 4H), 2.94-2.85 (m, 4H), 2.85-2.77 (m, 1H), 2.59 (s, 3H), 2.17 (s, 3H), 1.37 (br d, J=6.6 Hz, 6H).


Example 3
1-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)piperazin-1-yl)-2-(dimethylamino)ethan-1-one



embedded image


A solution of 6-(3-isopropyl-5-(piperazin-1-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine, TFA (18.9 mg, 0.0376 mmol) in methanol was converted to the HCl salt form by adding 1 mL of 4N HCl in dioxane and concentrating to dryness. The material was taken up in methanol a second time, 1 mL of 4N HCl in dioxane was added, and the material was concentrated to dryness. The material was then suspended in DMF (1 mL) and dimethylglycine (28 mg, 0.272 mmol), Et3N (0.10 mL, 0.717 mmol) and T3P 50% in DMF (0.110 mL, 0.188 mmol) were added. The reaction mixture was stirred for 1 hour at room temperature. Upon completion, the reaction was quenched by addition of water, aqueous K2HPO4 1.5M solution, and DCM. The organic layer was separated, concentrated, taken up in methanol and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5 μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM ammonium acetate; Gradient: a 0 minute hold at 13% B, 13-53% B over 20 minutes, then a 4 minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS and UV signals. Fractions containing the product were combined and dried via centrifugal evaporation to afford 1-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)piperazin-1-y l)-2-(dimethylamino)ethan-1-one (12.8 mg, 0.026 mmol, 69.4% yield). LCMS retention time 0.86 min [QC-ACN-TFA-XB]. MS (E+) m/z: 475.3 (M+H). 1H NMR (500 MHz, DMSO-d6) δ10.87 (s, 1H), 8.70 (s, 1H), 8.44 (s, 1H), 7.57 (d, J=8.9 Hz, 1H), 6.78 (d, J=8.9 Hz, 1H), 3.16 (s, 2H), 2.84-2.73 (m, 1H), 2.56 (s, 3H), 2.14 (s, 3H), 1.35 (br d, J=6.7 Hz, 6H).


Example 4
4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-((1-(methylsulfonyl)cyclopropyl)methyl)cyclohexan-1-amine



embedded image


Intermediate 4A: tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To a solution of tert-butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (19.00 g, 56.0 mmol), 4,4,5,5-tetramethyl-2-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane (16.40 g, 61.6 mmol) and 2 M aqueous potassium phosphate tribasic (84 mL, 168 mmol) in THF (300 mL) was added PdCl2 (dppf)-CH2Cl2 adduct (1.372 g, 1.680 mmol). The bi-phasic mixture was degassed with nitrogen gas for 10 minutes and the sealed vial was stirred at 70° C. for 2 hours. The reaction mixture was cooled to room temperature and diluted with ethyl acetate and water. The mixture was transferred to a separatory funnel and the layers were separated. The combined organics were washed with saturated sodium sulfate, filtered and concentrated to dryness. Further purification was done by silica gel chromatography, which afforded tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (18.00 g, 45.0 mmol, 86% yield) as a light yellow solid. LCMS retention time 1.09 min [A1]. MS m/z: 399.5 (M+H).


Intermediate 4B: tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To tert-butyl3-isopropyl-5-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1H-pyrrolo[3,2-b] pyridine-1-carboxylate (18.00 g, 45.0 mmol) in a Parr bottle were added MeOH (15 mL) and 10% w/w Pd/C (1.490 g, 1.400 mmol). The vessel was placed on the Parr high pressure hydrogenation apparatus and pump/purged three times with nitrogen gas. After evacuation, the vessel was back-filled with hydrogen gas to approximately 40 psi and the reaction mixture was allowed to shake for 2 hours. The vessel was diluted with MeOH (200 mL) and ethyl acetate (200 mL) and the contents was filtered through tightly packed Celite. Upon concentration, collected 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-indole (19.00 g, 47.0 mmol, 100% yield) as a dark oil. LCMS retention time 0.95 min [A1]. MS m/z: 401.6 (M+H).


Intermediate 4C: 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine



embedded image


A solution containing tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (1.600 g, 3.99 mmol) and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.467 mL, 7.19 mmol) in dry THF (9.99 mL), under a nitrogen atmosphere was cooled in a dry-ice/acetone bath at −78° C. After stirring at −78° C. for 20 minutes, LDA (2 M in THF) (5.99 mL, 11.98 mmol) was added. The mixture was stirred at −78° C. for 30 min and allowed to warm to −30° C. over 1 hour and stirred at −30° C. for 30 minutes. The reaction mixture was treated with 1.5 M aqueous KH2PO4 solution. Water and ethyl acetate were added and the mixture was transferred to a separatory funnel. The layers were separated and the combined organics were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was further purified by silica gel chromatography, which afforded tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (1.7 g, 3.22 mmol, 81% yield). LCMS retention time 1.00 min [A1]. MS m/z: 527.3 (M+H).


tert-Butyl3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (1.7 g, 3.22 mmol) was added to a tall vial and the vial was capped. The vial was pump/purged three times with nitrogen gas and set to heat at 165° C. under a nitrogen atmosphere for 1.5 hours. The reaction mixture was cooled to room temperature and 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine (1.4 g, 3.28 mmol, 100% yield) was obtained and used as such. LCMS retention time 0.61 min [A1]. MS m/z: 345.8 (M+H) (observed the mass of the corresponding boronic acid).


Intermediate 4D: 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexan-1-one



embedded image


In a 40 mL reaction vial were added 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-13]pyridine (0.500 g, 1.173 mmol), 1,1′-bis(di-tert-butylphosphino)ferrocene palladium dichloride (0.023 g, 0.035 mmol), 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (0.265 g, 1.173 mmol) and THF (20 mL). The reaction vial was sealed and pump/purged three times with nitrogen gas. To this was added 2 M aqueous potassium phosphate tribasic (1.759 mL, 3.52 mmol) and the reaction mixture was heated to 65° C. for 1 hour. Following cooling to room temperature, the mixture was diluted with ethyl acetate and washed with water, then brine and dried over anhydrous sodium sulfate. The solids were filtered and the filtrate was concentrated. The residue was further purified by silica gel chromatography. Following concentration of the fractions, 6-(3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine was collected as a tan solid. To this intermediate was added DCM (0.5 mL), TFA (5 mL) and water (0.02 mL). The reaction vial was capped and stirred at room temperature for 4 hours, then concentrated under a stream of nitrogen. To this was added 1.5 M potassium phosphate solution, water and DCM. The mixture was poured into a separatory funnel and the layers were separated. The organics were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to afford 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexan-1-one (0.22 g, 0.548 mmol, 47% yield). LCMS retention time 0.61 min [A1]. MS m/z: 402.2 (M+H).


Example 4

4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b] pyridin-5-yl)cyclohexan-1-one (0.500 g, 1.245 mmol), (1-(methylsulfonyl)cyclopropyl) methanamine hydrochloride (0.347 g, 1.868 mmol) and TEA (0.694 mL, 4.98 mmol) were mixed in DCM (5 mL). The reaction vial was capped and the reaction mixture stirred under nitrogen overnight at room temperature. The volatiles were removed under a stream of nitrogen and the residue was placed under a nitrogen atmosphere and diluted with MeOH (5 mL). This was cooled to −78° C. and lithium borohydride (0.081 g, 3.74 mmol) was added. The reaction mixture was allowed to warm to room temperature in the dry ice bath overnight. The reaction was quenched via addition of 1.5M K2HPO4. Ethyl acetate was added and the mixture was extracted three times. The organics were washed with saturated NaCl solution, dried over sodium sulfate, filtered and concentrated. The material was further purified by silica gel chromatography and then SFC. The major and first eluting isolate was collected to afford 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-((1-(methylsulfonyl)cyclopropyl)methyl)cyclohexan-1-amine (0.300 g, 0.555 mmol, 45% yield) as an off-white solid. HPLC retention time 1.44 min [Method C]. MS m/z: 535.4 (M+H). HPLC retention time 0.845 min [Method D]. 1H NMR (499 MHz, DMSO-d6) δ11.14-11.02 (m, 1H), 8.80 (s, 1H), 8.49 (s, 1H), 7.66-7.55 (m, 1H), 7.07-6.94 (m, 1H), 3.41-3.29 (m, 2H), 3.17 (d, J=2.9 Hz, 1H), 3.14-3.12 (m, 1H), 3.14 (s, 1H), 3.02 (br d, J=7.0 Hz, 2H), 2.96-2.84 (m, 1H), 2.71 (tt, J=12.0, 3.5 Hz, 1H), 2.45 (br d, J=2.0 Hz, 1H), 2.18 (s, 3H), 2.08-1.99 (m, 2H), 1.94 (br d, J=11.8 Hz, 2H), 1.89-1.76 (m, 1H), 1.75-1.56 (m, 2H), 1.40 (d, J=6.8 Hz, 6H), 1.29-1.13 (m, 5H), 1.08-0.94 (m, 2H).


EXAMPLE 5
2-(3,4-dimethoxyphenyl)-5-(1′-isobutyl-[1,4′-bipiperidin]-4-yl)-3-methyl-1H-pyrrolo[3,2-b]pyridine



embedded image


Intermediates 5A-1 and 5A-1: 5-bromo-2-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrrolo[3,2-b]pyridine and 5-bromo-3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[3,2-b]pyridine



embedded image


To a mixture of 6-bromo-2-iodopyridin-3-amine (100 mg, 0.34 mmol), 1,2-dimethoxy-4-(prop-1-yn-1-yl)benzene (74 mg, 0.42 mmol), lithium chloride (18 mg, 0.42 mmol), sodium carbonate (180 mg, 1.68 mmol) and Pd(dppf)Cl2 (12.5 mg, 0.017 mmol) in a screw cap vial was added DMF (2 mL). The vial was fitted with a Teflon-lined septum cap. The system was evacuated under vacuum (via a needle from a nitrogen/vacuum manifold line) and backfilled with nitrogen gas. The procedure was repeated three times. The needle was removed and the vial was heated at 100° C. for 16 h. LCMS analysis shows formation of two isomers, in approximately 3:1 ratio. 1H NMR analysis suggested the major product to be 5-bromo-2-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrrolo[3,2-b]pyridine (5A-1). The reaction mixture was diluted with EtOAc (50 mL), poured into a separatory funnel and washed with 10% aqueous LiCl solution (2×10 mL) and saturated aqueous NaCl solution (10 mL), dried (Na2SO4), filtered and the filtrate was concentrated. The crude product was dissolved in a small amount of DCM and purified on a silica gel column chromatography with a 15 min gradient from 0%-100% DCM/EtOAc to afford 5-bromo-2-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrrolo[3,2-b]pyridine (Intermediate 5A-1) that was contaminated with Intermediate 5A-2, 5-bromo-3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[3,2-b] pyridine, m/z (303, M+1), 80 mg (67%).


Intermediate 5B: tert-butyl 4-(2-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate



embedded image


To a mixture containing 5-bromo-2-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrrolo[3,2-b]pyridine (Intermediate 5A-1) and Intermediate 5A-2 (100 mg, 0.29 mmol), tert-butyl4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (111 mg, 0.36 mmol), and Pd(dppf)Cl2 (10.5 mg, 0.014 mmol) in a screw cap vial was added THF (2.5 mL) followed by 3M aqueous solution of tripotassium phosphate (0.10 mL, 0.3 mmol). The vial was fitted with a Teflon lined septum cap. The system was evacuated under vacuum (via a needle from a nitrogen/vacuum manifold line) and backfilled with nitrogen gas. The procedure was repeated three times. The needle was removed and the vial was heated at 75° C. for 3 h. The reaction mixture was cooled to room temperature and treated with saturated aqueous NaCl solution (5 mL) and extracted with ethyl acetate (3×10 mL). The extracts were combined, dried (Na2SO4), filtered and concentrated. The crude product was dissolved in a small amount of DCM and purified on silica gel column chromatography eluting with a 10 min gradient from 5%-100% DCM/EtOAc. No separation was observed. A mixture of tert-butyl 4-(2-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-5,6-dihydropyridine-1(2H)-carboxylate (Intermediate 5B) and the regioisomer tert-butyl 4-(3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-5,6-dihydropyridine-1(2H)-carboxylate was isolated (100 mg,77% yield), m/z (550, M+1) and was used as such in subsequent step.


Intermediate 5C: tert-butyl 4-(2-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrrolo[3,2-b]pyridin-5-yl)piperidine-1-carboxylate



embedded image


A mixture of tert-butyl4-(2-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-5,6-dihydropyridine-1(2H)-carboxylate (Intermediate 5B) and regioisomer tert-butyl 4-(3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-5,6-dihydropyridine-1(2H)-carboxylate (95 mg, 0.21 mmol) was dissolved in MeOH (5 mL) and transferred to a Parr bottle. The mixture was purged with nitrogen. Pearlman's Catalyst (25 mg, 0.036 mmol) was added and the bottle was pressurized with hydrogen gas (50 psi) and shaken for 22 h. The reaction mixture was filtered through a pad of Celite and the filtrate was concentrated. The resulting residue was dissolved in a small amount of DCM and charged to a silica gel column, which was eluted over a 10 min gradient with 1%-5% MeOH/DCM to afford a mixture of tert-butyl 4-(2-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrrolo[3,2-b] pyridin-5-yl)-5,6-dihydropyridine-1(2H)-carboxylate (Intermediate 5C) and the regioisomer tert-butyl 4-(3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-5,6-dihydropyridine-1(2H)-carboxylate (82 mg, 80%), m/z (452, M+H).


Intermediate 5D: 2-(3,4-dimethoxyphenyl)-3-methyl-5-(piperidin-4-yl)-1H-pyrrolo[3,2-b]pyridine



embedded image


The mixture of isomers (tert-butyl 4-(2-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrrolo[3,2-b]pyridin-5-yl)piperidine-1-carboxylate (Intermediate 5C) and tert-butyl 4-(3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[3,2-b]pyridin-5-yl)piperidine-1-carboxylate (80 mg, 0.18 mmol) were suspended in 4 N HCl in dioxane (4 mL, 16.00 mmol), stirred for 30 min, and concentrated to dryness. The resulting residue was suspended in diethyl ether (1 mL) and the solids were filtered and dried to give a mixture of 2-(3,4-dimethoxyphenyl)-3-methyl-5-(piperidin-4-yl)-1H-pyrrolo[3,2-b]pyridine (Intermediate 5D) and 3-(3,4-dimethoxyphenyl)-2-methyl-5-(piperidin-4-yl)-1H-pyrrolo[3,2-b]pyridine as bis HCl salts (50 mg, 65%), m/z (352, M+H).


Example 5

To a solution containing a mixture of 3-(3,4-dimethoxyphenyl)-2-methyl-5-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridine 2 HCl (Intermediate 5D) and 2-(3,4-dimethoxyphenyl)-3-methyl-5-(piperidin-4-yl)-1H-pyrrolo[3,2-b]pyridine, 2 HCl (30 mg, 0.07 mmol) in DMF (1 mL) was added 1-isobutylpiperidin-4-one (55 mg, 0.35 mmol) followed by the addition of sodium triacetoxyborohydride (75 mg, 0.35 mmol) and a drop of acetic acid. The reaction mixture was stirred and treated with aqueous 1 N NaOH solution (1 mL). The mixture was extracted with ethyl acetate (3×2 mL). The extracts were combined and washed with 10% aqueous LiCl solution (2×2 mL) and concentrated. The residue was suspended in DMF (2 mL), filtered through a 0.45 micron nylon syringe filter. The crude material was purified via preparative LC/MS with the following conditions: Column: Waters XBridge C18, 19×250 mm, 5 μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: 0-40% B over 25 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation to afford 2-(3,4-dimethoxyphenyl)-5-(1′-isobutyl-[1,4′-bipiperidin]-4-yl)-3-methyl-1H-pyrrolo[3,2-b] pyridine, 3 TFA (25 mg, 0.03 mmol, 42%), m/z (491, M+H). Retention time, 1.3 min using LCMS Column: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.11 mL/min; Detection: UV at 220 nm. 1H NMR (500 MHz, DMSO-d6) δ8.31-8.17 (m, 1H), 7.35 (br m, 2H), 7.33-7.28 (m, 1H), 7.18 (br d, J=8.1 Hz, 1H), 3.88 (s, 3H), 3.86 (m, 3H), 2.55 (m, 3H), 0.98 (d, J=6 Hz, 6H).


Example 6
N-(2-(dimethylamino)ethyl)-N-ethyl-3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-5-carboxamide



embedded image


Intermediate 6A: 6-bromo-2-iodo-5-methylpyridin-3-amine



embedded image


To a solution of 6-bromo-5-methylpyridin-3-amine (10 g, 53.5 mmol) in DMF (150 mL) was added NIS (12.03 g, 53.5 mmol). The resulting reaction mixture was stirred at room temperature for 12 h. The reaction mass was diluted with DCM (100 mL), washed with sodium thiosulfate solution (100 mL), the organic layer was dried over sodium sulfate, filtered and concentrated to get crude compound. The crude material was purified by combiflash using 120 g silica column, the compound was eluted with 22% EtOAc in petroleum ether, the fractions was collected and concentrated to afford 6-bromo-2-iodo-5-methylpyridin-3-amine (16 g, 51.1 mmol, 96% yield) as a pale yellow solid. LCMS retention time 2.14 min [I]. MS m/z: 314.1 (M+2H).


Intermediate 6B: (E)-6-bromo-2-(2-ethoxyvinyl)-5-methylpyridin-3-amine



embedded image


To a solution of 6-bromo-2-iodo-5-methylpyridin-3-amine (16 g, 51.1 mmol), and (E)-2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (15.19 g, 77 mmol) in THF (350 mL) was added sodium hydroxide (6.14 g, 153 mmol). The mixture was degassed for 10 min with nitrogen, tetrakis(triphenylphosphine)palladium (1.182 g, 1.023 mmol) was added, and the mixture was further degassed for 5 min. The resulting mixture was stirred at 80° C. for 16 h. The reaction mass was filtered through Celite, extracted with EtOAc (100 mL) and washed with water (2×100 mL), dried over sodium sulfate, filtered and concentrated to get crude compound. The crude compound was purified by combiflash using 120 g silica column, compound was eluted with 22% EtOAc in petroleum ether, the fractions were collected, concentrated to afford (E)-6-bromo-2-(2-ethoxyvinyl)-5-methylpyridin-3-amine (7 g, 27.2 mmol, 53.2% yield) as a brown solid. LCMS retention time 2.41 min [D]. MS m/z: 259.1 (M+2H).


Intermediate 6C: 5-bromo-6-methyl-1H-pyrrolo[3,2-b]pyridine



embedded image


To a solution of (E)-6-bromo-2-(2-ethoxyvinyl)-5-methylpyridin-3-amine (7.0 g, 27.2 mmol) in methanol (300 mL) was added hydrochloric acid (8.27 mL, 272 mmol). The reaction mixture was heated at 85° C. for 16 h. The reaction mass was concentrated to afford 5-bromo-6-methyl-1H-pyrrolo[3,2-b]pyridine (5.1 g, 24.16 mmol, 89% yield) as a brown solid. LCMS retention time 1.19 min [R]. MS m/z: 213.1 (M+2H).


Intermediate 6D: Methyl 6-methyl-1H-pyrrolo[3,2-b]pyridine-5-carboxylate



embedded image


To a solution of 5-bromo-6-methyl-1H-pyrrolo[3,2-b]pyridine (2.0 g, 9.48 mmol) in methanol (70 mL) and DMF (70 mL) were added DPPF (1.576 g, 2.84 mmol) and Pd(OAc)2 (0.425 g, 1.895 mmol). The reaction mixture was degassed for 10 min with nitrogen and TEA (2.64 mL, 18.95 mmol) was added. The mixture was stirred at 90° C. in presence of CO with 8 kg pressure for 12 h. The reaction mass was concentrated, the residue was dissolved in DCM (100 mL), washed with water (2×100 mL), dried over sodium sulfate, filtered and concentrated to get crude compound. The crude compound was purified by silica gel column chromatography, the compound was eluted with 70% ethyl acetate in petroleum ether, the fractions were collected and concentrated to afford methyl 6-methyl-1H-pyrrolo[3,2-b]pyridine-5-carboxylate (1.1 g, 5.71 mmol, 60.3% yield) as a pale yellow solid product. LCMS retention time 0.80 min [R].


Intermediate 6E: Methyl 3-bromo-6-methyl-1H-pyrrolo[3,2-b]pyridine-5-carboxylate



embedded image


To a solution of methyl 6-methyl-1H-pyrrolo [3,2-b]pyridine-5-carboxylate (1.0 g, 5.26 mmol) in DMF (30 mL) was added dropwise NBS (0.936 g, 5.26 mmol) in DMF (15.00 mL). The resulting mixture was stirred at room temperature for 15 min. The reaction mass was poured into ice water (100 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated to afford methyl 3-bromo-6-methyl-1H-pyrrolo [3,2-b] pyridine-5-carboxylate (1.2 g, 4.24 mmol, 81% yield) as a brown solid. LCMS retention time 1.17 min [R]. MS m/z: 269.1 (M+2H).


Intermediate 6F: 1-tert-butyl 5-methyl 3-bromo-6-methyl-1H-pyrrolo[3,2-b]pyridine-1,5-dicarboxylate



embedded image


To a solution of methyl 3-bromo-6-methyl-1H-pyrrolo[3,2-b]pyridine-5-carboxylate (1.2 g, 4.46 mmol) in THF (10 mL) were added BOC2O (1.139 mL, 4.91 mmol), TEA (1.243 mL, 8.92 mmol) and DMAP (0.109 g, 0.892 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 0.5 h. The reaction mass was quenched with water (50 mL), extracted with ethyl acetate (3×50 mL), combined organic layers was dried over sodium sulfate, filtered and concentrated to get crude compound. The crude compound was purified by silica gel column chromatography by eluting with 9% EtOAc in petroleum ether, the fractions was collected and concentrated to afford 1-tert-butyl 5-methyl 3-bromo-6-methyl-1H-pyrrolo[3,2-b] pyridine-1,5-dicarboxylate (1.3 g, 3.49 mmol, 78% yield) as a white solid. LCMS retention time 3.15 min [R]. MS m/z: 371.1 (M+H).


Intermediate 6G: 1-tert-butyl 5-methyl 6-methyl-3-(prop-1-en-2-yl)-1H-pyrrolo[3,2-b]pyridine-1,5-dicarboxylate



embedded image


To a solution of 1-tert-butyl 5-methyl 3-bromo-6-methyl-1H-pyrrolo[3,2-b]pyridine-1,5-dicarboxylate (1.3 g, 3.52 mmol) in THF (25 mL) and water (4 mL) was added potassium phosphate, tribasic (1.840 g, 10.56 mmol). The mixture was degassed for 10 minutes with nitrogen, XPhos Pd G2 (0.083 g, 0.106 mmol) was added, and the mixture was further degassed for 5 min. Next, 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (0.769 g, 4.58 mmol) was added and the mixture was stirred at 70° C. for 12 h. The reaction mass was filtered through Celite, extracted with EtOAc (100 mL), washed with water (2×100 mL), dried over sodium sulfate and concentrated to get crude compound. The crude compound was purified by silica gel column chromatography. The compound was eluted with 6% EtOAc in petroleum ether, and the fractions were collected and concentrated to afford 1-tert-butyl5-methyl 6-methyl-3-(prop-1-en-2-yl)-1H-pyrrolo [3,2-b]pyridine-1,5-dicarboxylate (1.1 g, 3.26 mmol, 93% yield) as a pale yellow solid. LCMS retention time 3.08 min [R]. MS m/z: 331.1 (M+H).


Intermediate 6H: 1-tert-butyl 5-methyl 3-isopropyl-6-methyl-1H-pyrrolo[3,2-b] pyridine-1,5-dicarboxylate



embedded image


To a solution of 1-tert-butyl 5-methyl 6-methyl-3-(prop-1-en-2-yl)-1H-pyrrolo[3,2-b]pyridine-1,5-dicarboxylate (1.1 g, 3.33 mmol) in methanol (20 mL) was added Pd/C (0.6 g, 0.564 mmol). The slurry was stirred at room temperature under a hydrogen bladder for 3 h. The suspension was filtered through Celite bed, the filtrate was collected and concentrated to afford 1-tert-butyl 5-methyl 3-isopropyl-6-methyl-1H-pyrrolo[3,2-b]pyridine-1,5-dicarboxylate (0.65 g, 1.869 mmol, 56% yield) as an off-white solid. LCMS retention time 3.7 min [R]. MS m/z: 333.1 (M+H).


Intermediate 6I: 1-tert-butyl 5-methyl 2-bromo-3-isopropyl-6-methyl-1H-pyrrolo[3,2-b]pyridine-1,5-dicarboxylate



embedded image


To a solution of 1-tert-butyl 5-methyl 3-isopropyl-6-methyl-1H-pyrrolo[3,2-b]pyridine-1,5-dicarboxylate (0.55 g, 1.655 mmol) in DCE (20 mL) was added NBS (0.442 g, 2.482 mmol) portion-wise. The resulting mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with water (50 mL), extracted with DCM (2×50 mL), combined organic layers was dried over sodium sulfate, filtered and concentrated to get crude compound. The crude compound was purified by silica gel column chromatography, the compound was eluted with 5% EtOAc/petroleum ether, the fractions were collected and concentrated to afford 1-tert-butyl 5-methyl 2-bromo-3-isopropyl-6-methyl-1H-pyrrolo[3,2-b]pyridine-1,5-dicarboxylate (0.4 g, 0.807 mmol, 49% yield) as a yellow oil. LCMS retention time 4.12 min [D]. MS m/z: 411.1 (M+H).


Intermediate 6J: 1-tert-butyl 5-methyl 3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-1,5-dicarboxylate



embedded image


A solution of 1-tert-butyl 5-methyl 2-bromo-3-isopropyl-6-methyl-1H-pyrrolo[3,2-b]pyridine-1,5-dicarboxylate (0.2 g, 0.486 mmol), 8-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (0.147 g, 0.535 mmol) and potassium phosphate tribasic (0.254 g, 1.459 mmol) in dioxane (10 mL) and water (1 mL) solvent mixture was degassed with N2 for 10 min. Next, PdCl2(dppf)-CH2Cl2 adduct (0.040 g, 0.049 mmol) was added and the mixture was degassed again for 5 min. The resulting mixture was stirred at 80° C. for 3 h. The reaction mixture was extracted with ethyl acetate (20 mL), washed with water (2×10 mL), brine (50 mL), dried over sodium sulfate, and concentrated to get crude product. The crude product was purified by silica gel column chromatography, the compound was eluted with 22% ethyl acetate in petroleum ether, the fractions were collected and concentrated to afford 1-tert-butyl 5-methyl 3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-6-methyl-1H-pyrrolo[3,2-b] pyridine-1,5-dicarboxylate (0.2 g, 0.396 mmol, 81% yield) as a brown solid. LCMS retention time 2.96 min [R]. MS m/z: 480.1 (M+H).


Intermediate 6K: Methyl 3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-5-carboxylate



embedded image


To a solution of 1-tert-butyl 5-methyl 3-isopropyl-2-(8-methoxy-[1,2,4]triazolo [1,5-a]pyridin-6-yl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-1,5-dicarboxylate (0.2 g, 0.417 mmol) in DCM (2 mL) was added 4 M hydrochloric acid in dioxane (0.209 mL, 0.834 mmol) drop wise. The reaction mixture was stirred at room temperature for 1 h. The solvent was removed under vacuum and the solids were washed with diethyl ether to afford methyl 3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-5-carboxylate (0.15 g, 0.376 mmol, 95% yield) as a yellow solid. LCMS retention time 1.91 min [R]. MS m/z: 380.1 (M+H).


Intermediate 6L: 3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6-methyl -1H-pyrrolo[3,2-b]pyridine-5-carboxylic Acid



embedded image


To a solution of methyl 3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-5-carboxy late (0.15 g, 0.395 mmol) in methanol (2 mL), THF (2 mL) and water (1 mL) solvent mixture was added lithium hydroxide (0.095 g, 3.95 mmol). The resulting mixture was stirred at room temperature for 5 h. The volatiles were removed under vacuum, diluted with water (5 mL) and neutralized with 1.5 N HCl. The aqueous layer was extracted with DCM (3×50 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated to afford 3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid (0.1 g, 0.235 mmol, 59.5% yield) as a yellow solid. LCMS retention time 0.98 min [R]. MS m/z: 366.1 (M+H).


Example 6

To a solution of 3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid (0.02 g, 0.055 mmol) in DMF (2 mL) were added N1-ethyl-N2,N2-dimethylethane-1,2-diamine (6.36 mg, 0.055 mmol), TEA (0.015 mL, 0.109 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) (0.023 g, 0.060 mmol) at room temperature. Next, the mixture was stirred at same temperature for 3 h. The reaction mixture was diluted with EtOAc (20 mL) and washed with water (2×20 mL), dried over sodium sulfate, and concentrated to get crude product. The crude product was purified via preparative LC/MS using method D2, the fractions containing the product were combined and dried via centrifugal evaporation to afford N-(2-(dimethylamino)ethyl)-N-ethyl-3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-6-methyl-1H-pyrrolo[3,2-b] pyridine-5-carboxamide (7.8 mg, 0.017 mmol, 31% yield) as a pale yellow solid. LCMS retention time 1.30 min [E]. MS m/z: 464.1 (M+H). 1H NMR (400 MHz, DMSO-do) δ ppm 11.49-11.45 (m, 1H), 8.66 (s, 1H), 8.52 (d, J=1.2 Hz, 1H), 7.62 (s, 1H), 7.21 (s, 1H), 4.08 (d, J=1 .0 Hz, 3H), 3.90 (s, 1H), 3.63 (t, J=7.1 Hz, 2H), 3.56-3.50 (m, 1H), 3.19-3.07 (m, 3H), 2.72 (br. s., 2H), 2.40 (br. s., 4H), 2.32 (s, 3H), 1.97-1.89 (m, 3H), 1.55-1.47 (m, 6H).


Examples 7, 8, and 9
3-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclopentan-1-one



embedded image


p Intermediate 7A: 3-bromocyclopent-2-en-1-one



embedded image


To a stirred solution of triphenylphosphine (23.53 g, 90 mmol) in DCM (350 mL), was added bromine (4.62 mL, 90 mmol) at 0° C. The reaction mixture was stirred at same temperature for 15 min. Next, TEA (13.64 mL, 98 mmol) and cyclopentane-1,3-dione (8 g, 82 mmol) in DCM (350 mL) were added. The mixture was stirred at room temperature for 16 h. The reaction mass was concentrated, purified by silica gel column chromatography, the fractions were collected and concentrated to afford 3-bromocyclopent-2-en-1-one (8.9 g, 55.3 mmol, 68% yield) as an oil. 1H NMR (400 MHz, DMSO-d6) δppm 6.57 (s, 1H), 2.99 (m, 2H), 2.52 (m, 2H).


Intermediate 7B: 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-2-en-1-one



embedded image


To a stirred solution of 3-bromocyclopent-2-en-l-one (10 g, 62.1 mmol) in 1,4-dioxane (250 mL) were added bis(pinacolato)diboron (18.93 g, 74.5 mmol) and potassium acetate (12.19 g, 124 mmol). The reaction mixture was degassed with N2 for 10 min, PdCl2(dppf)-CH2Cl2 adduct (3.55 g, 4.35 mmol) was added, and the reaction mixture was stirred at 100° C. for 16 h. The reaction mass was diluted with EtOAc, filtered through Celite, washed with EtOAc, the filtrate was collected and concentrated to get crude product. The crude product was purified by ISCO using silica gel column chromatography, the fractions was collected and concentrated to afford 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-2-en-1-one (10.9 g, 52.4 mmol, 84% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 6.43 (s, 1H), 2.66 (m, 2H), 2.26 (m, 2H), 1.18 (s, 9H).


Intermediate 7C: tert-butyl5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To a stirred solution of 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine (5 g, 20.91 mmol) in THF (100 mL) were added DIPEA (41.8 mmol) and Boc-anhydride (7.28 mL, 31.4 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 3 h. The reaction mass was extracted with ethyl acetate and washed with water, brine, dried over sodium sulfate and concentrated to get crude compound. The crude compound was purified by silica gel column chromatography, the fractions were collected and concentrated to afford tert-butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (6.5 g, 19.16 mmol, 92% yield) as an off-white solid. LCMS retention time 2.03 min [L]. MS m/z: 341 (M+H).


Intermediate 7D: tert-butyl 3-isopropyl-5-(3-oxocyclopent-1-en-1-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To a stirred solution of tert-butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (16 g, 47.2 mmol) in dioxane (400 mL) were added 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-2-en-1-one (14.72 g, 70.7 mmol) and potassium phosphate tribasic (20.02 g, 94 mmol). The reaction mixture was degassed with nitrogen for 10 min, and then PdCl2(dppf)-CH2Cl2 adduct (3.85 g, 4.72 mmol) was added. The reaction mixture was stirred at 100° C. for 16 h. The reaction mass was filtered through a Celite bed, washed with EtOAc and concentrated to get crude product. The crude product was purified by silica gel column chromatography, the fractions were collected and concentrated to afford tert-butyl 3-isopropyl-5-(3-oxocyclopent-1-en-1-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (15 g, 44.1 mmol, 93% yield) as a brown solid. LCMS retention time 1.76 min [L]. MS m/z: 341.6 (M+H).


Intermediate 7E: tert-butyl 5-(3-hydroxycyclopentyl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To a stirred solution of tert-butyl 3-isopropyl-5-(3-oxocyclopent-1-en-1-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (10 g, 29.4 mmol) in MeOH (20 mL) at 0° C. were added nickel(II) chloride hexahydrate (0.698 g, 2.94 mmol) and NaBH4 (4.45 g, 118 mmol). The reaction mixture was stirred at room temperature for 10 min. The reaction was quenched with NH4Cl solution. The reaction mixture was concentrated to remove methanol, the residue was extracted with EtOAc, washed with water, dried over sodium sulfate and concentrated to afford tert-butyl5-(3-hydroxycyclopentyl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (10 g, 29.0 mmol, 99% yield) as a brown solid. LCMS retention time 1.71 min [L]. MS m/z: 345.6 (M+H).


Intermediate 7F: tert-butyl 3-isopropyl-5-(3-oxocyclopentyl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To a stirred solution of tert-butyl 5-(3-hydroxycyclopentyl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (1 g, 2.90 mmol) in DCM (25 mL) was added Dess-Martin periodinane (6.16 g, 14.52 mmol) at 0° C. The reaction mixture was stirred at room temperature for 16 h. The reaction mass was diluted with aqueous NaHCO3 solution, the solids were filtered, the aqueous layer was extracted with DCM, the organic layer was dried over sodium sulfate and concentrated to get crude product. The crude product was purified by silica gel column chromatography, the fractions was collected and concentrated to afford tert-butyl 3-isopropyl-5-(3-oxocyclopentyl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (380 mg, 1.110 mmol, 38% yield) as an off-white solid. LCMS retention time 1.75 min [L]. MS m/z: 343.6 (M+H).


Intermediate 7G: 3-isopropyl-5-(1,4-dioxaspiro[4.4]nonan-7-yl)-1H-pyrrolo[3,2-b]pyridine



embedded image


To a stirred solution of tert-butyl 3-isopropyl-5-(3-oxocyclopentyl)-1H-pyrrolo[3,2-b] pyridine-1-carboxylate (2.8 g, 8.18 mmol) in toluene (40 mL) were added ethylene glycol (0.692 mL, 12.26 mmol) and p-toluenesulfonic acid (0.282 g, 1.635 mmol) at room temperature. Next, the mixture was stirred at 130° C. for 16 h. The reaction mass was concentrated, diluted with EtOAc, and washed with saturated NaHCO3, dried over sodium sulfate and concentrated to get crude material. The crude material was purified by silica gel column chromatography, the fractions were collected and concentrated to afford 3-isopropyl-5-(1,4-dioxaspiro[4.4]nonan-7-yl)-1H-pyrrolo[3,2-b] pyridine (2.8 g, 7.24 mmol, 89% yield) as an off-white solid. LCMS retention time 1.18 min [L]. MS m/z: 287.5 (M+H).


Intermediate 7H: tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.4]nonan-7-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To a stirred solution of 3-isopropyl-5-(1,4-dioxaspiro[4.4]nonan-7-yl)-1H-pyrrolo[3,2-b]pyridine (2.2 g, 7.68 mmol) in THF (30 mL), were added Boc-anhydride (2.68 mL, 11.52 mmol), DIPEA (2.68 mL, 15.36 mmol) and DMAP (0.939 g, 7.68 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 h. The reaction was quenched with water. The reaction mixture was extracted with EtOAc, dried over sodium sulfate and concentrated to get crude material. The crude material was purified by ISCO using silica gel column chromatography, the fractions were collected and concentrated to afford tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.4]nonan-7-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (2.8 g, 7.24 mmol, 94% yield) as a white foam. LCMS retention time 1.96 min [L]. MS m/z: 387.6 (M+H).


Intermediate 7I: tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.4]nonan-7-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate.



embedded image


To a stirred solution of tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.4]nonan-7-yl)-1H-pyrrolo [3,2-b]pyridine-1-carboxylate (2.8 g, 7.24 mmol) in THF (20 mL) was added LDA (10.87 mL, 21.73 mmol) at −78° C. The reaction mixture was stirred at the same temperature for 2 h, and then 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.00 mL, 14.49 mmol) was added slowly. The reaction mixture was brought to room temperature and stirred at room temperature for 1 h. The reaction was quenched with water. The reaction mixture was extracted with EtOAc, dried over sodium sulfate and concentrated to get crude compound. The crude compound was purified by silica gel column chromatography, the fractions were collected and concentrated to afford tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.4]nonan-7-y l)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (2.9 g, 5.66 mmol, 78% yield) as an off-white solid. LCMS retention time 2.29 min [L]. MS m/z: 513.7 [M+H]+.


Intermediate 7J: tert-butyl 3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(1,4-dioxaspiro[4.4]nonan-7-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To a stirred solution of tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.4]nonan-7-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (3 g, 5.85 mmol) in dioxane (100 mL) and water (2 mL) were added 6-bromo-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (1.602 g, 7.03 mmol) and potassium phosphate tribasic (3.73 g, 17.56 mmol). The reaction mixture was degassed with N2 for 10 minutes and PdCl2(dppf)-CH2Cl2 adduct (0.478 g, 0.585 mmol) was added. The mixture was stirred at 100° C. for 16 h. The reaction mass diluted with EtOAc, filtered, and the filtrate was concentrated to get crude product. The crude product was purified by silica gel column chromatography, the fractions were collected and concentrated to afford tert-butyl 3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(1,4-dioxaspiro[4.4]nonan-7-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (2.9 g, 5.43 mmol, 93% yield) as an off-white solid. LCMS retention time 1.62 min [L]. MS m/z: 534.7 [M+H]+.


Intermediate 7K: 3-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclopentan-1-one



embedded image


To a stirred solution of tert-butyl 3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(1,4-dioxaspiro [4.4]nonan-7-yl)-1H-pyrrolo [3 ,2-b] pyridine-1-carboxylate (2.9 g, 5.43 mmol) in DCM (20 mL) was added TFA (2.093 mL, 27.2 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 16 h. The reaction mixture was concentrated, extracted with EtOAc, washed with water, dried over sodium sulfate and concentrated to afford 3-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo [1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclopentan-1-one (2.1 g, 5.43 mmol, 93% yield) as a gummy solid. LCMS retention time 1.14 min [L]. MS m/z: 390.6 [M+H]+.


Examples 7, 8, and 9

To a stirred solution of 3-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclopentan-1-one (2.5 g, 6.42 mmol) in THF (3 mL), DMF (3 mL) were added ammonium acetate (4.95 g, 64.2 mmol), ammonium chloride (3.43 g, 64.2 mmol) and acetic acid (0.367 mL, 6.42 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 16 h, then was added NaCNBH3 (1.210 g, 19.26 mmol) and stirred another 2 h at room temperature. The reaction mass was concentrated to get crude compound. The crude compound was purified by Prep HPLC to separate the isomers. After Prep HPLC purifications, the fractions were collected, concentrated and lyophilized to isolate three isomers/mixtures.

  • Example 7: Isomer 1: diastereomer mixture, LCMS retention time 1.79 min [E]. MS m/z: 391.4 (M+H).
  • Example 8: Isomer 2: homochiral, LCMS retention time 1.78 min [E]. MS m/z: 391.2 (M+H).
  • Example 9: Isomer 3: diastereomer mixture, LCMS retention time 1.56 min [E]. MS m/z: 391.3 (M+H).


Example 10
24(3-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclopentyl)amino)-N-methylacetamide



embedded image


To a stirred solution of 3-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclopentan-1-amine (20 mg, 0.051 mmol) (Example 9) in DMF (2 mL) were added TEA (0.021 mL, 0.154 mmol) and 2-chloro-N-methylacetamide (6.61 mg, 0.061 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 16 h. The crude material was purified via preparative LC/MS using method D2, the fractions containing the product were combined and dried via centrifugal evaporation to afford 2-((3-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclopentyl)amino)-N-methylacetamide (3 mg). LCMS retention time 1.29 min [E]. MS m/z: 462.3 (M+H). 1H NMR (400 MHz, DMSO-d6) δ ppm 11.30 (s, 1H), 8.63 (d, J=1.0 Hz, 1H), 8.53 (s, 1H), 7.64 (d, J=8.3 Hz, 1H), 7.20 (d, J=1.0 Hz, 1H), 7.04 (d, J=8.6 Hz, 1H), 4.09 (s, 3H), 3.17-3.11 (m, 41-1), 2.90 (s, 1H), 2.63 (d, J=4.9 Hz, 3H), 2.32-2.23 (m, 1H), 2.00(q, J=7.4 Hz, 2H), 1.94-1.81 (m, 3H), 1.74-1.61 (m, 2H), 1.61-1.50 (m, 6H).


Example 11
6-(6-fluoro-3-isopropyl-5-(piperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


Intermediate 11A: 6-bromo-5-fluoropyridin-3-amine



embedded image


To a solution of 5-fluoropyridin-3-amine (4.5 g, 40.1 mmol) in DMF (80 mL) was added NBS (7.14 g, 40.1 mmol) portion wise at 0° C. The reaction mixture was stirred at room temperature for 20 min. The mixture was then partitioned between EtOAc (300 mL) and water (300 mL), both the layers were separated, the organic layer was washed with saturated NaHCO3, brine, dried over sodium sulfate, filtered and concentrated to get crude compound. The crude compound was purified by silica gel column chromatography, the compound was eluted with 52% ethyl acetate\hexane, the fractions were collected and concentrated to afford 6-bromo-5-fluoropyridin-3-amine (4.7 g, 24.61 mmol, 61% yield) as a brown solid. LCMS retention time 0.98 min [R]. MS m/z: 193.1 (M+2H).


Intermediate 11B: tert-butyl 5-amino-3-fluoro-5′,6′-dihydro-[2,4′-bipyridine]-1′(2′H)-carboxylate



embedded image


tert-butyl 5-amino-3-fluoro-5′,6′-dihydro-[2,4′-bipyridine]-1′(TH)-carboxylate (6.5 g, 22.16 mmol, 94% yield) was prepared according to the general procedure described in Intermediate 5B using 6-bromo-5-fluoropyridin-3-amine (4.5 g, 23.56 mmol) as the starting intermediate. LCMS retention time 1.94 min [R]. MS m/z: 293.1 (M+H).


Intermediate 11C: Tert-butyl 4-(5-amino-3-fluoropyridin-2-yl)piperidine-1-carboxylate



embedded image


A solution of tert-butyl 5-amino-3-fluoro-5′,6′-dihydro-[2,4′-bipyridine]-1′(2′H)-carboxylate (6.5 g, 22.16 mmol) and ethyl acetate (150 mL) was purged with nitrogen (N2). Next, Pd/C (3.30 g, 3.10 mmol) was added and the reaction mixture was again purged with N2 three times. Hydrogen gas (H2) was introduced via a balloon to the mixture. The reaction mixture was stirred at room temperature for 12 h. The suspension was filtered through Celite bed, the filtrate was collected and concentrated to afford tert-butyl 4-(5-amino-3-fluoropyridin-2-yl)piperidine-1-carboxylate (5.8 g, 19.64 mmol, 89% yield) as a yellow oil. LCMS retention time 1.68 min [R]. MS m/z: 296.1 (M+H).


Intermediate 11D: tert-butyl 4-(5-amino-3-fluoro-6-iodopyridin-2-yl)piperidine-1-carboxylate



embedded image


To a solution of tert-butyl 4-(5-amino-3-fluoropyridin-2-yl) piperidine-1-carboxylate (5.6 g, 18.96 mmol) in DMF (120 mL) was added NIS (4.27 g, 18.96 mmol) portion wise. The mixture was stirred for 2 h at room temperature. The reaction mass was diluted into water (200 mL) and extracted with ethyl acetate (3×200 mL). The organic extracts were combined, dried over sodium sulfate, filtered and concentrated to get crude compound. The crude compound was purified by combiflash using silica gel column chromatography, the compound was eluted with 25% ethyl acetate/petroleum ether, the fractions was collected and concentrated to afford tert-butyl 4-(5-amino-3-fluoro-6-iodopyridin-2-yl) piperidine-1-carboxylate (5.8 g, 13.77 mmol, 73% yield) as a brown solid. LCMS retention time 2.46 min [R]. MS m/z: 322.1 (M+H).


Intermediate 11E: tert-butyl 4-(3-fluoro-6-iodo-5((3-methylbut-2-en-1-yl)amino) pyridin-2-yl)piperidine-1-carboxylate



embedded image


To a solution of tert-butyl 4-(5-amino-3-fluoro-6-iodopyridin-2-yl)piperidine-1-carboxylate (3.0 g, 7.12 mmol) and 3-methylbut-2-enal (2.72 mL, 28.5 mmol) in MeOH (50 mL) was added acetic acid (1 mL, 17.47 mmol). The resulting light yellow solution was stirred at room temperature for 6 h. Next, sodium cyanoborohydride (2.238 g, 35.6 mmol) was added at 0° C. and the reaction mixture was stirred at room temperature for 2 h. The reaction mass was concentrated to remove methanol, diluted with water (100 mL) and extracted with ethyl acetate (3×100 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated to get crude compound. The crude compound was purified by silica gel column chromatography. The compound was eluted with 28% ethyl acetate/petroleum ether, the fractions were collected and concentrated to afford tert-butyl 4-(3-fluoro-6-iodo-5((3-methylbut-2-en-1-yl)amino) pyridin-2-yl)piperidine-1-carboxylate (1.7 g, 3.35 mmol, 47% yield) as a pale yellow oil. LCMS retention time 3.39 min [R]. MS m/z: 490.1 (M+H).


Intermediate 11F: 4-(6-fluoro-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)piperidine-1-carboxylate



embedded image


A solution of tert-butyl 4-(3-fluoro-6-iodo-5-((3-methylbut-2-en-1-yl)amino) pyridin-2-yl)piperidine-1-carboxylate (1.6 g, 3.27 mmol), potassium carbonate (0.497 g, 3.60 mmol) and tetrabutylammonium bromide (3.16 g, 9.81 mmol) in DMF (20 mL) was degassed for 10 minutes with nitrogen, and Pd(OAc)2 (0.073 g, 0.327 mmol) was added. The reaction mixture was further degassed for 5 min. The reaction mixture was stirred at 80° C. for 14 h. The reaction mixture was diluted with ethyl acetate (200 mL). The reaction mixture was washed with water (2×100 mL), brine (100 mL), dried over sodium sulfate, and concentrated to get crude product. The crude product was purified by silica gel column chromatography, the compound was eluted with 65% ethyl acetate/petroleum ether, the fractions were collected, and concentrated to afford tert-butyl 4-(6-fluoro-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl) piperidine-1-carboxylate (0.5 g, 1.383 mmol, 42% yield) as a pale yellow oil. LCMS retention time 3.80 min [R]. MS m/z: 362.1 (M+H).


Intermediate 11G: tert-butyl 5-(1-(tert-butoxycarbonyl)piperidin-4-yl)-6-fluoro-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To a solution of tert-butyl 4-(6-fluoro-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl) piperidine-1-carboxylate (0.3 g, 0.830 mmol) in THF (2 mL) were added TEA (0.231 mL, 1.660 mmol), BOC2O (0.212 mL, 0.913 mmol), and DMAP (0.020 g, 0.166 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to get crude compound. The crude compound was purified by silica gel column chromatography by eluting with 9% EtOAc: petroleum ether, the fractions were collected and concentrated to afford t-butyl 5-(1-(tert-butoxycarbonyl)piperidin-4-yl)-6-fluoro-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (0.33 g, 0.715 mmol, 86% yield) as a white solid. LCMS retention time 3.92 min [R]. MS m/z: 462.1 (M+H).


Intermediate 11H: tert-butyl 2-bromo-5-(1-(tert-butoxycarbonyl)piperidin-4-yl)-6-fluoro-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


tert-butyl 2-bromo-5-(1-(tert-butoxycarbonyl)piperidin-4-yl)-6-fluoro-3-isopropyl-1H-pyrrolo [3,2-b]pyridine-1-carboxylate (0.6 g, 0.766 mmol, 58.9% yield) was prepared according to the general procedure described in Intermediate 61 using tert-butyl 5-(1-(tert-butoxycarbonyl)piperidin-4-yl)-6-fluoro-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (0.6 g, 1.300 mmol) as the starting intermediate. LCMS retention time 4.32 min [D]. MS m/z: 541.1 (M+H).


Intermediate 11I: tert-butyl 5-(1-(tert-butoxycarbonyl)piperidin-4-yl)-6-fluoro-3-isopropyl-2-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


tert-butyl 5-(1-(tert-butoxycarbonyl)piperidin-4-yl)-6-fluoro-3-isopropyl-2-(8-methyl-[1,2,4] triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (0.25 g, 0.359 mmol, 64% yield) was prepared according to the general procedure described in Intermediate 7J using tert-butyl 2-bromo-5-(1-(tert-butoxycarbonyl) piperidin-4-yl)-6-fluoro-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (0.3 g, 0.555 mmol) as the starting material. LCMS retention time 4.16 min [R]. MS m/z: 593.1 (M+H).


Example 11

To a solution of tert-butyl 5-(1-(tert-butoxycarbonyl)piperidin-4-yl)-6-fluoro-3-isopropyl-2-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (0.25 g, 0.422 mmol) in DCM (2 mL) was added 4 M hydrochloric acid in dioxane (2 mL, 8.00 mmol) drop-wise. The reaction mixture was stirred at room temperature for 1 h. The reaction mass was concentrated to get crude product. The crude product was purified via preparative LC/MS using method D2, the fractions containing the product were combined and dried via centrifugal evaporation to afford 6-(6-fluoro-3-isopropyl-5-(piperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methyl-[1,2,4]triazolo [1,5-a]pyridine (11.3 mg, 0.029 mmol, 7% yield) as a pale yellow solid. LCMS retention time 1.26 min [E]. MS m/z: 393.1 (M+H). NMR (400 MHz, DMSO-d6) δ ppm 11.45 (br. s., 1H), 8.85 (s, 1H), 8.54 (s, 1H), 7.62 (s, 1H), 7.53 (d, J=11.0 Hz, 1H), 3.89 (s, 1H), 3.18-3.13 (m, 2H), 2.82-2.72 (m, 2H), 2.63 (s, 3H), 2.06 (s, 2H), 1.83-1.76 (m, 2H), 1.53 (d, J=6.8 Hz, 6H).


Example 39
4-(1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidin-3-yl)morpholine



embedded image


Intermediate 39A: tert-butyl 3-((tert-butyldiphenylsilyl)oxy)azetidine-1-carboxylate



embedded image


tert-Butyl 3-hydroxyazetidine-1-carboxylate (2.05 g, 11.8 mmol) was dissolved in DCM (40 mL), and imidazole (1.61 g, 23.7 mmol) and tert-butylchlorodiphenylsilane (3.58 g, 13.0 mmol) were added sequentially. The reaction mixture was stirred for 17 hours at room temperature. Upon completion, the reaction was quenched by the addition of water and DCM. The layers were separated, and the aqueous layer was extracted with DCM. The combined organic layer was dried over sodium sulfate, filtered, and concentrated to afford a clear oil. This material was purified by silica gel column chromatography on a Teledyne Isco instrument eluting with Hex/EtOAc 0-15% to afford tert-butyl 3-((tent-butyldiphenylsilyl) oxy)azetidine-1-carboxylate (11.8 mmol). LCMS retention time 1.22 [TS]. MS (E+) m/z: 823.4 (2M+H). NMR (499 MHz, CHLOROFORM-d) δ7.63-7.57 (m, 4H), 7.46-7.41 (m, 2H), 7.41-7.35 (m, 4H), 4.52 (tt, J=6.6, 4.7 Hz, 1H), 3.97-3.90 (m, 2H), 3.89-3.83 (m, 2H), 1.42 (s, 9H), 1.06 (s, 9H).


Intermediate 39B: 3-((tent-butyldiphenylsilyl)oxy)azetidine



embedded image


Intermediate 39A (11.8 mmol)) was dissolved in DCM (20 mL), cooled to 0° C., and precooled 0° C. TFA (20 mL) was added. When the reaction was completed as judged by LCMS analysis, the reaction mixture was concentrated, redissolved in DCM, and made basic by the addition of 1 M aqueous NaOH solution. The aqueous layer was extracted with DCM, and the combined organics were dried over sodium sulfate, filtered, and concentrated to afford 3-((tert-butyldiphenylsilyl)oxy)azetidine (11.8 mmol). LCMS retention time 0.84 [TS]. MS (E+) m/z: 312.2 (M+1). 1H NMR (499 MHz, CHLOROFORM-d) δ7.64-7.59 (m, 4H), 7.44-7.40 (m, 2H), 7.39-7.34 (m, 4H), 4.62 (quin, J=6.5 Hz, 1H), 3.70-3.61 (m, 2H), 3.55-3.47 (m, 2H), 1.05 (s, 9H).


Intermediate 39C: tert-butyl 5-(3-((tert-butyldiphenylsilyl)oxy)azetidin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


tert-Butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (1 g, 2.95 mmol), 3-((tert-butyldiphenylsilyl)oxy)azetidine (1.19 g, 3.83 mmol), 2nd generation RuPhos precatalyst (0.114 g, 0.147 mmol), and Cs2CO3 (2.88 g, 8.84 mmol) were suspended in 1,4-dioxane (20 mL) in a reaction vial with a pressure-relief septum-lined cap and a stir bar. The suspension was degassed with nitrogen gas for 10 minutes and then sealed and placed in a heating block with stirring at 130° C. for 45 minutes. Upon completion, the reaction mixture was cooled to room temperature, filtered, concentrated and purified by silica gel column chromatography on a Teledyne Isco instrument eluting with Hex/EtOAc 0-30% to afford tert-butyl 5-(3-((tert-butyldiphenylsilyl)oxy)azetidin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b] pyridine-1-carboxylate (1.42 g, 2.49 mmol, 85% yield). LCMS retention time 1.09 [TS]. MS (E+) m/z: 570.4 (M+H). NMR (499 MHz, CHLOROFORM-d) δ8.06 (br s, 1H), 7.69-7.63 (m, 4H), 7.47-7.33 (m, 7H), 6.23 (d, J=8.8 Hz, 1H), 4.79-4.71 (m, 1H), 4.14 (dd, J=8.6, 6.5 Hz, 2H), 3.95 (dd, J=8.7, 5.0 Hz, 2H), 3.25-3.15 (m, 1H), 1.64 (s, 9H), 1.36 (d, J=6.8 Hz, 6H), 1.07 (s, 9H).


Intermediate 39D; tert-butyl 5-(3-((tert-butyldiphenylsilyl)oxy)azetidin-1-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b] pyridine-1-carboxylate



embedded image


A solution containing tert-butyl 5-(3-((tert-butyldiphenylsilyl)oxy)azetidin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (1.42 g, 2.49 mmol) and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.661 mL, 3.24 mmol) in dry THF (12.5 mL), under a nitrogen atmosphere was cooled in a dry ice/acetone bath to −78° C. and treated with LDA (2M in THF, 1.87 mL, 3.74 mmol). The mixture was allowed to warm to −30° C. over 30 min and stirred at −30° C. for 30 min. Upon completion, the reaction was quenched by the addition of saturated aqueous NH4Cl solution, water, and DCM. The organic layer was separated, dried over sodium sulfate, filtered and concentrated. The crude material was purified by silica gel column chromatography on a Teledyne Isco instrument loading in hexanes and eluting with Hex/EtOAc 0-40% to afford tert-butyl 5-(3-((tert-butyldiphenylsilyl)oxy)azetidin-1-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (1.64 g, 2.36 mmol, 95% yield). LCMS retention time 1.14 [TS]. MS (E+) m/z: 696.5 (M+H).


Intermediate 39E: 5-(3-((tert-butyldiphenylsilyl)oxy)azetidin-1-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine



embedded image


tert-Butyl5-(3-((tert-butyldiphenylsilyl)oxy)azetidin-1-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (1.64 g, 2.36 mmol) was heated neat at 165° C. in a vial with a pressure-relief septum-lined cap and a stir bar under an atmosphere of nitrogen with a line of nitrogen gas. The reaction mixture was heated for a two hours, sat at room temperature overnight, and then was heated for another hour for a total of three hours of neat heating at 165° C. Upon completion, the reaction mixture was dissolved in DCM and concentrated to obtain 5-(3-((tert-butyldiphenylsilyl)oxy)azetidin-1-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine (1.40 g, 2.35 mmol, 100% yield) as a light brown foam. Note: observed partial conversion to the corresponding boronic acid on LCMS, although NMR indicated that the product was purely the compound. Boronic acid LCMS retention time 0.98 [TS]. Boronic acid MS (E+) m/z: 514.1 (M+H). Product characterization: LCMS retention time 1.07 [TS]. MS (E+) m/z: 596.1 (M+H). 1H NMR (499 MHz, CHLOROFORM-d) δ8.04 (s, 1H), 7.69-7.63 (m, 4H), 7.46-7.37 (m, 7H), 6.27 (d, J=8.8 Hz, 1H), 4.80-4.70 (m, 1H), 4.13 (dd, J=8.7, 6.4 Hz, 2H), 3.95 (dd, J=8.7, 5.2 Hz, 2H), 3.64 (spt, J=7.0 Hz, 1H), 1.50 (d, J=7.0 Hz, 6H), 1.35 (s, 12H), 1.07 (s, 9H).


Intermediate 39F: 6-(5-(3-((tert-butyldiphenylsilyl)oxy)azetidin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a mixture of 5-(3-((tert-butyldiphenylsilyl)oxy)azetidin-l-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine (500 mg, 0.839 mmol), 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (209 mg, 0.923 mmol), and 2end generation XPhos precatalyst (33.0 mg, 0.042 mmol) in 1,4-dioxane (6 mL) was added aqueous K3PO4(2M, 1.26 mL, 2.52 mmol). The biphasic mixture was degassed with nitrogen gas for 10 min. The reaction vial was sealed with a pressure-relief septum-lined cap and stirred at 70° C. for 1.5 hours. Upon completion, the reaction mixture was cooled to room temperature, concentrated, and suspended in DCM for purification by silica gel column chromatography on a Teledyne Isco instrument eluting with Hex/EtOAc 0-100% to afford 6-(5-(3-((tert-butyldiphenylsilyl)oxy)azetidin-l-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (355 mg, 0.577 mmol, 68.8% yield). LCMS retention time 0.99 [TS]. MS (E+) m/z: 615.2 (M+H).


Intermediate 39G: 1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidin-3-ol



embedded image


To a stirred solution of 6-(5-(3-((tert-butyldiphenylsilyl)oxy)azetidin-l-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (355 mg, 0.577 mmol) in THF (3.8 mL) was added TBAF (0.69 mL, 0.69 mmol). The reaction mixture was stirred at room temperature for 1 hour. Upon completion, the reaction mixture was concentrated directly, taken up in DCM, and purified by silica gel column chromatography on a Teledyne Isco instrument eluting with 0-100% Hex/EtOAc to afford 1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidin-3-ol (195 mg, 0.518 mmol, 90% yield). LCMS retention time 0.59 [TS]. MS (E±) m/z: 377.1 (M+H).


Intermediate 39H: 1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidin-3-yl methanesulfonate



embedded image


To a stirred solution of 1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidin-3-ol (190 mg, 0.505 mmol) in THF (10 mL) at 25° C. was added Et3N (176 μL, 1.26 mmol) and MsC (43.3 0.555 mmol) sequentially. The reaction mixture was stirred for 2 hours at room temperature, and then another aliquot each of Et3N (176 μL, 1.26 mmol) and MSCI (43.3 μL, 0.555 mmol) were added. Upon addition of these aliquots, the reaction reached completion quickly. The reaction was quenched by the addition of water and DCM. The layers were separated, and the aqueous layer was extracted with DCM. The combined organic layer was dried over sodium sulfate, filtered, and concentrated to afford 1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidin-3-yl methanesulfonate (219 mg, 0.482 mmol, 95% yield. LCMS retention time 0.64 [TS]. MS (E+) m/z: 455.1 (M+H). 1H NMR (499 MHz, CHLOROFORM-d) δ8.55 (br s, 1H), 8.35 (s, 1H), 8.28 (s, 1H), 7.56 (d, J=8.7 Hz, 1H), 6.32 (d, J=8.7 Hz, 1H), 5.42 (tt, J=6.4, 4.5 Hz, 1H), 4.47-4.40 (m, 2H), 4.19 (dd, J=10.3, 4.6 Hz, 2H), 3.08 (s, 3H), 2.87 (spt, J=6.9 Hz, 1H), 2.56 (s, 3H), 2.12 (s, 3H), 1.39 (d, J=6.8 Hz, 6H).


Example 39

A solution of 1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-ypazetidin-3-ylmethanesulfonate (22 mg, 0.048 mmol), Et3N (0.034 mL, 0.242 mmol) and morpholine (0.013 mL, 0.145 mmol) in DMF (1 mL) was heated to 80° C. with stirring for 2.5 hours and the reaction was cooled to room temperature. Another aliquot of morpholine (0.050 mL, 0.574 mmol) was added, and the reaction was heated to 100° C. for 20 hours. Upon completion, the reaction was diluted with DMF and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 19-59% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. The fractions containing the product were combined and dried via centrifugal evaporation to give 4-(1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidin-3-yl)morpholine (5.3 mg, 0.011 mmol, 23% yield). LCMS retention time 0.77 [QC-ACN-TFA-XB]. MS (E+) m/z: 446.1 (M+H). 1H NMR (500 MHz, DMSO-d6) δ10.85 (s, 1H), 8.76 (s, 1H), 8.47 (s, 1H), 7.52 (d, J=8.6 Hz, 1H), 6.28 (d, J=8.7 Hz, 1H), 3.99 (br t, J=7.2 Hz, 2H), 3.73 (br t, J=6.4 Hz, 2H), 3.64-3.54 (m, 4H), 3.27-3.18 (m, 1H), 2.80 (dt, J=13 .7 , 6.9 Hz, 1H), 2.58 (s, 3H), 2.35 (br s, 4H), 2.15 (s, 31-1), 1.35 (br d, J=6.4 Hz, 6H).


Example 96
6-(3-isopropyl-5-(4-methylpiperazin-1-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


6-(3-isopropyl-5-(piperazin-1-yl)-1H-pyrrolo[3,2-13]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine, TFA (18.93 mg, 0.0376 mmol) and Et3N (0.1 mL, 0.717 mmol) were mixed in DMF (1 mL) at room temperature. Formaldehyde (37 wt % in water, 25μL, 0.336 mmol) was added to the reaction vial followed by sodium triacetoxyborohydride (36 mg, 0.170 mmol). After 1 hour, the reaction was quenched by the addition of water, aqueous 1.5 M K2HPO4 solution, and DCM. The organic layer was separated, concentrated, taken up in methanol and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 15% B, 15-55% B over 19 minutes, then a 5-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by UV signals. The fractions containing the product were combined and dried via centrifugal evaporation to afford 6-(3-isopropyl-5-(4-methylpiperazin-1-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (13.9 mg, 0.033 mmol, 88% yield). LCMS retention time 1.31 min [QC-ACN-AA-XB]. MS (E+) m/z: 404.3 (M+H). Select NMR peaks: 1H NMR (500 MHz, DMSO-d6) δ10.91 (s, 1H), 8.71 (s, 1H), 8.45 (s, 1H), 7.59 (d, J=8.9 Hz, 1H), 6.80 (d, J=8.9 Hz, 1H), 2.84-2.73 (m, 1H), 2.59 (br s, 3H), 2.57 (s, 3H), 2.14 (s, 314), 1.35 (br d, J=6.7 Hz, 6H).


Example 105
1-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)piperazin-1-yl)-2-methylpropan-2-ol



embedded image


6-(3-isopropyl-5-(piperazin-1-yl)-1H-pyrrolo[3,2-13]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine, TFA (18.93 mg, 0.0376 mmol) and potassium carbonate (27 mg, 0.195 mmol) were mixed in ethanol (1 mL). 2,2-dimethyloxirane (24 mg, 0.333 mmol) was added to the reaction mixture. The reaction vessel was sealed and heated to 80° C. with stirring for 3 hours. Upon completion, the reaction mixture was cooled to room temperature, filtered, concentrated, taken up in DMSO and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 27% B, 27-67% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS and UV signals. The fractions containing the product were combined and dried via centrifugal evaporation to afford 1-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)piperazin-1-yl)-2-methylpropan-2-ol (9.9 mg, 0.021 mmol, 57.0% yield). LCMS retention time 1.92 [QC-ACN-AA-XB]. MS (E+) m/z: 461.9 (M+H). 1H NMR (500 MHz, DMSO-d6) δ10.81 (s, 1H), 8.72 (s, 1H), 8.45 (s, 1H), 7.53 (d, J=8.9 Hz, 1H), 6.72 (d, J=8.9 Hz, 1H), 3.54-3.38 (m, 4H), 2.82-2.72 (m, 1H), 2.66 (br s, 4H), 2.57 (s, 3H), 2.26 (s, 2H), 2.16 (s, 3H), 1.36 (br d, J=6.7 Hz, 61-), 1.12 (s, 6H).


Example 164
1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-(oxetan-3-yl)pyrrolidin-3-amine



embedded image


Intermediate 164A: 5-bromo-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine



embedded image


A solution containing tert-butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (3.00 g, 8.84 mmol) and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.71 mL, 13.27 mmol) in dry THF (30 mL) under a nitrogen atmosphere was cooled in a dry ice/acetone bath at −78° C. and treated with LDA (2M in THF) (5.53 mL, 11.05 mmol). The mixture was stirred at −78° C. for 30 minutes and allowed to warm to −30° C. over 1 hour and stirred at −30° C. for 30 minutes. The reaction was treated with 1.5 M aqueous KH2PO4 solution, water, and DCM. The layers were separated and the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel chromatography to afford tert-butyl 5-bromo-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate. LCMS retention time 1.32 min [Method A]. MS m/z: 465.1 (M+H). This material was transferred to a 40 mL tall vial, which was capped and flushed with nitrogen gas. The reaction mixture was stirred and heated at 160° C. for 1.5 hours and 5-bromo-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine (2.1 g, 5.75 mmol, 65% yield) was obtained as a yellow solid. Note: material converted to the free boronic acid on LCMS and was observed as such: LCMS retention time 0.85 min [Method A]. MS m/z: 282.9/284.9 (M+H/(M+2)+H).


Intermediate 164B: tert-butyl5-bromo-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


In a 40 mL reaction vial was added 5-bromo-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine (1.500 g, 4.11 mmol), 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (1.14 g, 4.90 mmol), and 2nd generation XPhos precatalyst (0.162 g, 0.205 mmol) and THF (20 mL). The reaction vial was sealed and pump/purged three times with nitrogen gas. Potassium phosphate, tribasic (6.16 mL, 12.33 mmol) was added and the reaction mixture was heated to 65° C. for 1 hour. The mixture was diluted with ethyl acetate and washed with water, then brine and dried over anhydrous sodium sulfate. The solids were filtered off and the filtrate was concentrated. To this was added THF (20 mL), a crystal of DMAP and BOC-anhydride (0.954 mL, 4.11 mmol). The reaction mixture was stirred for 18 hours and was concentrated under a stream of nitrogen gas. The residue was purified by silica gel chromatography to afford tert-butyl 5-bromo-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b] pyridine-1-carboxylate (2.1 g, 5.75 mmol, 65% yield) as a tan solid. LCMS retention time 1.22 min [Method A]. MS m/z: 486.2 (M+H).


Intermediate 164C: 1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)pyrrolidin-3-one



embedded image


In a 1 dram vial was added tert-butyl 5-bromo-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (0.150 g, 0.310 mmol), 2nd generation RuPhos precatalyst (0.024 g, 0.031 mmol), 1,4-dioxa-7-azaspiro[4.4]nonane (0.060 g, 0.464 mmol) and cesium carbonate (0.303 g, 0.929 mmol). The reaction vial was capped with a Teflon-lined cap and pump/purged two times with nitrogen gas. To this, under nitrogen, was added dioxane (2 mL) and the reaction vial was pump/purged three times and was set to heat at 100° C. for 18 hours. The reaction mixture was diluted with ethyl acetate and filtered through Celite. The filtrate was concentrated and purified by silica gel chromatography to afford tert-butyl dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-5-(1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate as a tan oil. LCMS retention time 1.06 min [Method A]. MS m/z: 533.4 (M+H). To this was added TFA (2 mL) and 1 drop of water and the reaction mixture was stirred for 6 hours, then was concentrated under a stream of nitrogen gas. The residue was diluted with 1.5M K2HPO4 solution and DCM. The mixture was transferred to a separatory funnel and the layers were separated. The organics were dried over anhydrous sodium sulfate, filtered and concentrated to afford 1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)pyrrolidin-3-one (50 mg, 0.206 mmol, 42% yield) as a brownish solid. LCMS retention time 0.79 min [Method A]. MS m/z: 389.3 (M+H).


Example 164

In a 1 dram vial was added 1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)pyrrolidin-3-one (0.025 g, 0.064 mmol), DCM (1 mL) and oxetan-3-amine (0.014 g, 0.193 mmol). The reaction mixture was stirred for 4 hours at 25° C., then sodium triacetoxyborohydride (0.041 g, 0.193 mmol) was added. The reaction mixture was stirred for 12 hours at the same temperature. The sample was concentrated, diluted with DMF, filtered and was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 24 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation to afford 1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-(oxetan-3-yl)pyrrolidin-3-amine as a racemic mixture (6.7 mg, 0.0150 mmol, 23% yield), m/z (446.4, M+H). Retention time, 1.450 min using LCMS Column: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM.


Example 368
2-((4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexyl)(methyl)amino)-N,N-dimethylacetamide



embedded image


Intermediate 368A: 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-methylcyclohexanamine



embedded image


4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexan-1-one (0.015 g, 0.037 mmol) and methylamine in THF (0.093 mL, 0.187 mmol) were mixed in DMF (1 mL) and AcOH (6.42 μL, 0.112 mmol). To this was added sodium triacetoxyborohydride (0.040 g, 0.187 mmol). The reaction mixture was stirred for 12 hours. The reaction was quenched via addition of 1.5M K2HPO4. Ethyl acetate was added and the mixture was extracted three times (3×50 mL). The organics were combined, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, filtered and concentrated to obtain Intermediate 368A. Intermediate 368A was separated into cis/trans isomers according to the conditions below. Alternatively, crude Intermediate 368A could be carried forward as a cis/trans mixture for further derivatization and subsequent separation to afford the individual derivatized isomers.


Example 367 (Isomer 1) and Example 369 (Isomer 2)



embedded image


Intermediate 368A was purified and separated into the cis and trans isomers via preparative LC/MS with the following conditions: Column: XBridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the individual isomers were dried via centrifugal evaporation to afford the following:


Example 367: Isomer 1: 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-methylcyclohexanamine (4.3 mg, 0.00970 mmol, 26% yield), m/z (417.2, M+H). Retention time, 1.204 min [Method C]. 1H NMR (500 MHz, DMSO-d6) δ11.16-10.99 (m, 1H), 8.79 (s, 1H), 8.48 (s, 1H), 7.62 (d, J=8.2 Hz, 1H), 7.07 (d, J=8.2 Hz, 1H), 3.18 (s, 1H), 2.90 (br s, 2H), 2.71 (br s, 1H), 2.60 (s, 2H), 2.55 (s, 1H), 2.32 (s, 2H), 2.18 (s, 2H), 2.06 (br d, J=14.3 Hz, 1H), 1.86 (br s, 2H), 1.81-1.72 (m, 1H), 1.65 (br s, 2H), 1.56-1.47 (m, 1H), 1.40 (br d, J=6.7 Hz, 4H), 1.24 (s, 31-1), 1.00 (d, J6.4 Hz, 1H), 0.86 (br t, J=6.7 Hz, 1H).


Example 369: Isomer 2: 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-methylcyclohexanamine (2.4 mg, 0.00576 mmol, 11% yield), m/z (417.2, M+H). Retention time, 1.323 min [Method C]. 1H NMR (500 MHz, DMSO-d6) δ11.19-11.01 (m, 1H), 8.78 (s, 1H), 8.48 (s, 1H), 7.60 (d, J=8.2 Hz, 1H), 7.01 (br d, J=8.5 Hz, 1H), 2.96-2.83 (m, 1H), 2.72 (br t, J=11.9 Hz, 1H), 2.60 (s, 3H), 2.39 (s, 3H), 2.18 (s, 2H), 2.11-1.92 (m, 4H), 1.83 (br s, 3H), 1.75-1.58 (m, 2H), 1.40 (br d, J=6.7 Hz, 6H), 1.34-1.20 (m, 2H).


Example 368

To a 1 dram vial was added Intermediate 368a, 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-methylcyclohexanamine (0.020 g, 0.048 mmol), DCM (1 mL) and DBU (0.025 mL, 0.164 mmol). The material went into solution and 2-chloro-N,N-dimethylacetamide (0.018 g, 0.144 mmol) was added. The reaction mixture was stirred at 25° C. for 18 hours. The mixture was then concentrated under a steam of nitrogen gas, was diluted with 90:10:0.1 acetonitrile:water:TFA, filtered and was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19×200 mm, 5-pm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 24 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation to afford 2-((4(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexyl)(methyl)amino)-N,N-dimethylacetamide as a single cyclohexyl isomer (0.9 mg, 0.00160 mmol, 3.3% yield), m/z (502.3, M+H). Retention time, 1.249 min using LCMS Column: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM. 1H NMR (500 MHz, DMSO-d6) δ11.23-11.03 (m, 1H), 8.81 (s, 1H), 8.49 (s, 1H), 7.67-7.50 (m, 1H), 7.00 (d, J=8.3 Hz, 1H), 3.06 (s, 2H), 2.93-2.79 (m, 4H), 2.77-2.66 (m, 2H), 2.60 (s, 4H), 2.23 (s, 3H), 2.18 (s, 3H), 1.99 (br d, J=12.6 Hz, 2H), 1.89 (br s, 2H), 1.66 (br d, J=11.9 Hz, 3H), 1.50-1.35 (m, 9H).


Example 424 and Example 430
N-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexyl)-N-methyloxetan-3-amine



embedded image


Intermediate 368A, 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-methylcyclohexanamine (0.025 g, 0.060 mmol) and oxetan-3-one (8.65 mg, 0.120 mmol) were mixed in DCM (1 mL). To this was added AcOH (0.344μL, 6.00 μmol) and sodium triacetoxyborohydride (0.038 g, 0.180 mmol). The mixture was stirred for 2 hours at 25° C. then was quenched via addition of 1.5M K2HPO4 solution. Additional DCM was added and the contents were transferred to a separatory funnel and the layers were separated. The combined organics were washed with a saturated NaCl solution, dried over anhydrous sodium sulfate, filtered, concentrated and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 24 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the products were combined and dried via centrifugal evaporation to afford the following resolved products:


Example 424: Isomer 1: N-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1h-pyrrolo[3,2-b]pyridin-5-yl)cyclohexyl)-N-methyloxetan-3-amine (2.5 mg, 0.00519 mmol, 7% yield), m/z (473.2, M+H). Retention time, 1.384 min [Method C]. 1H NMR (500 MHz, DMSO-d6) δ11.08 (s, 1H), 8.78 (s, 1H), 8.48 (s, 1H), 7.60 (br d, J=8.2 Hz, 1H), 7.00 (br d, J=8.2 Hz, 1H), 4.52 (br d, J=6.7 Hz, 4H), 4.04-3.90 (m, 1H), 3.18 (br s, 2H), 2.95-2.84 (m, 1H), 2.68 (br s, 1H), 2.60 (s, 3H), 2.45-2.32 (m, 1H), 2.18 (s, 6H), 1.97 (br d, J=11.3 Hz, 2H), 1.75 (br d, J=11.6 Hz, 2H), 1.64 (br d, J=12.8 Hz, 2H), 1.40 (br d, J=6.7 Hz, 8H).


Example 430: Isomer 2: N-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexyl)-N-methyloxetan-3-amine (6.8 mg, 0.0140 mmol, 18% yield), m/z (473.3, M+H). Retention time, 1.537 min [Method C]. 1H NMR (500 MHz, DMSO-d6) δ11.10 (s, 1H), 8.82 (s, 1H), 7.96 (s, 1H), 7.63 (d, J=8.2 Hz, 1H), 7.08 (d, J=8.2 Hz, 1H), 4.48 (quin, J=6.3 Hz, 4H), 3.95-3.81 (m, 1H), 3.10 (br s, 1H), 2.90 (s, 21-1), 2.61 (s, 2H), 2.41-2.16 (m, 61-I), 2.07 (s, 3H), 1.90 (br s, 2H), 1.74 (br s, 3H), 1.45 (br d, J=7.0 Hz, 7H).


Example 438
6(1r,4r)-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexyl)-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide



embedded image


Intermediate 438A: 2-thia-6-azaspiro[3.3]heptane 2,2-dioxide hydrochloride



embedded image


Intermediate 438B: 6-tosyl-2-oxa-6-azaspiro[3.3]heptane



embedded image


To a solution of EtOH (500 mL) and 3-bromo-2,2-bis(bromomethyl)propan-1-ol (14.00 g, 43.1 mmol) was added 4-methylbenzenesulfonamide (16.23 g, 95 mmol) at 25° C. and the reaction mixture was refluxed for 20 h. The solvent was removed by evaporation and to this was added 100 mL of an 8% NaOH solution. The suspension was stirred for another 2 hours, filtered and the yellow filter cake was rinsed with water and dried overnight through air to give 6-tosyl-2-oxa-6-azaspiro[3.3]heptane (9.05 g, 35.7 mmol, 83% yield) as a light yellow solid. LCMS retention time 0.72 min [Method A]. MS m/z: 254.3 (M+H).


Intermediate 438C: (3-(bromomethyl)-1-tosylazetidin-3-yl) methanol



embedded image


To a suspension of 6-tosyl-2-oxa-6-azaspiro[3.3]heptane (10.50 g, 41.5 mmol) in diethyl ether (300 mL) at 0° C. was added a solution of hydrobromic acid in acetic acid (7.16 mL, 43.5 mmol) in 20 mL of ether, dropwise. The resulting solution was stirred at 0° C. for 2 hours, then 1N NaOH was added to pH=8. The phases were separated and the aqueous phase was extracted with ethyl acetate (3×150 mL). The combined organics were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford the (3-(bromomethyl)-1-tosylazetidin-3-yl)methanol (13.5 g, 36.4 mmol, 88% yield) as a solid. LCMS retention time 0.80 min [Method A]. MS m/z: 336.2 (M+H)


Intermediate 438D: 3,3-bis(bromomethyl)-1-tosylazetidine



embedded image


In a 500 mL round bottom flask (3-(bromomethyl)-1-tosylazetidin-3-yl) methanol (14.44 g, 38.9 mmol) was dissolved in DCM (250 mL) and carbon tetrabromide (21.93 g, 66.1 mmol) was added. The solution was cooled in an ice bath and triphenylphosphine (17.34 g, 66.1 mmol) was added in one portion. The resulting mixture was stirred at 0° C. for 2 hours, then warmed to 25° C. and stirred for 4 hours. Diethyl ether (200 mL) was added and the resulting yellow precipitate was filtered and discarded. The filtrate was concentrated under reduced pressure and purified by silica gel chromatography to afford 3,3-bis(bromomethyl)-1-tosylazetidine (11 g, 27.7 mmol, 71.2% yield) as a white solid. LCMS retention time 0.99 min [Method A]. MS m/z: 398.1 (M+H)


Intermediate 438E: 6-tosyl-2-thia-6-azaspiro[3.3]heptane



embedded image


To a solution of 3,3-bis(bromomethyp-1-tosylazetidine (36.0 g, 91 mmol) in a mixture of acetonitrile (30 mL) and water (5 mL) was added sodium sulfide nonahydrate (43.5 g, 181 mmol) and the reaction mixture was stirred at 50° C. for 4 hours. This was concentrated under reduced pressure and diluted with EtOAc (100 mL) and 1N NaOH solution (30 mL). The phases were separated and the aqueous phase was extracted with EtOAc (2×100 mL). The combined organics were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give 6-tosyl-2-thia-6-azaspiro[3.3]heptane (21.2 g, 79 mmol, 87% yield) as a yellow solid. LCMS retention time 0.9 min [Method A]. MS m/z: 270.2 (M+H).


Intermediate 438F: 6-tosyl-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide



embedded image


To a 100 mL round bottom flask was added 6-tosyl-2-thia-6-azaspiro[3.3]heptane (3.50 g, 12.99 mmol) and DCM (50 mL). The mixture was cooled to 0° C. and mCPBA (8.74 g, 39.0 mmol) was added. The reaction mixture was warmed to 25° C. and stirred for 4 hours. The mixture was concentrated, diluted with MeOH (50 mL) and stirred for 30 minutes. The suspension was filtered and the solid was washed with additional MeOH and dried through air to afford 6-tosyl-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide (3.5 g, 11.61 mmol, 90% yield) as a white solid. LCMS retention time 0.72 min [Method A]. MS m/z: 302.2 (M+H)


Intermediate 438A: 2-thia-6-azaspiro[3.3]heptane 2,2-dioxide hydrochloride



embedded image


In a 250 mL round bottom flask was dissolved 6-tosyl-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide (0.750 g, 2.489 mmol) in MeOH (30 mL). Fresh magnesium (0.907 g, 37.3 mmol) was added and the reaction was heated at 50° C. for 16 hours with vigorous stirring. The reaction mixture was then concentrated to near dryness and the resulting greyish material was suspended in diethyl ether (100 mL). Sodium sulfate decahydrate (8.02 g, 24.89 mmol) was added and the slurry was stirred for 1 hour, then filtered, dried over anhydrous sodium sulfate and filtered. The white solid was dissolved in DCM (2 mL) and 4M HCl/dioxane (5 mL) was added. A white solid precipitated out and the suspension was allowed to sit for 30 minutes, then concentrated. Diethyl ether was added and the suspension was stirred for 30 minutes. The solid was filtered through a frit and washed with diethyl ether to afford 2-thia-6-azaspiro[3.3]heptane 2,2-dioxide HCl (0.250 g, 1.361 mmol, 54.7% yield) as a white solid.


Example 438

4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b] pyridin-5-yl)cyclohexan-1-one (Intermediate 4D, 0.755 g, 1.880 mmol), 2-thia-6-azaspiro[3.3]heptane 2,2-dioxide hydrochloride (0.518 g, 2.82 mmol) and DBU (0.567 mL, 3.76 mmol) were mixed in DCM (6 mL) with acetic acid (1.076 μ, 0.019 mmol). The reaction vial was capped. The reaction mixture was stirred overnight at 25° C. The volatiles were removed under a stream of nitrogen gas and the residue was diluted with MeOH (1 mL). The reaction mixture was cooled to −78° C. and lithium borohydride (2M in THF) (2.82 mL, 5.64 mmol) was added drop-wise over 10 minutes. The mixture was stirred at the same temperature for 1 hour, and then the reaction was quenched by addition of 1.5 M aqueous K2HPO4. DCM was added and the mixture was transferred to a separatory funnel and the layers were separated. The aqueous layer was extracted with DCM (3×50 mL) and the combined organics were washed with a saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered and concentrated to afford 1.4 g of crude material. The crude material was purified by preparative SFC using the following conditions: Sample preparation: 1.4 g/36 mL MeOH:DCM(4:1), 38.88 mg/mL; Column: Cellulose-4 (3×25cm, 5 μm, #121391); temperature=35° C.; flow rate: 200 mL/min; BPR pressure: 100 bars; mobile Phase: CO2/MeOH:MeCN (1:1) w 0.1% NH4OH (45/55); separation program: Stack injection; Injection: 3.5 mL with cycle time: 4.2 mins; throughput: 1.9 g/hr; Detector Wavelength: 220 nm. The fractions containing the product were concentrated and further purified using the following procedure: Approximately 900 mg of the white solid from SFC purification was dissolved in a boiling mixture of ethyl acetate:methanol (4:1). The flask was capped and maintained at room temperature for 48 hours. A white solid was filtered off and washed with ethyl acetate, followed by MeOH. The solid was dried and collected to afford 6-((1r,4r)-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexyl)-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide (0.57 g, 1.070 mmol, 56.9% yield) as a white solid. LCMS retention time 0.56 min [Method A]. MS m/z: 533.5 (M+H).


Exploration of reductive amination conditions in the preparation of Example 438:


















*cis:trans:**alcohol


Reducing Agent
Solvent
Temp.
ratio



















NaBH4
DMF
25°
C.
8:1:0


NaBH4
DCM
25°
C.
8:1:0


NaBH4
MeOH
−78°
C.
No Reaction


LiBH4
MeOH
−78°
C.
1:3:1










LiBH4
***DCM/
25° C./−78° C.
1:6:1



MeOH





*Approximate ratios were obtained via HPLC.


**Alcohol ratio refers to the ketone reduction to the alcohol.


***Iminium was pre-generated in DCM at 25° C., The reduction was performed at −78° C. in MeOH.






Alternate Synthesis of Example 438
Intermediate 1A: 2-bromo-5-hydrazinylpyridine



embedded image


To a solution of 6-bromopyridin-3-amine (50 g, 289 mmol) in HBr in 47% water (570 mL) at 0° C. in a 5 L multi-neck round bottom flask, was added dropwise a solution of sodium nitrite (19.94 g, 289 mmol) in water (312.5 mL). After 1 hour at 0° C., a solution of tin (II) chloride dihydrate (157 g, 694 mmol) in HBr, 47% in water (345 mL) is slowly added at 0° C. After this addition was complete, the reaction mixture was allowed to stir for 1 hour at 0° C. The solid was collected by filtration and dried for 30 minutes through air and then washed with diethyl ether (500 mL). Following drying to remove the diethyl ether, 2-bromo-5-hydrazineylpyridine dihydrobromide (65 g, 186 mmol, 64.3% yield) was collected as a solid. LCMS retention time 0.68 min [DDS]. MS m/z: 188.1 (M+H).


Intermediate 1B: 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine



embedded image


Isovaleraldehyde (23.70 mL, 220 mmol) was added to a solution of 2-bromo-5-hydrazineylpyridine dihydrobromide (70 g, 200 mmol) in sulfuric acid (70 mL, 1313 mmol) in water (630 mL) and the reaction mixture was stirred for 30 minutes at room temperature. The reaction mixture was heated to 110° C. and stirred for 18 hours. The reaction mixture was diluted with ethyl acetate (2000 mL) and washed with water (200 mL). The separated organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduce pressure to afford 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine (200 mmol) as brown liquid. Material carried forward without additional purification. LCMS retention time 1.64 min [DDS]. MS m/z: 241.1 (M+H).


Intermediate 1C: tert-butyl5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To a solution of 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine (55 g, 193 mmol) in THF (550 mL) at 0° C. was added TEA (42.4 mL, 304 mmol) over 10 minutes followed by the addition of DMAP (2.360 g, 19.32 mmol). At 0° C., BOC-anhydride 30% in toluene (16.73 g, 23.0 mmol) was added in a single portion and the reaction mixture was stirred for 1 hour. Another aliquot of Boc-anhydride (67.3 mL, 290 mmol) was added and the reaction mixture was stirred for 18 hours at 25° C. Upon completion, the reaction mixture was concentrated in vacuo and the crude material was purified on silica gel chromatography to afford tert-butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (37 g, 104 mmol, 53.6% yield). LCMS retention time 1.59 min [DDS]. MS m/z: 339.0 (M+H). 1H NMR (400 MHz, DMSO-d6) δ8.22 (d, J=8.5 Hz, 1H), 7.71 (s, 1H), 7.52 (d, J=8.5 Hz, 1H), 3.27-3.08 (m, 1H), 1.63 (s, 9H), 1.32 (d, J=7.0 Hz, 6H).


Intermediate 4A: tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To a 1000 mL sealed tube was added tert-butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (42 g, 124 mmol) and 4,4,5,5-tetramethyl-2-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane (34.6 g, 130 mmol) in a mixture of tetrahydrofuran (360 mL) and water (42 mL). To this was added potassium phosphate tribasic (52.6 g, 248 mmol) and 2nd generation X-Phos precatalyst (3.90 g, 4.95 mmol. The bi-phasic mixture was degassed with nitrogen gas for 10 minutes and the sealed vial was stirred at 70° C. for 12 hours. The reaction mixture was cooled to room temperature and diluted with ethyl acetate and water. The mixture was transferred to a separatory funnel and the layers were separated. The combined organics were washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated to dryness. Further purification was done by silica gel chromatography to afford tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (39.00 g, 98.0 mmol, 79% yield) LCMS retention time 2.53 min [DDS2]. MS m/z: 399.5 (M+H). 1H NMR (400 MHz, DMSO-d6) δ9.08 (d, J=9.0 Hz, 1H), 8.48 (s, 1H), 8.41 (d, J=9.0 Hz, 1H), 7.50-7.40 (m, 1H), 7.24-7.14 (m, 1H), 4.82 (s, 2H), 4.75 (s, 2H), 4.20 (s, 3H), 3.69-3.59 (m, 1H), 3.36-3.29 (m, 1H), 3.17-3.01 (m, 2H), 2.74 (s, 1H), 2.48 (s, 1H), 2.25 (d, J=7.0 Hz, 3H), 2.08 (s, 9H).


Intermediate 4B: tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (80 g, 201 mmol) in ethyl acetate (800 mL) was added 10% w/w Pd-C (29.9 g, 28.1 mmol). The flask was placed under vacuum and pump/purged with nitrogen gas. After evacuation, the vessel was back-filled with hydrogen gas via a hydrogen filled bladder and the reaction mixture was allowed to stir for 2-3 hours. The vessel was diluted with ethyl acetate and the contents was filtered through tightly packed Celite. Upon concentration, the crude material was purified by silica gel chromatography to afford tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (67.00 g, 167.0 mmol, 83% yield) as a yellow oil. LCMS retention time 1.86 min [DDS2]. MS m/z: 401.4 (M+H). 1H NMR (400 MHz, DMSO-d6) δ8.22-8.08 (m, 1H), 7.58-7.52 (m, 1H), 7.21-7.13 (m, 1H), 4.01 (d, J=7.0 Hz, 1H), 3.89-3.86 (m, 2H), 3.84 (s, 2H), 2.25-2.18 (m, 2H), 2.18-2.10 (m, 2H), 1.89-1.72 (m, 6H), 1.60 (s, 3H), 1.59-1.53 (m, 1H), 1.32 (d, J=7.0 Hz, 4H), 1.23-1.18 (m, 1H), 1.16-1.13 (m, 1H), 1.18-1.13 (m, 2H), 1.16-1.12 (m, 2H)


Intermediate 4E: tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


In 1 L round bottom flask was added tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (45 g, 112 mmol) in tetrahydrofuran (675 mL) under a nitrogen atmosphere. The reaction mixture was cooled in a dry ice/acetone bath to −78° C. To this was added slowly LDA (112 mL, 225 mmol) and the mixture was stirred at −78° C. for 45-50 min. 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (34.5 mL, 169 mmol) was added and the reaction mixture was stirred at the same temperature for 1-2 hours. The reaction was quenched with saturated aqueous KH2PO4 solution at the same temperature, then water and ethyl acetate were added and the mixture was transferred to a separatory funnel. The layers were separated and the combined organics were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was further purified by silica gel chromatography to afford tert-butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (35.0 g, 66.5 mmol, 60% yield). LCMS retention time 2.05 min [DDS2]. MS m/z: 527.5 (M+H).


Intermediate 4C: 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine



embedded image


tert-Butyl 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (35 g, 66.5 mmol) was added to a 500 mL round bottom flask. The reaction mixture was pump/purged three times with nitrogen gas and set to heat at 150° C. under a nitrogen atmosphere for 7-8 hours. The reaction mixture was cooled to room temperature, then 200 mL petroleum ether was added and distilled completely. The solid was washed with ether and dried for 1-2 hours to afford 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine (23.0 g, 54.0 mmol, 81% yield) as a yellow solid. LCMS retention time 1.47 min [DDS2]. MS m/z: 427.5 (M+H). 1H NMR (499 MHz, CHLOROFORM-d) δ8.25 (br s, 1H), 7.52 (d, J=8.6 Hz, 1H), 7.05 (d, J=8.6 Hz, 1H), 4.03 (t, J=2.6 Hz, 4H), 3.83-3.71 (m, 1H), 2.98-2.86 (m, 1H), 2.13-1.90 (m, 6H), 1.79 (br s, 2H), 1.56 (d, J=6.9 Hz, 6H), 1.39 (s, 12H).


Intermediate 4F: 6-(3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


In a 1 L sealed tube, 3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine (22.5 g, 52.8 mmol), and 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (11.93 g, 52.8 mmol) were dissolved in tetrahydrofuran (225 mL) and water (22.5 mL). Potassium phosphate tribasic (33.6 g, 158 mmol) was added, then the mixture was purged with nitrogen gas for 5 minutes. 1,1′-bis(di-tert-butylphosphino)ferrocene palladium dichloride (1.720 g, 2.64 mmol) was added and the reaction mixture was heated to 70° C. for 2-3 hours. Following cooling to room temperature, the mixture was diluted with ethyl acetate and washed with water, then brine and dried over anhydrous sodium sulfate. The solids were filtered and the filtrate was concentrated. The residue was further purified by silica gel chromatography to afford 6-(3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (19.0 g, 42.6 mmol, 81% yield) as an off-white solid. LCMS retention time 1.70 min [DDS2]. MS m/z: 446.6 (M+H). NMR (300 MHz, DMSO-d6) δ11.04 (s, 1H), 8.80 (s, 1H), 8.48 (s, 1H), 7.60 (d, J=8.6 Hz, 1H), 7.01 (d, J=8.6 Hz, 1H), 3.91 (t, J=2.8 Hz, 4H), 3.09-3.08 (m, 1H), 2.97-2.74 (m, 2H), 2.60 (s, 3H), 2.18 (s, 3H), 1.97-1.77 (m, 5H), 1.75-1.58 (m, 2H), 1.41 (d, J=6.9 Hz, 6H)


Intermediate 4D: 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1 H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexan-1-one



embedded image


In a 1 L sealed tube, 6-(3-isopropyl-5-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (36 g, 81 mmol) was mixed in tetrahydrofuran (660 mL). Next, HCl (101 mL, 1212 mmol) was added and the mixture was stirred at room temperature for 18 hours. To the reaction mixture was added saturated potassium phosphate solution to pH=8 and ethyl acetate (500 mL×2). The mixture was poured into a separatory funnel and the layers were separated. The organics were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was treated with petroleum ether (200 mL) and stirred for 15 minutes. The filter cake was washed with additional petroleum ether and dried to afford 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexan-1-one (30.0 g, 74.8 mmol, 92% yield) as an off-white solid. LCMS retention time 1.53 min [DDS2]. MS m/z: 402.4 (M+H). NMR (400 MHz, DMSO-d6) δ11.12-10.98 (m, 1H), 8.78 (s, 1H), 8.47 (s, 1H), 7.58 (d, J=8.5 Hz, 1H), 6.98 (d, J=8.5 Hz, 1H), 4.31 (s, 4H), 2.97-2.81 (m, 1H), 2.59 (s, 2H), 2.17 (s, 3H), 2.13-2.00 (m, 1H), 1.97-1.76 (m, 4H), 1.72-1.53 (m, 2H), 1.39 (d, J=6.5 Hz, 3H), 1.18-0.98 (m, 2H)


Example 438

To a 2 L round bottom flask was added 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexan-1-one (29 g, 72.2 mmol), 2-thia-6-azaspiro[3.3]heptane 2,2-dioxide hydrochloride (19.90 g, 108 mmol), DCM (435 mL) and acetic acid (0.413 mL, 7.22 mmol). To this was added DBU (32.7 mL, 217 mmol) and the reaction mixture was stirred for 18 hours at room temperature. The volatiles were removed under reduced pressure and the resulting residue was dissolved in methanol (435 mL). The mixture was cooled to −78° C. and to this was added lithium borohydride (54.2 mL, 217 mmol) via syringe over 30-40 minutes. The reaction was stirred at −78° C. for 2 hours. The reaction mixture was allowed to warm to room temperature and was quenched with a saturated potassium phosphate solution. This was diluted with water (150 mL), extracted with ethyl acetate (300 mL×3), dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was taken into 100 mL of IPA and stirred for 30-40 minutes at 50° C. The mixture was cooled to room temperature, filtered, and washed with 20 mL of IPA to give an off-white solid containing 90% of the trans product. Further purification was performed by preparative SFC using the following conditions: Sample preparation: 18 g of crude material; Column: Lux Cellulose-4 (250 ×4.6) mm 5 μm; temperature=30° C.; BPR pressure: 100 bar; mobile Phase: 0.2% NH4OH in ACN:MeOH (1:1) ; Injection: 10 mL; Detector Wavelength: 220 nm. The fractions containing product were concentrated and further purified using the following procedure: This material was then trapped with (methanol, THF, acetonitrile) and the solid was taken into 30% aqueous IPA 60 mL (18 mL water: 48 mL IPA), then heated to 70° C. for 1 hour. The mixture was brought to room temperature, filtered, washed with IPA (20 mL) and dried for 10-12 hours to afford 6-((1r,4r)-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexyl)-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide (16.0 g, mmol, 41.4% yield)) as a white solid. LCMS retention time 1.31 min [DDS2]. MS m/z: 533.4 (M+H). 1H NMR (499 MHz, DMSO-d6) δ11.16-11.02 (m, 1H), 8.80 (s, 1H), 8.48 (s, 1H), 7.59 (d, J=8.2 Hz, 1H), 6.99 (d, J=8.5 Hz, 1H), 4.32 (s, 4H), 4.10 (q, J=5.2 Hz, 1H), 3.17 (d, J=5.2 Hz, 314), 2.88 (quin, J=6.9 Hz, 1H), 2.74-2.56 (m, 4H), 2.17 (s, 3H), 2.13-1.99 (m, 1H), 1.98-1.88 (m, 2H), 1.84 (br d, J=10.7 Hz, 2H), 1.71-1.55 (m, 2H), 1.40 (d, J=6.9 Hz, 6H), 1.19-0.97 (m, 2H).


Alternate synthesis of Intermediate 438A: 2-thia-6-azaspiro[3.3]heptane 2,2-dioxide hydrochloride



embedded image


Intermediate 438B: 6-tosyl-2-oxa-6-azaspiro[3.3]heptane



embedded image


KOH (276 g, 4926 mmol) was dissolved in ethanol (2.5 L) and to this solution was added 3-bromo-2,2-bis(bromomethyl)propan-1-ol(500 g, 1539 mmol) and 4-methylbenzenesulfonamide (316 g, 1847 mmol). The reaction mixture was heated to 85° C. for 2 days, then cooled to room temperature and to this was added 8% sodium hydroxide solution (2.5 L). The mixture was stirred for 2 hours and a white solid was filtered off. The collected solid was stirred in water (1 L) and filtered. This process was repeated 3 times. The solid was then stirred with methanol (1 L), filtered and dried through air to afford 6-tosyl-2-oxa-6-azaspiro[3.3]heptane (250 g, 984 mmol, 64% yield) as an off-white solid. LCMS retention time 1.16 min [DDS2]. MS m/z: 254.2 (M+H)


Intermediate 438C: (3-(bromomethyl)-1-tosylazetidin-3-yl)methanol



embedded image


To a suspension of 6-tosyl-2-oxa-6-azaspiro[3.3]heptane (240 g, 947 mmol) in diethyl ether (2.5 L) at 0° C. was added a solution of hydrobromic acid in acetic acid (171 mL, 1042 mmol) in diethyl ether (1.5 L) drop-wise. The resulting solution was stirred at 0° C. for 30 minutes, warmed to room temperature and stirred for an additional 2 hours. To this was added a 10% sodium bicarbonate solution until pH=8 was reached. MTBE was added and the phases were separated. The aqueous phase was extracted with ethyl acetate, and the combined organics were washed with water and then brine, then dried over anhydrous sodium sulfate, filtered and concentrated in vaccuo to afford the (3-(bromomethyl)-1-tosylazetidin-3-yl)methanol (302 g, 904 mmol, 95% yield) as a white solid. LCMS retention time 1.34 min [DDS2]. MS m/z: 334.1/336.1 (M+H). 1H NMR (300 MHz, CHLOROFORM-d) δ7.83-7.64 (m, 21-1), 7.47-7.32 (m, 2H), 3.69 (d, J=5.0 Hz, 2H), 3.65-3.59 (m, 2H), 3.58-3.52 (m, 2H), 3.46 (s, 2H), 2.48 (s, 3H), 1.71 (t, J=5.0 Hz, 1H).


Intermediate 438D: 3,3-bis(bromomethyl)-1-tosylazetidine



embedded image


In a 1 L round bottom flask, (3-(bromomethyl)-1-tosylazetidin-3-yl)methanol (54 g, 162 mmol) was dissolved in DCM (540 mL) and carbon tetrabromide (86 g, 259 mmol was added. The solution was cooled in an ice bath and triphenylphosphine (67.8 g, 259 mmol) was added portion-wise. The resulting mixture was warmed to 25° C. and stirred for 18 hours. The reaction mixture was concentrated and ethyl acetate was added and the mixture was stirred for 10 minutes, then a white solid was filtered off. The filtrate was concentrated under reduced pressure and purified by silica gel chromatography to afford 3,3-bis(bromomethyl)-1-tosylazetidine (50 g, 126 mmol, 78% yield) as a white solid. LCMS retention time 1.87 min [DDS2]. MS m/z: 398.1 (M+H). NMR (400 MHz, CHLOROFORM-d) δ7.81-7.70 (m, 2H), 7.42 (d, J=8.0 Hz, 2H), 3.61 (s, 4H), 3.55 (s, 4H), 2.50 (s, 3H).


Intermediate 438E: 6-tosyl-2-thia-6-azaspiro[3.3]heptane



embedded image


To a solution of 3,3-bis(bromomethyl)-1-tosylazetidine (35 g, 88 mmol) in a mixture of acetonitrile (350 mL) and water (35 mL) was added sodium sulfide nonahydrate (106 g, 441 mmol) and the reaction mixture was stirred at 50° C. for 3 hours. The reaction mixture was concentrated under reduced pressure and diluted with EtOAc and water. The phases were separated and the aqueous phase was extracted with EtOAc. The combined organics were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give 6-tosyl-2-thia-6-azaspiro[3.3]heptane (21 g, 78 mmol, 88% yield) as a white solid LCMS retention time 1.56 min [DDS2]. MS m/z: 270.1 (M+H). 1H NMR (300 MHz, CHLOROFORM-d) δ7.76-7.68 (m, 2H), 7.37 (d, J=7.9 Hz, 2H), 3.78 (s, 4H), 3.14 (s, 4H), 2.46 (s, 3H).


Intermediate 438F: 6-tosyl-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide



embedded image


To a 4 L flask was added 6-tosyl-2-thia-6-azaspiro[3.3]heptane (175 g, 650 mmol) and DCM (2.75 L). The mixture was cooled to 0° C. and mCPBA (320 g, 1299 mmol) was added over 30 minutes, then the reaction mixture was warmed to 25° C. and stirred for 3 hours. The mixture was diluted with DCM and washed with a 5% NaOH solution (3×1 L). The combined organics were washed with water and brine, then dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by silica gel chromatography to afford 6-tosyl-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide (135 g, 449 mmol, 69% yield) as a white-solid. LCMS retention time 1.16 min [DDS2]. MS m/z: 302.1 (M+H). NMR (300 MHz, CHLOROFORM-d) δ7.79-7.66 (m, 2H), 7.40 (d, fr-7.9 Hz, 2H),1.12 (s, 4H), 3.97 (s,/4H), 2.47 (s, 3H).


Intermediate 438A: 2-thia-6-azaspiro[3.3]heptane 2,2-dioxide hydrochloride



embedded image


6-tosyl-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide (40 g, 133 mmol) and magnesium (32.3 g, 1327 mmol) were taken in dry methanol (1600 mL) and heated to 50° C. for 18 hours. The mixture was cooled to room temperature and stirred for an additional 18 hours. To this was added sodium sulfate decahydrate (428 g, 1327 mmol) and DCM (2 L) and the mixture was stirred for 1 hour and filtered. The solid was suspended in DCM (2 L), stirred and the suspension was filtered. The combined filtrate was concentrated to near dryness. Residual water was evaporated and the resulting solid was taken in DCM (200 mL). The suspension was filtered through sodium sulfate and the filtrate collected. To this was added 4M HCl in dioxane (25 mL) and the resulting solid was filtered and washed with DCM to afford 2-thia-6-azaspiro[3.3]heptane 2,2-dioxide HCl (15.2 g, 65% yield) as a white solid. 1H NMR (499 MHz, DMSO-d6) δ9.47-9.16 (m, 2H), 4.50 (s, 4H), 4.30-4.09 (m, 4H).


Example 491
6-(3-isopropyl-5-(2-azaspiro[3.5]nonan-7-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


Intermediate 491A: 5-chloro-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine



embedded image


tent-Butyl 5-chloro-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate was prepared according to the general method described above for Intermediate 1C. A solution containing tert-butyl 5-chloro-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (3.00 g, 10.18 mmol) and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.11 mL, 15.27 mmol) in dry THF (25 mL), under a nitrogen atmosphere, was cooled in a dry ice/acetone bath at −78° C. and treated with LDA (2M in THF) (6.36 mL, 12.72 mmol). The mixture was stirred at −78° C. for 30 minutes and allowed to warm to −30° C. over 1 hour and stirred at −30° C. for 30 minutes. The reaction mixture was treated with 1.5 M aqueous KH2PO4 solution, water and DCM. The organic layer was collected, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel chromatography to afford tert-butyl 5-chloro-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate. LCMS retention time 1.31 min [Method A]. MS m/z: 420.8/422.3 (M+H). This material was transferred to a 40 mL vial and flushed with nitrogen gas. The mixture was sealed and was heated at 160° C. for 1.5 hours to afford 5-chloro-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine (2.4 g, 7.49 mmol, 74% yield) as a tan solid. LCMS retention time 1.16 min [Method A]. MS m/z: 321.1/323.1 (M+H).


Intermediate 491B: tert-butyl5-chloro-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


In a 40 mL reaction vial was added 5-chloro-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine (1.000 g, 3.12 mmol), 1,1′-bis(di-tert-butylphosphino)ferrocene palladium dichloride (0.041 g, 0.062 mmol)6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (0.705 g, 3.12 mmol) and THF (40 mL). The reaction was sealed and pump/purged three times with nitrogen gas. To this was added aqueous potassium phosphate, tribasic (2M, 4.68 mL, 9.36 mmol) and the reaction was heated to 65° C. for 1 hour. The mixture was diluted with ethyl acetate and washed with water, then brine and dried over anhydrous sodium sulfate. The solids were filtered off and the filtrate was concentrated. The crude material was purified by silica gel chromatography to give 6-(5-chloro-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine as a tan/brown solid. To this was added THF (100 mL) and BOC-anhydride (0.724 mL, 3.12 mmol). A crystal of DMAP was added and the reaction was capped and stirred for 18 hours at 25° C., then concentrated under reduced pressure. To this residue was added DCM and water and the mixture was transferred to a separatory funnel. The layers were separated and the combined organics were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to afford 5a: tert-butyl 5-chloro-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (0.9 g, 2.046 mmol, 65% yield). LCMS retention time 1.17 min [Method A]. MS m/z: 440.1 (M+H)


Example 491

To a solution of tert-butyl 5-chloro-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (0.20 g, 0.455 mmol), tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-azaspiro[3.5]non-6-ene-2-carboxylate (0.119 g, 0.341 mmol), and potassium phosphate, tribasic (0.682 mL, 1.364 mmol) in THF (300 mL) was added PdCl2(dppf)-CH2Cl2 adduct (9.28 mg, 0.011 mmol) and the biphasic mixture was degassed with nitrogen for 10 minutes. The reaction vessel was sealed. The reaction mixture was stirred at 90° C. for 2 hours, then was diluted with ethyl acetate and washed with saturated sodium chloride solution. The organic layer was dried with magnesium sulfate, filtered and concentrated. The crude material was purified by silica gel chromatography to give tert-butyl 5-(2-(tert-butoxycarbonyl)-2-azaspiro[3.5]nonan-7-yl)-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate. LCMS retention time 1.114 min [Method A]. MS m/z: 629.5 (M+H). To 0.2 g of this intermediate, in a Parr bottle was added ethyl acetate (15 mL) and 10% Pd/C (0.015 g, 0.014 mmol) under a nitrogen atmosphere. The vessel was placed on the Parr apparatus and pump/purged three times with nitrogen gas. The vessel was then pressurized to 50 psi with hydrogen gas and shaken for 1 hour. The vessel was diluted with 100 mL of methanol and the contents was filtered through tightly packed Celite. Upon concentration 0.020 g of the crude residue was purified by preparative LC-MS with the following conditions: Column: XBridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 24 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation to afford 6-(3-isopropyl-5-(2-azaspiro[3.5]nonan-7-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (6.0 mg, 0.0140 mmol); m/z (429.4, M+H). Retention time, 1.262 min using LCMS Column: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM. 1H NMR (500 MHz, DMSO-d6) δ11.12-11.08 (m, 1H), 8.77 (s, 1H), 8.48 (s, 1H), 7.61 (d, J=8.2 Hz, 1H), 7.01 (d, J=8.2 Hz, 1H), 3.61-3.39 (m, 1H), 2.89 (br t, J=6.9 Hz, 1H), 2.70 (br s, 1H), 2.59 (s, 3H), 2.55 (s, 5H), 2.17 (s, 3H), 2.14-2.03 (m, 2H), 1.91-1.75 (m, 6H), 1.68-1.50 (m, 4H), 1.39 (br d, J=6.7 Hz, 6H).


EXAMPLE 590
6-(3-isopropyl-5-((1-methylpiperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 1 dram vial with pressure relief septum was added 6-(3-isopropyl-5-(piperidin-4-ylmethoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (15 mg, 0.023 mmol), DMF (1 mL), and DIEA (4.04 μL, 0.023 mmol). Formaldehyde (37% in water) (8.61 μL, 0.116 mmol) was added. The reaction mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added acetic acid (1.324 μL, 0.023 mmol) and sodium triacetoxyborohydride (4.90 mg, 0.023 mmol). The reaction mixture was stirred at room temperature overnight. The crude material was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 0-100% B over 19 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 14-39% B over 25 minutes, then a 2-minute hold at 39% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters XBridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 435.39 (M+H); Retention Time: 1.17 min. Injection 2 conditions: Column: Waters XBridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 435.43 (M+H); Retention Time: 0.94 min. Isolated 6-(3-isopropyl-5-((1-methylpiperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (5.9 mg, 0.013 mmol, 56.9% yield). 1H NMR (500 MHz, DMSO-d6) δ11.30-11.25 (m, 1H), 8.51 (s, 1H), 8.46 (s, 1H), 7.69 (d, J=8.9 Hz, 1H), 7.12 (s, 1H), 6.58 (d, J=8.9 Hz, 1H), 4.20-4.14 (m, 2H), 4.04 (s, 1H), 3.63-3.51 (m, 1H), 3.30-3.20 (m, 2H), 3.03 (br d, J=11.6 Hz, 2H), 2.37-2.28 (m, 4H), 1.81 (br d, J=11.0 Hz, 4H), 1.52-1.46 (m, 6H), 1.45-1.35 (m, 2H).


Example 591
6-(3-isopropyl-5-((1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 1 dram vial containing 6-(3-isopropyl-5-(piperidin-4-ylmethoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (15 mg, 0.023 mmol) was added DMF (0.5 mL), DIEA (0.012 mL, 0.069 mmol), and dihydro-2H-pyran-4(3H)-one (2.316 mg, 0.023 mmol). The reaction mixture was stirred for 5 minutes. Sodium triacetoxyborohydride (14.71 mg, 0.069 mmol) and acetic acid (1.324 μL, 0.023 mmol) were added, and the reaction mixture was stirred for 6 hours. The crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 19 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 505.53 (M+H); Retention Time: 1.23 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 505.52 (M+H); Retention Time: 1 min. Isolated 6-(3-isopropyl-5-((1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (10.8 mg, 0.021 mmol, 89% yield). 1H NMR (500 MHz, DMSO-d6) δ11.29 (s, 1H), 8.59 (s, 1H), 8.50 (s, 1H), 7.67 (d, J=8.9 Hz, 1H), 7.17 (s, 1H), 6.57 (d, J=8.5 Hz, 1H), 4.17 (br d, J=6.4 Hz, 2H), 4.07 (s, 3H), 3.89-3.82 (m, 2H), 3.29-3.22 (m, 2H), 2.91 (br d, J=10.4 Hz, 2H), 2.09 (br t, J=11.1 Hz, 2H), 1.90 (s, 2H), 1.82-1.71 (m, 3H), 1.66 (br d, J=12.5 Hz, 2H), 1.54-1.50 (m, 6H), 1.41 (qd, J=12.0, 4.7 Hz, 2H), 1.33-1.21 (m, 2H).


Example 592
6-(3-isopropyl-5-(1-isopropylazetidin-3-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 20 mL scintillation vial containing 6-(5-(azetidin-3-ylmethoxy)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (15 mg, 0.038 mmol) was added DMF (1 mL) and propan-2-one (2.220 mg, 0.038 mmol). The reaction mixture was stirred at room temperature for 10 minutes. Acetic acid (2.188 uL, 0.038 mmol) and sodium triacetoxyborohydride (24.30 mg, 0.115 mmol) were added and the reaction mixture was stirred at room temperature overnight. A drop of water was added, and the crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 22 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 p.m particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 435.24 (M+H); Retention Time: 1.27 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 435.21 (M+H); Retention Time: 1.08 min. Isolated 6-(3-isopropyl-5-(1-isopropylazetidin-3-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (5.4 mg, 0.012 mmol, 31.5% yield). 1H NMR (500 MHz, DMSO-d6) δ11.32 (s, 1H), 8.57 (s, 1H), 8.50 (s, 1H), 7.68 (d, J=8.9 Hz, 1H), 7.17 (s, 1H), 6.57 (d, J=8.5 Hz, 1H), 4.41 (br d, J=6.7 Hz, 2H), 4.06 (s, 3H), 3.33-3.19 (m, 3H), 2.98 (br t, J=6.7 Hz, 2H), 2.81-2.70 (m, 1H), 2.36-2.25 (m, 1H), 1.56-1.48 (m, 6H), 0.86-0.81 (m, 6H).


Example 593
6-(3-isopropyl-5-((1-propylpiperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 1 dram vial containing 6-(3-isopropyl-5-(piperidin-4-yloxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (15 mg, 0.024 mmol) was added DMF (500 gL), DIEA (12.39 gL, 0.071 mmol), and propionaldehyde (4.12 mg, 0.071 mmol). The reaction mixture was stirred at room temperature for 5 minutes. Acetic acid (1.353 gL, 0.024 mmol) and sodium triacetoxyborohydride (15.03 mg, 0.071 mmol) were added to the reaction mixture. The reaction mixture was stirred for 1 hour. The crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 15-55% B over 19 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 448.94 (M+H); Retention Time: 1.3 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 449.05 (M+H); Retention Time: 1.05 min. Isolated 6-(3-isopropyl-5-(1-propylpiperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (8.6 mg, 0.019 mmol, 79% yield). NMR (500 MHz, DMSO-d6) δ11.29 (s, 1H), 8.58 (s, 1H), 8.51 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.18 (s, 1H), 6.55 (d, J=8.9 Hz, 1H), 5.05-4.93 (m, 1H), 4.08 (s, 3H), 3.31-3.19 (m, 1H), 2.77 (br s, 2H), 2.27 (br t, J=7.3 Hz, 2H), 2.19 (br t, J=9.8 Hz, 2H), 2.12-2.03 (m, 2H), 1.75-1.64 (m, 2H), 1.51 (s, 6H), 1.48-1.41 (m, 2H), 0.86 (t, J=7.2 Hz, 3H).


Example 594
6-(3-isopropyl-5-((1-methylpiperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 1 dram vial containing 6-(3-isopropyl-5-(piperidin-4-yloxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (27 mg, 0.044 mmol) was added DMF (0.5 mL), DIEA (0.023 mL, 0.131 mmol), and formaldehyde (0.016 mL, 0.218 mmol). The reaction mixture was stirred for 5 minutes. Acetic acid (2.499 μL, 0.044 mmol) and sodium triacetoxyborohydride (27.8 mg, 0.131 mmol) were added. The reaction mixture was stirred for 10 minutes. The material was dissolved in DMF (2 mL) and purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μrn particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 405.36 (M+H); Retention Time: 1.01 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 405.37 (M+H); Retention Time: 1.25 min. Isolated 6-(3-isopropyl-5-((1-methylpiperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.8 mg, 1.879 μmol, 4.3% yield). 1H NMR (500 MHz, DMSO-d6) δ11.33 (br s, 1H), 8.85 (s, 1H), 8.54 (s, 1H), 7.67-7.61 (m, 2H), 6.53 (d, J=8.7 Hz, 1H), 4.99 (br s, 1H), 3.33-3.12 (m, 2H), 2.26-2.11 (m, 5H), 2.06 (br d, J=10.9 Hz, 2H), 1.76 (s, 4H), 1.74-1.65 (m, 2H), 1.54-1.44 (m, 6H).


Example 595
6-(3-isopropyl-5-((1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)oxy)-1H-pyrrolo [3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 1 dram vial containing 6-(5-(azetidin-3-yloxy)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (10 mg, 0.026 mmol) was added DMF (1 mL), DIEA (0.014 mL, 0.079 mmol), and tetrahydro-4H-pyran-4-one (2.65 mg, 0.026 mmol). The reaction mixture was stirred for 5 minutes. Acetic acid (1.513 μL, 0.026 mmol) and sodium triacetoxyborohydride (28.0 mg, 0.132 mmol) were added and the reaction mixture was stirred for 1 hour. The crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 22 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: 5-45% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 463.0 (M+H); Retention Time: 1.45 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 463.4 (M+H); Retention Time: 1.09 min. Isolated 6-(3-isopropyl-5-((1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (2.8 mg, 3.95 μmol, 15% yield). 1H NMR (500 MHz, DMSO-d6) δ8.82 (s, 1H), 8.57 (s, 1H), 8.47 (d, J=8.9 Hz, 1H), 7.21 (d, J=8.9 Hz, 1H), 7.16 (s, 1H), 5.71 (br s, 1H), 5.41 (br t, J=10.3 Hz, 1H), 5.10-5.02 (m, 1H), 4.13-4.04 (m, 3H), 3.96-3.88 (m, 2H), 3.63-3.52 (m, 1H), 3.65-3.52 (m, 2H), 2.00-1.88 (m, 2H), 1.60-1.47 (m, 2H), 1.32 (dd, J=17.1, 7.1 Hz, 6H).


Example 596
6-(3-isopropyl-5-(1-methylazetidin-3-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 1 dram vial containing 6-(5-(azetidin-3-yloxy)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (10 mg, 0.026 mmol) was added DMF (1 mL), formaldehyde (9.84 μL, 0.132 mmol) and DIEA (0.014 mL, 0.079 mmol). The reaction mixture was stirred at room temperature for 30 minutes and acetic acid (1.513μL, 0.026 mmol) and sodium triacetoxyborohydride (28.0 mg, 0.132 mmol) were added to the reaction mixture. After 10 min, a drop of water was added and the crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 393.08 (M+H); Retention Time: 1.01 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 393.22 (M+H); Retention Time: 1 min. Isolated 6-(3-isopropyl-5-(1-methylazetidin-3-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a] pyridine (1.6 mg, 3,95 gmol, 15% yield). 1H NMR (500 MHz, DMSO-d6) δ11.38 (br s, 1H), 8.60 (s, 1H), 8.55-8.49 (m, 1H), 7.74-7.67 (m, 1H), 7.19 (s, 1H), 6.60 (br d, J=8.5 Hz, 1H), 5.16-5.07 (m, 1H), 4.09 (s, 3H), 3.82 (br t, J=6.1 Hz, 1H), 3.32-3.19 (m, 1H), 3.19-3.11 (m, 1H), 3.05-2.93 (m, 2H), 2.32 (s, 3H), 1.55-1.48 (m, 6H).


Example 597
1-(4-(((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo [1,5-a] pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)methyl)piperidin-1-yl)-2-methylpropan-2-ol



embedded image


To a 1 dram vial containing 6-(3-isopropyl-5-(piperidin-4-ylmethoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (25 mg, 0.039 mmol) was added MeOH (500 μL), potassium carbonate (10.65 mg, 0.077 mmol), and 2,2-dimethyloxirane (8.34 mg, 0.116 mmol). The vial was sealed and the reaction mixture was stirred at room temperature overnight. The reaction mixture was filtered and concentrated under vacuum. The solid material was dissolved in DMF and the crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 15-55% B over 19 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 493.58 (M+H); Retention Time: 1.28 min. Isolated 1-(4-(((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)methyl)piperidin-1-yl)-2-methylpropan-2-ol (11 mg, 0.022 mmol, 57.9% yield). 1H NMR (500 MHz, DMSO-d6) δ11.33-11.26 (m, 1H), 8.55 (s, 1H), 8.48 (s, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.15 (s, 1H), 6.57 (d, J=8.5 Hz, 1H), 4.17 (br d, J=6.1 Hz, 2H), 4.08-4.03 (m, 3H), 3.29-3.18 (m, 1H), 2.99 (br d, J=11.0 Hz, 2H), 2.72 (s, 2H), 2.26 (s, 2H), 2.17 (br t, J=11.3 Hz, 2H), 1.69 (br d, J=12.2 Hz, 2H), 1.54-1.47 (m, 6H), 1.43-1.29 (m, 2H), 1.10-1.04 (m, 6H).


Example 598
6-(3-isopropyl-5-(1-isopropylpiperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 1 dram vial with pressure relief septum was added 6-(3-isopropyl-5-(piperidin-4-ylmethoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (15 mg, 0.023 mmol), DMF (1 mL), and DIEA (4.04 μL, 0.023 mmol). Acetone (8.49μL, 0.116 mmol) was added. The reaction mixture was stirred at room temperature for 10 minutes. Acetic acid (1.324 μL, 0.023 mmol) and sodium triacetoxyborohydride (4.90 mg, 0.023 mmol) were added. The reaction mixture was stirred at room temperature overnight. The crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: 5-50% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 463.26 (M+H); Retention Time: 1.46 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm).


Injection 2 results: Observed Mass: 462.98 (M+H); Retention Time: 1.22 min. Isolated 6-(3-isopropyl-5-(1-isopropy 1piperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (11.1 mg, 0.016 mmol, 67.4% yield). 1H NMR (500 MHz, DMSO-d6) δ11.35 (s, 1H), 8.56 (s, 1H), 8.53-8.47 (m, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.30 (s, 1H), 6.59 (d, J=8.5 Hz, 1H), 4.22 (d, J=5.8 Hz, 2H), 4.06 (s, 3H), 3.45-3.36 (m, 2H), 3.28-3.19 (m, 1H), 3.02-2.84 (m, 3H), 2.14-2.05 (m, 1H), 2.02 (br d, J=15.3 Hz, 2H), 1.66-1.54 (m, 2H), 1.51 (d, J=7.0 Hz, 6H), 1.24 (d, J=6.4 Hz, 6H).


Example 600
6-(3-isopropyl-5-(1-methylpiperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 20 mL vial containing tert-butyl 5-(1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo [3,2-b]pyridine-1-carboxylate (60 mg, 0.099 mmol) was added DCM (500 μl) and TFA (500 μl). The reaction mixture was stirred at rt for 3 hours. The reaction mixture was concentrated under a stream of nitrogen and dried under vacuum. To the reaction mixture was added DMF (1 mL), DIEA (17.27 μl, 0.099 mmol), formaldehyde (37% in water) (36.8 μL, 0.494 mmol), and acetic acid (5.66 μl, 0.099 mmol). The reaction mixture was stirred for 5 minutes. Sodium triacetoxyborohydride (62.9 mg, 0.297 mmol) was added and the reaction mixture was stirred at rt for 1 hour. A drop of water was added and the crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7-μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm. Injection 2 conditions: Column: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7-μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm. Isolated 6-(3-isopropyl-5-((1-methylpiperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (25.9 mg, 0.060 mmol, 61.0% yield). LC MS rt=0.971 (m+1=421) [QC-ACN-TFA-XB]. 1H NMR (500 MHz, DMSO-d6) δ11.30 (s, 1H), 8.58 (s, 1H), 8.51 (s, 1H), 7.67 (d, J=8.9 Hz, 1H), 7.18 (s, 1H), 6.55 (d, J=8.5 Hz, 1H), 5.00 (br s, 1H), 4.08 (s, 3H), 3.32-3.11 (m, 1H), 2.70 (br s, 1H), 2.57-2.54 (m, 1H), 2.20 (s, 3H), 2.07 (br s, 2H), 1.91 (br s, 2H), 1.72 (br d, J=9.8 Hz, 2H), 1.52 (br d, J=6.7 Hz, 6H).


Example 601
6-(3-isopropyl-5-methoxy-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


Intermediate 601A: tert-butyl 5-chloro-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To a 100 mL round-bottom flask cooled to 0° C. was added 5-chloro-3-isopropyl-1H-pyrrolo[3,2-b]pyridine (1.33 g) [material synthesized similarly as above for Intermediate 1B] THF (10 mL), TEA (1.428 mL, 10.25 mmol), and DMAP (0.083 g, 0.683 mmol). BOC-anhydride (1.745 mL, 7.52 mmol) was added slowly over 10 minutes and the reaction stirred for 30 minutes. The reaction was concentrated under vacuum to give an oil. The oil was purified by column chromatography on a Teledyne Isco instrument (24 g Silica, 100% Hexanes-80% EtOAc/Hexanes). Like fractions were combined and concentrated under vacuum to give a slight yellow oil, tert-butyl 5-chloro-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (2.06 g). LC MS rt=1.20 min. (m+1=295) [B1]. 1H NMR (400 MHz, DMSO-d6) δ8.28 (d, J=8.7 Hz, 1H), 7.71 (s, 1H), 7.38 (d, J=8.7 Hz, 1H), 3.22-3.08 (m, 1H), 1.62 (s, 9H), 1.31 (d, J=6.8 Hz, 6H).


Intermediate 601B: tert-butyl 5-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-3-isopropyl-1H-pyrrolo [3,2-b] pyridine-1-carboxylate



embedded image


A 1 dram vial containing tert-butyl 4-hydroxypiperidine-1-carboxylate (137 mg, 0.678 mmol), cesium carbonate (166 mg, 0.509 mmol), toluene (1 mL), and methanesulfonato(2-(di-t-butylphosphino)-3-methoxy-6-methyl-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (8.53 mg, 10.18 μmol) under a nitrogen atmosphere was heated to 90° C. for 3 minutes. tert-butyl 5-chloro-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (100 mg, 0.339 mmol) is added to the reaction and heated overnight at 90° C. The temperature was increased to 110° C. for 4 hours. The reaction was filtered through a pad of Celite and concentrated under vacuum. The resulting oil was purified by column chromatography on a Teledyne Isco instrument (24 g Silica, 100% Hexanes-100% EtOAc). Like fractions were combined and concentrated under vacuum to afford tert-butyl 5-(1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (37 mg, 0.081 mmol, 24% yield). LC MS rt=1.33 min. (m+1=460) [B1].


Intermediate 601C: tert-butyl 5-((1-(tert-butoxycarbonyl)azetidin-3-yl)methoxy)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


A 1 dram vial containing tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (60.7 mg, 0.324 mmol), cesium carbonate (158 mg, 0.486 mmol), toluene (2 mL), and methanesulfonato(2-(di-t-butylphosphino)-3-methoxy-6-methyl-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (8.16 mg, 9.73 μmol) under a nitrogen atmosphere was heated to 105° C. for 5 minutes. tert-butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (110 mg, 0.324 mmol) in toluene (1 mL) was added to the reaction and heated overnight at 105° C. The reaction was diluted with water (10 mL) and extracted with EtOAc (3×10 mL). The organic layers were combined and passed over a pad of Celite and concentrated under vacuum to give clear oil. Purified by column chromatography on a Teledyne Isco instrument (24 g Silica, 100% Hexanes-50% EtOAc/hexanes). Like fractions were combined and concentrated under vacuum to give tert-butyl 5-(1-(tert-butoxycarbonyl)azetidin-3-yl)methoxy)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (107 mg, 0.228 mmol, 70.4% yield). LC MS rt=1.26 min. (m+1=446) [B1]. 1H NMR (400 MHz, CHLOROFORM-d) δ8.27-8.09 (m, 1H), 7.44 (br. s., 1H), 6.64 (d, J=8.9 Hz, 1H), 4.51 (d, J=6.7 Hz, 2H), 4.08 (t, J=8.6 Hz, 2H), 3.85 (dd, J=8.7, 5.4 Hz, 2H), 3.21 (dt, J=13.2, 6.7 Hz, 1H), 3.02 (dquin, J=13.6, 6.8 Hz, 1H), 1.67 (s, 9H), 1.46 (s, 9H), 1.38 (d, J=7.0 Hz, 6H).


Intermediate 601D: tert-butyl5-((1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


A 1 dram vial containing tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (337 mg, 1.565 mmol), cesium carbonate (765 mg, 2.348 mmol), toluene (5 mL), and methanesulfonato(2-(di-t-butylphosphino)-3-methoxy-6-methyl-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (39.4 mg, 0.047 mmol) under a nitrogen atmosphere was heated to 105° C. for 5 minutes. tert-Butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (531 mg, 1.565 mmol) in toluene (1 mL) was added to the reaction and heated for 3 hours at 105° C. The reaction was diluted with water (10 mL) and extracted with EtOAc (3×10 mL). The organic layers were combined and passed over a pad of Celite and concentrated under vacuum to give a clear oil. Purified by column chromatography on a Teledyne Isco instrument (24 g Silica, 100% Hexanes-50% EtOAc/hexanes). Like fractions were combined and concentrated under vacuum to give tert-butyl 5-(1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (408 mg, 0.861 mmol, 55.0% yield). LC MS rt=1.33 min (m+1=474) [B1]. 1H NMR (400 MHz, CHLOROFORM-d) δ8.26-8.00 (m, 1H), 7.50-7.33 (m, 1H), 6.67-6.57 (m, 1H), 4.24 (d, J=6.5 Hz, 2H), 4.21-4.02 (m, 2H), 3.26-3.14 (m, 1H), 2.64 (br d, J=7.5 Hz, 2H), 2.10-1.92 (m, 11-1), 1.87-1.79 (m, 2H), 1.74-1.61 (m, 9H), 1.49-1.44 (m, 9H), 1.38 (d, J=6.8 Hz, 6H), 1.33-1.22 (m, 2H).


Intermediate 601E: tert-butyl 3-isopropyl-5-methoxy-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


A 1 dram vial containing methanol (0.918 mL, 22.70 mmol), cesium carbonate (1109 mg, 3.40 mmol), toluene (5 mL), and methanesulfonato(2-(di-t-butylphosphino)-3-methoxy-6-methyl-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (38.1 mg, 0.045 mmol) under a nitrogen atmosphere was heated to 105° C. for 5 minutes. tert-Butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (770 mg, 2.270 mmol) in toluene was added to the reaction and heated at 105° C. After 30 minutes, the reaction was diluted with water (10 mL) and extracted with EtOAc (3×10 mL). The organic layers were combined and passed over a pad of Celite and concentrated under vacuum to give a clear oil. Purified by column chromatography on a Teledyne Isco instrument (24 g Silica, 100% Hexanes-50% EtOAc/hexanes). Like fractions were combined and concentrated under vacuum to give tert-butyl 3-isopropyl-5-methoxy-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (48 mg, 0.165 mmol, 7.3% yield. LC MS rt=1.22 min. (m+1=291) [B1].


Intermediate 601F: tert-butyl 3-isopropyl-5-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


To a nitrogen flushed 20 mL vial with a pressure relief septum was added tert-butyl 3-isopropyl-5-methoxy-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (70 mg, 0.241 mmol), THF (2 mL), and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.054 mL, 0.265 mmol). The vial was cooled to −40° C. in a dry ice/NMP bath. LDA (0.301 mL, 0.603 mmol) was added dropwise over 15 minutes. The reaction was warmed to 0° C. The reaction was cooled to −40° C. and quenched with saturated KHSO4. The reaction was warmed to room temperature, diluted with water (10 mL) and extracted with EtOAc (3×10 mL). Organic layers were combined, dried over sodium sulfate, filtered, and concentrated under vacuum to give a clear oil. The clear oil was purified by column chromatography on a Teledyne Isco instrument (12 g Silica, 100% Hexanes-50% EtOAc/Hexanes). Like fractions were combined and concentrated under vacuum to give tert-butyl 3-isopropyl-5-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (50 mg, 0.120 mmol, 49.8% yield). LC MS rt=1.34 min. (m+1=417) [B1].


Example 601

To a 2 dram vial with pressure relief septum was added tert-butyl 3-isopropyl-5-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (50 mg, 0.120 mmol),6-bromo-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (27.4 mg, 0.120 mmol), 2nd generation Xphos precatalyst (4.72 mg, 6.00 μmol), and THF (1 mL). The reaction was evacuated and flushed with nitrogen several times. Aqueous tripotassium phosphate (3 M, 0.040 mL, 0.120 mmol) was added and the vial was evacuated and flushed with nitrogen several times. The reaction was heated at 65° C. for 1 hour. The reaction mixture was diluted with brine (1 mL) and extracted with EtOAc (3×2 mL). The organic layers were combined, dried over sodium sulfate, filtered, and dried under vacuum. The resulting oil was purified by column chromatography on a Teledyne Isco instrument (12 g Silica, 100% hexanes-100% EtOAc). Like fractions were combined and concentrated under vacuum. The resulting oil was treated with 1:1 TFA:DCM for 30 minutes, then concentrated under a stream of nitrogen. The resulting oil was neutralized with sodium bicarbonate and extracted with EtOAc. The organic layer was dried over sodium sulfate, filtered and concentrated to give a solid, 6-(3-isopropyl-5-methoxy-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (11.4 mg, 0.032 mmol, 26.7% yield). LC MS rt=0.77 min. (m+1=338) [B1]. 1H NMR (400 MHz, DMSO-d6) δ11.31 (s, 1H), 8.60 (d, J=1 .2 Hz, 1H), 8.52 (s, 1H), 7.68 (d, J=8.7 Hz, 1H), 7.19 (d, 1=1.1 Hz, 1H), 6.59 (d, J=8.7 Hz, 1H), 4.08 (s, 3H), 4.06-3.98 (m, 1H), 3.89 (s, 3H), 1.57-1.52 (m, 6H).


Example 602
2-(4-(((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)methyl)piperidin-1-yl)-N,N-dimethylacetamide



embedded image


To a 1 dram vial containing 6-(3-isopropyl-5-(piperidin-4-ylmethoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (15 mg, 0.023 mmol) was added DMF (1 mL), DIEA (0.012 mL, 0.069 mmol), and 2-chloro-N,N-dimethylacetamide (4.22 mg, 0.035 mmol). The reaction mixture was stirred at room temperature overnight. The crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-11m particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 15-55% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 506.1 (M+H); Retention Time: 1.28 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 506.25 (M+H); Retention Time: 1.01 min. Isolated 2-(4-(((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)methyl)piperidin-1-yl)-N,N-dimethylacetamide (4.2 mg, 8.06 34.8% yield). 1H NMR (500 MHz, DMSO-d6) δ11.30 (s, 1H), 8.59 (s, 1H), 8.50 (s, 1H), 7.67 (d, J=8.9 Hz, 1H), 7.18 (s, 1H), 6.57 (d, J=8.5 Hz, 1H), 4.18 (d, J=6.1 Hz, 2H), 4.07 (s, 3H), 3.29-3.20 (m, 1H), 3.09 (s, 2H), 3.02 (s, 3H), 2.88-2.82 (m, 2H), 2.80 (s, 3H), 2.00 (br t, J=10.7 Hz, 2H), 1.86-1.76 (m, 1H), 1.73 (br d, J=12.2 Hz, 2H), 1.53 (br d, J=1.0 Hz, 6H), 1.37-1.25 (m, 2H).


Example 603
6-(3-isopropyl-5-((1-isopropylpiperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 2 dram vial containing tert-butyl 5-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (31 mg, 0.051 mmol) was added DCM (1 mL) and TFA (1 mL). The reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under a stream of nitrogen and dried under vacuum. To the resulting oil was added DMF (1 mL), D1EA (0.027 mL, 0.153 mmol), and acetone (0.019 mL, 0.255 mmol). The reaction mixture was stirred at room temperature for 30 minutes. Sodium triacetoxyborohydride (54.1 mg, 0.255 mmol) and acetic acid (2.93 μL, 0.051 mmol) were added, and the reaction mixture was stirred at room temperature overnight. The crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: 5-45% B over 27 minutes, then a 3-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. The yield of the product was 4.5 mg. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 449 (M+H); Retention Time: 1.22 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed.Mass: 449.29 (M+H); Retention Time: 1.07 min.


Example 604
6-(3-isopropyl-5-((1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 1 dram vial containing 6-(3-isopropyl-5-(piperidin-4-ylmethoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (15 mg, 0.023 mmol) was added DMF (0.75 mL), DIEA (4.04μL, 0.023 mmol), and 1-bromo-2-(methylsulfonyl)ethane (4.33 mg, 0.023 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was heated to 70° C. for 3 hours. The crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 20-60% B over 19 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 527.45 (M+H); Retention Time: 1.5 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 527.47 (M+H); Retention Time: 0.98 min. Isolated 6-(3-isopropyl-5-((1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (3.8 mg, 7.00 μmol, 30.3% yield). 1H NMR (500 MHz, DMSO-d6) δ11.29 (s, 1H), 8.58 (s, 1H), 8.50 (s, 1H), 7.67 (d, J=8.9 Hz, 1H), 7.17 (s, 1H), 6.57 (d, J=8.9 Hz, 1H), 4.18 (br d, J=6.4 Hz, 2H), 4.07 (s, 3H), 3.89 (s, 1H), 3.29-3.20 (m, 2H), 3.02 (s, 3H), 2.92 (br d, J=11.0 Hz, 2H), 2.68 (t, J=6.7 Hz, 2H), 1.95 (br t, J=10.8 Hz, 2H), 1.87-1.79 (m, 1H), 1.78-1.72 (m, 2H), 1.55-1.49 (m, 6H), 1.37-1.24 (m, 2H).


Examples 605 and 611
4(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)-N,N-dipropylcyclohexan-1-amine



embedded image


To a 1 dram vial containing 4-((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)cyclohexan-1-amine, 2 TFA (15 mg, 0.023 mmol) was added DCM (1 mL), DMF (0.5 mL), DIEA (8.08 0.046 mmol), and propionaldehyde (3.32μL, 0.046 mmol). The reaction mixture was stirred at room temperature for 30 minutes. Acetic acid (1.324μL, 0.023 mmol) and sodium triacetoxyborohydride (14.71 mg, 0.069 mmol) were added to the reaction mixture. The reaction mixture was stirred for 3 hours. A drop of water and DMF (1 mL) were added, and then the crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 22-62% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation to afford two compounds: Isolate 1 and Isolate 2. These compounds were cis and trans isomers, but the identities of isomers in the isolates were not assigned.


Example 605: Isolate 1: 44(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)-N,N-dipropylcyclohexan-1-amine (9.9 mg, 0.020 mmol, 85% yield). LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 505.48 (M+H); Retention Time: 1.51 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 505.46 (M+H); Retention Time: 1.24 min. 1H NMR (500 MHz, DMSO-d6) δ11.28 (s, 1H), 8.58 (s, 1H), 8.50 (s, 1H), 7.68-7.60 (m, 1H), 7.18 (s, 1H), 6.50 (d, J=8.9 Hz, 1H), 4.86 (br s, 1H), 4.27 (q, J=7.0 Hz, 1H), 4.07 (s, 2H), 3.25 (br dd, J=10.2, 6.0 Hz, 1H), 3.19-3.10 (m, 1H), 2.89 (s, 1H), 2.70-2.67 (m, 1H), 2.73 (s, 1H), 2.47-2.33 (m, 3H), 2.26 (br s, 1H), 1.79 (br s, 1H), 1.53 (br d, J=6.7 Hz, 6H), 1.44-1.33 (m, 6H), 1.32-1.20 (m, 1H), 0.99 (d, J=6.4 Hz, 3H), 0.84 (t, J=7.3 Hz, 4H).


Example 611: Isolate 2: 4-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)-N,N-dipropylcyclohexan-1-amine (4.2 mg, 7.91 μmol, 34.2% yield). LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 505.46 (M+H); Retention Time: 1.57 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 505.46 (M+H); Retention Time: 1.3 min. 1H NMR (500 MHz, DMSO-d6) δ11.28 (s, 1H), 8.58 (s, 1H), 8.50 (s, 1H), 7.94 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.17 (s, 1H), 6.58 (d, J=8.5 Hz, 1H), 5.20 (br s, 1H), 4.07 (s, 3H), 3.29-3.22 (m, 1H), 3.19-3.11 (m, 1H), 2.89 (s, 1H), 2.73 (s, 1H), 2.46-2.34 (m, 2H), 2.13 (br s, 1H), 1.76 (br s, 1H), 1.60 (br d, J=8.9 Hz, 3H), 1.51 (br d, J=6.7 Hz, 5H), 1.42-1.35 (m, 4H), 0.99 (d, J=6.1 Hz, 3H), 0.84 (t, J=7.2 Hz, 6H).


Example 606
6-(3-isopropyl-5-(1-propylpiperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 1 dram vial containing 6-(3-isopropyl-5-(piperidin-4-ylmethoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (15 mg, 0.023 mmol) was added DMF (0.5 mL), DIEA (0.012 mL, 0.069 mmol), propionaldehyde (6.72 mg, 0.116 mmol). The reaction mixture was stirred for 5 minutes. Sodium triacetoxyborohydride (14.71 mg, 0.069 mmol) and acetic acid (1.324 μL, 0.023 mmol) were added and the reaction was stirred at room temperature for 6 hours. One drop of water was added, and the crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 25 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 462.94 (M+H); Retention Time: 1.51 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 463.3 (M+H); Retention Time: 1.25 min. Isolated 6-(3-isopropyl-5-(1-propylpiperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (8.6 mg, 0.019 mmol, 80% yield). 1NMR (500 MHz, DMSO-d6) δ11.33-11.26 (m, 1H), 8.62-8.55 (m, 1H), 8.53-8.47 (m, 1H), 7.71-7.63 (m, 1H), 7.18 (s, 1H), 6.58 (d, J=8.5 Hz, 1H), 4.21-4.16 (m, 2H), 4.08 (s, 3H), 3.30-3.19 (m, 1H), 2.89 (br d, J=10.7 Hz, 2H), 2.23 (br t, J=7.3 Hz, 2H), 1.93-1.80 (m, 3H), 1.75 (br d, J=12.2 Hz, 2H), 1.52 (br d, J=7.0 Hz, 6H), 1.44 (dq, J=14.5, 7.4 Hz, 2H), 1.38-1.26 (m, 2H), 0.84 (t, J=7.5 Hz, 3H).


Example 607
6-(3-isopropyl-5-((1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 1 dram vial containing 6-(3-isopropyl-5-(piperidin-4-yloxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (15 mg, 0.024 mmol) is added DMF (500 μL), DIEA (12.39 μL, 0.071 mmol), and dihydro-2H-pyran-4(3H)-one (2.367 mg, 0.024 mmol). The reaction mixture was stirred at room temperature for 5 minutes. Acetic acid (1.353 μL, 0.024 mmol) and sodium triacetoxyborohydride (15.03 mg, 0.071 mmol) were added to the reaction. The reaction mixture was stirred overnight. The crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 5-45% B over 20 minutes, then a 3-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection) results: Observed Mass: 491.21 (M+H); Retention Time: 1.33 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and IJV (220 nm). Injection 2 results: Observed Mass: 491.16 (M+H); Retention Time: 1.07 min. Isolated 6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (6.7 mg, 0.013 mmol, 56% yield). 1H NMR (500 MHz, DMSO-d6) δ11.28 (s, 1H), 8.57 (s, 1H), 8.50 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.16 (s, 1H), 6.54 (d, J=8.5 Hz, 1H), 5.03-4.93 (m, 1H), 4.11-4.03 (m, 3H), 3.88 (br d, J=7.6 Hz, 2H), 3.32-3.21 (m, 3H), 2.86 (br d, J=10.4 Hz, 2H), 2.41-2.32 (m, 2H), 2.13-2.03 (m, 2H), 1.94-1.86 (m, 1H), 1.73-1.61 (m, 4H), 1.51 (br d, J=7.0 Hz, 6H), 1.48-1.36 (m, 2H).


Example 608
6-(3-isopropyl-5-(1-methylazetidin-3-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 20 mL scintillation vial containing tert-butyl 5-((1-(tert-butoxycarbonyl) azetidin-3-yl)methoxy)-3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (40 mg, 0.067 mmol) was added DCM (500 mL) and TFA (500 mL). The reaction mixture was stirred at room temperature for 3 hours, concentrated under a stream of nitrogen and dried under vacuum. The resulting oil was dissolved in DMF (1 mL) and DIEA (0.035 mL, 0.202 mmol) and formaldehyde (37% in water) (0.025 mL, 0.337 mmol) were added. The reaction mixture was stirred at room temperature for 10 minutes. Acetic acid (3.86 pL, 0.067 mmol) and sodium triacetoxyborohydride (42.9 mg, 0.202 mmol) were added and the reaction mixture was stirred at room temperature overnight. The crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 19 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: 8-33% B over 25 minutes, then a 2-minute hold at 33% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 407.34 (M+H); Retention Time: 0.96 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 406.93 (M+H); Retention Time: 1.11 min. Isolated 6-(3-isopropyl-5-(1-methylazetidin-3-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (1.7 mg, 2.63 μmol, 3.9% yield). 1H NMR (500 MHz, DMSO-d6) δ11.47-11.38 (m, 1H), 8.61 (s, 1H), 8.53 (s, 1H), 7.74 (d, J=8.7 Hz, 1H), 7.19 (s, 1H), 6.68 (dd, J=8.5, 5.9 Hz, 1H), 4.54-4.40 (m, 2H), 4.08 (s, 3H), 3.99-3.90 (m, 1H), 3.60-3.50 (m, 1H), 3.49-3.42 (m, 1H), 3.29-3.23 (m, 2H), 2.90-2.81 (m, 3H), 2.73 (s, 1H), 1.54 (br d, J=5.6 Hz, 6H).


Example 609
2-(4-((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)piperidin-1-yl)-N,N-dimethylacetamide



embedded image


To a 1 dram vial containing 6-(3-isopropyl-5-(piperidin-4-yloxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (20 mg, 0.032 mmol) was added DMF (1 mL), DIEA (0.017 mL, 0.095 mmol), and 2-chloro-N,N-dimethylacetamide (11.50 mg, 0.095 mmol). The reaction mixture was stirred at room temperature overnight. The crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 492.13 (M+H); Retention Time: 1.25 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 492.01 (M+H); Retention Time: 1.28 min. Isolated 2-(4-((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)piperidin-1-yl)-N,N-dimethylacetamide (11.2 mg, 0.023 mmol, 71.6% yield). 1H NMR (500 MHz, DMSO-d6) δ11.30 (s, 1H), 8.60 (s, 1H), 8.52 (s, 1H), 7.67 (d, J=8.9 Hz, 1H), 7.19 (s, 1H), 6.55 (d, J=8.5 Hz, 1H), 5.04-4.96 (m, 1H), 4.08 (s, 3H), 3.32-3.22 (m, 1H), 3.18 (s, 2H), 3.04 (s, 2H), 2.89-2.73 (m, 4H), 2.36 (br t, J=9.3 Hz, 2H), 2.12-2.05 (m, 2H), 1.90 (br s, 1H), 1.74-1.64 (m, 2H), 1.56-1.48 (m, 6H), 1.24 (s, 1H).


Examples 610 and 614
4(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)-N,N-dimethylcyclohexan-1-amine



embedded image


To a 1 dram vial containing 4-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)cyclohexan-1-amine, 2 TFA (15 mg, 0.023 mmol) was added DMF (0.5 mL), DCM (1 mL), DIEA (8.08 μL, 0.046 mmol), and formaldehyde (1.911 μL, 0.069 mmol). The reaction mixture was stirred at room temperature for 30 minutes. Acetic acid (1.324 μL, 0.023 mmol) and sodium triacetoxyborohydride (14.71 mg, 0.069 mmol) were added and the reaction mixture was stirred at room temperature for 1 hour. The crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: 5-50% B over 20 minutes, then a 6-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation to afford two compounds: Isolate 1 and Isolate 2. These compounds are cis and trans isomers, but the identities of the isomers in the isolates were not assigned.


Example 610: Isolate 1: 4-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)-N,N-dimethylcyclohexan-1-amine, 2 TFA (8.5 mg, 0.012 mmol, 53.2% yield). LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 449.37 (M+H); Retention Time: 1.11 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 449.36 (M+H); Retention Time: 0.91 min. 1H NMR (500 MHz, DMSO-d6) δ11.36 (s, 1H), 8.59 (s, 1H), 8.52 (s, 1H), 7.69 (d, J=8.9 Hz, 1H), 7.17 (s, 1H), 6.54 (d, J=8.5 Hz, 1H), 4.96-4.86 (m, 1H), 4.12-4.04 (m, 3H), 3.31-3.20 (m, 2H), 2.38 (br d, J=11.6 Hz, 2H), 2.18-2.07 (m, 2H), 1.73-1.58 (m, 3H), 1.55-1.38 (m, 11H).


Example 614: Isolate 2: 4-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)-N,N-dimethylcyclohexan-1-amine, 2 TFA (3.1 mg, 4.44 μmol, 19% yield). LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 449.38 (M+H); Retention Time: 1.26 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and IJV (220 nm). Injection 2 results: Observed Mass: 449.38 (M+H); Retention Time: 0.99 min. 1H NMR (500 MHz, DMSO-d6) δ11.39-11.32 (m, 1H), 8.61-8.56 (m, 1H), 8.52 (s, 1H), 7.71 (d, J=8.9 Hz, 1H), 7.17 (s, 1H), 6.60 (d, J=8.9 Hz, 1H), 5.25 (br s, 1H), 4.08 (s, 3H), 3.31-3.23 (m, 2H), 2.25 (br d, J=10.7 Hz, 2H), 1.95-1.84 (m, 2H), 1.81-1.66 (m, 4H), 1.55-1.47 (m, 6H).


Example 612
6-(3-isopropyl-5-(1-isopropylazetidin-3-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a 1 dram vial containing 6-(5-(azetidin-3-yloxy)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (10 mg, 0.026 mmol) was added DMF (1 mL), DIEA (0.014 mL, 0.079 mmol), and propan-2-one (1.535 mg, 0.026 mmol). The reaction mixture was stirred at room temperature for 30 minutes. Acetic acid (1.513 μL, 0.026 mmol) and sodium triacetoxyborohydride (28.0 mg, 0.132 mmol) were added and the reaction mixture was stirred at room temperature overnight. The crude material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 15-55% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 p.m particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 1 results: Observed Mass: 421.04 (M+H); Retention Time: 1.4 min. Injection 2 conditions: Column: Waters Xbridge C18, 2.1 mm×50 mm, 1.7 particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0% B to 100% B over 3 min, then a 0.75 min hold at 100% B; Flow: 1 mL/min; Detection: MS and UV (220 nm). Injection 2 results: Observed Mass: 420.96 (M+H); Retention Time: 1.17 min. Isolated 6-(3-isopropyl-54(1-isopropylazetidin-3-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (5.2 mg, 0.012 mmol, 44.9% yield).


Example 613
1-(4-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)piperidin-1-yl)-2-methylpropan-2-ol



embedded image


To a 1 dram vial containing 6-(3-isopropyl-5-(piperidin-4-yloxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine, 2 TFA (15 mg, 0.024 mmol) was added MeOH (500 μL), potassium carbonate (9.80 mg, 0.071 mmol), and 2,2-dimethyloxirane (1.705 mg, 0.024 mmol). The reaction mixture was stirred at rt overnight then filtered and concentrated under vacuum. The crude material was dissolved in DMF and purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 15-55% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation. LC/MS was used to analyze the final compound. Injection 1 conditions: Column: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7-μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm. Injection 2 conditions: Column: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7-μm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm. Isolated 1-(4-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3;2-b]pyridin-5-yl)oxy)piperidin-1-yl)-2-methylpropan-2-ol (9.8 mg, 0.019 mmol, 81% yield). LCMS retention time 1.20 min, m/z=479.2 (M+H) [QC-ACN-AA-XB]. 1H NMR (500 MHz, DMSO-d6) δ11.30 (s, 1H), 8.59 (s, 1H), 8.51 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.18 (s, 1H), 6.55 (d, J=8.9 Hz, 1H), 4.98 (br s, 1H), 4.08 (s, 3H), 3.25 (dt, J=13.6, 6.6 Hz, 1H), 2.91 (br d, J=11.0 Hz, 2H), 2.38 (br t, J=9.2 Hz, 2H), 2.06 (br d, J=10.7 Hz, 2H), 1.79-1.62 (m, 2H), 1.57-1.46 (m, 6H), 1.23 (s, 3H), 1.10 (s, 6H).


Example 649
6-(5-(azetidin-3-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


Intermediate 649A: tert-butyl 5-(1-(tert-butoxycarbonyl)azetidin-3-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


A suspension of tert-butyl5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (150 mg, 0.442 mmol), tert-butyl 3-bromoazetidine-1-carboxylate (209 mg, 0.884 mmol), tris(trimethylsilyl)silane (165 mg, 0.663 mmol), [Ir(dF(CF3)ppy)2(dtbbpy)]PF6 (1.24 mg, 1.11 μmol), and Na2CO3 (187 mg, 1.77 mmol) in 1,4-dioxane (3.5 mL) in a vial with a pressure-relief septum-lined cap and a stir bar was degassed with nitrogen gas for 5 minutes. To a separate vial was added nickel(II) chloride ethylene glycol dimethyl ether complex (7.29 mg, 0.033 mmol) and 4,4′-di-tert-butyl-2,2′-bipyridine (10.7 mg, 0.040 mmol), which was evacuated and backfilled with nitrogen gas followed by 1,4-dioxane (0.88 mL). This mixture was degassed with nitrogen gas for 10 minutes and stirred. The resulting solution containing the nickel complex was added to the suspension containing all other reagents, and then the resulting mixture was further degassed with nitrogen gas for another 10 minutes. The vessel was then sealed and placed in a rack with stirring and irradiation with 34 W Kessil KSH 150B blue grow lamps and a cooling fan for 17 hours. Upon completion, the reaction mixture was diluted with DCM, filtered, and concentrated. The crude material was taken up in hexanes with a trace of DCM for solubility and purified by silica gel column chromatography on a Teledyne Isco instrument eluting with Hex/DCM 0-100%, then Hex/EtOAc 0-50% to afford tert-butyl5-(1-(tert-butoxycarbonypazetidin-3-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxy late (100 mg, 0.241 mmol, 54.4% yield). LCMS retention time 1.04 [TS]. MS (E+) m/z: 416.3 (M+H). This reaction was repeated several times to obtain larger quantities of material.


Intermediate 649B: tert-butyl 5-(1-(tert-butoxycarbonyl)azetidin-3-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


A solution containing tert-butyl 5-(1-(tert-butoxycarbonyl)azetidin-3-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (456 mg, 1.10 mmol) and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (448 μL, 2.195 mmol) in dry THF (5.5 mL) under a nitrogen atmosphere was cooled in a dry ice/acetone bath to −78° C. and treated with LDA (2M in THF, 2.75 mL, 5.50 mmol). The mixture was allowed to warm to −30° C. over 30 min and stirred at −30° C. for 30 min. The reaction was then quenched with saturated aqueous NH4Cl solution, water, and DCM. The organic layer was separated, dried over sodium sulfate, filtered and concentrated. The crude material was combined with the crude material from a similar experiment following the same procedure using 100 mg (0.241 mmol) of starting material tert-butyl 5-(1-(tert-butoxycarbonyl)azetidin-3-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate. The combined crude materials were purified by silica gel column chromatography on a Teledyne Isco instrument loading in hexanes and eluting with Hex/EtOAc 0-50% to afford tert-butyl 5-(1-(tert-butoxycarbonyl)azetidin-3-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (340 mg) combined from both experiments. LCMS retention time 1.18 [TS]. MS (E+) m/z: 542.3 (M+H). 1H NMR (499 MHz, CHLOROFORM-d) δ7.96 (d, J=8.4 Hz, 1H), 7.03 (d, J-8.5 Hz, 1H), 4.34-4.27 (m, 2H), 4.27-4.22 (m, 2H), 3.99-3.89 (m, 1H), 3.37-3.26 (m, 1H), 1.66 (s, 9H), 1.47 (s, 9H), 1.48 (br d, J=7.0 Hz, 6H), 1.44 (s, 12H).


Intermediate 649C: tert-butyl 3-(3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidine-1-carboxylate



embedded image


In a reaction vial with a pressure-relief septum-lined cap and stir bar, neat tert-butyl 5-(1-(tert-butoxycarbonyl)azetidin-3-yl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (340 mg, 0.628 mmol) under a nitrogen atmosphere was heated to 160° C. with slow stirring for 45 minutes. Upon completion, the material was dissolved in DCM and concentrated to afford tert-butyl 3-(3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidine-1-carboxylate as an off-white foam considered to be quantitative yield. Carried forward as is. Note: material converted to the free boronic acid on LCMS and was observed as such, although NMR indicated that the product was purely the compound. LCMS retention time (boronic acid) 0.67 [TS]. MS (E+) m/z: 360.2 (M+H, boronic acid). 1H NMR (499 MHz, CHLOROFORM-d) δ8.23 (br s, 1H), 7.53 (d, J=8.4 Hz, 1H), 7.01 (d, J=8.5 Hz, 1H), 4.36-4.24 (m, 4H), 4.01-3.92 (m, 1H), 3.73 (spt, J=7.0 Hz, 1H), 1.53 (d, J=7.0 Hz, 6H), 1.48 (s, 9H), 1.36 (s, 12H).


Intermediate 649D: tert-butyl 3-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidine-1-carboxylate



embedded image


To a mixture of tert-butyl 3-(3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidine-1-carboxylate (138 mg, 0.313 mmol), 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (78 mg, 0.344 mmol), and 2nd generation Xphos precatalyst (12.3 mg, 0.016 mmol) in 1,4-dioxanc (2.1 mL) was added aqueous K3PO4 (3M, 0.31 mL, 0.93 mmol) and the biphasic mixture was degassed with nitrogen gas for 10 min. The reaction vial was sealed and stirred at 65° C. for 1.5 hours. Upon completion, the reaction mixture was cooled to room temperature and concentrated. The crude material was suspended in DCM and purified by silica gel column chromatography on a Teledyne Isco instrument eluting with Hex/EtOAc 0-100% to afford tert-butyl3-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidine-1-carboxylate (111 mg, 0.241 mmol, 77% yield). LCMS retention time 0.72 [TS]. MS (E+) m/z: 461.3 (M+H).


Example 649

To a solution of tert-butyl 3-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)azetidine-1-carboxylate (111 mg, 0.241 mmol) in DCM (4.8 mL) at room temperature was added 4M HCl in 1,4-dioxane (1.2 mL, 4.80 mmol). The reaction mixture was stirred at room temperature for 5 minutes. Upon completion, the reaction mixture was concentrated to afford 6-(5-(azetidin-3-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine, HCl (0.241 mmol) in recovery considered to be quantitative. The majority of this material was carried forward as is. An aliquot of this material (approximated to be 0.012 mmol) was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 5-90% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. The fractions containing the product were combined and dried via centrifugal evaporation to afford 6-(5-(azetidin-3-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (2.5 mg, 6.80 μmop. LCMS retention time 0.69 [QC-ACN-TFA-XB]. MS (E+) m/z: 361.3 (M+H). 1H NMR (500 MHz, DMSO-d6) δ8.80 (s, 1H), 8.47 (s, 1H), 7.65 (d, J=8.2 Hz, 1H), 7.08 (d, J=8.5 Hz, 1H), 4.18-4.09 (m, 1H), 4.09-3.96 (m, 2H), 3.91-3.80 (m, 2H), 2.96-2.87 (m, 1H), 2.59 (s, 3H), 2.16 (s, 3H), 1.42 (br d, J=6.7 Hz, 6H).


Example 653
6-(3-isopropyl-5-(1-(2-(methylsulfonyl)ethyl)azetidin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


To a solution of 6-(5-(azetidin-3-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine, HCl (18.26 mg, 0.046 mmol) in DMF (1 mL) was added Et3N (0.032 mL, 0.230 mmol) and 1-bromo-2-(methylsulfonyl)ethane (12.9 mg, 0.069 mmol). The resulting solution was stirred for 90 minutes at room temperature, and then another aliquot of 1-bromo-2-(methylsulfonyl)ethane (12.9 mg, 0.069 mmol) was added. The reaction mixture was stirred for 60 minutes more and then diluted with a few drops of water, DMF, and purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-100% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. The fractions containing the product were combined and dried via centrifugal evaporation to afford 6-(3-isopropyl-5-(1-(2-(methylsulfonyl)ethyl)azetidin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (15.7 mg, 0.033 mmol, 71.7% yield). LCMS retention time 0.8 min [QC-ACN-TFA-XB]. MS (E+) m/z: 467.4 (M+H). 1H NMR (500 MHz, DMSO-d6) δ11.17 (s, 1H), 8.76 (s, 1H), 8.46 (s, 1H), 7.63 (d, J=8.2 Hz, 1H), 7.08 (d, J=8.2 Hz, 1H), 3.83 (quin, J=7.6 Hz, 1H), 3.75-3.69 (m, 2H), 3.38 (t, J=7.2 Hz, 2H), 3.20-3.12 (m, 2H), 3.05 (s, 3H), 2.93-2.83 (m, 3H), 2.58 (s, 3H), 2.15 (s, 3H), 1.40 (br d, J=7.0 Hz, 6H).


Example 660
4-isopropyl-2-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine



embedded image


2-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine, TFA (22.99 mg, 0.0454 mmol) and Et3N (0.05 mL, 0.359 mmol) were mixed in DMF (0.454 mL). Acetone (0.018 mL, 0.245 mmol) was added to the reaction vial followed by sodium triacetoxyborohydride (28.9 mg, 0.136 mmol) and the reaction mixture was stirred for 17 hours at room temperature. At this time, another aliquot of acetone (0.018 mL, 0.245 mmol) and sodium triacetoxyborohydride (28.9 mg, 0.136 mmol) were each added. The reaction mixture was stirred for 7 hours more at room temperature. The reaction was quenched by the addition of water, 1.5 M aqueous K2HPO4 solution, and DCM. The organic layer was separated, concentrated, and diluted with DMSO. The material was purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 11% B, 11-51% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS and UV signals. Fractions containing the product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: a 0-minute hold at 12% B, 12-35% B over 25 minutes, then a 2-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by UV signals. Fractions containing the product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 200 mm×30 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 10% B, 10-50% B over 20 minutes, then a 2-minute hold at 100% B; Flow Rate: 45 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS and UV signals. Fractions containing the product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: a 0-minute hold at 11% B, 11-35% B over 25 minutes, then a 2-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by UV signals. The fractions containing the product were combined and dried via centrifugal evaporation to afford 4-isopropyl-2-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine, TFA (10.5 mg, 0.019 mmol, 41.2% yield). LCMS retention time 1.02 [QC-ACN-TFA-XB]. MS (E+) m/z: 435.1 (M+H). 1H NMR (500 MHz, DMSO-d6) δ11.49 (br s, 1H), 8.61 (s, 1H), 8.48 (s, 1H), 7.82 (br d, J=8.3 Hz, 1H), 7.32 (br d, J=8.4 Hz, 1H), 7.17 (s, 1H), 5.06-4.89 (m, 1H), 4.36-4.17 (m, 1H), 4.08 (s, 3H), 4.01 (br t, J=12.1 Hz, 1H), 3.77-3.15 (m, 6H), 1.58-1.47 (m, 6H), 1.40-1.26 (m, 6H).


Example 671
2-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo [1,5-a] pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine



embedded image


Intermediate 671A: tert-butyl2-(1-(tert-butoxycarbonyl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine-4-carboxylate



embedded image


A solution of tert-butyl 5-bromo-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (0.925 g, 2.73 mmol), 4-(tent-butoxycarbonyl)morpholine-2-carboxylic acid (0.946 g, 4.09 mmol), [Ir(dF(Me)ppy)2(dtbbpy)]PF6 (0.028 g, 0.027 mmol), 2-tert-butyl-1,1,3,3-tetramethylguanidine (0.701 g, 4.09 mmol), nickel(II) chloride ethylene glycol dimethyl ether complex (0.030 g, 0.136 mmol), 4,4′-di-tert-butyl-2,2′-bipyridine (0.037 g, 0.136 mmol) in DMSO (27.3 mL) in a vial with a pressure-relief septum-lined cap and stir bar was degassed with nitrogen for 15 minutes. The resulting solution was sealed and placed in a rack with stirring and irradiation with 34 W Kessil KSH 150B blue grow lamps and a cooling fan for 68 hours. This reaction was set up in duplicate vials side by side. Upon completion, the duplicate reaction vials were combined and diluted with water and DCM. The organic layer was washed with water three times, dried over sodium sulfate, filtered, and concentrated to afford a crude brown oil. This material was purified by silica gel column chromatography on a Teledyne Isco instrument eluting with Hex/EtOAc 0-50% to afford tert-butyl2-(1-(tert-butoxycarbonyl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine-4-carboxylate (1.7 g). LCMS retention time 1.23 [TS]. MS (E+) m/z: 446.3 (M+H). 1H NMR (400 MHz, CHLOROFORM-d) δ8.29 (br s, 1H), 7.51 (br s, 1H), 7.39 (d, J=8.5 Hz, 1H), 4.64 (dd, J=10.5, 2.7 Hz, 1H), 4.55-4.25 (m, 1H), 4.16-3.88 (m, 2H), 3.76 (td, J=11.7, 2.4 Hz, 1H), 3.38-3.25 (m, 1H), 3.18-3.01 (m, 1H), 3.00-2.91 (m, 1H), 1.67 (s, 9H), 1.49 (s, 9H), 1.38 (d, J=6.6 Hz, 6H).


Intermediate 671B: tert-butyl2-(1-(tert-butoxycarbonyl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine-4-carboxylate



embedded image


A solution containing tert-butyl 2-(1-(tert-butoxycarbonyl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine-4-carboxylate (1.67 g, 3.75 mmol) and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.918 mL, 4.50 mmol) in dry THF (19 mL) under a nitrogen atmosphere was cooled in a dry ice/acetone bath to −78° C. and treated with LDA (2M in THF, 2.81 mL, 5.62 mmol). The mixture was allowed to warm to −20° C. slowly over 2 hours. The reaction mixture was then re-cooled to −60° C. and additional 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.31 mL, 1.52 mmol) and LDA (2M in THF, 0.93 mL, 1.86 mmol) were added sequentially. The reaction mixture darkened, the bath was quickly changed to a −40° C. bath, and the reaction was quickly finished. Upon completion, the reaction mixture was treated with saturated aqueous NH4Cl solution, water, and DCM. The organic layer was separated, dried over sodium sulfate, filtered and concentrated. The crude isolate was purified via silica gel column chromatography on a Teledyne Isco instrument eluting with Hex/EtOAc 0-50%. Concentration of the fractions containing product provided tert-butyl 2-(1-(tert-butoxycarbonyl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine-4-carboxylate (1.65 g, 2.89 mmol, 77% yield). LCMS retention time 1.32 [TS]. MS (E+) m/z: 572.5 (M+H). 1H NMR (499 MHz, CHLOROFORM-d) δ8.01 (d, J=8.7 Hz, 1H), 7.32 (d, J=8.6 Hz, 1H), 4.67-4.55 (m, 1H), 4.54-4.34 (m, 1H), 4.16-3.84 (m, 2H), 3.81-3.70 (m, 1H), 3.36-3.26 (m, 1H), 3.16-2.90 (m, 2H), 1.66 (s, 9H), 1.50 (s, 9H), 1.46-1.42 (m, 18H).


Intermediate 671C: tert-butyl 2-(3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine-4-carboxylate



embedded image


A vial with a pressure-relief septum-lined cap containing tert-butyl 2-(1-(tert-butoxycarbonyl)-3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine-4-carboxylate (1.65 g, 2.89 mmol) was heated with slow stirring at 165° C. under nitrogen atmosphere with an inlet of nitrogen gas from a manifold line and then remained at room temperature overnight. Heating was then resumed for 90 minutes until the material had formed a brown melt that solidified into a brown glass upon cooling to room temperature. The material was dissolved in DCM, transferred to a round bottom flask, and concentrated to obtain an off-white foam, tert-butyl 2-(3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine-4-carboxylate, treated as quantitative recovery (2.88 mmol) and carried forward as is. Note: observed conversion to boronic acid when analyzed on LCMS, although NMR indicated that the product was purely the compound. LCMS retention time 0.73 (boronic acid) [TS]. MS (E+) m/z: 390.2 (boronic acid). 1H NMR (499 MHz, CHLOROFORM-d) δ8.27 (br s, 1H), 7.58 (d, J=8.5 Hz, 1H), 7.30 (d, J=8.5 Hz, 1H), 4.65-4.61 (m, 1H), 4.59-4.32 (m, 1H), 4.13-3.86 (m, 2H), 3.82-3.67 (m, 2H), 3.04 (br dd, J=13.4, 10.7 Hz, 2H), 1.52-1.48 (m, 15H), 1.36 (s, 12H).


Intermediate 671D: tert-butyl 2-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine-4-carboxylate



embedded image


To a solution of tert-butyl 2-(3-isopropyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine-4-carboxylate (197 mg, 0.418 mmol), 6-bromo-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (105 mg, 0.460 mmol), and 2nd generation Xphos precatalyst (16.4 mg, 0.021 mmol) in 1,4-dioxane (2.8 mL) was added aqueous K3PO4 (2M, 627 μl, 1.254 mmol), and the biphasic mixture was degassed with nitrogen for 5 min. The reaction vessel was sealed and stirred at 70° C. for 2 hours. Upon completion, the reaction mixture was cooled to room temperature and concentrated. The crude material was suspended in DCM and purified by silica gel column chromatography on a Teledyne Isco instrument eluting with Hex/EtOAc 0-100% to give tert-butyl 2-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine-4-carboxylate (177 mg, 0.359 mmol, 86% yield). LCMS retention time 0.82 [TS]. MS (ES+) m/z: 493.6 (M+H).


Example 671

To a solution of tert-butyl 2-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine-4-carboxylate (8.9 mg, 0.018 mmol) in DCM (0.5 mL) at room temperature was added TFA (0.5 mL). The reaction mixture was concentrated after 30 minutes to give crude material which was taken up in DMF with a few drops of Et3N and purified via preparative LC/MS with the following conditions: Column: Xbridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 3-40% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. The fractions containing the product were combined and dried via centrifugal evaporation to afford 2-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine (5.3 mg, 0.013 mmol, 72.4% yield). LCMS retention time 0.97 [QC-ACN-AA-XB]. MS (E+) m/z: 393.1. NMR (500 MHz, DMSO-d6) δ11.43 (s, 1H), 8.62 (s, 1H), 8.51 (s, 1H), 7.73 (br d, J=8.5 Hz, 1H), 7.22 (br d, J=8.2 Hz, 1H), 7.18 (s, 1H), 4.57 (br d, J=8.5 Hz, 1H), 4.07 (s, 3H), 3.93 (br d, J=10.4 Hz, 1H), 3.74-3.62 (m, 1H), 3.56-3.44 (m, 1H), 3.36-3.23 (m, 1H), 3.23-3.16 (m, 1H), 2.81 (br s, 2H), 2.71 (br t, J=11.3 Hz, 1H), 1.52 (br d, J=6.7 Hz, 6H). For the derivatization of this material, this procedure was repeated on larger scale as described here: To a solution of tert-butyl 2-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine-4-carboxylate (112 mg, 0.227 mmol) in DCM (6 mL) at room temperature was added TFA (3 mL). The reaction mixture was concentrated after 30 minutes to give material considered quantitative recovery of 2-(3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)morpholine, TFA (0.227 mmol). Carried forward as is.


Example 680
6-(3-isopropyl-5-(piperazin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


A mixture of tert-butyl 5-bromo-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (72.3 mg, 0.100 mmol), 1,4-bis(tert-butoxycarbonyl)piperazine-2-carboxylic acid (49.6 mg, 0.150 mmol), [Ir(dF(Me)ppy)2(dtbbpy)]PF6 (1.0 mg, 1.000 μmol), 2-tert-butyl-1,1,3,3-tetramethylguanidine (25.7 mg, 0.150 mmol), nickel(II) chloride ethylene glycol dimethyl ether complex (1.1 mg, 5.00 μmol), and 4,4′-di-tert-butyl-2,2′-bipyridine (1.3 mg, 5.00 μmop in DMSO (3 mL) in a vial with a pressure-relief septum-lined cap and stir bar was degassed with nitrogen for 15 minutes. The resulting mixture was sealed and placed in a rack with stirring and irradiation with 34 W Kessil KSH 150B blue grow lamps and a cooling fan for 48 hours. Upon completion, the reaction mixture was diluted with water and DCM. The organic layer was washed with water three times, dried over sodium sulfate, filtered, and concentrated to afford a crude brown oil. The crude material was partially purified by silica gel column chromatography on a Teledyne Isco instrument eluting with Hex/EtOAc 0-50% to give material that still contained a significant amount of impurities. This material was carried forward and suspended in DCM (1 mL) and TFA (1 mL) and stirred for 30 minutes at room temperature. Upon completion, the material was concentrated and suspended in TFA (2 mL) with stirring for 3 hours at room temperature. Upon completion, the reaction mixture was concentrated, dissolved in methanol with a few drops of Et3N, and purified via the following conditions: Column: Xbridge C18, 200 mm×30 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: a 0-minute hold at 0% B, 0-40% B over 20 minutes, then a 2-minute hold at 100% B; Flow Rate: 45 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS and UV signals. Fractions containing the product were combined and dried via centrifugal evaporation to afford 6-(3-isopropyl-5-(piperazin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine, TFA (9.5 mg, 0.019 mmol, 19% yield). LCMS retention time 0.91 [QC-ACN-TFA-XB]. MS (E+) m/z: 390.0 (M+H). Select NMR peaks: 1H NMR (500 MHz, DMSO-d6) δ11.60 (s, 1H), 8.82 (s, 1H), 8.48 (s, 1H), 7.86 (d, J=8.5 Hz, 1H), 7.30 (br d, J=8.5 Hz, 1H), 4.83 (br d, J=10.4 Hz, 1H), 3.92 (br d, J=13.4 Hz, 1H), 2.97 (dt, J=13.5, 6.5 Hz, 1H), 2.59 (s, 3H), 2.13 (s, 31-1), 1.40 (br d, J=4.9 Hz, 6H)


The following examples were prepared according to the general procedures described in the above examples.














TABLE 1





Ex.



Ret
HPLC


No.
Structure
Mol Wt.
LCMS M+
Time (min)
Method




















12


embedded image


403.53
404.3
1.2
QC- ACN- AA-XB





13


embedded image


405.51
406.3
0.71
QC-ACN- TFA- XB





314


embedded image


375.48
376.3
0.96
QC-ACN- TFA-XB





15


embedded image


460.59
461.5
0.76
QC-ACN- TFA-XB





16


embedded image


377.45
378.2
0.67
QC- ACN- TFA- XB





17


embedded image


462.56
463.4
1.06
QC- ACN- AA-XB





18


embedded image


462.56
463.2
0.7
QC- ACN- TFA-XB





19


embedded image


474.61
475.1
1
QC- ACN- TFA-XB





20


embedded image


389.51
390.2
1.14
QC- ACN- AA-XB





21


embedded image


474.61
475.2
0.76
QC- ACN- TFA-XB





22


embedded image


460.59
460.9
0.97
QC- ACN- TFA-XB





23


embedded image


389.51
390.1
1.05
QC- ACN- TFA-XB





24


embedded image


473.63
474.2
1.52
QC- ACN- AA-XB





25


embedded image


474.61
475.1
1.18
QC- ACN- TFA-XB





26


embedded image


460.59
460.9
0.68
QC- ACN- TFA-XB





27


embedded image


462.56
463.4
0.81
QC- ACN- AA-XB





28


embedded image


476.59
477.4
1.04
QC- ACN- AA-XB





29


embedded image


461.57
462.1
0.73
QC- ACN- TFA-XB





30


embedded image


461.57
462.3
1.41
QC- ACN- AA-XB





31


embedded image


391.48
392.2
0.67
QC- ACN- TFA-XB





32


embedded image


360.47
361.2
1.19
QC- ACN- AA-XB





33


embedded image


444.58
445.1
1.37
QC- ACN- AA-XB





34


embedded image


445.57
446.1
0.82
QC- ACN- TFA-XB





35


embedded image


360.47
361.1
0.82
QC- ACN- AA-XB





36


embedded image


444.58
445.2
1.12
QC- ACN- AA-XB





37


embedded image


445.57
446.1
0.72
QC- ACN- TFA-XB





38


embedded image


376.46
377.2
0.88
QC- ACN- TFA-XB





39


embedded image


445.57
446.1
0.77
QC- ACN- TFA-XB





40


embedded image


.459.60
460.1
1.25
QC- ACN- AA-XB





41


embedded image


493.63
494
1.46
QC- ACN- AA-XB





42


embedded image


502.62
503.1
1.66
QC- ACN- AA-XB





43


embedded image


429.57
430.4
1.1
QC- ACN- AA-XB





44


embedded image


514.58
515.4
1.29
QC- ACN- AA-XB





45


embedded image


535.71
536.4
0.84
QC- ACN- TFA-XB





46


embedded image


471.65
472.1
1.42
QC- ACN- AA-XB





47


embedded image


485.64
486.4
0.8
QC- ACN- TFA-XB





48


embedded image


565.69
566.6
0.81
QC- ACN- TFA-XB





49


embedded image


487.65
488.3
1.46
QC- ACN- AA-XB





50


embedded image


403.53
404.3
0.74
QC- ACN- TFA-XB





51


embedded image


466.59
467.2
1.27
QC- ACN- AA-XB





52


embedded image


466.59
467.2
1.36
QC- ACN- AA-XB





53


embedded image


494.66
495.2
1.56
QC- ACN- AA-XB





54


embedded image


558.73
559.2
1.64
QC- ACN- AA-XB





55


embedded image


501.68
502.2
0.8
QC- ACN- TFA-XB





56


embedded image


501.66
502.2
1.62
QC- ACN- AA-XB





57


embedded image


457.63
458.2
0.85
QC- ACN- TFA-XB





58


embedded image


471.65
472.3
0.89
QC- ACN- TFA-XB





59


embedded image


471.65
471.9
1.58
QC- ACN- AA-XB





60


embedded image


509.66
510.2
1.49
QC- ACN- AA-XB





61


embedded image


569.71
570.2
1.64
QC- ACN- AA-XB





62


embedded image


511.68
512.2
0.85
QC- ACN- TFA-XB





63


embedded image


512.67
513
0.82
QC- ACN- TFA-XB





64


embedded image


523.59
524.2
1.72
QC- ACN- AA-XB





65


embedded image


473.63
474.2
0.79
QC- ACN- TFA-XB





66


embedded image


445.62
446.1
1.22
QC- ACN- AA-XB





67


embedded image


539.69
540.3
0.84
QC- ACN- TFA-XB





68


embedded image


512.67
513.2
1.28
QC- ACN- AA-XB





69


embedded image


555.69
556.1
1.14
QC- ACN- TFA-XB





70


embedded image


459.64
460.3
1.39
QC- ACN- AA-XB





71


embedded image


707.84
708.5
1.13
QC- ACN- TFA-XB





72


embedded image


525.66
526.3
1.64
QC- ACN- AA-XB





73


embedded image


593.74
594.1
1.56
QC- ACN- AA-XB





74


embedded image


615.79
616.2
1.18
QC- ACN- TFA-XB





75


embedded image


647.79
648.5
1.07
QC- ACN- TFA-XB





76


embedded image


593.74
594.2
1.54
QC- ACN- AA-XB





77


embedded image


515.68
516.8
1.67
QC- ACN- AA-XB





78


embedded image


509.66
510.3
1.15
QC- ACN- AA-XB





79


embedded image


405.51
406.1
0.65
QC- ACN- TFA-XB





80


embedded image


489.62
490.4
0.73
QC- ACN- TFA-XB





81


embedded image


461.57
462.3
0.62
QC- ACN- TFA-XB





82


embedded image


489.62
489.9
1.32
QC- ACN- AA-XB





83


embedded image


444.54
445.4
1.33
QC- ACN- AA-XB





84


embedded image


490.61
491
1.24
QC- ACN- TFA-XB





85


embedded image


490.61
490.9
0.9
QC- ACN- TFA-XB





86


embedded image


459.60
460
0.83
QC- ACN- TFA-XB





87


embedded image


535.71
536.2
0.89
QC- ACN- TFA-XB





88


embedded image


375.48
376.3
1.09
QC- ACN- AA-XB





89


embedded image


391.48
392.3
0.98
QC- ACN- AA-XB





90


embedded image


476.59
477.22
1.44
QC- ACN- AA-XB





91


embedded image


405.51
406.2
1.48
QC- ACN- AA-XB





92


embedded image


433.56
434.4
1.01
QC- ACN- TFA-XB





93


embedded image


447.54
448.4
0.93
QC- ACN- TFA-XB





94


embedded image


430.52
431.3
1.58
QC- ACN- AA-XB





95


embedded image


497.62
498.2
1.6
QC- ACN- AA-XB





96


embedded image


403.53
404.3
1.31
QC- ACN- AA-XB





97


embedded image


473.63
474.4
1.84
QC- ACN- AA-XB





98


embedded image


488.64
489.4
1.23
QC- ACN- AA-XB





99


embedded image


490.61
491.2
1.12
QC- ACN- AA-XB





100


embedded image


431.59
432.11
1.62
QC- ACN- AA-XB





101


embedded image


473.63
474.4
1.5
QC- ACN- AA-XB





102


embedded image


475.60
476.4
0.84
QC- ACN- TFA-XB





103


embedded image


461.57
462.2
1.47
QC- ACN- AA-XB





104


embedded image


457.60
476.4
0.84
QC- ACN- TFA-XB





105


embedded image


461.61
461.9
1.92
QC- ACN- AA-XB





106


embedded image


463.59
464
1.5
QC- ACN- AA-XB





107


embedded image


475.60
476.2
1.72
QC- ACN- AA-XB





108


embedded image


445.57
446.2
1.13
QC- ACN- TFA-XB





109


embedded image


447.59
447.9
2.18
QC- ACN- AA-XB





110


embedded image


461.61
462.2
2.07
QC- ACN- AA-XB





111


embedded image


461.61
462.2
1.3
QC- ACN- TFA-XB





112


embedded image


463.59
464.2
1.7
QC- ACN- AA-XB





113


embedded image


489.62
490.2
1.04
QC- ACN- TFA-XB





114


embedded image


475.64
475.9
1.42
QC- ACN- TFA-XB





115


embedded image


447.59
448.3
1.89
QC- ACN- AA-XB





116


embedded image


487.53
488.3
2.06
QC- ACN- AA-XB





117


embedded image


449.56
450.3
1.47
QC- ACN- AA-XB





118


embedded image


463.59
463.9
1.42
QC- ACN- AA-XB





119


embedded image


419.53
420.13
1.04
QC- ACN- TFA-XB





120


embedded image


445.57
446.2
0.97
QC- ACN- TFA-XB





121


embedded image


516.65
517.1
1.54
QC- ACN- AA-XB





122


embedded image


375.48
376.11
1.17
QC- ACN- AA-XB





123


embedded image


460.59
461.2
0.88
QC- ACN- TFA-XB





124


embedded image


474.61
475.4
0.67
QC- ACN- TFA-XB





125


embedded image


389.51
390.3
1.25
QC- ACN- AA-XB





126


embedded image


417.56
418.3
0.75
QC- ACN- TFA-XB





127


embedded image


459.60
460.4
1.43
QC- ACN- AA-XB





128


embedded image


476.59
477.4
1.41
QC- ACN- AA-XB





129


embedded image


486.58
487.4
0.87
QC- ACN- TFA-XB





130


embedded image


448.53
449.4
1.29
QC- ACN- AA-XB





131


embedded image


449.56
450.37
0.93
QC- ACN- TFA-XB





132


embedded image


511.65
512.2
1.51
QC- ACN- AA-XB





133


embedded image


523.66
524.3
1.65
QC- ACN- AA-XB





134


embedded image


512.63
513.3
1.47
QC- ACN- AA-XB





135


embedded image


501.56
502.4
1.14
QC- ACN- TFA-XB





136


embedded image


490.61
491.2
1.08
QC- ACN- TFA-XB





137


embedded image


462.56
463
1.28
QC- ACN- AA-XB





138


embedded image


462.56
463.4
1.4
QC- ACN- AA-XB





139


embedded image


403.49
404.2
0.87
QC- ACN- TFA-XB





140


embedded image


459.55
460.3
1.05
QC- ACN- TFA-XB





141


embedded image


488.60
489.4
1.28
QC- ACN- AA-XB





142


embedded image


417.52
418.3
1.34
QC- ACN- AA-XB





143


embedded image


516.65
517.4
1.49
QC- ACN- AA-XB





144


embedded image


474.61
475.1
1.11
QC- ACN- TFA-XB





145


embedded image


500.65
501.2
1.47
QC- ACN- TFA-XB





146


embedded image


486.62
487.4
0.8
QC- ACN- TFA-XB





147


embedded image


509.67
510.4
1.41
QC- ACN- AA-XB





148


embedded image


442.57
443.2
1.82
QC- ACN- AA-XB





149


embedded image


460.59
460.9
1.41
QC- ACN- AA-XB





150


embedded image


403.49
404.4
1.36
QC- ACN- AA-XB





151


embedded image


524.69
525.1
1.74
QC- ACN- AA-XB





152


embedded image


403.53
404.1
1.95
QC- ACN- AA-XB





153


embedded image


403.53
404.1
1.31
QC- ACN- AA-XB





154


embedded image


516.65
517.2
1.14
QC- ACN- TFA-XB





155


embedded image


516.65
517.2
1.49
QC- ACN- AA-XB





156


embedded image


500.65
501.2
1.4
QC- ACN- AA-XB





157


embedded image


488.64
488.9
1.38
QC- ACN- AA-XB





158


embedded image


490.61
491.1
1.05
QC- ACN- TFA-XB





159


embedded image


504.64
1009.4  (2M + H)
1.4
QC- ACN- AA-XB





160


embedded image


530.68
531.2
1.35
QC- ACN- AA-XB





161


embedded image


500.65
501.20
1.43
QC- ACN- TFA-XB





162


embedded image


403.53
404.3
0.8
QC- ACN- TFA-XB





163


embedded image


488.64
489.3
1.38
QC- ACN- AA-XB





164


embedded image


445.57
446.4
1.43
QC- ACN- AA-XB





165


embedded image


521.68
522.4
0.83
QC- ACN- TFA-XB





166


embedded image


471.61
471.9
1.06
QC- ACN- TFA-XB





167


embedded image


446.60
447.2
1.06
QC- ACN- TFA-XB





168


embedded image


460.63
461.2
1.35
QC- ACN- AA-XB





169


embedded image


462.60
463
1.21
QC- ACN- AA-XB





170


embedded image


460.63
461
1.56
QC- ACN- AA-XB





171


embedded image


458.61
459.4
0.77
QC- ACN- TFA-XB





172


embedded image


458.61
459.3
1.49
QC- ACN- AA-XB





173


embedded image


488.64
489
1.28
QC- ACN- AA-XB





174


embedded image


458.61
459.2
1.02
QC- ACN- TFA-XB





175


embedded image


471.61
472.2
0.75
QC- ACN- TFA-XB





176


embedded image


403.49
404.2
1.68
QC- ACN- AA-XB





177


embedded image


432.57
433.1
1.29
QC- ACN- AA-XB





178


embedded image


460.58
461.4
0.73
QC- ACN- TFA-XB





179


embedded image


432.57
433.1
1
QC- ACN- TFA-XB





180


embedded image


460.58
461.1
1.6
QC- ACN- AA-XB





181


embedded image


489.62
490.3
1.14
QC- ACN- AA-XB





182


embedded image


472.64
473.4
0.92
QC- ACN- TFA-XB





183


embedded image


472.64
473.3
1.42
QC- ACN- AA-XB





184


embedded image


443.60
444.2
1.51
QC- ACN- AA-XB





185


embedded image


443.60
444.3
0.88
QC- ACN- TFA-XB





186


embedded image


460.58
461.5
0.75
QC- ACN- TFA-XB





187


embedded image


432.57
433.3
1.26
QC- ACN- AA-XB





188


embedded image


418.55
419.2
0.67
QC- ACN- TFA-XB





189


embedded image


418.55
419.1
1.28
QC- ACN- AA-XB





190


embedded image


510.65
511.2
1.23
QC- ACN- AA-XB





191


embedded image


462.60
463
1.07
QC- ACN- AA-XB





192


embedded image


465.61
459.1
1.31
QC- ACN- AA-XB





193


embedded image


446.60
447.1
1.48
QC- ACN- AA-XB





194


embedded image


474.61
475.2
0.98
QC- ACN- TFA-XB





195


embedded image


458.61
459.3
0.76
QC- ACN- TFA-XB





196


embedded image


510.65
511.5
1.43
QC- ACN- AA-XB





197


embedded image


488.64
489
1.16
QC- ACN- AA-XB





198


embedded image


476.63
477.3
1.19
QC- ACN- AA-XB





199


embedded image


458.61
459.2
0.79
QC- ACN- TFA-XB





200


embedded image


486.66
487.4
1.58
QC- ACN- AA-XB





201


embedded image


486.66
487.1
1.53
QC- ACN- AA-XB





202


embedded image


524.67
525.2
0.81
QC- ACN- TFA-XB





203


embedded image


524.67
525.4
0.81
QC- ACN- TFA-XB





204


embedded image


485.59
486.3
1.26
QC- ACN- AA-XB





205


embedded image


493.66
494.2
1.17
QC- ACN- TFA-XB





206


embedded image


485.59
486.2
1.7
QC- ACN- AA-XB





207


embedded image


493.66
494.2
0.94
QC- ACN- TFA-XB





208


embedded image


510.65
511.4
0.87
QC- ACN- TFA-XB





209


embedded image


510.65
511.32
1.19
QC- ACN- AA-XB





210


embedded image


489.62
490.4
1.06
QC- ACN- TFA-XB





211


embedded image


503.65
504.4
1.11
QC- ACN- AA-XB





212


embedded image


475.60
476.1
1.17
QC- ACN- AA-XB





213


embedded image


503.65
504.3
1.16
QC- ACN- AA-XB





214


embedded image


474.61
475.3
0.85
QC- ACN- TFA-XB





215


embedded image


460.58
461.1
1.21
QC- ACN- AA-XB





216


embedded image


489.62
490.3
0.78
QC- ACN- TFA-XB





217


embedded image


510.65
511.4
0.83
QC- ACN- TFA-XB





218


embedded image


485.60
486.1
1.06
QC- ACN- AA-XB





219


embedded image


536.70
537.3
1.62
QC- ACN- AA-XB





220


embedded image


460.58
461.3
0.76
QC- ACN- TFA-XB





221


embedded image


485.60
486.1
0.63
QC- ACN- TFA-XB





222


embedded image


489.62
490.3
1.07
QC- ACN- AA-XB





223


embedded image


536.70
537.3
0.85
QC- ACN- TFA-XB





224


embedded image


510.65
511.3
1.03
QC- ACN- AA-XB





225


embedded image


475.60
476.4
1.37
QC- ACN- AA-XB





226


embedded image


503.65
504.4
1.32
QC- ACN- AA-XB





227


embedded image


489.62
490.1
0.73
QC- ACN- TFA-XB





228


embedded image


489.62
490.3
1.53
QC- ACN- AA-XB





229


embedded image


474.61
475.1
0.76
QC- ACN- TFA-XB





230


embedded image


503.65
504.3
1.24
QC- ACN- AA-XB





231


embedded image


489.62
490.3
1.1
QC- ACN- AA-XB





232


embedded image


489.62
490.3
1.26
QC- ACN- AA-XB





233


embedded image


458.61
459.4
1.27
QC- ACN- AA-XB





234


embedded image


458.61
459.3
1.09
QC- ACN- AA-XB





235


embedded image


460.58
461.3
0.62
QC- ACN- TFA-XB





236


embedded image


519.71
520
1.8
QC- ACN- AA-XB





237


embedded image


498.68
499.2
1.79
QC- ACN- AA-XB





238


embedded image


519.71
520.3
0.93
QC- ACN- TFA-XB





239


embedded image


498.68
499.3
1.9
QC- ACN- AA-XB





240


embedded image


474.61
475.2
1.53
QC- ACN- AA-XB





241


embedded image


524.68
525.2
0.76
QC- ACN- TFA-XB





242


embedded image


524.68
525.3
1.58
QC- ACN- AA-XB





243


embedded image


427.60
428.1
1.52
QC- ACN- AA-XB





244


embedded image


486.62
487.3
1.1
QC- ACN- AA-XB





245


embedded image


469.63
470.3
1.35
QC- ACN- AA-XB





246


embedded image


474.61
475.3
0.63
QC- ACN- TFA-XB





247


embedded image


493.67
494.3
0.92
QC- ACN- TFA-XB





248


embedded image


534.68
535.2
1.52
QC- ACN- AA-XB





249


embedded image


462.64
463.1
0.75
QC- ACN- TFA-XB





250


embedded image


448.61
449
1.55
QC- ACN- AA-XB





251


embedded image


493.67
494.3
1.47
QC- ACN- AA-XB





252


embedded image


474.61
475.3
1.34
QC- ACN- AA-XB





253


embedded image


534.68
535.2
1.32
QC- ACN- AA-XB





254


embedded image


462.64
463.3
1.55
QC- ACN- AA-XB





255


embedded image


517.69
518.1
1.45
QC- ACN- AA-XB





256


embedded image


517.69
518.2
1
QC- ACN- TFA-XB





257


embedded image


564.75
565.3
1.3
QC- ACN- AA-XB





258


embedded image


561.75
562.4
1.23
QC- ACN- AA-XB





259


embedded image


611.82
612.2
1.52
QC- ACN- AA-XB





260


embedded image


480.63
481.3
1.49
QC- ACN- AA-XB





261


embedded image


564.75
565.5
0.9
QC- ACN- AA-XB





262


embedded image


611.82
612.4
1.74
QC- ACN- AA-XB





263


embedded image


426.57
427.3
1.28
QC- ACN- AA-XB





264


embedded image


493.67
494.1
0.88
QC- ACN- TFA-XB





265


embedded image


471.65
472.4
1.37
QC- ACN- AA-XB





266


embedded image


563.76
564.2
0.92
QC- ACN- TFA-XB





267


embedded image


471.65
472.4
1.48
QC- ACN- AA-XB





268


embedded image


496.66
497.4
1.47
QC- ACN- AA-XB





269


embedded image


493.67
494.4
1.27
QC- ACN- AA-XB





270


embedded image


426.57
427.3
1.38
QC- ACN- AA-XB





271


embedded image


563.76
564.1
1.44
QC- ACN- AA-XB





272


embedded image


497.65
498.4
0.98
QC- ACN- TFA-XB





273


embedded image


518.68
519.1
1.57
QC- ACN- AA-XB





274


embedded image


496.66
497.2
1.44
QC- ACN- AA-XB





275


embedded image


518.68
519.3
1.47
QC- ACN- AA-XB





276


embedded image


497.65
498.4
1.41
QC- ACN- AA-XB





277


embedded image


499.62
500
1.27
QC- ACN- TFA-XB





278


embedded image


521.72
522.3
0.99
QC- ACN- TFA-XB





279


embedded image


444.58
445.3
1.31
QC- ACN- AA-XB





280


embedded image


473.63
474.4
0.81
QC- ACN- TFA-XB





281


embedded image


470.62
471.2
0.77
QC- ACN- TFA-XB





282


embedded image


418.59
419
1.55
QC- ACN- AA-XB





283


embedded image


444.62
445
1.45
QC- ACN- AA-XB





284


embedded image


444.58
445.3
0.79
QC- ACN- TFA-XB





285


embedded image


521.72
522.4
1.96
QC- ACN- AA-XB





286


embedded image


444.62
445.19
1.57
QC- ACN- TFA-XB





287


embedded image


418.59
419.3
0.62
QC- ACN- TFA-XB





288


embedded image


470.62
471.2
0.79
QC- ACN- TFA-XB





289


embedded image


485.68
486.3
1.07
QC- ACN- TFA-XB





290


embedded image


483.66
484.4
1.05
QC- ACN- TFA-XB





291


embedded image


486.66
487.4
1.06
QC- ACN- TFA-XB





292


embedded image


485.68
486.4
1.58
QC- ACN- AA-XB





293


embedded image


402.54
403.2
1.62
QC- ACN- AA-XB





294


embedded image


483.66
484.3
1.52
QC- ACN- AA-XB





295


embedded image


431.58
432.2
1.12
QC- ACN- TFA-XB





296


embedded image


402.55
403.3
1.06
QC- ACN- AA-XB





297


embedded image


402.55
403.32

QC- ACN- AA-XB





299


embedded image


431.58
432.4
0.78
QC- ACN- TFA-XB





300


embedded image


402.55
403.1
1.49
QC- ACN- TFA-XB





301


embedded image


402.55
403.3
1.14
QC- ACN- AA-XB





302


embedded image


401.56
402.1
0.8
QC- ACN- TFA-XB





303


embedded image


473.63
474.2
1.14
QC- ACN- AA-XB





304


embedded image


494.66
495.2
0.64
QC- ACN- TFA-XB





305


embedded image


472.64
473.3
1.22
QC- ACN- AA-XB





306


embedded image


526.66
527.1
1.68
QC- ACN- AA-XB





307


embedded image


500.57
501.4
1.53
QC- ACN- AA-XB





308


embedded image


500.57
501.1
1.01
QC- ACN- TFA-XB





309


embedded image


474.61
475.3
1.6
E





310


embedded image


488.64
489
1.66
E





311


embedded image


488.64
489.4
1.81
E





312


embedded image


502.66
503.3
1.5
E





313


embedded image


460.63
461.3
1.44
E





314


embedded image


490.65
491.4
1.46
E





315


embedded image


502.66
503
1.67
E





316


embedded image


474.61
475.4
1.69
E





317


embedded image


500.65
501.3
1.51
E





318


embedded image


418.55
419.3
1.24
E





319


embedded image


500.65
501.3
1.5
E





320


embedded image


460.63
461.4
1.44
E





321


embedded image


490.65
491.4
1.4
E





322


embedded image


482.58
483.3
2.01
E





323


embedded image


418.55
419.3
1.26
E





324


embedded image


482.58
483
2.16
E





325


embedded image


458.61
459
1.39
E





326


embedded image


458.61
459
1.15
E





327


embedded image


476.63
477.4
1.46
E





328


embedded image


488.64
489
1.45
E





329


embedded image


488.64
489
1.52
E





330


embedded image


488.64
489
1.8
E





331


embedded image


488.64
489.3
1.83
E





332


embedded image


527.68
528.4
1.51
E





333


embedded image


527.68
528.4
1.49
E





334


embedded image


502.71
503
1.8
E





335


embedded image


476.63
477
1.43
E





336


embedded image


502.71
503
1.89
E





337


embedded image


494.59
495.3
2.1
E





338


embedded image


494.59
495.3
2.35
E





339


embedded image


485.64
486.3
1.95
E





340


embedded image


485.64
486.4
2
E





341


embedded image


506.63
507
1.57
E





342


embedded image


506.63
507
1.76
E





343


embedded image


504.61
505.3
1.54
E





344


embedded image


504.61
505.3
1.71
E





345


embedded image


478.57
479.3
1.65
E





346


embedded image


478.57
479.3
1.77
E





347


embedded image


436.54
437
1.33
E





348


embedded image


436.54
437
1.41
E





349


embedded image


401.51
402.3
1.69
QC- ACN- AA-XB





350


embedded image


458.61
459.5
1.32
QC- ACN- AA-XB





351


embedded image


458.61
459
1.67
QC- ACN- AA-XB





352


embedded image


487.65
488.5
0.8
QC- ACN- TFA-XB





353


embedded image


430.60
431.5
1.19
QC- ACN- AA-XB





354


embedded image


487.65
488.4
0.8
QC- ACN- TFA-XB





355


embedded image


430.60
431.3
0.8
QC- ACN- TFA-XB





356


embedded image


430.60
431.1
1.31
QC- ACN- AA-XB





357


embedded image


508.67
509
1.26
QC- ACN- AA-XB





358


embedded image


444.63
445.4
0.81
QC- ACN- TFA-XB





359


embedded image


508.67
509
1.42
QC- ACN- AA-XB





360


embedded image


456.64
457.1
0.85
QC- ACN- TFA-XB





361


embedded image


469.64
470.2
0.74
QC- ACN- TFA-XB





362


embedded image


472.64
473.2
1.28
QC- ACN- AA-XB





363


embedded image


444.63
445.4
1.37
QC- ACN- AA-XB





364


embedded image


458.65
459.1
1.43
QC- ACN- AA-XB





365


embedded image


460.63
461.2
1.25
QC- ACN- AA-XB





366


embedded image


469.64
470
1.69
QC- ACN- AA-XB





367


embedded image


416.57
418.3
1.2
QC- ACN- AA-XB





368


embedded image


501.68
502.3
1.23
QC- ACN- AA-XB





369


embedded image


416.57
417.1
1.32
QC- ACN- AA-XB





370


embedded image


478.59
478.9
2.06
QC- ACN- AA-XB





371


embedded image


440.60
440.9
1.7
QC- ACN- AA-XB





372


embedded image


486.66
486.9
1.08
QC- ACN- TFA-XB





373


embedded image


498.60
498.9
1.87
QC- ACN- AA-XB





374


embedded image


478.59
479.2
1.12
QC- ACN- TFA-XB





375


embedded image


440.60
441.2
1.06
QC- ACN- TFA-XB





376


embedded image


498.60
499.2
1.68
QC- ACN- AA-XB





377


embedded image


486.66
486.9
1.32
QC- ACN- AA-XB





378


embedded image


458.65
458.97
1.1
QC- ACN- TFA-XB





379


embedded image


446.60
446.9
0.95
QC- ACN- TFA-XB





380


embedded image


456.64
457.1
1.41
QC- ACN- AA-XB





381


embedded image


506.65
506.9
1.14
QC- ACN- TFA-XB





382


embedded image


520.70
521.2
1.08
QC- ACN- TFA-XB





383


embedded image


520.70
521.1
1.82
QC- ACN- AA-XB





384


embedded image


455.61
456.2
1.45
QC- ACN- AA-XB





385


embedded image


506.65
506.9
1.13
QC- ACN- TFA-XB





386


embedded image


442.61
443.19
1.01
QC- ACN- AA-XB





387


embedded image


456.64
457.2
0.78
QC- ACN- TFA-XB





388


embedded image


444.63
445.3
0.78
QC- ACN- TFA-XB





389


embedded image


474.65
475.1
1.27
QC- ACN- AA-XB





390


embedded image


444.63
445.3
1.3
QC- ACN- AA-XB





391


embedded image


474.65
475.3
1.36
QC- ACN- AA-XB





392


embedded image


486.66
487.4
0.79
QC- ACN- TFA-XB





393


embedded image


486.66
487
1.17
QC- ACN- AA-XB





394


embedded image


522.70
523.1
1.56
QC- ACN- AA-XB





395


embedded image


538.70
539.3
1.85
QC- ACN- AA-XB





396


embedded image


501.68
502.3
1.27
QC- ACN- AA-XB





397


embedded image


497.65
498.2
1.3
QC- ACN- AA-XB





398


embedded image


473.63
474.3
1.56
QC- ACN- AA-XB





399


embedded image


497.65
520.1
1.4
QC- ACN- AA-XB





400


embedded image


487.65
488.2
0.79
QC- ACN- TFA-XB





401


embedded image


472.64
473.2
1.54
QC- ACN- AA-XB





402


embedded image


522.70
523.2
1.8
QC- ACN- AA-XB





403


embedded image


487.65
488.1
1.66
QC- ACN- AA-XB





404


embedded image


501.68
502.2
1.49
QC- ACN- AA-XB





405


embedded image


538.70
539.2
0.86
QC- ACN- TFA-XB





406


embedded image


473.63
474.1
1.53
QC- ACN- AA-XB





407


embedded image


456.64
457.2
1.43
QC- ACN- AA-XB





408


embedded image


501.68
502.2
1.44
QC- ACN- AA-XB





409


embedded image


446.60
447
0.99
QC- ACN- TFA-XB





410


embedded image


501.68
502.2
0.84
QC- ACN- TFA-XB





411


embedded image


458.65
459.4
1.39
QC- ACN- AA-XB





412


embedded image


483.62
484.1
1.19
QC- ACN- AA-XB





413


embedded image


483.62
484.4
1.48
QC- ACN- AA-XB





414


embedded image


522.70
523.2
0.83
QC- ACN- TFA-XB





415


embedded image


522.70
523.4
1.37
QC- ACN- AA-XB





416


embedded image


483.62
484.1
1.57
QC- ACN- AA-XB





417


embedded image


508.67
509.2
1.41
QC- ACN- AA-XB





418


embedded image


508.67
509.3
1.55
QC- ACN- AA-XB





419


embedded image


534.72
535.3
1.66
QC- ACN- AA-XB





420


embedded image


487.65
488.3
1.37
QC- ACN- AA-XB





421


embedded image


442.61
443.1
1.29
QC- ACN- AA-XB





422


embedded image


487.65
488.29
1.48
QC- ACN- AA-XB





423


embedded image


562.66
563.4
1.39
QC- ACN- TFA-XB





424


embedded image


472.64
473.3
1.38
QC- ACN- AA-XB





425


embedded image


522.71
523.2
1.44
QC- ACN- AA-XB





426


embedded image


442.61
443.3
1.31
QC- ACN- AA-XB





427


embedded image


522.71
523.2
1.62
QC- ACN- AA-XB





428


embedded image


495.68
496.2
2.22
QC- ACN- AA-XB





429


embedded image


460.63
461
1.21
QC- ACN- AA-XB





430


embedded image


472.64
473.4
0.77
QC- ACN- TFA-XB





431


embedded image


460.63
461
0.83
QC- ACN- TFA-XB





432


embedded image


455.61
456.2
1.23
QC- ACN- TFA-XB





433


embedded image


495.68
496.1
2.34
QC- ACN- AA-XB





434


embedded image


467.62
467.9
0.79
QC- ACN- TFA-XB





435


embedded image


484.65
485.2
0.81
QC- ACN- TFA-XB





436


embedded image


467.62
468.3
1.96
QC- ACN- AA-XB





437


embedded image


484.65
485.3
1.14
QC- ACN- AA-XB





438


embedded image


532.71
533.4
1.41
QC- ACN- AA-XB





439


embedded image


458.61
459.4
1.01
QC- ACN- TFA-XB





440


embedded image


458.61
459.3
0.97
QC- ACN- TFA-XB





441


embedded image


497.65
497.9
1.77
QC- ACN- AA-XB





442


embedded image


499.66
500.2
1.51
QC- ACN- AA-XB





443


embedded image


499.66
500.2
1.58
QC- ACN- AA-XB





444


embedded image


502.66
503.1
1.45
QC- ACN- AA-XB





445


embedded image


520.70
521.4
0.81
QC- ACN- TFA-XB





446


embedded image


509.67
510.3
0.78
QC- ACN- TFA-XB





447


embedded image


509.67
510.4
0.8
QC- ACN- TFA-XB





448


embedded image


520.70
521.4
0.83
QC- ACN- TFA-XB





449


embedded image


529.69
530.3
1.4
QC- ACN- AA-XB





450


embedded image


508.69
509.4
1.25
QC- ACN- AA-XB





451


embedded image


486.66
487.3
0.9
QC- ACN- TFA-XB





452


embedded image


508.69
509.4
0.84
QC- ACN- TFA-XB





453


embedded image


486.66
487.4
1.41
QC- ACN- AA-XB





454


embedded image


536.74
537.2
0.84
QC- ACN- TFA-XB





455


embedded image


536.74
537.4
1.86
QC- ACN- AA-XB





456


embedded image


526.69
527.4
1.09
QC- ACN- TFA-XB





457


embedded image


547.72
548.4
1.86
QC- ACN- AA-XB





458


embedded image


547.72
548.1
1.78
QC- ACN- AA-XB





459


embedded image


526.69
527.4
1.8
QC- ACN- AA-XB





460


embedded image


536.74
537.2
0.77
QC- ACN- TFA-XB





461


embedded image


552.74
553.4
0.86
QC- ACN- TFA-XB





462


embedded image


515.71
516.1
0.94
QC- ACN- TFA-XB





463


embedded image


531.71
532.4
0.95
QC- ACN- TFA-XB





464


embedded image


548.75
549.1
0.85
QC- ACN- TFA-XB





465


embedded image


520.70
521.4
1.46
QC- ACN- AA-XB





466


embedded image


402.55
403.3
0.85
QC- ACN- TFA-XB





467


embedded image


515.71
516.4
0.78
QC- ACN- TFA-XB





468


embedded image


531.71
532.4
1.52
QC- ACN- AA-XB





469


embedded image


402.55
403.3
0.87
QC- ACN- TFA-XB





470


embedded image


520.70
521.4
1.84
QC- ACN- AA-XB





471


embedded image


548.75
549.4
0.96
QC- ACN- TFA-XB





472


embedded image


472.64
473.4
0.8
QC- ACN- TFA-XB





473


embedded image


472.64
473.4
0.82
QC- ACN- TFA-XB





474


embedded image


486.66
487.1
1.18
QC- ACN- AA-XB





475


embedded image


573.76
574.5
1.86
QC- ACN- AA-XB





476


embedded image


548.75
549.4
2.17
QC- ACN- AA-XB





477


embedded image


486.66
487.5
1.34
QC- ACN- AA-XB





478


embedded image


573.76
574.2
1.62
QC- ACN- TFA-XB





479


embedded image


548.75
549.5
1.95
QC- ACN- AA-XB





480


embedded image


562.78
563.5
0.93
QC- ACN- TFA-XB





481


embedded image


578.78
579.3
1.85
QC- ACN- AA-XB





482


embedded image


578.78
579.3
1.85
QC- ACN- AA-XB





483


embedded image


488.64
489.4
0.76
QC- ACN- TFA-XB





484


embedded image


488.64
489.2
1.04
QC- ACN- TFA-XB





485


embedded image


515.71
516.5
1.59
QC- ACN- AA-XB





486


embedded image


531.71
267
1.13
QC- ACN- TFA-XB





487


embedded image


501.68
502.4
0.81
QC- ACN- TFA-XB





488


embedded image


531.71
532.6
1.52
QC- ACN- AA-XB





489


embedded image


515.71
516.5
1.9
QC- ACN- AA-XB





490


embedded image


529.69
552.2
1.38
QC- ACN- AA-XB





491


embedded image


428.58
429.4
1.26
QC- ACN- AA-XB





492


embedded image


470.67
236.1
1.51
QC- ACN- AA-XB





493


embedded image


470.67
471.4
2.55
QC- ACN- TFA-XB





494


embedded image


541.74
542.3
2.34
QC- ACN- AA-XB





495


embedded image


515.71
516.5
0.88
QC- ACN- TFA-XB





496


embedded image


557.74
558.3
1.03
QC- ACN- TFA-XB





497


embedded image


541.74
564.2
2.33
QC- ACN- AA-XB





498


embedded image


557.74
558.4
0.92
QC- ACN- TFA-XB





499


embedded image


546.72
547.4
1.56
QC- ACN- AA-XB





500


embedded image


546.72
547
1.09
QC- ACN- TFA-XB





501


embedded image


473.63
474.5
0.87
QC- ACN- TFA-XB





502


embedded image


472.64
473.4
1.69
E





503


embedded image


472.64
473.3
1.74
E





504


embedded image


504.65
505.3
1.48
E





505


embedded image


504.65
505.4
1.54
E





506


embedded image


420.54
421.3
1.31
E





507


embedded image


420.54
421.3
1.36
E





508


embedded image


533.70
534
1.59
E





509


embedded image


533.70
534.3
1.66
E





510


embedded image


554.73
555.4
2.09
E





511


embedded image


554.73
555.3
2.03
E





512


embedded image


348.49
349.3
1.63
QC- ACN- AA-XB





513


embedded image


350.47
351.3
0.58
QC- ACN- TFA-XB





514


embedded image


365.48
366
0.67
QC- ACN- TFA-XB





515


embedded image


364.49
365.3
0.99
QC- ACN- AA-XB





516


embedded image


374.49
375.1
1.15
QC- ACN- AA-XB





517


embedded image


375.48
376
0.99
QC- ACN- TFA-XB





518


embedded image


374.49
374.9
0.95
QC- ACN- AA-XB





519


embedded image


378.52
379
1.47
QC- ACN- AA-XB





520


embedded image


390.49
391.4
0.52
B1





521


embedded image


388.52
389.3
0.58
B1





522


embedded image


362.52
363.3
1.46
E





523


embedded image


404.52
405.1
1.25
E





524


embedded image


408.48
409.1
1.23
E





525


embedded image


388.52
389.2
2.46
R





526


embedded image


379.50
380.7
2.524
D





527


embedded image


448.61
449.3
0.52
B1





528


embedded image


420.56
421.3
0.51
B1





529


embedded image


449.60
450.3
0.52
B1





530


embedded image


435.57
436.3
0.51
B1





531


embedded image


449.60
450.3
0.51
B1





532


embedded image


445.57
446.3
0.54
B1





533


embedded image


459.60
460.3
0.55
B1





534


embedded image


430.56
431.3
0.55
B1





535


embedded image


446.56
447
0.53
B1





536


embedded image


461.57
462
1.4
QC- ACN- AA-XB





537


embedded image


475.60
476.1
0.72
QC- ACN- TFA-XB





538


embedded image


444.58
445.3
0.55
B1





539


embedded image


459.60
460.3
0.55
B1





540


embedded image


473.63
474.4
0.56
B1





541


embedded image


460.63
461.4
0.58
B1





542


embedded image


434.58
435.4
0.53
B1





543


embedded image


462.64
463.4
0.55
B1





544


embedded image


449.60
450.4
0.52
B1





545


embedded image


463.63
464.4
0.54
B1





546


embedded image


450.63
451.4
0.55
B1





547


embedded image


446.60
447.3
0.55
B1





548


embedded image


462.60
463.9
0.52
B1





549


embedded image


475.60
476.4
1.15
QC- ACN- AA-XB





550


embedded image


459.60
460
1.4
QC- ACN- AA-XB





551


embedded image


473.63
474
0.53
B1





552


embedded image


480.63
481.3
0.53
B1





553


embedded image


413.53
414.3
0.63
B1





554


embedded image


496.63
497.3
0.56
B1





555


embedded image


429.53
430.9
0.58
B1





556


embedded image


494.66
495.3
0.6
B1





557


embedded image


427.56
428.3
0.66
B1





558


embedded image


447.54
448
1.12
QC- ACN- AA-XB





559


embedded image


431.54
432.4
0.67
QC- ACN- AA-XB





560


embedded image


445.57
446
1.16
QC- ACN- AA-XB





561


embedded image


471.61
471.9
0.53
B1





562


embedded image


487.61
487.9
0.51
B1





563


embedded image


485.64
485.9
0.52
B1





564


embedded image


483.05
471.9
0.53
B1





565


embedded image


470.01
470.3
1.46
QC- ACN- AA-XB





566


embedded image


455.00
455.4
0.71
QC- ACN- TFA-XB





567


embedded image


484.04
484.5
0.74
QC- ACN- TFA-XB





568


embedded image


441.02
441.1
1.39
QC- ACN- AA-XB





569


embedded image


455.04
455.15
0.84
QC- ACN- TFA-XB





570


embedded image


484.04
483.9
0.53
B1





571


embedded image


471.04
471.9
0.54
B1





572


embedded image


460.63
461.2
1.6
E





573


embedded image


514.62
515.2
2.14
E





574


embedded image


464.55
465.2
1.66
E





575


embedded image


472.64
473.2
1.5
E





576


embedded image


489.62
490.2
1.52
E





577


embedded image


493.59
494.1
1.85
E





578


embedded image


444.58
445.2
1.94
E





579


embedded image


460.58
461.2
1.88
E





580


embedded image


477.59
478.3
1.4
E





581


embedded image


473.63
474.2
1.54
E





582


embedded image


498.62
499.3
1.63
E





583


embedded image


493.59
494.3
1.36
E





584


embedded image


489.62
490.2
1.5
E





585


embedded image


477.59
478.2
1.89
E





586


embedded image


473.63
474.2
1.55
E





587


embedded image


476.63
477.2
1.56
E





588


embedded image


448.55
449.3
1.71
E





589


embedded image


488.64
489.2
1.46
E





590


embedded image


434.54
435.4
0.94
QC- ACN- TFA-XB





591


embedded image


504.64
505.5
1.23
QC- ACN- AA-XB





592


embedded image


434.54
435.2
1.08
QC- ACN- TFA-XB





593


embedded image


448.57
448.9
1.3
QC- ACN- AA-XB





594


embedded image


404.52
405.4
1.01
QC- ACN- TFA-XB





595


embedded image


462.55
463.3
1.31
QC- ACN- AA-XB





596


embedded image


392.46
393.2
1
QC- ACN- TFA-XB





597


embedded image


492.62
493.6
1.28
QC- ACN- AA-XB





598


embedded image


462.60
463
1.22
QC- ACN- TFA-XB





599


embedded image


464.57
465.2
1.11
QC- ACN- TFA-XB





600


embedded image


420.52
421.2
1.17
QC- ACN- AA-XB





601


embedded image


337.38
338
0.77
B1





602


embedded image


505.62
506.2
1.01
QC- ACN- TFA-XB





603


embedded image


448.57
449
1.22
QC- ACN- AA-XB





604


embedded image


526.66
527.5
0.98
QC- ACN- TFA-XB





605


embedded image


504.68
505.5
1.51
QC- ACN- AA-XB





606


embedded image


462.60
462.9
1.51
QC- ACN- AA-XB





607


embedded image


490.61
491.2
1.33
QC- ACN- AA-XB





608


embedded image


406.49
407.3
0.96
QC- ACN- TFA-XB





609


embedded image


491.60
492
1.28
QC- ACN- AA-XB





610


embedded image


448.57
449.4
1.11
QC- ACN- AA-XB





611


embedded image


504.68
505.5
1.3
QC- ACN- TFA-XB





612


embedded image


402.52
421
1.4
QC- ACN- AA-XB





613


embedded image


478.60
479.2
1.2
QC- ACN- AA-XB





614


embedded image


448.57
449.4
0.99
QC- ACN- TFA-XB





615


embedded image


473.63
474.25
1.31
QC- ACN- AA-XB





616


embedded image


460.58
461.3
1.38
QC- ACN- AA-XB





617


embedded image


374.49
375
0.7
QC- ACN- TFA-XB





618


embedded image


402.55
403.2
0.99
QC- ACN- TFA-XB





619


embedded image


461.57
462.2
1.24
QC- ACN- AA-XB





620


embedded image


376.46
377.4
0.96
QC- ACN- AA-XB





621


embedded image


494.66
495.2
0.77
QC- ACN- TFA-XB





622


embedded image


473.63
474.1
0.98
QC- ACN- TFA-XB





623


embedded image


402.55
402.9
0.72
QC- ACN- TFA-XB





624


embedded image


408.63
481.4
1.19
QC- ACN- AA-XB





625


embedded image


475.60
476.3
1.22
QC- ACN- AA-XB





626


embedded image


472.64
473.2
0.78
QC- ACN- TFA-XB





627


embedded image


475.60
476.2
0.73
QC- ACN- TFA-XB





628


embedded image


447.54
448.2
0.67
QC- ACN- TFA-XB





629


embedded image


404.52
405
1.1
QC- ACN- AA-XB





630


embedded image


475.60
476.4
0.74
QC- ACN- TFA-XB





631


embedded image


445.57
446.2
1.19
QC- ACN- AA-XB





632


embedded image


460.58
461.2
1.19
QC- ACN- AA-XB





633


embedded image


542.73
543.3
1.04
QC- ACN- TFA-XB





634


embedded image


482.60
483
1.22
QC- ACN- AA-XB





635


embedded image


458.61
459.22
1.23
QC- ACN- AA-XB





636


embedded image


494.66
495.2
1.54
QC- ACN- AA-XB





637


embedded image


458.61
459.1
1.43
QC- ACN- AA-XB





638


embedded image


461.57
462.4
0.74
QC- ACN- TFA-XB





639


embedded image


404.52
405
1.12
QC- ACN- AA-XB





640


embedded image


496.63
497.1
1.42
QC- ACN- AA-XB





641


embedded image


460.63
461.1
0.78
QC- ACN- AA-XB





642


embedded image


496.63
497.1
1.47
QC- ACN- AA-XB





643


embedded image


474.61
475.3
0.71
QC- ACN- TFA-XB





644


embedded image


459.60
460.5
1.2
QC- ACN- AA-XB





645


embedded image


419.49
420.3
0.93
QC- ACN- AA-XB





646


embedded image


417.52
418.4
0.96
QC- ACN- AA-XB





647


embedded image


468.58
469.4
0.78
QC- ACN- TFA-XB





648


embedded image


362.44
363.3
0.65
QC- ACN- TFA-XB





649


embedded image


360.47
361.3
0.69
QC- ACN- TFA-XB





650


embedded image


445.57
446
0.98
QC- ACN- TFA-XB





651


embedded image


443.52
444.4
0.74
QC- ACN- TFA-XB





652


embedded image


447.54
448.4
0.68
QC- ACN- TFA-XB





653


embedded image


466.60
467.4
0.8
QC- ACN- TFA-XB





654


embedded image


432.57
433.4
0.84
QC- ACN- TFA-XB





655


embedded image


404.52
405.2
1.2
QC- ACN- AA-XB





656


embedded image


402.55
403.3
0.89
QC- ACN- TFA-XB





657


embedded image


434.54
435.41
0.83
QC- ACN- TFA-XB





658


embedded image


432.57
433.2
1.48
QC- ACN- AA-XB





659


embedded image


476.58
477.4
1.42
QC- ACN- AA-XB





660


embedded image


434.54
435.1
1.02
QC- ACN- TFA-XB





661


embedded image


406.49
407.3
1.26
QC- ACN- AA-XB





662


embedded image


390.49
391.2
0.99
QC- ACN- AA-XB





663


embedded image


475.60
476.2
0.79
QC- ACN- TFA-XB





664


embedded image


474.61
475.3
1.41
QC- ACN- AA-XB





665


embedded image


380.49
381.1
1.34
QC- ACN- AA-XB





666


embedded image


392.46
393.2
0.75
QC- ACN- TFA-XB





667


embedded image


422.53
423.2
0.75
QC- ACN- TFA-XB





668


embedded image


477.57
478.3
1.06
QC- ACN- AA-XB





669


embedded image


366.47
367.1
0.86
QC- ACN- AA-XB





670


embedded image


405.50
406.3
1.38
QC- ACN- AA-XB





671


embedded image


392.46
393.1
0.97
QC- ACN- AA-XB





672


embedded image


491.60
492.3
1.06
QC- ACN- AA-XB





673


embedded image


404.52
405.2
1.2
QC- ACN- AA-XB





674


embedded image


496.63
497.3
1.35
QC- ACN- AA-XB





675


embedded image


366.47
367
0.77
QC- ACN- TFA-XB





676


embedded image


392.46
393.3
0.76
QC- ACN- TFA-XB





677


embedded image


451.57
452.2
0.95
QC- ACN- AA-XB





678


embedded image


408.55
409.3
0.82
QC- ACN- TFA-XB





679


embedded image


366.47
367.2
0.97
QC- ACN- AA-XB





680


embedded image


389.51
390.1
1.13
QC- ACN- AA-XB





681


embedded image


402.55
403.1
1.24
QC- ACN- AA-XB





682


embedded image


418.55
419.4
0.77
QC- ACN- TFA-XB





683


embedded image


458.61
458.9
1.31
QC- ACN- AA-XB





684


embedded image


479.64
480.1
1.47
QC- ACN- AA-XB





685


embedded image


473.63
474.3
1.49
QC- ACN- AA-XB





686


embedded image


444.58
445.2
0.92
QC- ACN- AA-XB





687


embedded image


444.58
445.1
0.73
QC- ACN- TFA-XB





688


embedded image


471.57
472.2
1
QC- ACN- AA-XB





689


embedded image


475.60
475.9
1.28
QC- ACN- AA-XB





690


embedded image


373.50
374.1
0.84
QC- ACN- TFA-XB





691


embedded image


457.62
457.9
1.64
QC- ACN- AA-XB





692


embedded image


388.52
389.1
0.72
QC- ACN- TFA-XB





693


embedded image


462.60
463
1.29
QC- ACN- AA-XB





694


embedded image


429.57
430.2
0.71
QC- ACN- TFA-XB





695


embedded image


494.66
495.4
1.14
QC- ACN- AA-XB





696


embedded image


473.63
474.37
1.07
QC- ACN- AA-XB





697


embedded image


390.49
391.3
0.95
QC- ACN- AA-XB





698


embedded image


496.63
497.3
1.09
QC- ACN- AA-XB





699


embedded image


475.60
476.4
0.76
QC- ACN- TFA-XB





700


embedded image


446.56
447.3
1.08
QC- ACN- AA-XB





701


embedded image


460.63
461.4
1.1
QC- ACN- AA-XB





702


embedded image


472.64
473.4
1.12
QC- ACN- AA-XB





703


embedded image


458.61
459.4
1.2
QC- ACN- AA-XB





704


embedded image


454.58
454.9
1.35
QC- ACN- AA-XB





705


embedded image


469.60
470.47
0.74
QC- ACN- TFA-XB





706


embedded image


474.61
475.4
1.1
QC- ACN- AA-XB





707


embedded image


474.61
475.4
1.27
E





708


embedded image


504.60
505
1.26
E





709


embedded image


496.63
497
1.05
E





710


embedded image


474.61
475.3
1.27
E





711


embedded image


474.61
475.3
1.33
E





712


embedded image


475.60
476.3
1.55
E





713


embedded image


468.57
469
1.8
E





714


embedded image


515.66
516.4
1.35
E





715


embedded image


446.56
447.3
1.43
E





716


embedded image


429.53
430.3
1.94
E





717


embedded image


602.77
603.3
1.34
E





718


embedded image


474.61
475.4
1.34
E





719


embedded image


461.57
462.3
1.29
E





720


embedded image


504.60
505.3
1.26
E





721


embedded image


474.61
475
1.27
E





722


embedded image


560.70
561
1.5
E





723


embedded image


432.57
433.3
1.32
E





724


embedded image


458.61
459.3
1.46
E





725


embedded image


461.57
462.3
1.3
E





726


embedded image


602.77
603
1.34
E





727


embedded image


474.61
475.4
1.38
E





728


embedded image


474.61
475.3
1.35
E





729


embedded image


502.66
503.3
1.41
E





730


embedded image


468.57
469
1.8
E





731


embedded image


489.62
490.1
1.34
E





732


embedded image


449.56
450.1
1.19
E





733


embedded image


475.55
476.1
1.29
E





734


embedded image


474.49
475.1
1.86
E





735


embedded image


440.56
441.2
1.32
QC- ACN- AA-XB





736


embedded image


470.58
470.9
1.57
QC- ACN- AA-XB









Example 737
6-(5-((2S,5R)-2,5-dimethylpiperazin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


Intermediate 737A: tert-butyl 5-((2S,5R)-4-(tert-butoxycarbonyl)-2,5-dimethylpiperazin-1-yl)-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


A suspension of tert-butyl5-bromo-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (600 mg, 1.24 mmol), tert-butyl (2R,5S)-2,5-dimethylpiperazine-1-carboxylate, HCl (466 mg, 1.86 mmol), Pd2(dba)3 (113 mg, 0.124 mmol), dicyclohexyl(2′,6′-di-isopropoxy-[1,1′-biphenyl]-2-yl)phosphine (69.4 mg, 0.149 mmol), and Cs2CO3 (1.82 g, 5.57 mmol) in 1,4-dioxane (12.5 mL) in a reaction vial with a pressure-relief septum-lined cap and a stir bar was degassed with nitrogen gas for 5 minutes. The reaction vial was sealed and placed in a heating block with stirring at 105° C. for 6.5 hours, then cooled to room temperature, and remained at room temperature overnight. The reaction was then restarted by the addition of tert-butyl (2R,5S)-2,5-dimethylpiperazine-1-carboxylate, HCl (233 mg, 0.93 mmol), Pd2(dba)3 (57 mg, 0.062 mmol), dicyclohexyl(2′,6′-di-isopropoxy-[1,1′-biphenyl]-2-yl)phosphine (35 mg, 0.075 mmol), and Cs2CO3 (908 mg, 2.79 mmol), degassed with nitrogen gas, and heated to 105° C. with stirring for 4 hours more. Upon completion, the reaction mixture was cooled to room temperature and remained at room temperature overnight. The reaction mixture was then filtered, concentrated, and taken up in DCM. The crude material was purified by silica gel column chromatography on a Teledyne Isco instrument eluting in Hex/EtOAc 0-100% to afford tert-butyl 5-(2S,5R)-4-(tert-butoxycarbonyl)-2,5-dimethylpiperazin-1-yl)-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (698 mg, 1.130 mmol, 91% yield). LCMS retention time 1.26 [TS]. MS (E+) m/z: 618.7 (M+H).


Example 737

tert-Butyl 5-(2S,5R)-4-(tert-butoxycarbonyl)-2,5-dimethylpiperazin-1-yl)-2-(7,8-dimethyl-[1,2,4]triazolo [1,5-a]pyridin-6-yl)-3-isopropyl-1 H-pyrrolo[3,2-b]pyridine-1-carboxylate (698 mg, 1.13 mmol) was suspended in TFA (6 mL) at room temperature and stirred for 3 hours. The reaction mixture was then concentrated, redissolved in CHCl3/iPrOH 3/1 and neutralized with 1.5M aqueous K2HPO4 solution in a separatory funnel. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to afford material considered to be quantitative of 6-(5-((2S,5R)-2,5-dimethylpiperazin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (1.13 mmol).


For characterization purposes, a portion of the crude product from a separate preparation of 6-(5-(2S,5R)-2,5-dimethylpiperazin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine run on smaller scale was purified by preparative LC/MS using the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: a 0-minute hold at 0% B, 0-40% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS and UV signals. The fractions containing the product were combined and dried via centrifugal evaporation to afford 6-(5-(2S,5R)-2,5-dimethylpiperazin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4t]triazolo[1,5-a]pyridine, TFA (15.5 mg). LCMS retention time 0.93 [QC-ACN-TFA-XB]. MS (E+) m/z: 418.5 (M+H). Select NMR peaks: 1H NMR (500 MHz, DMSO-d6) δ11.09 (s, 1H), 9.03 (br s, 1H), 8.78 (s, 2H), 8.47 (s, 1H), 7.64 (br d, J=8.9 Hz, 1H), 6.82 (br d, J=8.5 Hz, 1H), 4.18-4.04 (m, 1H), 3.67-3.53 (m, 1H), 3.45-3.33 (m, 1H), 3.11-2.97 (m, 1H), 2.86-2.75 (m, 1H), 2.59 (s, 3H), 2.17 (s, 3H), 1.42-1.35 (m, 6H), 1.29 (br d, J=6.4 Hz, 3H), 1.16 (br d, J=6.4 Hz, 3H).


Example 738
1(2R,5S)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,5-dimethylpiperazin-1-yl)-2-(pyrrolidin-1-yl)ethan-1-one



embedded image


Intermediate 738A: 2-chloro-1-(2R,5S)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,5-dimethylpiperazin-1-yl)ethan-1-one



embedded image


6-(5-((2S,5R)-2,5-dimethylpiperazin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (0.496 mmol) was suspended in DCM (4 mL). Et3N (0.346 mL, 2.48 mmol) and 2-chloroacetyl chloride (0.079 mL, 0.992 mmol) were added sequentially. The reaction mixture was stirred at room temperature for 30 minutes. Another aliquot of 2-chloroacetyl chloride (0.025 mL, 0.314 mmol) was added. The reaction mixture was stirred for an additional 2 minutes. The reaction was quenched by addition of water, DCM, and 1.5 M aqueous K2HPO4 solution. The layers were separated, and the aqueous layer was extracted with DCM. The combined organic layer was dried over sodium sulfate, filtered, and concentrated to afford crude material which was considered quantitative recovery of 2-chloro-1-(2R,5S)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,5-dimethylpiperazin-1-yl)ethan-1-one (0.496 mmol). LCMS retention time 0.70 [TS]. MS (E+) m/z: 494.4 (M+H).


Example 738

2—Chloro-1-(2R,5S)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,5-dimethylpiperazin-1-yl)ethan-1-one (0.0496 mmol) was suspended in DMF (1 mL). Pyrrolidine (0.050 mL, 0.609 mmol) was added, and the reaction mixture was stirred for 19 hours at room temperature. Upon completion, the reaction mixture was diluted with a few drops of water, DMF, filtered, and purified by preparative LC/MS via the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 16% B, 16-56% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS signals. The fractions containing the product were combined and dried via centrifugal evaporation to afford 1-(2R,5S)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,5-dimethylpiperazin-1-yl)-2-(pyrrolidin-1-yl)ethan-1-one (14.2 mg, 0.027 mmol, 54.1% yield). LCMS retention time 1.46 [QC-ACN-AA-XB]. MS (E+) m/z: 529.5 (M+H). Select NMR peaks (rotamers present): 1H NMR (500 MHz, DMSO-d6) δ10.82 (s, 1H), 8.70 (br s, 1H), 8.45 (s, 1H), 7.54 (d, J=8.9 Hz, 1H), 6.71 (br dd, J=8.8, 6.0 Hz, 1H), 2.80-2.72 (m, 1H), 2.56 (s, 3H), 2.15 (s, 3H), 1.76-1.61 (m, 4H), 1.36 (br d, J=5.8 Hz, 6H), 1.29-0.93 (m, 6H).


Example 739
1-(2R,5S)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,5-dimethylpiperazin-1-yl)-3-(pyrrolidin-1-yl)propan-1-one



embedded image


Intermediates 739A and 739B: 3-chloro-1-(2R,5S)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,5-dimethylpiperazin-1-yl)propan-1-one and 14(2R,5S)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,5-dimethylpiperazin-1-yl)prop-2-en-1-one



embedded image


6-(5-(2S,5R)-2,5-dimethylpiperazin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (0.496 mmol) was suspended in DCM (4 mL). Et3N (0.35 mL, 2.48 mmol) and 3-chloropropanoyl chloride (0.095 mL, 0.992 mmol) were added sequentially and the reaction mixture was stirred for 15 minutes at room temperature. Upon completion, the reaction was quenched. The reaction mixture was worked up by dilution with water, DCM, and 1.5M aqueous K2HPO4 solution. The organic layer was separated and the aqueous layer was extracted with DCM. The combined organic layer was dried over sodium sulfate, filtered, and concentrated to afford crude material which was carried into the next steps as is and considered quantitative recovery of both materials (0.496 mmol total) as a mixture of an unidentified ratio of 3-chloro-1-(2R,5S)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,5-dimethylpiperazin-1-yl)propan-1-one (LCMS retention time 0.72 [TS]. MS (E+) m/z: 508.5 (M+H)) and 1-((2R,5S)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,5-dimethylpiperazin-1-yl)prop-2-en-1-one (LCMS retention time 0.68 [TS]. MS (E+) m/z: 472.5 (M+H).


Example 739

A mixture of 3-chloro-1-(2R,5S)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,5-dimethylpiperazin-1-yl)propan-1-one and 1-(2R,5S)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,5-dimethylpiperazin-1-yl)prop-2-en-1-one (0.0413 mmol) was suspended in DMF (1 mL). Pyrrolidine (0.05 mL, 0.609 mmol) was added and the reaction mixture was stirred at room temperature for 20 hours. Upon completion, the reaction mixture was diluted with a few drops of water, DMF, filtered, and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 15% B, 15-55% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS signals. The fractions containing the product were combined and dried via centrifugal evaporation to afford 1-(2R,5S)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5 a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,5-dimethylpiperazin-1-yl)-3-(pyrrolidin-1-yl)propan-1-one (18.0 mg, 0.032 mmol, 78% yield). LCMS retention time 1.07 [QC-ACN-TFA-XB]. MS (E+) m/z: 543.4 (M+H). Select NMR peaks (rotamers present): 1H NMR (500 MHz, DMSO-d6) δ10.83 (s, 1H), 8.73 (br s, 1H), 8.47-8.44 (m, 1H), 7.54 (d, J=9.0 Hz, 1H), 6.76-6.67 (m, 1H), 2.81-2.62 (m, 3H), 2.57 (s, 3H), 2.16 (s, 3H), 1.68 (br d, J=2.8 Hz, 4H), 1.37 (br d, J=6.6 Hz, 6H), 1.30-0.94 (m, 6H).


Example 740
6-(3-isopropyl-5-(2,6-diazaspiro[3.3]heptan-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


Intermediate 740A: tert-butyl 5-(6-(tert-butoxycarbonyl)-2,6-diazaspiro[3.3]heptan-2-yl)-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


A suspension of tert-butyl 5-bromo-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (150 mg, 0.310 mmol), tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate, 0.5 oxalic acid salt (113 mg, 0.464 mmol), 2nd generation RuPhos precatalyst (11 mg, 0.014 mmol), and Cs2CO3 (353 mg, 1.084 mmol) in 1,4-dioxane (3.1 mL) was degassed with nitrogen for 5 minutes in a reaction vial with a pressure-relief septum-lined cap. The reaction vial was sealed and placed in a heating block at 100° C. with stirring. After 2 hours, more RuPhos 2nd generation precatalyst (27 mg, 0.035 mmol) was added, the suspension was further degassed, and the reaction mixture was taken back up to 100° C. with stirring for 2 hours. Upon completion, the reaction mixture was filtered, concentrated, and purified by Silica gel column chromatography eluting with Hex/EtOAc 0-100% to afford tert-butyl 5-(6-(tert-butoxycarbonyl)-2,6-diazaspiro[3.3]heptan-2-yl)-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (124 mg, 66.5% yield) containing some co-eluting impurities. LCMS retention time 0.99 [TS]. MS (E+) m/z: 602.3 (M+H).


Example 740

A solution of tert-butyl 5-(6-(tert-butoxycarbonyl)-2,6-diazaspiro[3.3]heptan-2-yl)-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (124 mg, 0.206 mmol) in TFA (3 mL) was stirred at room temperature for 2 hours. Upon completion, the reaction mixture was concentrated and considered quantitative recovery of 6-(3-isopropyl-5-(2,6-diazaspiro[3.3]heptan-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine, TFA (0.206 mmol). 90% of this material was carried on as is. 10% of this material was purified by preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: a 0-minute hold at 0% B, 0-40% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS and UV signals. Fractions containing the product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 0% B, 0-40% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS signals. The fractions containing the product were combined and dried via centrifugal evaporation to afford 6-(3-isopropyl-5-(2,6-diazaspiro[3.3]heptan-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (3.1 mg, 0.0075 mmol). LCMS retention time 1.21 [QC-ACN-AA-XB]. MS (E+) m/z: 402.0 (M+H). Select NMR peaks: 1H NMR (500 MHz, DMSO-dc) δ10.85 (s, 1H), 8.75 (s, 1H), 8.46 (s, 1H), 7.52 (br d, J=8.5 Hz, 1H), 6.28 (br d, J=8.9 Hz, 1H), 4.00 (s, 4H), 2.84-2.77 (m, 1H), 2.16 (s, 3H), 1.36 (br d, J=6.7 Hz, 6H).


EXAMPLE 741
6-(3-isopropyl-5-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


6-(3-isopropyl-5-(2,6-diazaspiro[3.3]heptan-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine, TFA (15.93 mg, 0.0309 mmol) and Et3N (0.05 mL, 0.359 mmol) were mixed in DMF (1 mL). Formaldehyde (37% wt in water, 25 μL, 0.336 mmol) was added to the reaction vial followed by sodium triacetoxyborohydride (54 mg, 0.255 mmol). The reaction mixture was stirred at room temperature for 90 minutes. Upon completion, the reaction was quenched by the addition of water, 1.5 M aqueous K2HPO4 solution, and DCM. The organic layer was separated and concentrated. The crude material was dissolved in DMF for purification via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: a 0-minute hold at 0% B, 0-40% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS and UV signals. Fractions containing the product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 1% B, 1-41% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS signals. The fractions containing the product were combined and dried via centrifugal evaporation to afford 6-(3-isopropyl-5-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (3.2 mg, 7.70 μmol, 25% yield). LCMS retention time 1.29 [QC-ACN-AA-XB]. MS (E+) m/z: 415.9 (M+H). Select NMR peaks: 1H NMR (500 MHz, DMSO-d6) δ10.82 (s, 1H), 8.73 (s, 1H), 8.45 (s, 1H), 7.51 (d, J=8.5 Hz, 1H), 6.26 (d, J=8.5 Hz, 1H), 3.96 (s, 4H), 2.84-2.75 (m, 1H), 2.57 (s, 3H), 2.22 (s, 3H), 2.14 (s, 3H), 1.34 (br d, J=6.7 Hz, 6H).


Example 742
2-(6-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,6-diazaspiro[3.3]heptan-2-yl)-N,N-dimethylacetamide



embedded image


6-(3-isopropyl-5-(2,6-diazaspiro[3.3]heptan-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine, TFA (15.93 mg, 0.0309 mmol) and DBU (0.05 mL, 0.332 mmol) were mixed in DMF (1 mL). Excess 2-chloro-N,N-dimethylacetamide (approximately 184) was added to the reaction vial and the mixture was stirred for 1.5 hours. Upon completion, the reaction mixture was diluted with a few drops of water, DMF, and the crude material was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 10% B, 10-50% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS signals. The fractions containing the product were combined and dried via centrifugal evaporation to afford 2-(6-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,6-diazaspiro[3.3]heptan-2-yl)-N,N-dimethylacetamide (6.6 mg, 0.013 mmol, 43.6% yield). LCMS retention time 1.33 [QC-ACN-AA-XB]. MS (E+) m/z: 486.9 (M+H). Select NMR peaks: 1H NMR (500 MHz, DMSO-d6) δ10.81 (s, 1H), 8.74 (s, 1H), 8.46 (s, 1H), 7.51 (d, J=8.5 Hz, 1H), 6.27 (d, J=8.5 Hz, 1H), 2.58 (s, 3H), 2.15 (s, 3H), 1.35 (br d, J=6.4 Hz, 6H).


Example 743
1-(6-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,6-diazaspiro[3.3]heptan-2-yl)-2-(dimethylamino)ethan-1-one



embedded image


A solution of 6-(3-isopropyl-5-(2,6-diazaspiro[3.3]heptan-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine, TFA (15.93 mg, 0.0309 mmol) in methanol was converted to the HCl salt form by adding 1 mL of 4 N HCl in dioxane and concentrating to dryness. The material was taken up in methanol a second time, 1 mL of 4N HCl in dioxane was again added, and the material was concentrated to dryness. The material was then suspended in DMF (1 mL) and N,N-dimethylglycine (20 mg, 0.194 mmol), Et3N (0.1 mL, 0.717 mmol), and T3P (50% in DMF, 0.090 mL, 0.155 mmol) were added sequentially at room temperature with stirring. After 1.5 hours, another aliquot of N,N-dimethylglycine (9 mg, 0.087 mmol), Et3N (0.1 mL, 0.717 mmol), and T3P (50% in DMF, 0.090 mL, 0.155 mmol) were added and the reaction mixture was stirred for 26 hours at room temperature. Upon completion, the reaction was quenched by the addition of water, 1.5 M aqueous K2HPO4 solution, and DCM. The organic layer was separated, concentrated, and the crude isolate was diluted with DMF. The crude material was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 16% B, 16-56% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS signals. Fractions containing the product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: XBridge Phenyl, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 12% B, 12-52% B over 25 minutes, then a 6-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS signals. The fractions containing the product were combined and dried via centrifugal evaporation to afford 1-(6-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,6-diazaspiro[3.3]heptan-2-yl)-2-(dimethylamino)ethan-1-one (2.5 mg, 5.03 μmol, 16% yield). LCMS retention time 1.17 [QC-ACN-AA-XB]. MS (E+) m/z: 487.1 (M+H). NMR (500 MHz, DMSO-d6) δ10.85 (s, 1H), 8.72 (s, 1H), 8.45 (s, 1H), 7.53 (br d, J=8.9 Hz, 1H), 6.29 (br d, J=8.5 Hz, 1H), 4.35 (s, 2H), 4.07 (br s, 2H), 4.04 (s, 4H), 2.90 (s, 2H), 2.84-2.74 (m, 1H), 2.57 (s, 3H), 2.17 (s, 6H), 2.14 (s, 3H), 1.34 (br d, J=6.4 Hz, 6H).


Example 744
6-(5-(6-ethyl-2,6-diazaspiro[3.3]heptan-2-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


Alternate synthesis of Intermediate 740A: tert-butyl5-(6-(tert-butoxycarbonyl)-2,6-diazaspiro[3.3]heptan-2-yl)-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate




embedded image


A suspension of tert-butyl 5-bromo-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (332 mg, 0.685 mmol), Pd2(dba)3 (62.8 mg, 0.069 mmol), dicyclohexyl(2′,6′-di-isopropoxy-[1,1′-biphenyl]-2-yl)phosphine (38.4 mg, 0.082 mmol), and Cs2CO3 (902 mg, 2.77 mmol) in 1,4-dioxane (6.9 mL) in a vial with a pressure-relief septum-lined cap and stir bar was degassed with nitrogen for 5 minutes. The mixture was sealed and placed in a heating block at 105° C. with stirring for 7 hrs and then remained at room temperature overnight. The reaction mixture was filtered, concentrated, and purified by silica gel column chromatography eluting with Hex/EtOAc 0-100% to afford tert-butyl 5-(6-(tert-butoxycarbonyl)-2,6-diazaspiro[3.3]heptan-2-yl)-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (0.685 mmol) considered to be quantitative recovery.


Alternate Synthesis of Example 740: 6-(3-isopropyl-5-(2,6-diazaspiro[3.3]heptan-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


A solution of tert-butyl5-(6-(tert-butoxycarbonyl)-2,6-diazaspiro[3.3]heptan-2-yl)-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (0.685 mmol) in TFA (3.5 mL) at room temperature was stirred for 2 hours. Upon completion, the material was concentrated, taken up in 3/1 CHCl3/iPrOH and neutralized by mixing with 1.5 M aqueous K2HPO4 solution and water in a separatory funnel. The aqueous layer was extracted with 3/1 CHCl3/iPrOH. The combined organic layer was dried over sodium sulfate, filtered, and concentrated to afford crude material, considered quantitative recovery of 6-(3-isopropyl-5-(2,6-diazaspiro[3.3]heptan-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (0.685 mmol). LCMS retention time 0.53 [TS]. MS (E+) m/z: 402.3 (M+H).


Intermediate 744A: 1-(6-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,6-diazaspiro[3.3]heptan-2-yl)ethan-1-one



embedded image


To a stirred suspension of 6-(3-isopropyl-5-(2,6-diazaspiro[3.3]heptan-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (0.173 mmol) in DCM (3 mL) were sequentially added Et3N (0.121 mL, 0.865 mmol) and acetic anhydride (0.025 mL, 0.260 mmol). After 10 minutes, the reaction mixture was concentrated to afford crude material. This material was purified by silica gel column chromatography on a Teledyne Isco instrument eluting with Hex/EtOAc 0-100% then DCM/MeOH 0-10% to afford 1-(6-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,6-diazaspiro[3.3]heptan-2-yl)ethan-1-one (66 mg, 0.149 mmol, 86% yield). LCMS retention time 0.60 [TS]. MS (E+) m/z: 444.5 (M+H).


Example 744

To a stirred solution of 1-(6-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2,6-diazaspiro[3.3]heptan-2-yl)ethan-1-one (66 mg, 0.149 mmol) in THF (3 mL) was added LiAlH4 (17 mg, 0.446 mmol), and the vial was sealed at room temperature. After 90 minutes, the reaction was quenched by the addition of DCM and 1.5 M aqueous K2HPO4 solution. The organic layer was separated and the aqueous layer was extracted with DCM. The combined organic layer was dried over sodium sulfate, filtered, and concentrated. The obtained crude material was taken up in DMF and purified by preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×30 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 9% B, 9-49% B over 20 minutes, then a 2-minute hold at 100% B; Flow Rate: 45 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS and UV signals. Fractions containing the product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acelunitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 8% B, 8-48% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS and UV signals. The fractions containing the product were combined and dried via centrifugal evaporation to afford 6-(5-(6-ethyl-2,6-diazaspiro[3.3]heptan-2-yl)-3-isopropyl-1H pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (43.4 mg, 0.100 mmol, 67.5% yield). LCMS retention time 1.31 [QC-ACN-AA-XB]. MS (E+) m/z: 430.1 (M+H). 1H NMR (500 MHz, DMSO-d6) δ10.83 (s, 1H), 8.67 (s, 1H), 8.44 (s, 1H), 7.53 (d, J=8.9 Hz, 1H), 6.28 (d, J=8.5 Hz, 1H), 3.99 (s, 4H), 2.83-2.75 (m, 1H), 2.68-2.59 (m, 2H), 2.55 (s, 3H), 2.12 (s, 3H), 1.32 (br d, J=6.4 Hz, 6H), 0.93 (br t, J=7.0 Hz, 3H).


Example 745
6-(3-isopropyl-5-(2-azaspiro[3.3]heptan-6-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine



embedded image


Intermediate 745A: tert-butyl 6-((methylsulfonyl)oxy)-2-azaspiro[3.3]heptane-2-carboxylate



embedded image


To a solution of tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate (2.0 g, 9.38 mmol) in DCM (45 mL) at room temperature was added Et3N (3.27 mL, 23.4 mmol) and MsCl (1.1 mL, 14.1 mmol) sequentially. After 3.25 hours, the reaction was quenched by the addition of water and DCM. The layers were separated and the aqueous layer was extracted with DCM. The combined organic layer was dried over sodium sulfate, filtered, and concentrated to afford crude material considered to be quantitative of tert-butyl 6-((methylsulfonyl)oxy)-2-azaspiro[3.3]heptane-2-carboxylate (9.38 mmol, 100% yield).


Intermediate 745B: tert-butyl 6-iodo-2-azaspiro[3.3]heplane-2-carboxylate



embedded image


tert-Butyl 6-((methylsulfonypoxy)-2-azaspiro[3.3]heptane-2-carboxylate (4.69 mmol) was suspended in ethyl methyl ketone (19 mL) and sodium iodide (3.52 g, 23.5 mmol) was added. The mixture was degassed with nitrogen gas for 10 minutes, then the reaction vial sealed with a pressure-relief septum-lined cap and heated to 100° C. with stirring for 19.75 hours. An identical reaction was set up in duplicate and run in parallel. Upon completion, the reaction mixtures were cooled to room temperature and quenched by the addition of water and DCM. The parallel reaction mixtures were combined for workup. The layers were separated, and the aqueous layer was extracted with DCM. The combined organic layer was dried over sodium sulfate, filtered, and concentrated to afford a crude oil. This material was dissolved in DCM and purified on silica gel column chromatography on a Teledyne Isco instrument eluting with Hex/EtOAc 0-60%. The fractions containing the material were concentrated and repurified as above eluting with Hex/EtOAc 0-40% to give tert-butyl 6-iodo-2-azaspiro[3.3]heptane-2-carboxylate (2.1 g) total combined from both parallel runs as a white solid. 1H NMR (499 MHz, CHLOROFORM-d) δ4.29 (quin, J=7.8 Hz, 1H), 3.95 (s, 2H), 3.92 (s, 2H), 2.97-2.87 (m, 2H), 2.75-2.66 (m, 2H), 1.42 (s, 9H).


Intermediate 745C: tert-butyl5-(2-(tert-butoxycarbonyl)-2-azaspiro[3.3]heptan-6-yl)-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate



embedded image


In a 100-mL round-bottom flask with a stir bar, a suspension of tert-butyl 5-bromo-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (1.57 g, 3.25 mmol), tert-butyl 6-iodo-2-azaspiro[3.3]heptane-2-carboxylate (2.1 g, 6.50 mmol), tris(trimethylsilyl)silane (1.21 g, 4.87 mmol), [Ir(dF(CF3)ppy)2(dtbbpy)]PF6 (0.036 g, 0.032 mmol), and Na2CO3 (1.38 g, 13.0 mmol) in 1,4-dioxane (30 mL) was degassed through a rubber septum with a line of nitrogen gas for 15 minutes. To a vial with a stir bar was added nickel(II) chloride ethylene glycol dimethyl ether complex (0.018 g, 0.081 mmol) and 4,4′-di-tert-butyl-2,2′-bipyridine (0.026 g, 0.097 mmol), which was purged with nitrogen gas. 1,4-Dioxane (6 mL) was added and the resulting mixture was degassed with nitrogen gas for 10 minutes and stirred. The resulting solution was then added to the reaction flask. The resulting mixture was further degassed with nitrogen gas for another 15 minutes, and then the nitrogen gas line was removed and a nitrogen balloon was affixed to the flask via a needle through the septum. The reaction vessel was secured over a stir plate with stirring, a cooling fan, and irradiation from 34 W Kessil KSH 150B blue grow lamps (12 cm apart, flask in between) for 66 hours. Upon completion, the reaction mixture was filtered, concentrated, and redissolved in DCM. The material was purified by silica gel column chromatography on a Teledyne Isco instrument eluting with Hex/EtOAc 0-60% to afford tert-butyl 5-(2-(tert-butoxycarbonyl)-2-azaspiro[3.3]heptan-6-yl)-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (1.27 g, 2.11 mmol, 65.1% yield) containing a small amount of co-eluting impurities. LCMS retention time 1.13 [TS]. MS (E+) m/z: 601.7 (M+H). 1H NMR (499 MHz, CHLOROFORM-d) δ8.35 (s, 1H), 8.34 (d, J=8.6 Hz, 1H), 8.33 (s, 1H), 7.05 (d, J=8.6 Hz, 1H), 4.05 (s, 2H), 3.96 (s, 2H), 3.60 (quin, J=8.1 Hz, 1H), 2.86-2.77 (m, 1H), 2.66 (s, 3H), 2.65-2.56 (m, 4H), 2.13 (s, 3H), 1.46-1.41 (m, 15H), 1.22 (s, 9H).


Example 745

A solution of tert-butyl 5-(2-(tert-butoxycarbonyl)-2-azaspiro[3.3]heptan-6-yl)-2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (584 mg, 0.972 mmol) in TFA (6 mL) was stirred for 2 hours at room temperature. Upon completion, the reaction mixture was concentrated and dissolved in 3/1 CHCl3/iPrOH. This organic layer was neutralized by mixing in a separatory funnel with 1.5 M aqueous K2HPO4 solution. The aqueous layer was extracted with 3/1 CHCl3/iPrOH, and the combined organic layer was dried over sodium sulfate, filtered, and concentrated to afford material considered to be quantitative recovery of 6-(3-isopropyl-5 (2-azaspiro[3.3]heptan-6-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (0.972 mmol). The majority of this material was carried forward as is. A portion (5%) of this material was purified by preparative LCMS using the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 5% B, 5-45% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS and UV signals. Fractions containing the product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 5% B, 5-55% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS signals. The fractions containing the product were combined and dried via centrifugal evaporation to afford 6-(3-isopropyl-5-(2-azaspiro[3.3]heptan-6-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (4.5 mg, 0.0106 mmol). LCMS retention time 1.05 [QC-ACN-TFA-XB]. MS (E+) m/z: 401.3 (M+H). Select NMR peaks: 1H NMR (500 MHz, DMSO-d6) δ8.76 (s, 1H), 8.46 (s, 1H), 7.59 (d, J=8.5 Hz, 1H), 6.96 (d, J=8.2 Hz, 1H), 2.93-2.83 (m, 1H), 2.58 (s, 3H), 2.15 (s, 3H), 1.39 (br d, J=6.7 Hz, 6H).


Example 746
1-(6-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2-azaspiro[3.3]heptan-2-yl)-3-(dimethylamino)propan-1-one



embedded image


To a solution of 6-(3-isopropyl-5-(2-azaspiro[3.3]heptan-6-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine (19.5 mg, 0.0486 mmol), 3-(dimethylamino)propanoic acid (18 mg, 0.154 mmol), and Et3N (0.05 mL, 0.359 mmol) in DMF (1 mL) was added T3P (0.057 mL, 0.097 mmol). The mixture was stirred at room temperature for 1.5 hours. Upon completion, the reaction was quenched. The reaction mixture was worked up by the addition of water, 1.5 M aqueous K2HPO4 solution, and DCM. The organic layer was separated, concentrated, and diluted with DMF. The material was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 10% B, 10-50% B over 25 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fraction collection was triggered by MS signals. Fractions containing the product were combined and dried via centrifugal evaporation to afford 1-(6-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-2-azaspiro[3.3]heptan-2-yl)-3-(dimethylamino)propan-1-one (6.2 mg, 0.012 mmol, 24% yield). LCMS retention time 1.31 [QC-ACN-AA-XB]. MS (E+) m/z: 500.3 (M+H). Select NMR peaks, rotamers present: 1H NMR (500 MHz, DMSO-d6) δ11.13 (br s, 1H), 8.80 (s, 1H), 8.47 (s, 1H), 7.60 (d, J=8.5 Hz, 1H), 6.97 (br d, J=8.5 Hz, 1H), 4.25 (s, 1H), 4.17 (s, 1H), 3.96 (s, 1H), 3.84 (s, 1H), 3.62-3.52 (m, 1H), 2.94-2.86(m, 1H), 2.59 (s, 3H), 2.16 (s, 6H), 2.14 (s, 3H), 1.47-1.37 (m, 6H).


The following examples were prepared according to the general procedures described in the above examples.













TABLE 2







Obs. MS




Ex. No.
Structure
Ion
RT
QC Method







737


embedded image


418.40
1.26
QC-ACN-AA-XB





738


embedded image


529.30
0.89
QC-ACN-TFA-XB





739


embedded image


543.40
1.07
QC-ACN-TFA-XB





740


embedded image


402.30
0.97
QC-ACN-TFA-XB





741


embedded image


415.90
1.29
QC-ACN-AA-XB





742


embedded image


487.20
0.96
QC-ACN-TFA-XB





743


embedded image


486.90
0.99
QC-ACN-TFA-XB





744


embedded image


430.10
1.21
QC-ACN-AA-XB





745


embedded image


401.30
1.04
QC-ACN-TFA-XB





746


embedded image


500.30
1.31
QC-ACN-AA-XB





747


embedded image


501.50
1.45
QC-ACN-AA-XB





748


embedded image


522.30
1.17
QC-ACN-TFA-XB





749


embedded image


487.20
1.55
QC-ACN-AA-XB





750


embedded image


515.40
1.02
QC-ACN-TFA-XB





751


embedded image


536.20
2.02
QC-ACN-AA-XB





752


embedded image


503.40
1.42
QC-ACN-AA-XB





753


embedded image


489.40
0.87
QC-ACN-TFA-XB





754


embedded image


487.10
1.53
QC-ACN-AA-XB





755


embedded image


444.20
1.33
QC-ACN-AA-XB





756


embedded image


473.40
1.16
QC-ACN-AA-XB





757


embedded image


418.20
1.22
QC-ACN-AA-XB





758


embedded image


489.00
1.38
QC-ACN-AA-XB





759


embedded image


475.20
1.73
QC-ACN-AA-XB





760


embedded image


503.30
0.84
QC-ACN-TFA-XB





761


embedded image


517.30
0.87
QC-ACN-TFA-XB





762


embedded image


459.40
0.76
QC-ACN-TFA-XB





763


embedded image


472.90
1.33
QC-ACN-AA-XB





764


embedded image


508.10
0.98
QC-ACN-TFA-XB





765


embedded image


522.50
0.81
QC-ACN-TFA-XB





766


embedded image


440.90
1.76
QC-ACN-AA-XB





767


embedded image


501.20
1.49
QC-ACN-AA-XB





768


embedded image


458.10
0.96
QC-ACN-TFA-XB





769


embedded image


243.60
1.44
QC-ACN-AA-XB





770


embedded image


534.10
1.64
QC-ACN-AA-XB





771


embedded image


470.10
1.66
QC-ACN-AA-XB





772


embedded image


244.00
1.50
QC-ACN-AA-XB





773


embedded image


501.20
1.48
QC-ACN-AA-XB





774


embedded image


459.10
1.58
QC-ACN-AA-XB





775


embedded image


473.40
1.20
QC-ACN-AA-XB





776


embedded image


501.00
1.42
QC-ACN-AA-XB





777


embedded image


508.40
0.99
QC-ACN-TFA-XB





778


embedded image


522.20
1.40
QC-ACN-AA-XB





779


embedded image


458.10
0.98
QC-ACN-TFA-XB





780


embedded image


486.20
1.43
QC-ACN-AA-XB





781


embedded image


534.40
0.98
QC-ACN-TFA-XB





782


embedded image


236.30
0.99
QC-ACN-TFA-XB





783


embedded image


444.40
1.40
QC-ACN-AA-XB





784


embedded image


487.50
1.33
QC-ACN-AA-XB





785


embedded image


501.50
0.82
QC-ACN-TFA-XB





786


embedded image


444.20
0.81
QC-ACN-TFA-XB





787


embedded image


497.30
0.80
QC-ACN-TFA-XB





788


embedded image


503.00
1.13
QC-ACN-TFA-XB





789


embedded image


517.40
0.92
QC-ACN-TFA-XB





790


embedded image


503.40
0.84
QC-ACN-TFA-XB





791


embedded image


475.30
0.80
QC-ACN-TFA-XB





792


embedded image


446.20
1.15
QC-ACN-TFA-XB





793


embedded image


460.30
1.10
QC-ACN-TFA-XB





794


embedded image


489.30
0.98
QC-ACN-TFA-XB





795


embedded image


538.30
1.00
QC-ACN-TFA-XB





796


embedded image


503.30
1.49
QC-ACN-AA-XB





797


embedded image


517.40
0.95
QC-ACN-TFA-XB





798


embedded image


489.00
0.86
QC-ACN-TFA-XB





799


embedded image


475.20
0.88
QC-ACN-TFA-XB





800


embedded image


475.20
0.86
QC-ACN-TFA-XB





801


embedded image


489.50
1.36
QC-ACN-AA-XB





802


embedded image


476.20
1.70
QC-ACN-AA-XB





803


embedded image


489.60
1.69
QC-ACN-AA-XB





804


embedded image


475.10
0.76
QC-ACN-TFA-XB





805


embedded image


524.50
0.71
QC-ACN-TFA-XB





806


embedded image


524.10
1.05
QC-ACN-TFA-XB





807


embedded image


474.90
1.49
QC-ACN-AA-XB





808


embedded image


489.50
1.44
QC-ACN-AA-XB





809


embedded image


461.10
1.58
QC-ACN-AA-XB





810


embedded image


443.10
2.02
QC-ACN-AA-XB





811


embedded image


502.90
1.45
QC-ACN-AA-XB





812


embedded image


475.10
1.60
QC-ACN-AA-XB





813


embedded image


460.10
1.85
QC-ACN-AA-XB





814


embedded image


474.20
1.95
QC-ACN-AA-XB





815


embedded image


536.20
1.80
QC-ACN-AA-XB





816


embedded image


446.20
1.62
QC-ACN-AA-XB





817


embedded image


510.10
1.66
QC-ACN-AA-XB





818


embedded image


489.50
1.54
QC-ACN-AA-XB





819


embedded image


525.10
1.70
QC-ACN-AA-XB





820


embedded image


487.90
1.94
QC-ACN-AA-XB





821


embedded image


418.40
1.27
QC-ACN-AA-XB





822


embedded image


404.40
1.16
QC-ACN-AA-XB





823


embedded image


503.50
1.24
QC-ACN-AA-XB





824


embedded image


501.13
1.08
QC-ACN-TFA-XB





825


embedded image


515.60
1.00
QC-ACN-TFA-XB





826


embedded image


500.90
1.13
QC-ACN-TFA-XB





827


embedded image


502.90
1.15
QC-ACN-TFA-XB





828


embedded image


487.30
1.35
QC-ACN-AA-XB





829


embedded image


501.30
1.41
QC-ACN-AA-XB





830


embedded image


460.90
0.98
QC-ACN-TFA-XB





831


embedded image


481.60
1.30
QC-ACN-AA-XB





832


embedded image


447.10
1.26
QC-ACN-AA-XB





833


embedded image


446.50
1.02
QC-ACN-TFA-XB





834


embedded image


501.20
1.42
QC-ACN-AA-XB





835


embedded image


515.40
1.57
QC-ACN-AA-XB





836


embedded image


501.10
1.00
QC-ACN-TFA-XB





837


embedded image


503.20
1.57
QC-ACN-AA-XB





838


embedded image


495.20
1.53
QC-ACN-AA-XB





839


embedded image


503.00
1.64
QC-ACN-AA-XB





840


embedded image


517.70
0.98
QC-ACN-TFA-XB





841


embedded image


460.40
1.01
QC-ACN-TFA-XB





842


embedded image


503.40
1.52
QC-ACN-AA-XB





843


embedded image


517.00
1.51
QC-ACN-AA-XB





844


embedded image


460.40
1.59
QC-ACN-AA-XB





845


embedded image


538.30
1.66
QC-ACN-AA-XB





846


embedded image


538.30
0.95
QC-ACN-TFA-XB





847


embedded image


488.90
1.56
QC-ACN-AA-XB





848


embedded image


489.20
1.56
QC-ACN-AA-XB





849


embedded image


489.20
1.52
QC-ACN-AA-XB





850


embedded image


503.20
1.41
QC-ACN-AA-XB





851


embedded image


446.00
0.92
QC-ACN-TFA-XB





852


embedded image


474.90
1.45
QC-ACN-AA-XB





853


embedded image


489.30
0.92
QC-ACN-TFA-XB





854


embedded image


501.10
1.69
QC-ACN-AA-XB





855


embedded image


245.30
1.02
QC-ACN-TFA-XB





856


embedded image


524.30
0.88
QC-ACN-TFA-XB





857


embedded image


398.20
1.12
QC-ACN-AA-XB





858


embedded image


483.10
0.78
QC-ACN-TFA-XB





859


embedded image


489.20
0.78
QC-ACN-TFA-XB





860


embedded image


517.00
1.60
QC-ACN-AA-XB





861


embedded image


418.20
0.82
QC-ACN-TFA-XB





862


embedded image


503.30
1.52
QC-ACN-AA-XB





863


embedded image


503.20
1.38
QC-ACN-AA-XB





864


embedded image


517.40
1.33
QC-ACN-AA-XB





865


embedded image


460.40
1.66
QC-ACN-AA-XB





866


embedded image


475.10
0.84
QC-ACN-TFA-XB





867


embedded image


475.10
1.56
QC-ACN-AA-XB





868


embedded image


538.20
0.93
QC-ACN-TFA-XB





869


embedded image


538.10
1.64
QC-ACN-AA-XB





870


embedded image


489.00
1.38
QC-ACN-AA-XB





871


embedded image


503.40
1.42
QC-ACN-AA-XB





872


embedded image


503.40
1.42
QC-ACN-AA-XB





873


embedded image


503.40
0.87
QC-ACN-TFA-XB





874


embedded image


517.10
1.10
QC-ACN-TFA-XB





875


embedded image


517.00
2.03
QC-ACN-AA-XB





876


embedded image


531.40
1.74
QC-ACN-AA-XB





877


embedded image


503.00
1.10
QC-ACN-TFA-XB





878


embedded image


517.50
1.48
QC-ACN-AA-XB





879


embedded image


517.40
1.40
QC-ACN-AA-XB





880


embedded image


545.40
2.02
QC-ACN-AA-XB





881


embedded image


559.50
2.53
QC-ACN-AA-XB





882


embedded image


545.20
1.85
QC-ACN-AA-XB





883


embedded image


531.20
1.51
QC-ACN-AA-XB





884


embedded image


418.30
1.23
QC-ACN-AA-XB





885


embedded image


503.10
1.43
QC-ACN-AA-XB





886


embedded image


517.00
1.02
QC-ACN-TFA-XB





887


embedded image


489.40
0.85
QC-ACN-TFA-XB





888


embedded image


483.00
1.26
QC-ACN-AA-XB





889


embedded image


477.00
1.02
QC-ACN-TFA-XB





890


embedded image


485.40
1.25
QC-ACN-AA-XB





891


embedded image


491.30
0.76
QC-ACN-TFA-XB





892


embedded image


529.50
1.39
QC-ACN-AA-XB





893


embedded image


517.50
1.48
QC-ACN-AA-XB





894


embedded image


531.50
1.00
QC-ACN-TFA-XB





895


embedded image


531.00
1.72
QC-ACN-AA-XB





896


embedded image


557.00
1.62
QC-ACN-AA-XB





897


embedded image


503.30
0.86
QC-ACN-TFA-XB





898


embedded image


517.30
1.46
QC-ACN-AA-XB





899


embedded image


515.30
0.85
QC-ACN-TFA-XB





900


embedded image


543.40
0.87
QC-ACN-TFA-XB





901


embedded image


543.40
1.35
QC-ACN-AA-XB





902


embedded image


517.30
1.37
QC-ACN-AA-XB





903


embedded image


545.40
1.15
QC-ACN-TFA-XB





904


embedded image


531.50
1.53
QC-ACN-AA-XB





905


embedded image


531.40
1.59
QC-ACN-AA-XB





906


embedded image


531.00
1.59
QC-ACN-AA-XB





907


embedded image


559.00
1.75
QC-ACN-AA-XB





908


embedded image


571.40
0.91
QC-ACN-TFA-XB





909


embedded image


561.00
1.79
QC-ACN-AA-XB





910


embedded image


559.50
1.64
QC-ACN-AA-XB





911


embedded image


545.50
1.60
QC-ACN-AA-XB





912


embedded image


545.50
1.04
QC-ACN-TFA-XB





913


embedded image


515.40
0.90
QC-ACN-TFA-XB





914


embedded image


559.50
1.52
QC-ACN-AA-XB





915


embedded image


515.30
1.38
QC-ACN-AA-XB





916


embedded image


517.30
0.81
QC-ACN-TFA-XB





917


embedded image


519.20
1.51
QC-ACN-AA-XB





918


embedded image


529.20
1.60
QC-ACN-AA-XB





919


embedded image


537.40
0.90
QC-ACN-TFA-XB





920


embedded image


555.40
1.36
QC-ACN-AA-XB





921


embedded image


527.20
1.49
QC-ACN-AA-XB





922


embedded image


515.20
0.93
QC-ACN-TFA-XB





923


embedded image


529.40
0.96
QC-ACN-TFA-XB





924


embedded image


543.40
1.00
QC-ACN-TFA-XB





925


embedded image


573.50
1.49
QC-ACN-AA-XB





926


embedded image


545.50
1.59
QC-ACN-AA-XB





927


embedded image


517.20
0.84
QC-ACN-TFA-XB





928


embedded image


529.30
1.51
QC-ACN-AA-XB





929


embedded image


557.40
1.40
QC-ACN-AA-XB





930


embedded image


575.00
1.75
QC-ACN-AA-XB





931


embedded image


543.00
1.03
QC-ACN-TFA-XB





932


embedded image


503.50
1.41
QC-ACN-AA-XB





933


embedded image


517.20
1.48
QC-ACN-AA-XB





934


embedded image


531.50
0.96
QC-ACN-TFA-XB





935


embedded image


557.40
1.47
QC-ACN-AA-XB





936


embedded image


529.50
1.44
QC-ACN-AA-XB





937


embedded image


517.30
1.10
QC-ACN-TFA-XB





938


embedded image


531.50
1.53
QC-ACN-AA-XB





939


embedded image


545.10
1.73
QC-ACN-AA-XB





940


embedded image


543.20
1.52
QC-ACN-AA-XB





941


embedded image


515.30
1.50
QC-ACN-AA-XB





942


embedded image


503.20
1.44
QC-ACN-AA-XB





943


embedded image


517.00
1.07
QC-ACN-TFA-XB





944


embedded image


531.30
1.59
QC-ACN-AA-XB





945


embedded image


571.30
0.85
QC-ACN-TFA-XB





946


embedded image


517.30
1.00
QC-ACN-TFA-XB





947


embedded image


557.00
1.03
QC-ACN-TFA-XB





948


embedded image


531.00
1.01
QC-ACN-TFA-XB





949


embedded image


533.30
1.04
QC-ACN-TFA-XB





950


embedded image


545.00
1.81
QC-ACN-AA-XB





951


embedded image


577.20
1.01
QC-ACN-TFA-XB





952


embedded image


464.00
0.98
QC-ACN-TFA-XB





953


embedded image


561.20
1.65
QC-ACN-AA-XB





954


embedded image


575.50
0.98
QC-ACN-TFA-XB





955


embedded image


561.50
1.55
QC-ACN-AA-XB





956


embedded image


543.40
1.35
QC-ACN-AA-XB





957


embedded image


543.50
1.37
QC-ACN-AA-XB





958


embedded image


571.20
1.55
QC-ACN-AA-XB





959


embedded image


619.30
1.08
QC-ACN-TFA-XB





960


embedded image


585.50
1.42
QC-ACN-AA-XB





961


embedded image


585.30
1.09
QC-ACN-TFA-XB





962


embedded image


579.30
1.92
QC-ACN-AA-XB





963


embedded image


587.20
1.85
QC-ACN-AA-XB





964


embedded image


506.30
1.54
QC-ACN-AA-XB





965


embedded image


523.40
1.46
QC-ACN-AA-XB





966


embedded image


515.60
1.01
QC-ACN-TFA-XB





967


embedded image


517.60
0.91
QC-ACN-TFA-XB





968


embedded image


487.20
1.46
QC-ACN-AA-XB





969


embedded image


505.20
1.24
QC-ACN-AA-XB





970


embedded image


475.50
0.92
QC-ACN-TFA-XB





971


embedded image


545.40
1.25
QC-ACN-AA-XB





972


embedded image


432.10
1.25
QC-ACN-AA-XB





973


embedded image


416.10
1.29
QC-ACN-AA-XB





974


embedded image


430.00
1.44
QC-ACN-AA-XB





975


embedded image


223.90
1.28
QC-ACN-TFA-XB





976


embedded image


418.10
1.07
QC-ACN-TFA-XB





977


embedded image


418.10
1.08
QC-ACN-TFA-XB





978


embedded image


402.10
1.01
QC-ACN-TFA-XB





979


embedded image


416.10
1.31
QC-ACN-AA-XB





980


embedded image


416.10
1.02
QC-ACN-TFA-XB





981


embedded image


402.10
0.99
QC-ACN-TFA-XB





982


embedded image


416.20
1.31
QC-ACN-AA-XB





983


embedded image


432.10
1.19
QC-ACN-TFA-XB





984


embedded image


402.10
1.01
QC-ACN-TFA-XB





985


embedded image


402.10
1.32
QC-ACN-AA-XB





986


embedded image


432.40
1.45
QC-ACN-AA-XB





987


embedded image


420.00
1.27
QC-ACN-AA-XB





988


embedded image


418.40
1.36
QC-ACN-AA-XB





989


embedded image


404.40
1.25
QC-ACN-AA-XB





990


embedded image


418.40
1.26
QC-ACN-AA-XB





991


embedded image


418.20
1.50
QC-ACN-AA-XB





992


embedded image


432.30
0.94
QC-ACN-TFA-XB





993


embedded image


418.50
1.37
QC-ACN-AA-XB





994


embedded image


420.00
1.20
QC-ACN-AA-XB





995


embedded image


418.10
1.15
QC-ACN-AA-XB





996


embedded image


502.30
0.81
QC-ACN-TFA-XB





997


embedded image


503.30
0.81
QC-ACN-TFA-XB





998


embedded image


524.20
0.82
QC-ACN-TFA-XB





999


embedded image


418.10
1.00
QC-ACN-TFA-XB





1000 


embedded image


434.30
1.00
QC-ACN-TFA-XB





1001 


embedded image


364.00
1.09
QC-ACN-AA-XB





1002 


embedded image


449.10
0.79
QC-ACN-TFA-XB





1003 


embedded image


444.30
0.81
QC-ACN-TFA-XB





1004 


embedded image


473.90
0.99
QC-ACN-TFA-XB





1005 


embedded image


473.50
1.07
QC-ACN-AA-XB





1006 


embedded image


500.90
1.32
QC-ACN-AA-XB





1007 


embedded image


522.10
1.44
QC-ACN-AA-XB





1008 


embedded image


440.90
1.57
QC-ACN-AA-XB





1009 


embedded image


458.20
1.36
QC-ACN-AA-XB





1010 


embedded image


472.20
1.53
QC-ACN-AA-XB





1011 


embedded image


458.20
0.76
QC-ACN-TFA-XB





1012 


embedded image


486.20
0.79
QC-ACN-TFA-XB





1013 


embedded image


460.20
1.02
QC-ACN-TFA-XB





1014 


embedded image


455.10
1.44
QC-ACN-AA-XB





1015 


embedded image


444.20
0.83
QC-ACN-TFA-XB





1016 


embedded image


404.20
1.06
QC-ACN-AA-XB





1017 


embedded image


418.20
1.13
QC-ACN-AA-XB





1018 


embedded image


432.10
1.00
QC-ACN-TFA-XB





1019 


embedded image


446.20
1.32
QC-ACN-AA-XB





1020 


embedded image


446.20
1.27
QC-ACN-AA-XB





1021 


embedded image


476.20
1.23
QC-ACN-AA-XB





1022 


embedded image


415.10
1.35
QC-ACN-AA-XB





1023 


embedded image


443.20
1.46
QC-ACN-AA-XB





1024 


embedded image


485.20
1.44
QC-ACN-AA-XB





1025 


embedded image


485.20
1.37
QC-ACN-AA-XB





1026 


embedded image


507.30
1.46
QC-ACN-AA-XB





1027 


embedded image


971.40
1.51
QC-ACN-AA-XB





1028 


embedded image


473.10
1.34
QC-ACN-AA-XB





1029 


embedded image


472.30
0.93
QC-ACN-TFA-XB





1030 


embedded image


521.30
1.31
QC-ACN-AA-XB





1031 


embedded image


459.30
0.82
QC-ACN-TFA-XB





1032 


embedded image


475.30
1.45
QC-ACN-AA-XB





1033 


embedded image


529.40
1.27
QC-ACN-AA-XB





1034 


embedded image


503.00
1.43
QC-ACN-AA-XB









Example 1035
1-(aminomethyl)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexan-1-ol



embedded image


Intermediate 1035A: 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-1-(nitromethyl)cyclohexanol




embedded image


To a 2 dram vial were added 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexan-1-one (0.200 g, 0.498 mmol), MeOH (5 mL), diethylamine (0.052 mL, 0.498 mmol) and nitromethane (0.269 mL, 4.98 mmol). Next, 20μL of water was added and the reaction mixture was stirred for 5 days at 25° C. The reaction mixture was concentrated under a stream of nitrogen gas, diluted with water and stirred for 30 minutes. The white precipitate was filtered off and washed with water and dried through air to afford 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-1-(nitromethyl)cyclohexanol (0.200 g, 0.552 mmol, 100% yield) as a white solid. LCMS retention time 0.64 min [Method A]. MS m/z: 363.2 (M+H).


Example 1035

To a Parr bottle were added 4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-1-(nitromethyl)cyclohexanol, and 1:1 ethyl acetate: MeOH (7 mL). The vessel was purged with nitrogen gas and 10% Pd-C (0.053 g, 0.050 mmol) was added. The bottle was placed on the Parr apparatus and pump/purged with nitrogen gas three times and back-filled with hydrogen gas. The reaction vessel was set to shake for 6 hours at 40 psi. The reaction mixture was diluted with MeOH and then filtered through a pad of Celite and concentrated. The residue was suspended in DMF (2 mL), filtered through a 0.45 micron nylon syringe filter. The crude material was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm×19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 6% B, 6-42% B over 28 minutes, then a 6-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25° C. Fractions containing the product were combined and dried via centrifugal evaporation to afford 1-(aminomethyl)-4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)cyclohexan-1-ol (0.8 mg, 0.00185 mmol, 0.4% yield), m/z (432.9, M+H). Retention time, 1.253 min using LCMS Column: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7 μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM. 1NMR (500 MHz, DMSO-d6) δ11.15-10.98 (m, 1H), 8.79 (s, 1H), 8.47 (s, 1H), 7.60 (br d, J=8.5 Hz, 1H), 7.08-6.93 (m, 1H), 4.80-4.80 (m, 1H), 3.33-3.19 (m, 1H), 2.91 (br d, J=7.0 Hz, 2H), 2.68 (br d, J=7.0 Hz, 3H), 2.17 (s, 3H), 2.06-1.93 (m, 2H), 1.89 (s, 3H), 1.70 (br t, J=15.9 Hz, 4H), 1.40 (br d, J=6.4 Hz, 8H).


The following examples were prepared according to the general procedures described in the above examples.













TABLE 3





Ex.

Obs. MS

QC


No.
Structure
Ion
RT
Method







1035


embedded image


433.10
1.24
QC- ACN- AA-XB





1036


embedded image


470.30
1.27
QC- ACN- AA-XB





1037


embedded image


487.30
0.75
QC- ACN- TFA- XB





1038


embedded image


487.40
0.82
QC- ACN- TFA- XB





1039


embedded image


487.40
0.82
QC- ACN- TFA- XB





1040


embedded image


471.40
1.00
QC- ACN- TFA- XB





1041


embedded image


473.20
1.38
QC- ACN- AA-XB





1042


embedded image


473.40
1.39
QC- ACN- AA-XB





1043


embedded image


535.10
0.99
QC- ACN- TFA- XB





1044


embedded image


473.30
0.84
QC- ACN- TFA- XB





1045


embedded image


473.30
1.01
QC- ACN- TFA- XB





1046


embedded image


459.30
0.81
QC- ACN- TFA- XB





1047


embedded image


514.10
1.22
QC- ACN- AA-XB





1048


embedded image


459.00
1.08
QC- ACN- TFA- XD





1049


embedded image


459.10
0.75
QC- ACN- TFA- XB





1050


embedded image


514.40
0.87
QC- ACN- TFA- XB





1051


embedded image


443.10
1.45
QC- ACN- AA-XB





1052


embedded image


471.10
1.04
QC- ACN- TFA- XB





1053


embedded image


533.50
0.56
A1





1054


embedded image


459.50
1.54
QC- ACN- AA-XB





1055


embedded image


485.50
1.45
QC- ACN- AA-XB





1056


embedded image


459.10
1.48
QC- ACN- AA-XB





1057


embedded image


485.20
0.81
QC- ACN- TFA- XB





1058


embedded image


475.00
1.59
QC- ACN- AA-XB





1059


embedded image


513.40
0.85
QC- ACN- TFA- XB





1060


embedded image


499.10
1.41
QC- ACN- AA-XB





1061


embedded image


499.40
0.83
QC- ACN- TFA- XB





1062


embedded image


475.00
1.80
QC- ACN- AA-XB





1063


embedded image


499.40
1.02
QC- ACN- TFA- XB





1064


embedded image


473.00
1.82
QC- ACN- AA-XB





1065


embedded image


499.20
1.61
QC- ACN- AA-XB





1066


embedded image


513.50
0.85
QC- ACN- TFA- XB





1067


embedded image


477.20
0.77
QC- ACN- TFA- XB





1068


embedded image


501.30
0.78
QC- ACN- TFA- XB





1069


embedded image


501.00
0.99
QC- ACN- TFA- XB





1070


embedded image


501.00
1.00
QC- ACN- TFA- XB





1071


embedded image


475.30
1.52
QC- ACN- AA-XB





1072


embedded image


477.40
0.81
QC- ACN- TFA- XB





1073


embedded image


501.30
0.79
QC- ACN- TFA- XB





1074


embedded image


487.00
1.45
QC- ACN- AA-XB





1075


embedded image


486.90
1.59
QC- ACN- AA-XB





1076


embedded image


533.30
1.70
QC- ACN- AA-XB





1077


embedded image


533.10
0.80
QC- ACN- TFA- XB





1078


embedded image


403.10
1.43
QC- ACN- AA-XB









Biological Assays


The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays. The exemplified biological assays, which follow, have been carried out with compounds of the invention.


TLR7/8/9 Inhibition Reporter Assays

HEK-Blue™-cells (Invivogen) overexpressing human TLR7, TLR8 or TLR9 receptors were used for screening inhibitors of these receptors using an inducible SEAP (secreted embryonic alkaline phosphatase) reporter gene under the control of the IFN-β minimal promoter fused to five NF-κB and AP-1-binding sites. Briefly, cells are seeded into Greiner 384 well plates (15000 cells per well for TLR7, 20,000 for TLR8 and 25,000 for TLR9) and then treated with test compounds in DMSO to yield a final dose response concentration range of 0.05 nM-50 μM. After a 30 minute compound pre-treatment at room temperature, the cells are then stimulated with a TLR7 ligand (gardiquimod at a final concentration of 7.5 TLR8 ligand (R848 at a final concentration of 15.9 p.M) or TLR9 ligand (ODN2006 at a final concentration of 5 nM) to activate NF-κB and AP-1 which induce the production of SEAP. After a 22 hour incubation at 37° C., 5% CO2, SEAP levels are determined with the addition of HEK-Blue™ Detection reagent (Invivogen), a cell culture medium that allows for detection of SEAP, according to manufacturer's specifications. The percent inhibition is determined as the % reduction in the HEK-Blue signal present in wells treated with agonist plus DMSO alone compared to wells treated with a known inhibitor.









TABLE 4







TLR7/8/9 Reporter Assay Data













TLR7
TLR8
TLR9



Ex.
IC50
IC50
IC50



No.
(nM)
(nM)
(nM)
















1
20
3.8
7734



2
1.7
0.27
7325



3
0.93
1.1
8542



4
0.60
0.71
1072



5
471
4063
37



6
0.30
3.2
625



7
4.4
52
8124



8
4.7
21
8554



9
1.7
8.2
2248



10
0.42
5.3
1053



11
1.7
21
6794



12
10
1.6
10102



13
3.2
1.9
5020



14
11
4.2
4331



15
7.3
4.3
1940



16
0.60
2.1
635



17
3.7
7.7
1097



18
14
14
1494



19
125
73
6023



20
2.7
1.3
614



21
91
46
>50000



22
56
12
21148



23
>3125
>3125
>50000



24
40
2.7
13976



25
181
117
11662



26
1769
2131
>50000



27
>3125
>3125
>50000



28
263
1496
>50000



29
4.6
2.7
2832



30
70
43
22593



31
13
19
6059



32
7.3
6.9
1883



33
6.5
1.9
1915



34
17
6.0
1218



35
589
282
13783



36
>3125
>3125
22084



37
1269
465
>50000



38
21
5.2
44362



39
40
4.8
NT



40
24
1.7
7956



41
264
177
>50000



42
178
57
>50000



43
2.0
7.8
560



44
12
15
3374



45
22
20
7280



46
4.3
4.9
1682



47
NT
NT
NT



48
7.4
9.3
31274



49
1.0
0.62
2673



50
0.49
0.39
2839



51
5.1
7.0
16309



52
7.9
20
NT



53
0.62
0.23
1988



54
2.9
2.8
10376



55
2.1
0.39
3340



56
2.0
1.1
6340



57
7.4
1.3
5070



58
1.3
0.72
1969



59
1.3
1.1
2376



60
5.6
5.9
20242



61
4.4
1.8
2411



62
3.8
1.5
11497



63
7.4
4.0
42357



64
3.8
1.6
5084



65
1.9
1.3
25112



66
1.4
0.98
3870



67
0.98
0.42
963



68
1.4
0.79
6300



69
1310
1314
25816



70
2.3
1.2
2967



71
99
31
3897



72
2.9
0.90
3416



73
29
5.7
24942



74
2468
2562
>50000



75
18
9.8
>50000



76
34
15
>50000



77
4.8
2.0
11648



78
3.7
10
3171



79
373
355
9724



80
1.3
1.6
4558



81
1.3
0.95
20099



82
0.77
0.41
6376



83
3.6
6.9
5445



84
2196
>3125
>50000



85
1.8
5.8
5178



86
7.5
2.9
>50000



87
3.5
0.58
>50000



88
68
91
3595



89
0.51
0.59
3258



90
0.57
4.2
4999



91
0.68
0.53
6311



92
0.87
0.78
3992



93
5.3
7.2
35043



94
1.0
1.4
9352



95
4.9
3.6
>50000



96
1.5
0.28
9430



97
28
4.1
>50000



98
0.74
0.72
5226



99
0.51
2.9
4303



100
3.2
0.55
6146



101
3.7
0.25
6402



102
12
5.1
>50000



103
7.3
2.6
NT



104
2.3
0.75
4161



105
3.9
0.15
9237



106
2.2
0.28
7779



107
2.2
0.37
5627



108
2.5
0.99
3512



109
3.6
1.3
8014



110
1.9
0.76
4544



111
NT
NT
NT



112
2.2
1.2
6009



113
1.4
0.95
3363



114
4.7
1.8
7590



115
1.2
0.49
3482



116
9.7
5.0
35642



117
1.4
0.81
5643



118
1.8
0.86
5581



119
1.8
0.96
14141



120
2.3
0.60
5487



121
3.4
0.80
6348



122
1.7
1.1
7251



123
1.9
6.3
8648



124
1.2
4.7
5786



125
2.6
0.66
6544



126
5.9
1.5
6117



127
4.6
0.48
5898



128
5.4
2.6
35374



129
6.7
1.3
22827



130
4.3
4.7
>50000



131
3.3
0.63
8572



132
2.8
0.51
7393



133
4.3
1.4
>50000



134
3.7
1.1
26146



135
4.7
1.6
13167



136
5.7
0.79
8223



137
5.6
1.3
8446



138
11
4.6
>50000



139
37
14
>50000



140
127
186
>50000



141
134
148
>50000



142
107
45
>50000



143
7.8
4.5
>50000



144
8.4
1.2
>50000



145
1.5
0.49
8201



146
5.6
2.5
12892



147
5.0
0.26
18656



148
97
16
>50000



149
9.3
0.40
19497



150
12
2.7
>50000



151
1.2
1.2
11995



152
2.7
1.6
5877



153
0.87
1.6
7150



154
1919
600
>50000



155
401
56
>50000



156
1.5
0.79
6752



157
2.2
1.2
8844



158
2.3
0.96
8256



159
2.4
1.0
7735



160
1.8
1.2
10645



161
1.4
0.92
5918



162
2.8
2.8
23098



163
9.7
5.0
24797



164
33
2.0
19767



165
11
0.68
22656



166
1.5
18
2189



167
0.43
1.7
156



168
0.89
3.4
658



169
3.1
21
1224



170
2.0
17
1411



171
0.45
1.8
560



172
1.9
13
1792



173
2.0
10
578



174
4.3
37
1468



175
0.35
2.0
926



176
5.2
84
16006



177
0.28
2.5
148



178
0.48
1.8
895



179
0.92
7.0
1741



180
2.8
11
1871



181
1.7
13
561



182
0.48
1.1
301



183
5.6
15
1031



184
8.8
18
2054



185
38
110
10316



186
2.2
9.3
1011



187
2.1
20
4221



188
0.29
2.5
158



189
1.6
6.7
313



190
0.80
2.8
353



191
0.90
2.7
202



192
3.1
19
1106



193
1.5
6.0
648



194
8.6
47
3594



195
0.80
4.3
530



196
1.7
10
712



197
0.34
1.7
134



198
1.0
7.8
1142



199
0.16
6.4
1189



200
1.8
8.5
773



201
1.5
6.0
570



202
3.8
28
2030



203
2.0
7.9
537



204
0.98
2.9
1332



205
0.42
1.0
134



206
9.5
22
2389



207
1.9
4.4
253



208
2.2
16
1350



209
0.71
4.0
641



210
>3125
>3125
>50000



211
1.1
6.8
585



212
3.4
6.8
1192



213
9.5
17
706



214
3.9
6.3
833



215
6.0
7.6
2254



216
5.1
18
416



217
5.0
8.6
522



218
8.5
20
389



219
3.9
8.0
2484



220
6.7
6.1
1020



221
3.7
13
435



222
5.8
21
657



223
0.60
1.4
485



224
1.5
4.2
718



225
4.0
35
3360



226
2.7
14
1790



227
2.0
7.7
926



228
3.3
23
2387



229
19
18
1709



230
38
33
2460



231
0.61
3.0
365



232
3.0
9.8
484



233
11
24
2662



234
1.6
5.0
435



235
1.0
2.0
929



236
3.9
2.8
376



237
20
19
18183



238
0.71
0.97
297



239
106
181
>50000



240
5.4
16
5076



241
2.0
2.9
1754



242
1.5
15
2407



243
7.6
9.5
999



244
1.6
8.2
2349



245
2.7
4.7
343



246
1.9
2.6
4283



247
1.2
1.2
825



248
1.5
13
1785



249
25
7.3
5978



250
26
57
13721



251
8.6
13
1754



252
8.0
10
7255



253
0.65
0.72
1149



254
72
27
8734



255
0.60
0.25
218



256
1.2
3.7
335



257
35
25
175



258
13
3.5
100



259
19
7.1
321



260
527
173
10867



261
262
90
381



262
170
19
354



263
6.2
7.6
338



264
55
42
255



265
0.59
0.91
392



266
45
13
322



267
1.9
2.6
453



268
94
32
578



269
223
88
670



270
38
28
322



271
120
40
228



272
76
50
398



273
75
66
1114



274
8.5
3.7
474



275
14
8.5
684



276
8.9
9.0
309



277
0.40
1.6
1378



278
1.5
1.2
837



279
0.31
1.4
1817



280
1.1
7.2
1268



281
0.48
1.7
880



282
0.32
0.91
661



283
0.92
1.4
298



284
3.0
15
4038



285
3.6
5.5
2310



286
5.2
9.2
1566



287
25
33
2361



288
28
114
6454



289
3.5
11
967



290
2.1
6.3
425



291
2.6
11
735



292
99
127
1615



293
75
208
5641



294
85
174
2270



295
11
11
883



296
0.59
6.8
600



297
8.4
15
885



299
10
6.0
680



300
48
286
9048



301
2.0
42
4089



302
0.74
4.9
739



303
0.55
6.9
1233



304
0.53
1.8
1068



305
4.0
16
8237



306
13
61
10058



307
0.86
2.7
2978



308
11
11
3965



309
0.31
4.6
268



310
0.39
4.1
1782



311
2.8
44
2017



312
0.26
1.6
577



313
0.21
7.0
1200



314
2.4
47
5508



315
1.8
29
5223



316
1.4
41
3018



317
4.8
94
3611



318
0.17
2.1
1060



319
0.44
4.1
1690



320
1.0
22
1480



321
NT
3.0
1041



322
1.7
19
7409



323
1.1
31
1357



324
6.6
240
20509



325
1.5
38
3110



326
0.13
3.7
988



327
>3125
>3125
>50000



328
0.08
1.1
576



329
1.6
23
2066



330
0.14
4.8
2970



331
1.7
34
1914



332
1.3
88
2663



333
0.60
12
1456



334
4.6
127
2400



335
NT
4.0
1927



336
2.8
48
3439



337
21
350
>50000



338
81
1170
>50000



339
0.20
7.1
5888



340
1.4
51
1869



341
0.12
0.32
2643



342
0.98
3.9
1906



343
0.19
0.54
1251



344
0.72
4.8
2789



345
0.21
0.68
1675



346
0.32
6.0
6294



347
0.27
1.0
2466



348
0.82
8.3
6961



349
7.7
63
>50000



350
0.72
1.0
1155



351
2.3
4.3
1688



352
5.4
9.2
2321



353
0.64
0.96
940



354
1.0
2.3
790



355
2.6
10
4497



356
2.8
5.1
2865



357
3.9
4.4
1050



358
0.95
2.8
1325



359
9.1
29
4870



360
1.3
3.4
1414



361
0.79
1.0
1251



362
1.6
5.1
1634



363
3.3
6.6
1476



364
1.5
9.6
2523



365
4.2
7.9
3197



366
5.3
15
4693



367
1.5
3.5
838



368
1.5
2.5
1612



369
0.46
1.3
402



370
8.6
23
>50000



371
6.0
14
4358



372
3.2
7.6
1464



373
8.6
8.3
1956



374
36
187
21615



375
0.87
4.4
2716



376
0.71
1.2
1027



377
2.1
2.2
767



378
1.6
4.6
1636



379
2.6
4.7
909



380
1.4
1.6
1878



381
3.7
5.5
8062



382
7.8
22
>50000



383
33
167
>50000



384
13
25
1526



385
22
46
11236



386
1.5
4.2
1440



387
7.2
19
5513



388
0.87
2.2
891



389
0.45
1.6
923



390
1.6
7.6
3094



391
2.6
14
2451



392
3.2
6.1
1746



393
0.47
1.3
360



394
1.4
1.5
1412



395
7.4
10
1621



396
1.7
17
1531



397
6.3
10
2402



398
3.8
17
4119



399
0.83
1.8
988



400
0.74
2.9
1549



401
5.7
6.4
5719



402
31
43
5146



403
7.7
44
4281



404
3.8
9.3
1544



405
3.6
2.5
1425



406
1.4
3.0
1466



407
7.2
8.5
2457



408
18
43
6440



409
1.7
1.6
550



410
5.0
6.5
4925



411
6.3
8.0
2297



412
2.2
2.1
727



413
17
18
4737



414
5.1
12
1756



415
2.5
3.5
1240



416
0.85
1.2
1622



417
5.2
7.1
9504



418
NT
3.9
2865



419
4.1
2.5
1744



420
1.2
2.8
3530



421
1.6
1.8
2058



422
15
35
6239



423
175
83
>50000



424
0.89
0.74
1531



425
0.87
0.50
2915



426
2.5
2.6
1398



427
2.4
7.6
4904



428
7.4
6.4
9858



429
3.4
5.2
7002



430
13
14
15105



431
16
11
4657



432
0.37
0.55
584



433
42
60
>50000



434
1.5
2.4
7432



435
2.7
5.5
2176



436
8.9
27
8941



437
5.1
11
3752



438
0.77
0.39
1458



439
3.5
32
24228



440
6.4
14
>50000



441
0.79
0.63
1660



442
3.7
3.5
18317



443
15
57
NT



444
16
5.2
39175



445
1.5
3.6
4887



446
0.91
0.91
364



447
1.7
2.3
1637



448
7.5
24
7692



449
323
165
17986



450
0.61
0.71
1193



451
0.48
0.63
1045



452
2.7
4.4
3091



453
4.0
3.3
1440



454
1.2
0.68
2393



455
14
12
9203



456
2.6
8.1
7726



457
0.32
0.30
622



458
5.0
10
9840



459
6.2
4.3
2790



460
0.88
0.79
2063



461
2.6
1.7
8471



462
6.9
8.4
4538



463
7.4
24
16002



464
0.68
0.85
1774



465
1.1
1.9
5660



466
59
204
5796



467
1.2
3.5
413



468
46
99
NT



469
0.98
2.9
1709



470
1.3
6.0
7422



471
2.8
3.2
4706



472
0.34
1.1
2511



473
7.1
9.6
7373



474
0.46
0.43
1450



475
1.4
2.2
3504



476
0.81
2.6
9749



477
8.3
6.0
6162



478
13
15
24545



479
2.9
10
23712



480
2.0
14
11749



481
0.82
3.9
13037



482
96
238
>50000



483
0.94
1.2
5126



484
6.1
11
7071



485
1.1
2.2
2516



486
1.2
1.9
2367



487
0.75
0.49
2289



488
11
8.4
5364



489
20
20
6674



490
1.2
3.4
2127



491
0.89
8.0
677



492
1.4
1.9
1478



493
1755
3791
>50000



494
5.2
2.8
14070



495
3.3
1.3
3603



496
7.5
2.1
2615



497
52
67
>50000



498
NT
NT
NT



499
607
833
>50000



500
19
39
>50000



501
6.3
16
9553



502
0.79
5.1
2897



503
1.4
9.2
2503



504
0.55
0.64
3743



505
3.5
4.9
7601



506
0.41
0.42
3183



507
1.1
2.4
8492



508
1.1
3.3
6846



509
17
30
9105



510
5.9
28
>50000



511
5.8
4.8
>50000



512
1.1
5.6
304



513
319
307
545



514
38
44
7111



515
7.9
21
223



516
0.22
1.9
155



517
1.1
6.0
150



518
1.6
32
721



519
8.3
12
362



520
0.80
7.0
285



521
0.62
1.3
238



522
2.6
495
144



523
1.2
147
1470



524
0.88
6.7
407



525
0.18
48
771



526
8.8
14
666



527
7.3
3.0
1157



528
NT
23
5701



529
2.9
12
1833



530
7.1
8.8
4764



531
19
21
1289



532
0.58
4.4
3594



533
0.50
3.3
1459



534
1.2
8.0
4276



535
2.0
8.6
5717



536
0.66
4.1
2659



537
2.1
7.1
2853



538
2.0
3.3
8184



539
0.47
0.82
3322










540
1.1
1.4
1951



541
1.2
0.36
1429



542
24
17
9235



543
14
5.3
2279



544
11
6.4
5660



545
22
7.5
2464



546
9.5
1.6
1379



547
0.27
0.55
789



548
0.71
0.98
1090



549
1.8
18
401



550
0.87
15
796



551
0.94
5.5
582



552
0.83
2.1
4099



553
0.63
3.2
537



554
1.5
2.5
2861



555
0.85
3.0
341



556
1.7
1.1
5079



557
0.66
1.2
440



558
1.2
5.6
3427



559
0.72
4.6
4923



560
1.2
1.0
3821



561
0.64
3.0
5653



562
1.9
1.1
6484



563
0.83
2.4
4257



564
7.9
4.2
1764



565
8.8
6.9
3224



566
24
18
18988



567
18
18
2325



568
6.0
3.8
2081



569
11
3.0
2183



570
10
57
143



571
7.5
2.1
813



572
4.6
25
1197



573
0.99
9.1
3234



574
3.0
47
11936



575
0.44
121
1352



576
NT
NT
NT



577
0.69
7.4
1881



578
0.53
287
4190



579
0.39
79
1838



580
0.41
8.7
1789



581
0.30
79
4920



582
0.99
12
7463



583
0.32
5.1
1552



584
0.24
29
2006



585
0.46
8.6
1839



586
0.75
98
2897



587
0.31
27
1408



588
2.3
42
16107



589
0.25
62
1062



590
3.0
4.7
3549



591
4.8
7.7
2852



592
2.9
7.4
2244



593
1.4
2.6
974



594
3.9
16
7906



595
122
>3125
10867



596
13
67
3204



597
1.3
1.2
918



598
0.81
3.1
949



599
2.7
4.8
3047



600
0.75
6.2
2051



601
46
46
>50000



602
1.2
6.8
1430



603
1.5
5.2
1190



604
2.8
2.5
5914



605
13
17
4244



606
2.3
3.9
1711



607
2.1
2.6
1142



608
1.1
6.1
1713



609
2.6
23
2718



610
1.5
14
1771



611
8.4
17
1933



612
13
56
3927



613
2.0
3.2
1243



614
1.9
13
1014



615
2.4
7.9
1958



616
3.6
1.5
1282



617
2219
1325
20509



618
4.8
4.6
3699



619
0.43
3.0
865



620
0.73
2.4
223



621
7.0
7.5
14661



622
30
14
5071



623
1.6
2.0
3127



624
3.0
2.0
2568



625
0.72
10
978



626
29
8.0
13454



627
7.9
18
4504



628
2.1
3.3
343



629
2.6
6.5
1920



630
1.9
14
1284



631
4.0
1.9
3067



632
3.1
2.2
439



633
40
33
25537



634
2.0
3.0
2374



635
5.7
1.1
1785



636
46
28
21593



637
3.8
0.53
1359



638
2.9
7.3
1272



639
0.98
1.9
1472



640
4.9
4.9
13508



641
9.2
3.5
3344



642
14
26
18090



643
5.4
5.3
3170



644
2.7
4.5
2690



645
21
303
4087



646
2.1
11
4140



647
2.3
26
5888



648
2.1
40
2073



649
6.2
10
3283



650
6.7
18
3125



651
1.7
24
687



652
3.0
22
1600



653
5.5
13
13221



654
6.4
9.6
4917



655
1.4
11
2069



656
1.4
4.7
1853



657
2.1
10
842



658
3.8
8.2
13603



659
12
24
8538



660
3.3
15
14410



661
2.3
5.5
13871



662
1.8
1.0
9030



663
3.5
9.9
21144



664
22
14
38509



665
34
17
>50000



666
0.73
1.6
6563



667
145
711
>50000



668
1.7
22
17531



669
7.4
5.6
31553



670
56
58
>50000



671
1.4
2.1
4480



672
4.7
90
6244



673
5.2
6.9
14419



674
32
48
>50000



675
9.7
4.6
14462



676
1.0
2.5
5718



677
17
53
>50000



678
36
29
>50000



679
16
5.8
20652



680
12
5.2
1058



681
104
199
4236



682
16
24
1052



683
12
13
322



684
14
13
365



685
32
39
1576



686
>3125
>3125
>50000



687
39
16
5774



688
8.4
23
177



689
11
42
433



690
15
31
288



691
11
9.2
315



692
43
58
1528



693
6.5
15
437



694
2309
2850
14611



695
42
20
3952



696
75
36
1311



697
20
111
919



698
12
28
1004



699
12
46
430



700
26
43
2328



701
49
15
1748



702
41
14
2228



703
8.9
16
326



704
11
13
166



705
18
15
655



706
8.5
18
1020



707
1.5
5.3
1412



708
12
280
>50000



709
2330
>3125
>50000



710
2.0
3.2
4665



711
2.0
2.9
1699



712
1.9
11
3145



713
6.2
28
4878



714
1.8
9.3
203



715
1.7
11
8707



716
0.74
6.7
2526



717
1062
1101
2525



718
9.6
3.6
6211



719
2.8
7.0
2596



720
13
94
20336



721
0.41
0.53
982



722
6.5
46
18477



723
0.99
2.4
4391



724
0.63
2.0
2194



725
0.62
1.9
2059



726
1357
2090
39366



727
3.6
3.2
3352



728
0.74
0.67
3538



729
1.1
1.3
1941



730
3.3
23
10526



731
4.6
15
1640



732
10
70
4834



733
53
1014
>50000



734
26
252
>50000



735
25
61
262



736
631
269
>50000



737
0.59
0.55
7774



738
0.46
0.89
6226



739
0.85
1.6
5324



740
2.2
5.1
623



741
1.9
6.5
3034



742
2.9
3.1
4580



743
3.6
8.4
1881



744
2.0
7.1
3058



745
2.2
5.8
2446



746
1.1
10
3106



747
0.59
4.1
7379



748
7.5
15
37886



749
2.9
2.6
14893



750
1.2
3.7
6145



751
13
7.3
26035



752
0.38
0.53
10266



753
3.8
12
27862



754
5.2
1.7
5432



755
2.8
6.2
3734



756
3.9
6.0
9055



757
0.70
1.9
5215



758
0.89
1.7
18200



759
3.8
14
38197



760
4.2
27
7629



761
9.0
14
8170



762
3.8
8.6
18318



763
3.8
2.6
4579



764
1.9
2.8
14428



765
5.6
3.5
10263



766
0.86
1.2
3512



767
5.4
2.9
8300



768
6.4
9.6
20957



769
1.3
4.5
5569



770
11
24
18183



771
4.3
9.2
9843



772
3.2
10
4713



773
3.0
4.6
2706



774
3.7
5.7
18596



775
3.8
4.4
8447



776
6.0
5.3
13088



777
9.2
7.4
14795



778
2.7
2.3
7908



779
7.3
11
34519



780
1.9
5.4
5225



781
11
18
14380



782
1.3
4.7
5736



783
1.8
3.9
8377



784
2.9
9.4
4527



785
8.0
13
4684



786
7.7
12
14676



787
9.4
4.9
12254



788
2.1
3.2
8302



789
3.2
3.7
13321



790
0.42
0.85
8810



791
5.3
1.1
18146



792
4.0
1.0
8555



793
1.4
1.4
7829



794
1.4
1.5
18048



795
12
8.1
>50000



796
6.0
15
11322



797
10
14
17578



798
4.2
5.7
22334



799
5.0
21
>50000



800
20
26
>50000



801
0.57
0.56
10960



802
3.0
0.65
17918



803
4.3
4.0
39663



804
1.2
0.56
18116



805
2.1
0.57
24156



806
1.1
1.1
29426



807
0.95
1.3
16263



808
0.19
1.4
8946



809
2.2
3.1
35999



810
0.64
0.63
7355



811
0.36
0.59
5596



812
2.2
3.6
>50000



813
3.7
9.1
>50000



814
1.9
2.3
>50000



815
1.8
1.4
>50000



816
1.7
1.7
8723



817
2.1
2.9
>50000



818
0.78
0.43
12846



819
2.2
0.58
21064



820
2.7
2.0
9396



821
1.3
1.3
6694



822
1.1
0.24
6914



823
0.49
1.2
6932



824
1.6
2.1
5791



825
0.53
1.1
6277



826
0.70
1.0
15739



827
0.46
0.34
4852



828
0.88
1.4
7157



829
3.7
12
17264



830
0.62
0.63
7443



831
1.5
2.3
8550



832
4.0
2.3
16779



833
1.9
4.9
9782



834
0.46
2.5
4367



835
0.70
4.1
5560



836
2.4
4.1
16449



837
0.70
1.6
7822



838
0.60
3.5
9891



839
0.37
3.2
7869



840
0.38
1.5
7401



841
5.6
28
14253



842
0.38
0.47
6919



843
0.52
1.4
5479



844
2.0
11
8817



845
7.2
14
21276



846
0.55
1.2
22620



847
4.9
8.3
22521



848
1.2
2.2
17494



849
0.53
1.6
8120



850
0.72
1.6
6540



851
5.9
2.2
9978



852
5.2
0.82
16163



853
0.51
0.66
9571



854
11
5.0
32272



855
2.4
4.6
14322



856
7.3
0.46
27144



857
0.65
0.40
4396



858
1.1
1.3
7132



859
0.97
1.5
7308



860
0.30
0.62
5062



861
0.31
4.2
5010



862
0.29
2.2
7037



863
0.52
17
6065



864
1.5
12
5693



865
1.3
72
8891



866
3.2
74
47596



867
4.5
11
>50000



868
12
6.1
>50000



869
1.9
34
40301



870
0.56
3.3
14448



871
1.6
5.1
12728



872
0.97
3.8
9539



873
3.1
1.8
12788



874
1.2
5.3
15548



875
6.6
3.2
40475



876
644
517
13255



877
1.5
1.6
12556



878
0.48
2.2
9042



879
1.0
3.4
7546



880
6.4
30
19328



881
25
68
43465



882
3.3
11
7764



883
7.4
2.3
12546



884
0.90
0.17
6501



885
1.6
3.8
7846



886
2.8
1.7
2568



887
0.50
0.68
8121



888
1.2
0.59
12211



889
1.5
0.76
9839



890
1.8
1.4
14745



891
0.64
0.93
17965



892
0.62
1.4
3285



893
0.34
0.74
7440



894
0.37
0.89
10763



895
0.74
1.1
7926



896
0.69
0.37
8435



897
0.86
1.5
11982



898
2.1
3.2
17320



899
1.0
1.7
9780



900
1.1
1.4
15593



901
0.72
0.15
13255



902
1.1
1.4
15789



903
3.0
4.1
35228



904
1.0
4.2
14798



905
0.51
0.82
12016



906
0.39
0.67
7799



907
0.76
0.45
>50000



908
0.89
0.26
6457



909
0.54
0.91
6707



910
0.68
0.86
5398



911
0.68
1.5
7016



912
0.98
2.2
9330



913
1.0
1.8
8845



914
0.73
0.94
6046



915
2.3
1.0
11137



916
18
11
14537



917
5.2
2.9
43171



918
3.2
6.3
20583



919
23
1.0
13895



920
2.6
5.9
12088



921
0.61
3.4
5267



922
0.55
2.1
9372



923
1.2
3.6
6556



924
1.7
4.9
7234



925
0.79
9.2
10082



926
3.3
3.0
3040



927
2.9
3.7
4357



928
1.5
6.9
3640



929
2.6
3.9
5086



930
22
7.4
24293



931
2.5
3.9
14927



932
0.66
10
14343



933
0.63
18
18442



934
0.86
8.6
9746



935
0.48
2.9
5613



936
0.56
3.5
4638



937
0.52
14
14243



938
2.6
4.9
8560



939
1.5
9.8
11863



940
1.7
0.66
8343



941
0.66
0.66
7198



942
0.50
3.4
12005



943
1.1
1.1
10046



944
3.1
4.9
17114



945
4.8
0.94
7846



946
1.4
1.8
8950



947
1.9
0.66
8773



948
2.8
1.4
12817



949
2.6
1.6
31028



950
7.2
4.9
36119



951
6.5
1.5
>50000



952
1.8
0.70
7862



953
0.92
5.3
12031



954
1.9
36
20896



955
0.76
2.0
20450



956
1.0
1.9
9650



957
0.92
2.9
24415



958
0.27
2.3
11244



959
1.4
0.29
7681



960
0.77
0.32
3166



961
0.35
0.80
8337



962
3.7
17
>50000



963
0.84
1.9
35268



964
0.53
0.25
3095



965
0.39
1.1
6483



966
2.4
1.3
6022



967
7.9
1.2
38697



968
1.9
0.69
16436



969
1.3
0.12
7175



970
3.1
0.92
10709



971
3.0
0.85
9246



972
3.3
3.1
6915



973
6.7
1.7
15804



974
1.1
0.71
3918



975
12
0.61
6463



976
2.5
0.96
13425



977
1.4
2.1
8600



978
11
1.8
11451



979
1.1
0.80
4291



980
2.2
2.3
6271



981
0.95
0.51
3066



982
9.8
20
32827



983
0.82
0.12
6525



984
1.0
0.85
3427



985
1.6
1.1
3897



986
0.63
0.38
2821



987
2.9
0.50
11253



988
0.36
0.23
3767



989
0.69
0.31
7098



990
0.80
4.0
6024



991
0.27
0.32
5986



992
0.66
0.72
6311



993
0.82
1.5
7230



994
13
3.4
11830



995
0.56
0.48
7020



996
1.3
0.40
11011



997
2.4
2.4
13578



998
1.9
0.44
20008



999
7.5
2.1
10466



1000
18
3.2
6438



1001
70
40
11739



1002
10
4.6
1099



1003
1.8
3.7
3164



1004
2.1
1.3
2794



1005
4.4
7.4
1659



1006
3.6
9.6
339



1007
3.2
4.0
2337



1008
15
32
13326



1009
4.5
7.7
2657



1010
3.6
4.7
2431



1011
11
22
23736



1012
0.59
1.4
1686



1013
11
9.2
7677



1014
21
26
21927



1015
1.3
7.8
2384



1016
2.9
38
641



1017
1.3
16
3302



1018
1.7
8.9
2782



1019
1.7
16
3278



1020
1.8
17
3863



1021
4.3
11
5329



1022
0.91
1.9
3650



1023
10
3.6
6939



1024
1.8
1.2
4538



1025
3.0
0.86
5861



1026
4.5
6.3
14488



1027
0.60
9.2
3003



1028
7.6
2.1
16992



1029
1.4
5.0
8378



1030
3.1
1.9
6278



1031
18
2.0
12671



1032
1206
196
25365



1033
1086
974
22372



1034
1398
>3125
26595



1035
1.7
21
3666



1036
1.3
2.7
1931



1037
3.1
6.2
1609



1038
0.98
1.3
1910



1039
7.2
6.4
3068



1040
0.17
0.66
1106



1041
0.49
0.85
2424



1042
2.2
3.3
3316



1043
2.1
1.6
1749



1044
4.1
9.2
3595



1045
4.8
3.6
3236



1046
0.64
2.4
2502



1047
1.3
3.5
4493



1048
4.4
13
9827



1049
1.6
5.4
2599



1050
2.8
4.8
2657



1051
0.41
1.5
1908



1052
8.9
17
5920



1053
2.5
4.8
4807



1054
5.4
1.7
1692



1055
4.3
8.3
5471



1056
2.1
1.2
2992



1057
0.81
1.7
2698



1058
1.9
3.5
5275



1059
1.6
1.4
2247



1060
0.50
0.50
2598



1061
2.7
4.8
3175



1062
13
25
10182



1063
10
18
8057



1064
0.34
0.96
2455



1065
1.1
1.1
2796



1066
9.0
11
4291



1067
1.0
4.5
5396



1068
0.88
1.8
2957



1069
0.09
0.17
735



1070
0.54
0.72
845



1071
3.7
25
5951



1072
2.9
35
5841



1073
4.6
28
5832



1074
0.59
1.9
2126



1075
1.8
11
3354



1076
1.6
1.8
10583



1077
18
38
21801



1078
9.8
216
>50000







(NT = not tested)







In Vivo mouse TLR7 PD Model:


Adult male C57BL/6 mice were used for the experiments. Mice (7 to 10 per group) were randomized into different treatment groups based on body weight. Mice from the respective treatment groups were administered orally with vehicle or test compound. Thirty min after the oral administration of vehicle or test compound, mice were challenged with intraperitoneal injection of gardiquimod for TLR7 PD model. Ninety minutes after gardiquimod injection, mice were bled under isoflurane anaesthesia and plasma 1L-6 and IFN-alpha levels were estimated by using commercially available ELISA kit (BD Biosciences, PBL Life Sciences). At the end of experiment, mean cytokine data was plotted and one way ANOVA with Dunnett's test was performed to calculate the significance of test compound treated group vs. vehicle control group. Percent inhibition of cytokine induction was calculated for test compound treated group vs vehicle control group. Data from multiple studies with different test compounds is shown in Table 5.









TABLE 5







Percent inhibition of IL-6 and IFN-alpha in mouse TLR7 PD model


TLR7 PD model













Dose
% inhibition
% inhibition



Ex. No.
(mg/kg)
of IL6
of IFN-alpha
















3
0.005
0
29




0.01
24
37




0.05
75
94




0.25
90
99




0.5
91
100



4
0.0015
0
0




0.003
23
33




0.015
75
74




0.075
76
93




0.15
95
99



438
0.003
25
36




0.006
41
57




0.03
56
67




0.15
78
96




0.3
82
98










MRL/Ipr Model of SLE:

Male MRL//pr mice of 12-14 weeks age were screened and randomized based on the titres of anti-dsDNA antibodies and urinary NGAL (Neutrophil Gelatinase Associated Lipocalin). Mice were treated orally, once daily for 8 weeks with vehicle or test compound. The effect of test compound on disease severity was assessed by measuring end points including proteinuria, urinary-NGAL, urinary TIMP1, blood urea nitrogen (BUN), anti-dsDNA Ab, anti-smRNP Ab titer, and plasma levels of ILIO and IL12p40. At the end of experiment, all mice were euthanized by CO2 asphyxiation and kidney samples were subjected for histology. To calculate the significance of test compound treated group vs. vehicle control group, one way ANOVA with Dunnett's test was performed. Percent reduction in disease severity was calculated for each parameter, for test compound treated group vs vehicle control group. Data from a study with test compound is shown in Table 6.









TABLE 6







Inhibition of disease development by TLR7/8


inhibitors in MRL/lpr model of lupus
















Dose
Pro-
Uri-
Uri-
Anti-
Anti-




Ex.
(mg/
tein-
nary
nary
SmRNP
dsDNA
IL-
IL-


No.
kg)
uria
NGAL
TIMP1
Ab titer
Ab titer
12p40
10


















438
0.1
31
34
0
23
0
16
0



0.3
80
58
42
44
28
33
18



1
73
63
54
49
39
26
19



3
82
67
56
43
44
28
21



10
84
67
79
51
37
41
22








Claims
  • 1-15. (canceled)
  • 16. A compound of Formula (I)
  • 17. The compound according to claim 16, N-oxide, or a salt thereof, wherein: G is:
  • 18. The compound according to claim 16, N-oxide, or a salt thereof, wherein: G is
  • 19. The compound according to claim 16 or a salt thereof, wherein G is
  • 20. The compound according to claim 16 or a salt thereof, wherein: G is
  • 21. The compound according to claim 16 or a salt thereof, wherein: R6 is: (i) C1-2 alkyl, —CH2C(O)NHCH2CRxRxOH, —CH2C(O)NHCH2CH2CRxRxOH, —CH2C(O)NHCH2CH2NRxRx, or —CH2C(O)NHCH2CHFCRxRxOH; or(ii) azabicyclo[3.2.1]octanyl, azaspiro[5.5]undecanyl, azetidinyl, C3-6 cycloalkyl, diazabicyclo[2.2.1]heptanyl, diazaspiro[3.5]nonanyl, morpholinyl, tetrahydropyranyl, octahydrocyclopenta[c]pyrrolyl, piperazinyl, piperidinyl, pyrrolidinyl, or quinuclidinyl, each substituted with zero to 3 R6a; andeach R6a is independently F, —OH, C1-4 alkyl, C1-4 fluoroalkyl, hydroxyalkyl, —(CH2)1-2OCH3, —NRxRx, —N(C2-3 alkyl)2, —(CH2)1-2NRxRx, —(CH2)1-2S(O)2(C1-2 alkyl), —(CH2)1-2C(O)NRxRx, —C(O)CH2NRxRx, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, isobutylpiperidinyl, piperazinyl, or —O(piperidinyl).
  • 22. The compound according to claim 16 or a salt thereof, wherein: R6 is: (i) —CH3, —CH2C(O)NHCH2C(CH3)2OH, —CH2C(O)NHCH2CH2C(CH3)2OH, —CH2C(O)NHCH2CH2NH2, or —CH2C(O)NHCH2CHFC(CH3)2OH; or(ii) azabicyclo[3.2.1]octanyl, azaspiro[5.5]undecanyl, azetidinyl, cyclohexyl, diazabicyclo[2.2.1]heptanyl, diazaspiro[3.5]nonanyl, morpholinyl, octahydrocyclopenta[c]pyrrolyl, piperazinyl, piperidinyl, pyrrolidinyl, or quinuclidinyl, each substituted with zero to 2 R6a; andeach R6a is independently F, —OH, —CH3, —CH2CH2CH3, —C(CH3)2, —CH2CH(CH3)2, —CH2CH2CH2CF3, —CH2CH2OH, —CH2CH2CH2OH, —CH2CH(CH3)OH, —CH2C(CH3)2OH, —CH2CH2OCH3, —NH2, —N(CH3)2, —N(CH2CH2CH3)2, —CH2NH2, —CH2CH2NH2, —CH2CH2S(O)2CH3, —CH2C(O)N(CH3)2, —C(O)CH2N(CH3)2, oxetanyl, tetrahydropyranyl, piperidinyl, isobutylpiperidinyl, or —O(piperidinyl).
  • 23. The compound according to claim 16 or a salt thereof, wherein: A is —OR6 or —O(CRxRx)1-2—R6;R6 is: (a) —CH3; or(b) azetidinyl, cyclohexyl, or piperidinyl, each substituted with zero to 2 R6a; andeach R6a is independently —CH3, —CH2CH2CH3, —C(CH3)2, —CH2C(CH3)2OH, —N(CH3)2, —N(CH2CH2CH3)2, —CH2CH2S(O)2CH3, —CH2C(O)N(CH3)2, or tetrahydropyranyl.
  • 24. The compound according to claim 16, N-oxide, or a salt thereof, wherein said compound is selected from: 6-(3-isopropyl-5-(1-methylpiperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (590);6-(3-isopropyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (591);6-(3-isopropyl-5-(1-isopropylazetidin-3-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (592);6-(3-isopropyl-5-(1-propylpiperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (593);6-(3-isopropyl-5-((1-methylpiperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (594);6-(3-isopropyl-5-((1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (595);6-(3-isopropyl-5-((1-methylazetidin-3-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (596);1-(4-(((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)methyl)piperidin-1-yl)-2-methylpropan-2-ol (597);6-(3-isopropyl-5-((1-isopropylpiperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (598);1-(3-(((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b] pyridin-5-yl)oxy)methyl)azetidin-1-yl)-2-methylpropan-2-ol (599);6-(3-isopropyl-5-((1-methylpiperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (600);6-(3-isopropyl-5-methoxy-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (601);2-(4-(((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)methyl)piperidin-1-yl)-N,N-dimethylacetamide (602);6-(3-isopropyl-5-((1-isopropylpiperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (603);6-(3-isopropyl-5-((1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (604);4-((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)-N,N-dipropylcyclohexan-1-amine (605, 611);6-(3-isopropyl-5-((1-propylpiperidin-4-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (606);6-(3-isopropyl-5-((1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (607);6-(3-isopropyl-5-((1-methylazetidin-3-yl)methoxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (608);2-(4-((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)piperidin-1-yl)-N,N-dimethylacetamide (609);4-((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)-N,N-dimethylcyclohexan-1-amine (610);6-(3-isopropyl-5-((1-isopropylazetidin-3-yl)oxy)-1H-pyrrolo[3,2-b]pyridin-2-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (612);1-(4((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)piperidin-1-yl)-2-methylpropan-2-ol (613); and4-((3-isopropyl-2-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)oxy)-N,N-dimethylcyclohexan-1-amine (614).
  • 25. A pharmaceutical composition comprising a compound according to claim 16 or a pharmaceutically-acceptable salt thereof; and a pharmaceutically acceptable carrier.
  • 26. A method for treating a disease comprising administrating to a subject in need thereof, a therapeutically-effective amount of at least one compound according to claim 16 or a pharmaceutically-acceptable salt thereof, wherein the disease is an autoimmune disease or a chronic inflammatory disease.
  • 27. The method according to claim 26 or a pharmaceutically-acceptable salt thereof, wherein said autoimmune disease or chronic inflammatory disease is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis (MS), and Sjögren's syndrome.
CROSS REFERENCE

This application is a continuation application of U.S. non-provisional application Ser. No. 16/222,145, filed Dec. 17, 2018, which claims priority to U.S. Provisional Application Ser. No. 62/599,875, filed Dec. 18, 2017, which is incorporated herein in its entirety.

Provisional Applications (1)
Number Date Country
62599875 Dec 2017 US
Continuations (3)
Number Date Country
Parent 16910101 Jun 2020 US
Child 17245595 US
Parent 16695303 Nov 2019 US
Child 16910101 US
Parent 16222145 Dec 2018 US
Child 16695303 US